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Abstract 
Episodes of toxin-producing phytoplankton occur worldwide, causing both animal and 
human fatalities. Toxicity occurs through consumption of phycotoxins, including 
azaspiracid, which accumulate in filter-feeding shellfish. Microcystins are hepatotoxins, 
produced mainly by freshwater cyanobacteria. Aflatoxins are potent, fungal 
hepatocarcinogens, which occur mainly in food and feed products. The purpose of this 
research was to examine the cytotoxic and immunosuppressive effects of aflatoxins (B1, 
B2 and G1), azaspiracid-1 and microcystin-LR in vitro, using the murine macrophage 
cell line, J774A.1. The results clearly demonstrated that azaspiracid and microcystin had 
a significant effect on host defence functions, through deregulation of IL-6, IL-10, IL-
12p40 and TNF-α cytokine expression. Microcystin exposure significantly decreased 
IL-1β expression. ‘Toll-like’ receptor (TLR2 and CD14) expression was altered 
following aflatoxin exposure, while apoptotic marker (caspase-1) expression was 
affected following microcystin exposure. This knowledge should be taken into 
consideration in the implementation of detection limits, aimed at minimising risks to 
human health through toxin exposure.  
Increased awareness of the hazards presented by toxins led to the requirement for 
recombinant antibodies for these targets, for incorporation into sensitive detection 
immunoassays. This thesis describes the production of leprine and avian immune 
libraries for azaspiracid and microcystin, respectively. Attempts were made to isolate 
azaspiracid-specific antibodies with little success. Phage display was utilised to 
successfully isolate two single chain antibody fragments (scFvs) to microcystin from the 
avian library. Error-prone PCR resulted in the isolation of a mutant clone which 
displayed a 2.3-fold improvement in sensitivity by ELISA, with an LOD of 1.4 ng/mL. 
The mutant scFv displayed an altered cross-reactivity profile to the microcystin variants 
tested using Biacore™ inhibition analysis. The recombinant antibodies were 
successfully applied to the development of fluorescence-based immunoassay formats. 
The biotinylated mutant scFv was incorporated into a slide-based assay format on a 
functionalised glass substrate (IC50 ~ 1 µg/L). This assay had the potential to accurately 
detect microcystin and its variants, below the regulatory limit of 1 µg/L. The application 
of these highly-sensitive recombinant antibodies into rapid and inexpensive 
fluorescence detection systems could aid in the development of an early warning system 
for toxin outbreaks. 
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CHAPTER 1 
Introduction 
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1.1 Introduction  
 
This chapter will introduce the concepts of innate and adaptive immunity with a focus on 
inflammatory cells, including macrophages and their related inflammatory mediators, 
including cytokines and chemokines. Pattern recognition, including ‘toll-like’ receptor 
(TLR) and ‘nod-like’ receptor (NLR) recognition mechanisms and microbial sensing, 
especially in relation to macrophages, will be described. These concepts will be discussed 
to provide a basis for the investigation of the effects of phycotoxins and mycotoxins on the 
immune response to infection. Adaptive immunity, including T-cell and B-cell recognition 
and development, leading to a specific immune response and antibody development will be 
introduced. 
 
The area of recombinant antibody generation to small-molecular weight marine toxin 
targets, for the purpose of immunosensor development is also introduced. The key stages 
involved in successful immune response generation to hapten targets in host animals are 
outlined, including immunogen preparation, conjugate carriers, coupling chemistries and 
conjugate purification. Introductions to recombinant antibody technology and immune 
library preparation are given. The current literature on marine toxins and mycotoxins, 
including cases of toxin outbreaks, their chemical structures and properties, source 
organisms, occurrence and accumulation is reviewed.  
 
1.2 The immune system 
 
The body is protected from damage caused by infectious agents and from other harmful 
substances, including toxins, by the immune system. A successful immune response to an 
invading pathogen relies on recognition of the infection, recruitment and trafficking of 
relevant immune cells, and proper activation and execution of their effector functions. The 
immune system consists of several organs, lymphocytes and a large number of extracellular 
messengers. A vast array of receptor-ligand interactions control these events (Rudd et al., 
2004; Long et al., 2006).  
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Innate immunity represents a non-specific first line of defence to the body, in which the 
host’s cell surface receptors recognise components of foreign pathogens. The adaptive 
immune response is characterised by the production of antibodies and activation of T-cells 
and is developed during the lifetime of an individual in response to a specific infection. 
Considerable co-ordination occurs between the innate and adaptive immune systems (Akira 
et al., 2006). In the absence of vital innate effector functions, including antigen-
presentation and cytokine production, adaptive responses would be ineffectual. However, 
innate responses do not lead to immunological memory, as it is solely the adaptive immune 
response that provides such specificity and complexity. Essentially, the innate immune 
system functions as a delaying mechanism, temporarily preventing infection while a more 
specific adaptive response is mounted. 
 
1.3 Innate Immunity 
1.3.1 The frontline of host defence 
When an infectious agent is first encountered, the initial defences are physical and chemical 
barriers, which prevent microbes from entering the body. These have been reviews in detail 
by Janeway and Medzhitov (2002). The epithelial surfaces form a physical barrier that is 
highly impermeable to most infectious agents, acting as the first line of defence against 
invading organisms. In the gastrointestinal and respiratory tract, movement due to 
peristalsis or cilia aid in the removal of infectious agents. The trapping effect of mucus that 
lines these tracts aids in the protection of the lungs and digestive system from infection. 
The gut flora can prevent the colonisation of pathogenic bacteria by competing with 
pathogenic bacteria for nutrients or attachment to cell surfaces. The flushing action of tears 
and saliva helps prevent infection of the eyes and mouth. It is only when these barriers are 
overcome, that the immune system is activated.  
 
1.3.2 Inflammation 
 
The inflammatory response to an infection, as part of innate immunity, involves the 
triggering of physiological responses, including fever, pain, redness and swelling and a 
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build-up of white blood cells at the site of infection (White, 1999; Akira et al., 2006). This 
response will recruit effector cells (Section 1.3.3) and chemical factors (Section 1.3.4) of 
the innate immune system to the site of infection from local blood vessels. A local 
environment is formed, which promotes the migration of white blood cells to the site of 
infection, the destruction of the invasive agents and the repair of the damaged tissue. Acute 
inflammation is initiated by certain cells present in all tissues of the body, known as 
mononuclear phagocytes, or macrophages. These cells possess unique receptors on their 
surface, known as PRRs. PRRs recognise molecules that are broadly shared by pathogens, 
but distinguishable from other molecules and are referred to as pathogen-associated 
molecular patterns (PAMPs). Pattern recognition will be discussed in detail in Section 
1.3.5. On the on-set of infection, macrophages undergo activation and release inflammatory 
mediators, including TNF-α and IL-1, leading to the clinical signs of inflammation. 
Chemical factors including histamine, bradykinin, serotonin, leukotrienes and 
prostaglandins are produced by basophils and mast cells in response to inflammation 
(White, 1999). These factors are involved in the sensitisation of pain receptors, cause 
vasodilation of blood vessels and attract phagocytes, especially neutrophils.  
 
1.3.3 Macrophages 
 
A key element of the inflammatory response is the recruitment of polymorphonuclear 
neutrophils (PNMs) and macrophages to sites of infection. Pathogens that overcome the 
epithelial barrier first encounter macrophages in residing tissues and subsequently interact 
with PMNs, including neutrophils and monocytes, recruited to the site of infection, where 
they phagocytose and kill invading organisms internally. They also contribute to tissue 
damage which occurs during inflammation. These cells possess PRRs which induce the 
engulfing of microbes into membrane-bound vesicles or ‘phagosomes’ (Underhill et al., 
2002). Multiple receptors are simultaneously engaged to mediate internalisation, activate 
microbial killing, and induce the production of inflammatory cytokines and chemokines 
(Table 1.3.3.1). Binding to PRRs will ultimately trigger cell signaling, producing soluble 
mediators such as cytokines, chemokines, acute phase proteins and complement initiating 
an inflammatory response. The surface receptors of macrophages and other PMNs regulate 
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a number of key functions, including growth, differentiation, survival, phagocytosis and 
cytotoxicity (Janeway and Medzhitov, 2002; Russell and Ley, 2002). This ability to 
recognise and respond to a wide range of endogenous and exogenous ligands is essential for 
homeostasis, inflammation and host defence in innate and acquired cellular activation by 
the macrophage. 
 
Macrophages are immune effector cells which have a well established role in pathogen 
recognition, host defence and immune regulation. They have been reviewed extensively in 
relation to pattern recognition and innate immunity ( Tsan and Gao, 2004; Taylor et al., 
2005; Mosser and Edwards, 2008; Kumar et al., 2011). Macrophages were first recognised 
in 1905 as important phagocytes (Metchnikoff, 1968) and have been under constant 
investigation by immunologists since then. Macrophages originate from myeloid progenitor 
cells in the bone marrow and, when committed to the monocyte lineage, they exit the bone 
marrow and enter the blood stream. Macrophages can leave the circulation to migrate into 
tissues throughout the body. They also function in phagocytosis and intracellular killing, 
usually involving the production of reactive oxygen species (ROS) which can be released 
into a phagocytosed microbe following phagolysosome formation or engulfment. 
Furthermore, macrophages contribute to tissue repair and act as antigen-presenting cells, 
which are required for the induction of specific immune responses. Studies have shown that 
tissue macrophages express remarkably heterogeneous surface receptors and have very 
different phenotypes, which reflect specialisation of function within different 
microenvironments (Gordon and Taylor, 2005; Taylor et al., 2005; Mosser and Edwards, 
2008).  
 
Macrophages have distinct sub-populations in lymphoid and non-lymphoid tissue, 
including liver (Kupffer cells), lung (alveolar), nervous system (microglia), epidermis 
(Langerhans cells), reproductive organs and serosal cavities. Macrophages can also be 
found in the lamina propria of gut and the interstitial fluid of the heart, pancreas and 
kidney. In response to inflammatory stimulation, additional monocytes are recruited to the 
site of infection, where they will display different phenotypes to the already resident 
macrophages (Taylor et al., 2005). Macrophages have the ability to initiate adaptive 
immunity by presenting antigen to CD4+ T-cells via MHC class II molecules of the 
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adaptive immune system (Janeway et al. 2001). Macrophages can be stimulated through 
two distinct routes; classical activation and alternative activation, and regulatory 
macrophages also form an important homeostatic subset (Mosser and Edwards, 2008). 
 
Table 1.3.3.1: Overview of macrophage receptors involved in the innate response. 
Receptor 
Family 
Example Cell Type Function 
Scavenger 
 
SR-A  
CD36  
Macrophage  Phagocytosis of bacteria and 
apoptotic cells 
GPI-anchored CD14 Macrophage  LPS-binding 
 Interaction with MD2/MyD88 
 TLR signalling 
 Apoptotic cell recognition 
‘Toll-like’ 
receptors  
TLR2 
TLR4 
Macrophage  Response to Peptidoglycan 
 Response to LPS 
NOD 
(nucleotide-
binding 
oligomerisation 
domain) 
receptor 
NOD1 
NOD2 
Macrophage 
Epithelial cells 
Paneth cells of 
gut 
 
 Recognise Peptidoglycan and 
muramyl dipeptide (MDP) or stress 
responses and form oligomers 
 Activate inflammatory caspases 
(e.g. caspase-1), cleavage and 
activation of IL-1, and/or activate 
the NF-κB signaling  
IgG 
superfamily 
 
FcR (ITAM/ 
ITIM), TREM-1 
Macrophages, 
neutrophils, 
dendritic and 
mast cells 
 Antibody-dependent binding 
 Up-take and killing 
 Regulation of inflammation 
TNF-receptor 
superfamily 
 
CD40 B-cells, 
macrophages 
and dendritic 
cells 
 Macrophage signalling to CD4+ T-
cells 
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1.3.4 Cytokines 
 
Cells of the immune system are continuously sending and receiving messages. Cytokines 
are small protein molecules, usually less than 30 kDa in size, secreted by T-cells and 
macrophages (Stow et al., 2009). Cytokines are pleiotropic or multi-functional and the 
specific response elicited by a given cytokine is dependent upon the cellular context, the 
environment and the cell’s state of maturation. Cytokines frequently function in a 
redundant manner, in that multiple cytokines can produce the same physiological response. 
Furthermore, individual cytokines can be produced simultaneously and act synergistically. 
The response elicited by a cytokine or group of cytokines can have an expansive effect, in 
that one signal can trigger a cascade of cytokine signaling events. Cytokines usually operate 
in a targeted fashion, operate over short distances and have short life-spans. The overall 
result of successful cytokine signaling is the rapid activation and recruitment of the 
appropriate cells of the immune system in response to a pathogenic agent.  
 
There are five families of cytokines and cytokine receptors including: the Toll/IL-1 family, 
the tumor necrosis factor (TNF) family, the haematopoietic receptors, the interferon 
receptors and the chemokine receptors (Dinarello, 2000). Interleukins of the Toll/IL-1 
subgroup are produced mainly by T-cells, but are also produced by monocytes and 
macrophages. Cytokine signaling to B-cells and T-cells promotes growth, proliferation and 
differentiation. In addition to Toll/IL-1 cytokines, tumor necrosis factor (TNF) receptors 
and their associated cytokines are involved in the coordination and regulation of growth, 
proliferation and survival of leukocytes. They coordinate the development of lymphoid 
organs and temporary inflammatory structures and they play a central part in the adaptive 
immune response. TNF-type cytokines have a key role in homeostasis and the maintenance 
of stability in the inflammatory process. Hematopoietin receptors or Class I cytokine 
receptors are a family of over 20 signalling molecules involved in lymphocyte signalling. 
The interferon/IL-10 receptors or Class II cytokine receptors mediate anti-viral responses 
through signalling to other leukocytes and up-regulating anti-viral genes. Moreover, 
interferons act as anti-tumour agents through down-regulation of genes involved in 
proliferation and they are involved in regulating genes essential for the adaptive immune 
response. TNF-α acts as an inducer of the local inflammatory response, aiding in the 
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containment of infection. It also has systemic effects, many of which are harmful. IL-8 is 
involved in the local inflammatory response, which helps to attract neutrophils to the site of 
infection. IL-1β, IL-6 and TNF-α have a crucial role in acute phase response in the liver 
and fever induction. IL-12 activates natural killer (NK) cells of the innate immune response 
and favors the differentiation of CD4 T–cells into TH1 cells during adaptive immunity. 
Table 1.3.4.1 outlines the most prominent cytokines secreted by macrophages and dendritic 
cells as part of the inflammatory response. 
 
Table 1.3.4.1: Inflammatory cytokines  
Cytokine Producer Effect 
IL-1 Macrophages 
Keratinocytes 
 Proliferation and enhanced responses in lymphocytes 
 Induces acute-phase protein secretion 
IL-6 Macrophages 
Dendritic cells 
 Proliferation and differentiation and Ig production 
 Enhance innate immune response 
 Induces acute-phase protein secretion 
IL-8 Phagocytes  Chemoattractant for neutrophils 
IL-10 Monocytes  Inhibits cytokine production 
IL-12 Naïve T-cells  Diverts immune response to TH1 
 Pro-inflammatory cytokine secretion 
TNF-α Vascular 
endothelium 
 Induces changes in vascular endothelium  
 Changes in cell-cell junctions with increased fluid loss 
 Local blood clotting 
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1.3.5 Pattern recognition receptors 
 
Our innate immune system has evolved a number of pattern recognition receptors that 
cooperate to recognise microbial pathogens or endogenous danger signals. The two main 
receptor families include the ‘toll-like’ receptor system (TLRs) and the ‘nod-like’ receptors 
(NLRs), although a number of other receptor subtypes exist. The TLR and NLR family will 
be discussed in detail in this work. Pattern recognition is a concept first proposed by 
Janeway and Medzhitov (2002). It is based on the recognition of evolutionary conserved 
microbial structures, named pathogen-associated molecular patterns (PAMPs) (Takeda and 
Akira, 2005). These are recognised by a small number of non-clonal germline-encoded 
antigen-presenting cell (APC) pattern recognition receptors (PRRs). Individual PRRs with 
unique expression patterns react with specific PAMPs, resulting in the activation of a 
distinct signalling pathway and immune response. Some of the unique cell wall components 
of bacteria are recognised by immune cells and act as PAMPs, which are recognised by 
individual TLRs. 
 
Bacteria can be classified into two major groups, gram-positive and gram-negative, named 
for their staining characteristics of their cell walls. Gram-positive are stained dark blue by 
gram staining as they retain the crystal violet stain due to their substantial peptidoglycan 
cell wall. In contrast, gram-negative bacteria cannot retain the crystal violet dye because of 
their thin cell wall and are instead identifiable using a counter-stain, such as safranin. The 
innate immune response can be stimulated by components of the gram-positive cell wall, 
including lipoteichoic acid (LTA), lipoproteins and peptidoglycan. LTA is an amphiphilic 
molecule (contains both hydrophilic and lipophilic properties), negatively-charged 
glycolipid and functions as an immune activator. Lipoproteins and peptidoglycan, as 
components of both gram-positive and gram-negative bacteria, are potent immuno-
stimulators (Figure 1.3.5.1).  
 
Lipopolysaccharide (LPS) is a complex amphiphilic molecule which varies widely in 
chemical composition in bacterial species. Bacterial LPS is a cell-wall component of gram-
negative bacteria, which activates monocytes and macrophages to produce cytokines. LPS 
mediates inflammation through receptor interactions with various immune cells. LPS binds 
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the CD14/TLR4/MD2 receptor complex, which promotes the secretion of pro-inflammatory 
cytokines, including TNF-α, IL-1 and IL-6, in many cell types but especially in 
macrophages and B-cells. LPS is a large molecule, consisting of a lipid and a 
polysaccharide joined by a covalent bond (Figure 1.3.5.1). LPS also acts as an exogenous 
pyrogen or fever-inducing substance. The term "LPS challenge" refers to the process of 
exposing a subject to LPS that may act as a toxin. In humans, an over-exposure to LPS 
leads to a condition known as septic shock, which is caused by an overwhelming secretion 
of cytokines, as a result of systemic bacterial infection or sepsis.  
 
A detailed structure of LPS is illustrated in Figure 1.3.5.1. Lipid A is the lipid component 
of LPS which contains the hydrophobic, membrane-anchoring region. Lipid A consists of a 
phosphorylated N-acetylglucosamine dimer with 6 to 7 saturated fatty acid chains attached.  
The core antigen or polysaccharide of LPS is attached to the sixth position of the N-
acetylglucosamine and consists of a short chain of sugars. The O antigen is attached to the 
core antigen and consists of repeating oligosaccharide subunits made up of 3 to 5 sugars. 
The individual chains can be up to 40 repeat units in length. Moreover, the O antigen is 
much longer than the core antigen and is responsible for maintaining the hydrophilic 
domain of the LPS molecule. There is considerable variation in the composition of the 
sugars in the O antigen between species and strains of gram-negative bacteria and at least 
20 different sugars are known to occur (Lerouge and Vanderleyden, 2002).  
 
 
 
 
 
 
 
 
 
11 
 
Gram-positive bacterial cell wall
Lipoteichnoic Acid
Lipoprotein
Peptidoglycan
LPS Porin Peptidoglycan
Gram-negative bacterial cell wall 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3.5.1: Schematic representation of bacterial cell walls of gram-positive and gram-
negative bacteria. Gram negative cell walls are characterised by the presence of LPS, while 
gram-positive cell walls are characterised by a thick layer of peptidoglycan. A detailed 
structure of LPS is illustrated, containing the characteristic O-antigen, core and lipid A 
portions.  
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1.3.5.1 ‘Toll-like’ receptor (TLR) family 
 
It has been well established that ‘toll-like’ receptors (TLRs) represent a first line of defence 
against invading pathogens in mammals, plants and insects (Akira and Takeda, 2004; 
Kumar et al., 2011). TLRs are evolutionarily conserved from the worm Caenorhabditis 
elegans. Toll, one of the first members discovered of the TLR superfamily, was identified 
as a gene essential for the development of embryonic dorsoventral polarity in Drosophilia. 
TLRs are type I integral membrane glycoproteins. Recognition of microbial components by 
these receptors triggers the innate immune response and will eventually lead to the 
expression of inflammatory genes and clearance of the infection. Lipids, carbohydrates and 
nucleic acids are among the PAMPs recognised by TLRs (Table 1.3.5.1). TLR receptors are 
evolved to distinguish between different PAMP structures. However, this recognition is one 
of the most complex and undefined areas of TLR signalling (Hopkins and Sriskandan, 
2005; Ostuni et al., 2010). Eleven TLRs have been identified in humans, while 13 have 
been discovered, to date, in the mouse genome. TLRs 1-9 are conserved between these 
species.  
 
The TLR receptors all share a cytosolic TIR (Toll/ Interleukin-1 receptor) domain, which is 
also found in the Interleukin-1 receptor family, and an extracellular ‘leucine-rich’ repeat 
(LRR), which functions in microbial recognition. The LRR domains are composed of 19-25 
tandem LRR motifs, each of which is 25-29 amino acids in length, containing the motif 
XLXXLXLXX, as well as other conserved amino acid residues. Each LRR contains a β- 
strand and an α-helix, connected by loops. It has been suggested that the LRR motif forms a 
horseshoe structure, with the ligand binding on the concave surface (Bell et al., 2005). 
TLR1, TLR2, TLR4, TLR5 and TLR6 are all localised on the plasma membrane, whereas, 
TLR3, TLR7, TLR8 and TLR9 are preferentially expressed in intracellular compartments, 
such as endosomes. Based on their structural characteristics, TLRs can be further 
subdivided into subfamilies which recognise different PAMPs; TLR1, TLR2 and TLR6 
bind lipids, whereas TLR7, TLR8 and TLR9 bind nucleic acids (Table 1.3.5.1). However, 
some TLRs are capable of binding structurally diverse ligands. For example, TLR4 can 
recognise the lipopolysaccharide, LPS, the viral protein, RSV, fibronectin and heat shock 
proteins. TLRs are expressed on a number of different immune cell types, including 
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macrophages, dendritic cells, B-cells, some types of T-cells and non-immune cells, 
including fibroblasts and epithelial cells. Expression of TLR is constantly changing in 
response to different pathogenic stimuli, cytokines and environmental stimuli. 
 
TLR2 recognises a wide variety of microbial components including lipoproteins from 
various pathogens, peptidoglycan from gram-positive bacteria, glycophosphatidylinositol 
(GPI) anchors from malaria-causing parasites, zymosan from fungi and forms of LPS that 
are structurally distinct from those recognised by TLR4 (Figure 1.3.5.2). TLR2 is able to 
recognise a wide range of compounds because of its inherent ability to form heterodimers 
with other TLRs, namely TLR1 and TLR6. TLR1:TLR2 association allows for the 
recognition of triacyl lipopeptides, whereas TLR2:TLR6 heterodimers recognise diacyl 
lipopeptides. 
 
 
Figure 1.3.5.2: Putative ligands for TLR receptors.  TLR4 is required for the signaling of 
LPS from Gram-negative bacteria, LTA from Gram-positive bacteria and taxol. In contrast, 
TLR2 recognises PGN, zymosan, LAM and lipoproteins from various bacteria (Adapted 
from Takeuchi et al., 2001).  
TIR
LPS Taxol LTA
TIR
PGNLAM
Zymosan
Lipoproteins
TLR4 TLR2
CD14 CD14
MD2
14 
 
Table 1.3.5.1: TLR receptors and ligands (Adapted from Hopkins and Sriskandan, 2005) 
‘Toll-like’ Receptor Ligand 
TLR1  Soluble bacterial factors: Triacyl Lipopeptides (Mycobacteria, 
Neisseria and Borrelia) 
TLR2 
 
Bacterial: Diacyl Lipopeptides (Mycoplasma), PGN, LTA, 
porins, LPS (Pseudomonas, Helicobacter) 
Fungal: Zymosan  
Viral: HCV core, NS3 proteins, measles virus, human CMV, 
HSV-1 
Endogenous: HSP60 and 70, Cys3Pam, defensins 
TLR3 Viral: dsRNA 
Synthetic: Poly (I:C), siRNA, shRNA 
TLR4  
(with CD14 and  
MD-2) 
Bacterial: LPS (Gram-negative bacteria),  
Lipotechnoic acid (Gram-positive bacteria), Pseudomonas exoS, 
C. Pneumonia, H. pylori 
HSP60 
Viral: Virus envelope proteins (RSC, MMTV) 
Endogenous: Fibrinogen, HSP70, heparin, hyaluronic acid 
Synthetic: Taxol, MPL (LPS mimetic) 
TLR5 Bacterial: Flagellin 
Synthetic: Discontinous 13 amino acid peptide 
TLR6 Diacyl lipopeptides (Mycoplasma) 
TLR7 Viral: ssRNA (e.g. influenza, HIV) 
Synthetic: Imidazoquinolines 
TLR8 DNA: G-rich oligonucleotides 
Viral: ssRNA (e.g. influenza, HIV) 
Synthetic: Imidazoquinolines 
TLR9 Bacterial and viral DNA (HSV, CMV), Unmethylated CpG DNA 
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Cell surface receptors, including TLR receptors, utilise membrane-spanning hydrophobic 
residues to interact with the plasma membrane. There are a number of key co-receptors that 
are essential for TLR signaling, including CD14 and CD40. It has also been demonstrated 
that surface receptors can utilise GPI-based glycolipids e.g. CD14 for anchoring to the cell 
membrane. CD14 is relevant to macrophage immune recognition and is mainly expressed 
on cells of a myeloid lineage, including monocytes, macrophages and granulocytes and is 
also expressed on other cell types, including B-cells, liver parenchymal cells and 
fibroblasts. Various ligands for CD14 have been identified, including LTA (lipotechnoic 
acid), PGN and apoptotic cells (Schütt, 1999). CD14 does not have a transmembrane 
domain, accessory molecules or co-receptors, including TLR2 and TLR4 are essential for 
signal transduction (Triantafilou and Triantafilou, 2002). CD14 can be present as a soluble 
form (sCD14) or a glycosylphosphatidylinositol (GPI)-linked form (mCD14). TNF-α and 
LPS induce the secretion of sCD14, whereas IL-4 and IFN-γ inhibit it. In cases of septic 
shock, increased levels of sCD14 in serum correlate with increased mortality. 
 
The accessory molecule, CD40, is expressed on a number of different cell types, including 
antigen-presenting cells (APC), such as B-cells, macrophages and dendritic cells. The 
CD40 ligand, CD154, is primarily found on activated CD4+ T-cells. CD40 is a co-
stimulatory molecule that has an important role in the regulation of antigen-presentation. 
Binding of CD154 to CD40 on dendritic cells and macrophages causes T-cell expansion 
and macrophage activation. LPS is known to up-regulate CD40 on dendritic cells and it has 
been suggested that CD40 signalling regulates TLR4 and MD-2 expression and function 
(Frleta et al., 2003). MD-2 is a protein involved in binding LPS with TLR4. Binding of the 
MD/ LPS complex to CD40 on monocytes and macrophages results in an increased 
expression of pro-inflammatory cytokines including IL-1α and IL-1β, TNF-α, IL-6, IL-12, 
as well as chemokines, including IL-8. CD40 stimulation has additional effector functions, 
including the expression of matrix metalloproteinases and production of nitric oxide (NO). 
Matrix metalloproteinases are involved in the degradation of extracellular matrix proteins, 
the cleavage of surface receptors, cytokine/ chemokine release, and the release of apoptotic 
ligands. Overall, stimulation of CD40 directs macrophages, monocytes and dendritic cells 
to a phenotype which promotes antigen presentation and pro-inflammatory activation. 
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1.3.5.2  ‘Nod-like’ receptors and inflammasome activation 
 
For mammalian hosts to survive infection, the immune system must recruit an arsenal of 
defence mechanisms to combat invading microorganism, which has been widely discussed 
thus far in Section 1.3. It has now been widely demonstrated that in addition to sensing 
microbial components, PRRs have a key role in sensing endogenous products or danger 
signals, referred to as danger-associated molecular patterns (DAMPs), which are released 
from damaged or dying cells (Kono and Rock, 2008). Damaged cells release endogenous 
signalling molecules, including nucleic acid, ATP and uric acid crystals, which trigger the 
same responses as those produced during microbial detection by the innate immune system. 
These responses can however be detrimental to the host and often cause an inflammatory 
response. This is evident in the case of ‘nod-like’ receptors (NLRs), particularly the NLRP3 
inflammasome. Numerous microbial components, including LPS, single-stranded RNA, 
peptidoglycans and CPG DNA have been identified as activators of the NLRP3 
inflammasome (Kanneganti et al., 2006; Kanneganti et al., 2007).  
 
The NLRs are cytosolic receptors which regulate production of pro-inflammatory 
cytokines, including interleukins, IL-1β and IL-18. IL-1β is produced by many immune cell 
types and is a key mediator of systemic and local response to infection and immunological 
challenge by generating fever, activating lymphocytes and promoting translocation to sites 
of injury. IL-18 does not possess the pyrogenic activity of IL-1β, but it does induce 
interferon-γ (IFN-γ) production by activated T-cell and NK cells in the presence of IL-12, 
thereby contributing to TH1 polarisation. The production, processing and release of IL-1β 
are tightly controlled and it requires two distinct levels of stimulation Firstly, pro-IL-1β is 
accumulated in intracellular stores via transcriptional regulation and released upon 
stimulation to the mature cytokine, IL-1β. The first is a microbial stimulus, signalled 
though PRRs, for example TLR4, which results in the accumulation of intracellular pro-IL-
1β. The mechanisms controlling the transcription of pro-IL-1β are still not fully known, but 
NF-κB and mitogen-activated protein kinase (MAPK) signalling have been implicated 
(Gretten et al., 2007; Hedl and Abraham, 2011).  
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Macrophages are known to secrete IL-1β in response to stimulation with LPS and 
subsequent treatment with a high concentration of ATP (Ferrari et al., 2006). LPS is 
required both to induce expression of pro-IL-1β and to prime cells for caspase-1 activation 
in response to ATP. The effect of ATP is mediated by an ionotropic ATP receptor, P2X7, 
which upon activation, causes a rapid K
+
 efflux from the cytosol. Recently, it has been 
demonstrated that pannexin-1 is required for ATP release during apoptosis but not for 
inflammasome activation (Qu et al., 2011). The ATP-gated P2X7 receptor is an ATP-gated 
ion channel, responsible for potassium conductance through the cell membrane (Figure 
1.3.5.3). ATP-dependent activation of NLRP3 occurs through binding of ATP to the P2X7 
receptor, resulting in the opening of a pore via pannexin-1. Pannexin-1 is an ATP-releasing 
hemi-channel protein, associated with the P2X7 receptor and was also found to be essential 
for NLRP3 activation by ATP, maitotoxin (a potent marine phycotoxin), nigericin and LPS 
(Kanneganti et al., 2007; Pelgrin and Surprenant, 2007). It was shown that pannexin-1 is 
essential for caspase-1 activation and IL-1β secretion in LPS-stimulated macrophages 
pulsed with ATP (Pelegrin and Surprenant, 2006). Potassium ionophores (lipid membrane 
transporter), P2X7 and pore-forming toxins all induce IL-1β activation and secretion. 
Therefore, K
+
 efflux may be essential for NLRP3 activation.  
 
The second stimulus required for the cleavage of pro-IL-1β involves multi-protein 
complexes, known as inflammasomes. This dual stimulation may operate to control 
accidental or un-controlled NLRP3 activation, which could lead to host destruction. The 
fact that a priming stimulus is required for NLRP3 inflammasome activation suggest that 
immune cells, including macrophages, require either a signal which indicates the presence 
of infection via PRR activation or the presence of other pro-inflammatory cytokine-
stimulated cells in order to sense danger signals in their environment. Excess IL-1β 
production has been associated with a number of hereditary disorders, including 
autoimmune and inflammatory diseases, such as gout and rheumatoid arthritis (McDermott 
and Tschopp, 2007). Inflammasome signaling was shown to play a key role in the 
progression of auto-inflammatory and autoimmune diseases, particularly in the 
pathogenesis of obesity, atherosclerosis, multiple sclerosis and insulin resistance (Lukens et 
al., 2011; Stienstra et al., 2011). 
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Inflammasomes are multi-protein complexes and have an approximate molecular mass of 
700 kDa. The main role of the NALP3 inflammasome is to control the activation of the 
cysteine aspartic acid-specific protease -1 (caspase-1) and to control the cleavage of pro-IL-
1β. Caspases are described as apoptotic initiators or effectors and can be divided into two 
sub-classes, based on substrate specificity; pro-apoptotic and pro-inflammatory. Caspase-1 
can be described as pro-inflammatory. The NALP3 inflammasome functions to convert 
inactive pro-caspase-1 to active caspase-1, which then cleaves inactive cytokine precursors 
to a secreted and active form. The known substrates that are processed by caspase-1 are the 
precursors of IL-1β and IL-18. Studies have shown that NALP3 and the adapter protein, 
ASC are essential for caspase-1-mediated activation in response to bacterial ligands, 
nucleic acids and synthetic anti-viral components (Kanneganti et al., 2006; Sutterwala et 
al., 2006).  
 
Figure 1.3.5.3: The NLRP3 inflammasome. A priming signal through TLRs activates NF-
κB-dependent transcription of pro-IL-1β and pro-IL-18. Pro-IL-1β is cleaved to IL-1β by 
caspase-1. Caspase-1 is activated by the NLRP3. NLRP3 oligmerises upon activation by 
danger signals and recruits the adapter ASC, which subsequently recruits and activates 
caspase-1 (Adapted from Bauernfeind et al., 2011). 
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1.4 Adaptive Immunity 
 
The adaptive immune response consists of two main components, a cellular response 
mediated by T lymphocytes and a humoral response, mediated by antibodies, produced by 
B lymphocytes. It takes several days or weeks for the adaptive immune response to take 
effect and during this period the innate immune response contains the infection. Vertebrates 
are constantly under threat from invasion against microorganisms and over time have 
evolved systems of host defence in order to eliminate infectious agents from the body. The 
acquired or adaptive immune system is involved in the elimination of pathogens in the late 
phase of infection, as well as in the generation of immunological memory. The role of the 
adaptive immune response is to produce a specific response to a foreign substance, in the 
form of immune cells and antibodies, which can specifically interact with them and protect 
the host from invasion. Acquired immunity is characterised by specificity, which is 
generated by a complicated clonal selection process from a vast repertoire of lymphocytes 
bearing antigen-specific receptors generated by gene rearrangement.  
 
1.4.1 Antigen recognition by T-Cell and B-Cell receptors 
 
Adaptive immunity utilises antigen-specific receptors, which are mainly found on 
lymphocytes, including B-cells and T-cells, to direct effector functions (Pancer and Cooper, 
2006; Palm and Medzhitov, 2009). Lymphocytes, or white blood cells, are highly mobile 
cells which have the ability to migrate from blood into tissue and back into blood (Figure 
1.4.1.1). They respond to infection by attacking and destroying the causative agents, or 
pathogens. They are involved in inflammatory immune responses, innate immune responses 
and adaptive immune responses. Both T-cells and B-cells originate from progenitor cells in 
the bone marrow. T-cells mature and migrate to the thymus, whereas B-cells undergo 
further development in the bone marrow. Antigen specificity is conferred by B-cell 
receptors (BCRs) or membrane-bound antibodies and T-cell receptors (TCRs) on B-cells 
and T-cells, respectively. Specificity is attributed to rearrangements of the genes encoding 
membrane-bound antibodies and TCRs, resulting in a vast repertoire of antigen-binders 
(Arstila et al., 2000). Naïve lymphocytes enter peripheral lymphoid organs where the 
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majority of immune responses occur. Each lymphocyte cell bears surface receptors for a 
single antigen. However, high specificity combined with the huge repertoire of 
lymphocytes means only a small number of lymphocytes are able to recognise a given 
antigen. 
 
Figure 1.4.1.1: Diagrammatic representation of cellular response to infection. Foreign 
pathogens, including bacteria and viruses must first penetrate the physical barriers of innate 
immunity. Through a process of antigen recognition and presentation, innate immune cells, 
including macrophages, present potential pathogens to the acquired immune system, which 
mounts a specific cell-based immune response i.e. B- and T-cell development and antibody 
production. 
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Major histocompatability complexes (MHCs) play a key role in antigen recognition. To 
elicit a cellular response to infection, at least two distinct signals are required. The first step 
is antigen binding to the BCRs and TCRs, in association with CD4 and CD8 co-receptors. 
The B-cell ingests the antigen-antibody complex, processes the antigen, and in combination 
with an MHC Class II complex, the antigen is displayed on the B-cell surface. Activated 
helper T-cells (TH), which have specific receptors for this antigen, convey the second signal 
and trigger the production of cytokines. The second set of signals is sent into the cell via 
co-stimulatory pathways. The most prominent of the co-stimulatory pathways are the 
CD28/B7 system and the CD40/CD40L signalling pathway. These cytokines bind their 
receptors on the B-cell, which triggers B-cell differentiation and proliferation.  
 
TCRs recognise short peptide sequences, typically 8 to 15 residues long, which belong to 
antigens which have been processed and bound to MHC Class II molecules expressed on 
the surface of antigen-presenting cells. The TCR recognition process differs from BCR 
antigen recognition since the latter targets entire molecules, either denatured or native 
forms of proteins or cell-bound carbohydrates. MHC receptors are key in distinguishing 
self from non-self. Class I MHCs bind peptides derived from molecules encountered in the 
cytosol and are therefore able to display fragments of viral proteins on the cell surface. 
Class II members bind peptides from molecules broken down in endosomes and 
intracellular vesicles and display peptides derived from pathogens resident in macrophage 
vesicles or internalised by phagocytic cells and B cells. 
 
1.4.2 Humoral immune response and B-cell development 
 
Antibodies are produced by the host’s immune system in response to a foreign antigen by 
B-cell lymphocytes, which play a major role in generating the humoral response of the host 
immune system (LeBien and Tedder, 2008). Each B-cell is programmed to make a single 
type of antibody for a particular immunogen. When a B-cell encounters an antigen, a 
plasma cell is generated, which produces antibodies with specificity and affinity for an 
epitope on the antigen. B-cells are stimulated to proliferate when they are exposed to the 
CD40 ligand (CD40L) and interleukin-4 (IL-4), which is produced by activated TH2 cells 
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when they recognise their specific ligand on the B-cell surface. Therefore, IL-4 and CD40L 
cooperate in B-cell proliferation to drive the clonal expansion which precedes antibody 
production. The TNF receptor family members including CD30, the CD30 ligand and 
BLyS (B lymphocyte stimulator) and its receptor on B-cells, TACI, are also involved in B-
cell stimulation (Kurosaki et al., 2010). After several rounds of proliferation, B-cells can 
further differentiate into antibody-secreting plasma cells. Two additional cytokines, IL-5 
and IL-6, both secreted by TH2 cells, contribute to the later stages of B-cell activation. 
 
1.4.3 Antibody structure and function 
 
Immunoglobulins (IgGs) are natural biological scaffolds with structurally variable antigen-
binding domains, which are used by the immune system of higher organisms to mount a 
humoral immune response. More than 10
8
 different antibodies can be in circulation at any 
one time. Gene rearrangement is used in the production of a primary repertoire of 
antibodies. Foreign antigens trigger the clonal expansion of naїve B-lymphocytes that 
express a cognate antibody of low affinity. Rapid and specific affinity maturation is 
achieved by subjecting the immunoglobulin genes in the B-cells to a period of intense 
mutation. Due to clonal expansion and affinity maturation, immunoglobulins with highly 
evolved molecular recognition properties are generated. Affinity maturation is achieved by 
somatic hypermutation, a mutational process in which single nucleotide substitutions are 
introduced into rearranged variable (V) gene segments.  
 
Antibodies are large glycoprotein structures with a characteristic ‘Y’ shape (Figure 1.4.3.1). 
There are five main antibody classes, designated according to their heavy chain structure 
(IgG, IgA, IgM, IgD and IgE). All naïve B-cells express cell-surface IgM and IgD prior to 
isotype switching but little IgD is produced at any time, so the early stages of the antibody 
response are dominated by IgM. Later, IgG and IgA are the predominant isotypes, with IgE 
contributing a small but biologically important part of the response. The overall 
predominance of IgG1 results from its longer lifetime in the plasma of approximately 21 
days. An IgG antibody consists of two heavy chains and two light chains, which are 
covalently linked by disulfide bonds. In addition to an inter-chain disulfide bond, an IgG 
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has two intra-chain disulfide bonds. Each light chain has an N-terminal variable domain 
(VL) and a constant domain (CL). Each heavy chain is composed of an N-terminal variable 
domain (VH), three constant domains (CH1- CH3) and a hinge region. There are 5 classes of 
heavy chains α, γ, µ, δ, ε, and two classes of light chains, κ and λ. The heavy chains confer 
different biological functions to a specific isotype and they differ in their size and 
carbohydrate context. Most species produce both types of light chains, but the ratio of κ to 
λ varies with the species (Scott and Potter, 1983). 
 
Table 1.4.3.1: Structure and function of IgG components and recombinant fragments. 
Structure Function 
scFv molecule  Smallest recombinant fragment of ∼26-27 kDa.  
 Consists of a complete binding site of the individual heavy and 
light chain V domains 
 Connected with a short linker peptide of 10-25 amino acids 
Fab molecule  Recombinant fragment of ∼50 kDa with a shortened heavy chain. 
This heavy chain fragment is referred to as an Fd fragment. 
 Two domains, VL-VH and CL-CH1, interact to form the two-chain 
structure of the Fab molecule, which is further stabilised by a 
disulfide bridge between CL and CH1. 
Fragment antigen-
binding (Fab fragment) 
 Region on an antibody that binds to antigens. 
 It is composed of one constant and one variable domain of each of 
the heavy and the light chain. 
Fragment-crystallisable 
region (Fc region) 
 Tail region of an antibody that interacts with cell surface receptors 
called Fc receptors and some proteins of the complement system. 
 This property allows antibodies to activate the immune system. 
Disulphide bridges  Important for structural determination and conformation 
 Stabilise the interaction between heavy and light chains 
Carbohydrate 
 
 Fc regions of IgG’s have a highly conserved N-glycosylation site. 
Glycosylation of the Fc fragment is essential for Fc receptor-
mediated activity. The N-glycans attached to this site are 
predominantly core-fucosylated diantennary structures. 
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Each antibody has only one light chain and heavy chain type, which determine the subclass. 
The VH and VL chain form the antigen-binding site of the molecule. The sequence and 
structural variation in the variable domains is generally restricted to three short 
hypervariable loops, known as complementary determining regions (CDRs). The variable 
domain also consists of a framework region, which is highly conserved. The combination 
of amino acid residues in the CDRs determines the antibodies ability to recognise a specific 
antigenic determinant. A number of specific amino acid residues account for the 
predominant interaction of the antibody with the antigen. These locations are referred to as 
“hot spots” (Copley et al., 1996; Murphy et al., 2006). 
 
Full Length IgG 
 
Figure 1.4.3.1: Immunoglobulin formats. Structure of intact immunoglobulin G (IgG) 
molecule, an scFv molecule and a Fab molecule. Heavy chain domains are represented by 
blue boxes and light chain domains by red boxes. Variable domains of heavy and light 
chains are represented by striped blue and red boxes, respectively. S-S represents a 
disulphide bridge. N and C represent the N and C terminus, respectively.  
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1.5 Immune response generation 
1.5.1 Immunogen preparation for immunisation 
 
The ability of the antigen to generate an immune response depends on its immunogenicity. 
An antigen capable of generating a humoral or a cell-mediated immune response by itself is 
known as an immunogen. The immunogenicity of an antigen is conferred by distinctive 
molecular structural features, recognised as foreign by the host’s immune system. These 
features act as targets for the immune response to produce large numbers of antibodies with 
varying specificity, whose purpose is to bind the immunogen, rendering it ineffective. 
However, not all antigens are immunogens. Small molecules or “haptens” are unable to 
stimulate an immune response unless they are coupled to a larger reactive molecule, known 
as a carrier (Singh et al., 2004). When an immune response is generated against a hapten-
carrier molecule, the B-cells will produce antibodies that are specific for both the hapten 
and the carrier and possibly also to chemical linkers or any combination of the three. 
 
The first step in the successful production of an antibody to a hapten target, involves the 
careful consideration of a number of key issues including, conjugation strategy and point of 
attachment, functionalisation of the hapten, choice of carrier molecule, hapten to carrier 
ratio and purification and characterisation of the conjugate. 
 
1.5.1.1 Conjugate Carriers 
 
The most commonly used carriers are large molecules, which give haptens immunogenicity 
when they are coupled covalently to them. Examples of carriers include proteins, 
liposomes, polymers, such as dextran, agarose and poly-L-lysine, or synthetic organic 
molecules (dendrimers). A good carrier molecule will have suitable immunogenicity, 
functional groups for conjugation and reasonable solubility, even after derivitisation 
(Hermanson et al., 2008). The most common protein carriers are keyhole limpet 
haemocyanin (KLH), bovine from serum albumin (BSA), cBSA (cationised BSA), 
thyroglobulin, ovalbumin (OVA) and toxoid protein, such as tetanus toxoid. cBSA is 
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prepared by modification of BSAs carboxylate groups with ethylene diamine. This leads to 
the masking of BSAs native negatively-charged carboxylates and positively charged amines 
are created in their place. This highly positive charge dramatically increases BSAs 
immunogenicity by increasing the binding to antigen-presenting cells (APCs) in vivo. 
cBSA conjugates get incorporated by APCs faster and generate quicker immune response 
with a greater concentration of specific antibody (Muckerheide et al., 1987). Thyroglobulin 
and ovalbumin are widely used as conjugate carriers for antibody characterisation and 
screening. Table 1.5.1.1 outlines some of the most commonly used carrier proteins, along 
with details of their molecular weight, structural and stability properties and some 
requirements for conjugation. 
 
1.5.1.2 Coupling Chemistry 
 
The coupling chemistry used to prepare the immunogen is extremely important for the 
successful production of an antibody with the desired specificity. The conjugation process 
is dependent on the functional groups present primarily on the hapten and also on the 
carrier molecule. The most commonly used linkage involves the formation of an amide 
bond between a carboxylic acid moiety on the hapten and a primary amino group on the 
carrier. Usually, the correct functional group is not present on the hapten and needs to be 
introduced using a derivitisation step or alternatively, a structural analogue of the hapten 
can be used. As well as introducing a functional group for attachment, this step may also 
introduce a bridge or spacer arm between the hapten and the carrier. A spacer arm may 
have the advantage of reducing steric hindrance of the protein molecule on the hapten, 
allowing the hapten to be easily recognised by circulating lymphocytes. A disadvantage of 
a coupling molecule or spacer arm is the possibility of generating an antibody response to 
it. 
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Carrier Protein KLH BSA and cBSA Thyroglobulin Ovalbumin 
Molecular Weight (Da)  4.5 x 105 to 1.3 x 107  67,000  660,000  43,000 
Structure  Large, multi-subunit 
 At physiological pH, exists in 
multi-subunit aggregate states 
 Presence of numerous 
carboxylate groups confers 
BSA with a negative charge 
              
 Large multi-subunit 
protein composed of 
several polypeptide 
chains 
 Phosphoprotein containing 
one N-glycosylation site and 
386 amino acids 
Stability   Increased immunogenicity and 
solubility, when dissociated 
into subunits 
 Highly stable and soluble in 
0.9 M NaCl 
 Should not be frozen or freeze-
thawed 
 Cationisation significantly 
increases pI of protein 
 DMSO may be added to 
solubilise hapten molecules 
 Highly soluble, even after 
extensive hapten 
modification 
 Acidic pI (4.7) due to 
presence of multiple 
carboxylate groups 
 Sensitive to temperature 
(above 56oC), electric fields 
and vigorous shaking 
 Extremely soluble in 
DMSO (70 percent) 
Conjugation 
Requirements 
 High salt concentrations 
required for multi-subunit 
KLH to preserve solubility 
 DMSO may be added to 
solubilise hapten molecules 
 Limited solubility 
 DMSO may be added 
to solubilise hapten 
molecules 
 Care should be taken in 
handling to prevent 
denaturation and 
precipitation 
Functional Group 
Availability (per mole) 
 2,000 amines (lysine residues) 
 700 sulfhydryls (cysteine 
groups) 
 1,900 tyrosines 
 300-600 malemide groups 
(after SMCC* activation) 
 59 lysine ε-amine groups (35 
available) 
 1 free cysteine sulfhydryl (17 
disulphides buried in 
structure) 
 19 tyrosine phenolate 
residues 
 17 histidine imidazole groups 
 Large number of 
tyrosine residues 
 Glycosylated; contains 
8-10 carbohydrates 
 20 lysine residues 
 14 aspartic acids 
 33 glutamic acid groups 
 20 ε-amine groups, N-
terminal amine, 47 side 
chain carboxylates, C–
terminal carboxylate, 4 
sulfhydryl groups, 10 
tyrosine, 7 histidine groups 
Table 1.5.1.1: Properties of carrier proteins for conjugation 
* Succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate 
(Data modified from Hermanson, 2008) 
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A number of coupling strategies have been employed including, carbodiimide-mediated 
synthesis, NHS-ester mediated synthesis and glutaraldehyde-mediated synthesis. 
Carbodiimides are short cross-linking agents which react with carboxylate groups for 
coupling with amine-containing proteins. This results in the formation of an amide or a 
phosphoamidate linkage between a carboxylate and an amine or a phosphate and an 
amine, respectively. Hapten-carrier conjugation can also be carried out using 
homobifunctional reagents, containing NHS ester groups at both ends. The active esters 
are highly reactive to amines on proteins and form stable amide linkages. Crosslinking 
agents of various lengths can be used in this method, including sulfo-NHS ester analogs, 
which are more water soluble. Glutaraldehyde is a homobifunctional crosslinking agent 
that can be used in a one- or two-step conjugation reaction. It can react with primary 
amine groups to form Schiff bases or double bond (Michael-type) addition products. 
Schiff bases can form resonance-stabilised products with ,β-unsaturated aldehydes of 
the glutaraldehyde polymers, which predominate at basic pH. Reduction of the Schiff 
base can yield stable secondary amine linkages (Hermanson, 2008).  
 
Another important consideration is designing the conjugation so that the hapten is 
orientated in the correct manner for proper presentation to the immune system. 
Landsteiner’s principle determines the most suitable point of attachment to link the 
hapten and carrier molecules (Landsteiner, 1990). This law states that antibody 
specificity is directly related to the portion of the hapten molecule furthest away from 
the point of attachment or functional group that is used to link it to the carrier. The part 
of the hapten closest to the point of attachment is sterically hindered by the carrier 
protein. Landsteiner’s principle also states that the carrier protein should be attached at a 
site remote from the point of chemical or metabolic activity. Therefore, in carrying out 
hapten-carrier conjugation, consideration must be given to the reaction group chosen as 
the point of attachment, in addition to the number of reaction groups that are present on 
the hapten. This should result in the exposure of the portion of the hapten most desirable 
for antibody development. Pedersen and colleagues investigated the influence of 
different conjugation ratios and orientations on antibody affinity and titre to haptens 
(Pedersen et al., 2006). This report showed that differing types of molecular orientation 
influenced the antibody titre to the immunised molecule. It also appeared that a lower 
conjugation ratio of peptide to carrier increased the antibody affinity. 
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1.5.1.3 Purification and characterisation of conjugates 
 
Purification of the crude immunogen is essential for a number of reasons. Firstly, it is 
necessary to remove excess reagents and un-reacted starting material, which may cause 
toxicity when injected into an animal, and carrier which may result in a excessive 
carrier-only response. Purification ensures specificity of the immune response to the 
targeted epitope or antigenic determinant on the antigen. Secondly, it is essential for any 
subsequent conjugate characterisation, including determination of the carrier:hapten 
ratio. The most commonly used methods for purification involves initial dialysis and gel 
filtration chromatography, such as Sephadex G25, which is efficient at removing non-
covalently linked material based on size. If the hapten has a characteristic UV or visible 
absorbance spectrum that distinguishes it from the carrier protein, this property can be 
easily used to determine the degree of incorporation to the conjugate. Indirect methods 
can also be used if the reaction involves lysine ε-amino residues, as the extent of 
incorporation can be calculated by the degree of free amino groups remaining on the 
conjugate (Hermanson et al., 2008). Two of the main and most widely used methods for 
conjugate characterisation include nuclear magnetic resonance (NMR) and matrix-
assisted laser desorption time of flight mass spectrometry (MALDI-TOF- MS) (Singh et 
al., 2004). These advanced techniques are capable of unequivocally demonstrating 
effective conjugation. MALDI-TOF-MS has the advantage of also providing 
quantitative information on conjugation ratios. Nuclear magnetic resonance (NMR) has 
the advantage of discriminating between covalently and non-covalently bound hapten.  
 
1.5.2 Hapten and conjugate processing by B-cells 
 
As previously mentioned, most small molecular weight haptens do not provoke a 
significant immune response in animals. These haptens may be capable of binding cell 
surface receptors on B-cells and T-cells, but they are incapable of stimulating a B-cell 
response. Therefore it is necessary to functionalise haptens with large molecular weight 
carrier molecules to promote immunogenicity. The carrier molecule functions to 
stimulate T-helper cells, which cooperate with B-cells to provoke a response to the 
hapten. As shown in Figure 1.5.2.1, one determinant on a protein antigen can behave as 
a hapten in binding to the B-cell, while other determinants promote a carrier function in 
recruiting T-helper cells (Janeway et al., 2001). 
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Figure 1.5.2.1: Processing of antigens by B-cells and TH cells. T-helper cells interact 
with B-cells through antigenic determinants to aid in the response to a protein antigens 
and hapten:carrier conjugates by providing signals via accessory receptors and MHC 
molecules (Adapted from Roitt and Delves, 2001) .  
The requirement for a physical linkage between the hapten and large molecular weight 
protein carrier suggests that T-Helper (TH) cells must recognise the antigenic 
determinants of the carrier on the B-cell in order to provide the relevant accessory 
stimulus. However, T-cells only recognise processed membrane-bound antigen in 
complex with major histocompatibility complex (MHC) molecules. Therefore, TH cells 
cannot recognise native protein antigens or conjugates bound to the B-cell receptors, as 
depicted in simplified scheme in Figure 1.5.5.1. Protein antigens bound to surface B-
cell receptors are internalised to endosomes which fuse with vesicles containing MHC 
class II molecules. Processing of the protein antigen then occurs and the resulting 
antigenic peptide is recycled to the surface in association with the MHC class II 
molecules. These displayed peptides are now available for recognition by specific TH 
cells. Significantly, the carrier portion of a hapten:carrier complex causes the hapten to 
be simultaneously processed for B-cell recognition, leading to the stimulation of TH 
cells and the production of anti-hapten antibodies.  
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1.5.3 Immune response generation and diversification in a leporine host 
 
Rabbit antibodies are widely used in research due to their evolutionary distance of the 
animal from humans and mice, making them ideal for immune response generation to 
conserved antigens, otherwise not recognised by rodents. Rabbits also make very 
suitable hosts for peptides and hapten targets and often exhibit a better immune 
response, compared to mice and other animals (Rader et al., 2000). Unlike rodents and 
other mammals, the generation of diversity in rabbits does not depend on the use of 
many variable gene segments. Most B-lymphocytes produce the same VH gene in the 
V(D)J rearrangement. The advantage of this for recombinant antibody work is that a 
relatively small number of primer sets are required, compared to mice and other 
primates. Li et al. (2000) demonstrated that high-affinity scFv fragments could be 
successfully generated against four different hapten molecules simultaneously, namely 
the herbicides mecoprop, atrazine, simazine, and isoproturon, from a single immunised 
rabbit.  
 
Overall, the organisation of rabbit sequences are similar to that of humans and mice. 
The heavy chain locus of rabbits contains a single gene for the constant region of IgG 
and multiple copies of genes for the constant region of IgA (Mage et al., 1999). 
Combinational diversity is limited in rabbits, as only approximately 100 VH genes are 
known to be rearranged. The main diversification of the primary antibody repertoire is a 
result of somatic hypermutation and gene conversion-like changes of re-arranged VH in 
B-cells, which migrate to the appendix and other gut-associated lymphoid tissues 
(GALT) in young rabbits. The rabbit GALT is seen as the mammalian equivalent for the 
Bursa of Fabricus in chickens. Most rabbit B-cell development, including 
rearrangement and diversification of V genes, occurs early in life. However, some B-
cells in adult rabbits have rearranged VH sequences that are identical or near-identical to 
germ line sequences. Also, in rabbit CH rearrangement, there is a preference for 
expansion of B-lymphocytes that utilise VH1, the first gene in the locus, that is nearest 
to the DH and JH genes (Knight, 1992). This limited diversity means that less primers are  
used in the amplification of rabbit VH genes. There are a three allelic allotypes of the 
VH1 gene, namley a1, a2 and a3 (Figure 1.5.6.1). 
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Figure 1.5.3.1: Development of rabbit B lymphocyte repertoire (Adapted from Mage et 
al., 1999). There are multiple allelic forms of the VH1 gene, known as the VHa allotypes 
(a1, a2 and a3). There are multiple allelic allotypic forms of the rabbit kappa light chain 
(b4, b5, b6, and b9) due to many amino acid differences in the constant regions. 
The rabbit kappa light chain has four different variants (b4, b5, b6 and b9), due to 
amino acid substitutions in the constant regions. At some point in evolution of the rabbit 
ancestor, a duplication in the kappa locus occured, leading to two variants kappa 1, the 
major expressed type and kappa 2, the minor expressed type (Popkov et al., 2003). 
More diversity in the immune repertoire is contributed from the kappa light chain 
regions compared to the heavy chain regions. This is due to the presence of the two 
variants of the kappa locus and also due to germline VK-encoded variability in the 
length of complementarity determining region 3 (LCDR3) (Mage et al., 2006). 
Although, antibody diversity generated by VHDJH rearrangements in rabbits is much 
more restricted than in mice or humans, a significant amount of diversity is obtained 
from VKJK rearrangements. The unique diversification and gene rearrangement features 
of the rabbit make it an excellent choice for recombinant antibody development as it 
combines high specificity with high avidity and affinity. 
 
1.5.4 Immune response generation and diversification in an avian host 
 
Chickens or Gallus gallus domesticus are phylogenetically more distant from other 
mammalian laboratory animals, such as mice and rabbits. Therefore, the use of chickens 
is especially beneficial when generating recombinant antibodies to protein targets. This 
Immunoglobulin Heavy Chain Locus
VHN... VH1 (DH)n (JH)n Cµ Cγ (C)n
N = 100-200 n = 13n ~ 14-20 n =6
Immunoglobulin Light Chain Locus
(VK)n JK CK1 (VK)n JK CK2
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is especially true for mammalian targets, as they are recognised as foreign by the avian 
immune system, thus generating a greater immune response. Birds and mammals 
originated from a common reptilian ancestor and have evolved common immunological 
systems. The bursa of Fabricus, a sac-like structure attached to the proctodeal region of 
the bird’s cloaca (posterior opening) has been shown to be essential for antibody-
mediated immunity. In addition, the avian thymus has a role in cell-mediated immunity 
(Davison, 2008). The mammalian equivalent for the bursa of Fabricus is the bone 
marrow, were B– and T-cell development occurs simultaneously. The division of the 
adaptive immune response into B- and T- cell classes, originated from the early study of 
avian immunology, where the physical separation of antibody-mediated and cell-based 
immunity, allowed for a clear understanding of the functionality of the immune 
response. The term B-lymphocyte is derived from “bursa-derived lymphocyte” in 
honour of the originally investigated avian lymphoid structure. 
 
In humans and mice, the antibody repertoire of B-cells is produced by a process known 
as Ig gene rearrangement. Unlike humans and mice, the VL and JL genes in the antibody 
light chain sequences of chickens only have a single functional copy. Therefore, 
diversity due to VLJL linking is very limited and the effect of VJ rearrangement is 
minimal (Ratcliffe, 2008). Little diversity is generated by the antibody heavy chain 
locus as only single functional copies of the VH and JH genes are present to generate the 
VHDJH rearrangement. Clusters of pseudogenes upstream of the heavy and light chain Ig 
loci have a critical role to play in the generation of chicken antibody diversity. 
Pseudogenes are sequences of nucleotides that probably once were functional but have 
lost the ability to produce a gene product, because they lack the necessary promoter and 
leader sequences. Upstream of the functional variable gene sequences, 80-100 VH 
pseudogenes are present in the IgH locus and 26 VL pseudogenes are present in the VL 
locus (McCormack et al., 1991). There are approximately 16 DH sequences present in 
the IgH locus. An illustration of the development of diversity in the avian immune 
system is shown in Figure 1.5.4.1. 
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Figure 1.5.4.1: Development of avian B-lymphocyte repertoire (Adapted from Fellah et 
al., 2008). The chicken Ig light chain and heavy chain loci only carry a single functional 
variable gene (VL and V1 for the heavy chain) downstream from a cluster of pseudo-
genes. Between the two loci, there are unique JL and JH sequences. Approximately 15 
functional D elements are present on the IgH locus. The 3' ends of the heavy and light 
chain loci contain the constant (C) regions.  
In the process of somatic gene conversion in chickens, which solely occurs in the bursa 
of Fabricus, VH and VL gene sequences are replaced with pseudogene sequences. This 
process creates a high rate of diversity, as there is already substantial diversity in the 
hypervariable regions of the donor V pseudogenes. Therefore, somatic gene conversions 
can accumulate within single functional VH and VL genes. Chicken sequences have the 
unique ability to undergo somatic gene conversion to generate a large antibody 
repertoire, which is comparable to the repertoires of mammals that possess multiple 
functional copies of the VH and VL genes (Davison, 2008). In chicken, somatic gene 
conversion occurs continuously from the late embryonic stage and a mature antibody 
repertoire is formed at around 5-7 weeks, when the bursa is fully developed (Tizard, 
2002). 
Immunoglobulin Light Chain Locus
Pseudo-VL VL
VL  JL
CLJL
Immunoglobulin Heavy Chain Locus
Pseudo-VH V1 DS J Cµ C C
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1.6 Recombinant antibody library generation 
 
Recombinant antibodies, generated through phage display and bio-panning against a 
target of interest (Bradbury and Marks, 2004, Hoogenboom et al., 2005) have been 
utilised for the detection of a range of structurally diverse antigens, including haptens 
(Byrne et al., 2009), cell surface markers (Marty et al., 2006) and proteins (Tully et al., 
2008). Four types of libraries may be used as sources of antibody pools, synthetic, semi-
synthetic, naïve and immune. Synthetic and naїve antibody libraries are non-immune 
sources, derived from natural, rearranged V genes. Naїve libraries, consisting of the 
variable region repertoires can be generated from collections of variable genes from the 
IgM/IgG messenger RNA (mRNA) of B-cells of non-immunised human donors, 
isolated from peripheral blood lymphocytes, tonsils, bone marrow and spleen cells. 
Polymerase chain reaction (PCR) using specific primer sets are used to amplify variable 
regions from IgM and IgG mRNA and these regions are cloned into selection and 
screening vectors (Barbas et al., 1992).  
 
An ideal naїve library should contain a representative sample of the primary repertoire 
of immune systems, although it lacks antibodies with somatic hypermutations produced 
by natural immunisation. Therefore, naïve libraries often yield antibodies with low 
affinity, as they have not undergone somatic mutation or affinity maturation. Synthetic 
libraries are produced by PCR-based randomisation of complementarity-determining 
regions (CDR) from heavy and light chains. CDRs are modified by pre-determined 
levels of mutagenesis. These repertoires are cloned into an antibody domain framework 
and are sub-cloned into a phage display vector to generate a library of 10
7
 – 1010 clones. 
Semi-synthetic libraries can also be created using combinations of natural and synthetic 
sources by selecting one or more antibody frameworks within the CDR loops. The CDR 
loops can be partially or completely randomised using oligonucleotide primers. A high 
level of diversity in composition and length can be achieved, particularly in the CDRH3 
domain, which significantly contributes to antigen binding (Johnson and Wu, 1998). 
 
Immune libraries are constructed from RNA isolated from splenocytes or the bone 
marrow of a host (avian, murine, leporine etc.) immunised with an antigen that 
generates a specific immune response. Immune libraries do not need to be as large as 
non-immune libraries; 10
6-7
 unique and functional scFv clones are sufficient. Antibody 
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fragments isolated from immune libraries will generally be highly specific and have a 
high affinity, due to affinity maturation in the host. The RNA is converted into 
complementary DNA (cDNA), which in turn serves as a template for the amplification 
of variable heavy (VH) and variable light (VL) gene sequences. These are fused through 
an overlapping-extension splicing PCR reaction and subsequently cloned into a suitable 
phage or phagemid vector. The introduction of this construct into suppressor strains of 
Escherichia coli (E. coli) by electroporation, in conjunction with the packaging of 
phage particles via the addition of helper phage (a process referred to as rescuing), 
allows the encoded antibody structure to be ‘presented’ on the exterior of a 
bacteriophage particle. In the phage display technique, the scFv fragments encoded by 
the antibody library are expressed as fusion partners of a coat protein, pIII, on the 
surface of the phage molecule (See Figure 1.6.1).  
 
E. coli is the best choice as host because of its ease of use in transformation and 
manipulation. A number of alternative host options are also available, including 
mammalian, yeast and insect (Verma et al., 1998). A tight control over transcription is 
essential for efficient expression of antibody fragments. The lac promoter system is the 
most commonly used, as it can be readily induced with isopropyl-beta-D-
thiogalactopyranoside (IPTG) and repressed by glucose, if necessary. Bacterially-
expressed protein can be isolated from a number of locations, including the cytoplasm, 
the periplasm and the culture supernatant. Proteins with no signal sequence are 
expressed in the cytoplasm and are known to form aggregates of insoluble protein or 
inclusion bodies, which produces a low expression yield. With the inclusion of an N-
terminal signal sequence, the antibody fragment can be exported to the bacterial 
periplasm (Tudyka and Skerra, 1997). In the periplasmic space, the antibody fragment 
can fold correctly, remain soluble and form intra-domain disulphide bonds, which is 
only possible in the oxidation environment of the periplasm. 
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Figure 1.6.1: Overview of antibody generation strategies. Polyclonal antibodies can be 
isolated from immune serum and monoclonal antibodies can be generated using 
hybridoma technology. In recombinant antibody generation, the genetic material is 
harvested from the host’s lymphoid organs (spleen and bone marrow). The immune 
library can be displayed on the surface of filamentous phage and screened using bio-
panning. 
 
The linker between the variable region domains has to be long enough to span the 
distance from the C-terminal of one domain to the N-terminal of the second domain. It 
has been reported that longer linkers can increase antibody affinity and decrease the 
formation of aggregrates. (Whitlow et al., 2003). The linker can affect domain 
orientation, which influences the conformation and affinity of the binding site. The 
extent of scFv multimerisation is also determined by linker structure and length. The 
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number of advances involving both rational and evolutionary approaches have made it 
possible to produce scFv fragments with improved affinity and stability (Jermutus et al., 
2001; Wörn and Plückthun, 2001). Fragment antigen binding (Fab) antibodies are 
heterodimer structures containing an antibody light chain and the VH and the CH1 
domains of the heavy chain. In general, Fabs are difficult to assemble, have lower yields 
as soluble fragments and are more likely to be unstable in phage, due to the fact that 
Fabs have two protein chains (Barbas et al., 2001). Fabs also have a number of 
advantages; they do not undergo dimerisation, they are more stable and can be 
converted into full length IgG (Guo et al., 1997).  
 
1.6.1 Display Techniques 
 
The development of advanced display techniques has allowed the screening of large 
antibody libraries, leading to selection of an antibody with a desirable trait, for example 
in affinity antibody selection. Display techniques include bacterial (Daugherty et al., 
2007), yeast (Feldhaus and Siegel, 2004; Gai and Wittrup, 2007), mRNA (Gold, 2001; 
Fukuda et al., 2006), phage and ribosomal display. The choice of selection technology 
for a given antibody depends on a number of different parameters, including the 
diversity of the library, the properties of antigen and the intended use. It is desirable to 
have combinational libraries with the maximum functional diversity to increase the 
possibility of finding molecules with the desired function (Benhar et al., 2007).  
 
1.6.1.1 Phage Display 
 
Phage display, first described by Smith (1985), was the first molecular diversity 
selection platform and the forerunner of all subsequent molecular diversity techniques 
(Figure 1.6.1.1). Filamentous phage and phagemid (M13, f1 and fd) are the most 
commonly used for phage display, although T7 and lambda have also been used. 
McCafferty et al. (1990) was the first to use phage display to isolate antibodies from a 
large naïve library. Phage selection involves repeated rounds of growth, panning, and 
infection, which selects for binding of antibody fragments that are expressed on phage. 
Both phage and phagemid vectors can be used for the display of antibodies and other 
proteins on the surface of filamentous phage. Phage vectors are derived from the phage 
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genome and contain a phage origin of replication and genes for assembly of phage 
particles. Phagemid vectors contain a recombinant version of g3p on the plasmid 
(phagemid), which also contains the packaging signal for Ff phage. Phagemids contain 
both phage and phagemid origins of replication, but do not contain an antibiotic 
resistance gene. The phagemid will produce large amounts of the recombinant display 
protein, but it is unable to produce phage without the assistance of helper phage, such as 
M13K07 and VCSM13, which contain mutated or deleted pIII and a defective 
packaging signal for phage replication and assembly. The disabled packaging signal 
does not prevent the helper phage from making phage in bacteria. However, the 
presence of phagemid, which contains the optimal functional packaging signal, results 
in the preferential packaging of the phagemid over the helper phage. Overall, phagemid 
vectors are preferred over phage vectors because of their ease of use, selection of high 
affinity clones with large diversity and the presence of an amber stop codon for soluble 
expression (Bradbury and Marks, 2004). 
 
In phage display, the phagemid vector contains the expression genes which encode the 
phage coat protein to be displayed. Additionally, the 5’ end of the pIII protein is 
required for phage infectivity. It mediates the attachment of the phage to the tip of the 
F’ pilus of E.coli. Therefore, to allow infection with helper phage, the amino terminal 
domain of pIII in the fusion protein expressed by the phagemid vector should be 
deleted. Otherwise, the phagemid pIII would make the cell immune to super-infection 
with helper phage. A truncated pIII, consisting of the carboxyl terminal alone serve as a 
fusion partner for the displayed scFv. This mutant pIII can mediate the incorporation of 
the fusion protein into the phage coat, without producing immunity to helper phage 
infection. 
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Figure 1.6.1.1: Recombinant antibody phage display. Bio-panning, utilising conjugated 
antigen, immobilised on solid phase and repeated cycles of enrichment. 
 
Phage display is accomplished by fusing the antibody library to the N-terminus of either 
the minor coat protein (pIII) or the major coat protein (pVIII) of filamentous 
bacteriophages. Approximately 2,700 copies of pVIII are displayed per virion, while 
only 3-5 copies of pIII are displayed. The small number of copies per virion for pIII is 
used to great advantage for displaying large polypeptides and monovalent display 
allows for selection of high affinity clones, as avidity is not an issue (Kirsch et al., 
2005). pIII is the phage protein involved in bacterial infection and is responsible for 
binding to the F pilus. It has a tripartite structure consisting of three domains, separated 
by glycine-rich regions (Lubkowski et al., 1998). Expression of these fusion proteins in 
bacteria results in the incorporation of the antibody fragment into the mature phage coat, 
which is then displayed on the phage surface. Importantly, the genetic material that 
relates to the antibody fragment is still contained within the phage genome. This link 
between antibody genotype and phenotype allows for isolation of antigen-specific 
phage antibodies using immobilised antigen in the bio-panning process. Bound phage 
are eluted, re-infected into bacteria and re-grown for the next round of selection, 
resulting in enrichment of the phage pool. 
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Bio-panning (Figure 1.6.1.1) is used for the selection of binders from an antibody 
library which may contain between 10
7
 and 10
10
 different antibody-encoding gene 
sequences. In bio-panning, the antigen is immobilised onto a solid phase (e.g. on a 
column or immunotube) or bead-conjugated (in solution phase) and the antibody pool is 
subjected to recurrent rounds of selection against the antigen with increasing levels of 
stringency in terms of binding ability. Selected binders are retained and subjected to 
additional screening to increase their specificity for the target (affinity maturation), 
which can be monitored by ELISA-based analysis. Following selection, the phage 
particles can be infected into a non-suppressor strain of E.coli, such as Top10F' or 
HB2151 for soluble expression. These hosts recognise the amber (AUG) codon 
engineered between the scFv and gIII gene (Hoogenboom et al., 1991) producing scFv 
or Fab fragments independent of the phage coat proteins. 
 
1.6.1.2 Isolation and affinity maturation of toxin-specific antibodies 
 
A number of technological advances have made detection of hazardous toxins and 
organism faster and more reliable. Nucleic acid and immunosensor-based identification 
of hazardous microorganisms and their products, including antigens and toxins, have 
wide applications in testing of food, clinical and environmental samples. In order to 
develop an effective and applicable detection system for specific identification, the 
assay system must work on the requisite or ‘real’ sample. Immunological detection 
methodologies have been successful in the sensitive detection of bacterial cells, spores, 
viruses and toxins in the environment (Leonard et al., 2003; Byrne et al., 2009). 
Production of polyclonal or monoclonal antibodies requires continuous maintenance of 
animals or cultures of hybridomas, respectively. For both approaches, the life span of 
the animal and subsequent maintenance through a course of immunisations and 
bleedings is costly and time-consuming. Phage display has proven invaluable in 
selecting high affinity antibodies specific for toxins. Current detection methodologies 
for biological threats, including the use of phage display for toxin biosensors, have been 
widely reviewed (Iqbal et al., 2000; Petrenko and Vodyanoy, 2003; Petrenko and 
Sorokulova, 2004).  
 
For example, mRNA from mice immunised with botulinum neurotoxin was employed 
in the successful generation of a recombinant antibody library with a repertoire of 
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binding specificities. The combinatorial library was biopanned to select and isolate 
phage displayed antibodies that specifically recognised botulinum neurotoxin (Emanuel 
et al., 1996). These recombinant antibodies demonstrated a high affinity to the 
neurotoxin (0.9 –7 nM) and were superior to the related monoclonal antibody when 
analysed by surface plasmon resonance, flow cytometry, enzyme-linked immunosorbent 
assay (ELISA) and immunochromatographic assay (Emanuel et al., 2000). Phage 
display was also used to isolate anti-botulinum toxin scFvs with affinities in the 
nanomolar range from very large non-immune human library (Sheets et al., 1998). 
 
A commercially available phage peptide library (NEB) was employed to isolate phage 
specific for anthrax toxin and staphylococcal enterotoxin B (SEB), a toxin associated 
with food poisoning, (Goldman et al., 2000; Mourez et al., 2001, respectively). This 
combinational library consists of random peptides (12-mer) fused to the minor coat 
protein (pIII) of M13 phage. Mourez et al. (2001) panned the library on a cleaved 
heptamer of protective antigen (PA), which is responsible for binding and 
internalisation of the two different forms of anthrax toxin, lethal toxin and edema toxin. 
They subtractively panned on intact PA to avoid peptides that recognised the 
unprocessed protein. Goldman et al. (2000) labelled the phage particles, expressing the 
12-mer of an anti-SEB clone, with fluorescent tags and incorporated it into an 
immunofluorescence assay using the RAPTOR fiber-optic biosensor. Moghaddam et al. 
(2001) screened two phage antibody libraries, including a human lymphocyte antibody 
library and the semi-synthetic antibody library, against aflatoxin B1, conjugated to BSA 
and soluble aflatoxin B1. The isolated scFvs were specific for the conjugate molecule 
and were unable to bind soluble aflatoxin B1. A variation in the elution strategy, 
involving a switch from triethylamine elution to competitive elution with free aflatoxin 
B1 for 16 hours, resulted in the isolation of scFv with specific binding to soluble 
aflatoxin B1 with high affinity. Ma et al. (2006) constructed a number of cyclic peptide 
libraries, where the random amino acid sequences were surrounded by cysteine 
residues, which formed disulfide loops. These libraries were biopanned against 
Clostridium botulinum neurotoxin, resulting in the isolation of a single clone specific 
for neurotoxin A, while not binding other botulinum neurotoxins. Although 
recombinant antibody technology has allowed for the isolation of antibodies to almost 
any type of antigen, it remains difficult to obtain high affinity antibodies to certain rare 
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haptens. Either very large libraries have to be constructed or stringent selection 
strategies need to be employed, incorporating affinity maturation of isolated antibodies. 
1.7 Toxins and their occurrence in nature 
1.7.1 Azaspiracid Shellfish Poisoning  
 
Single-celled microalgae or phytoplankton have an important role in the aquatic 
environment. They provide nourishment for a large quantity of heterotrophic marine 
animals, including filter-feeding bivalve molluscs such as mussels, clams and scallops. 
Among the reported 5,000 species of marine phytoplankton, 300 have been shown to 
occur in high numbers causing algal blooms or ‘red-tide’ events. Of these 300 species, 
there are approximately 40 which have been shown to produce potent toxins as 
secondary metabolites, known as phycotoxins (Sournia et al., 1991). Algal blooms 
occur due to mass proliferation of phytoplankton in localised regions that have become 
temporarily rich in inorganic nutrients, such as nitrogen, phosphorus and iron. Most 
algal blooms are harmless, but if a bloom of toxic microalgae occurs, toxins are released 
to the aquatic marine environment. Blooms of toxic algae are also known as harmful 
algal blooms or HABs. HABs pose a threat to human health because of their potential to 
cause respiratory, neurological and gastrointestinal problems, including mortalities, at 
very low toxin concentrations. They also pose a threat to coastal economies and the 
shellfish industry. Lengthy port closures due to bloom events, reduced tourist activity 
and costly monitoring programs all contribute to economic losses.  
          
Phycotoxins include a variety of toxins from different phytoplankton groups. 
Phycotoxins are low molecular weight, non-proteinaceous compounds. They vary 
widely in their physical properties, chemical structure and toxic mechanisms. The type 
of poisoning and, therefore, the phycotoxin groups are classified according to the 
associated symptoms: paralytic shellfish poisoning (PSP), neurotoxic shellfish 
poisoning (NSP), amnesic shellfish poisoning (ASP), diarrhetic shellfish poisoning 
(DSP), and azaspiracid shellfish poisoning (AZP) associated with shellfish; and 
ciguatera poisoning associated with finfish. Health concerns have been raised around 
shellfish and fish poisoning which have been caused by different types of phycotoxins. 
A number of countries have established regulations and specific concentration limits to 
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monitor the levels of these phycotoxins in seafood (Van Egmond, 2004). AZP will be 
discussed in detail for the purpose of this research study. 
 
1.7.1.1  Cases and outbreaks of azaspiracid poisoning (AZP) 
 
Azaspiracids (AZAs) were first identified in 1995 in the Netherlands as a result of the 
consumption of mussels (Myltilus edulis) cultivated in Killary Harbour in Ireland 
(Satake et al., 1997). Similar mussel toxicity was recorded in Donegal in 1996, followed 
by a reoccurrence in 1998 (McMahon and Silke, 1996; 1998). Since these toxic events, 
AZA was isolated and characterised from shellfish as AZA-1 (Satake et al., 1998) and 
subsequently structurally revised (Nicolaou et al., 2006a, b, c).  AZA toxin outbreaks 
have since been identified in several parts of the world. However, the problem poses a 
major threat to the Irish shellfish industry, due to the re-occurrence of toxin outbreaks. 
In the past, detection has proven inaccurate due to massive underestimation of AZA 
concentrations in shellfish with the analytical tests currently in use (EFSA, 2008). 
Regulatory laboratories, public health laboratories and the aquaculture industry are 
demanding the ability to monitor for the presence of AZA toxin at very low 
concentrations. This would mean contaminated beds could be closed long before the 
toxin concentrations would be high enough to pose significant health threats to the 
consumer. Extensive studies on AZA have been limited by the poor availability of 
purified material. Certified reference material (CRM) has now become available in 
small quantities (Perez et al., 2010). Reference materials are simple mixtures, solutions 
or complex natural materials that have been collected and homogenised to provide a 
stable, representative matrix for proper evaluation of analytical techniques. Presently, 
reference standards and reference materials are not available or are in short supply for 
most toxin groups.  
 
1.7.1.2  Chemical structure and properties of AZP toxin 
 
Symptoms of AZP are closely related to diarrhetic shellfish poisoning (DSP) symptoms 
and AZP was initially classified as DSP (Satake et al., 1997). AZA was subsequently 
discovered to be a nitrogen-containing polyether toxin with a unique spiral ring 
assembly, a cyclic amine and a carboxylic acid (Satake et al., 1998) with a unique mode 
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of action (Ito et al., 2000). Therefore, AZP was re-classified into its own group. The 
structure which was reported in 1998 was found to contain an error, after attempts were 
made to synthesise the molecule in 2003 (Nicolaou et al, 2003 a,b). The product of this 
synthesis was found to have a different chromatographic pattern and differences in its 
nuclear magnetic resonance (NMR) spectrum, compared to naturally sourced 
compound. Further extensive research and analysis by NMR resulted in a revised 
structure (Nicolaou et al., 2006 a,b,c) (Figure 1.7.1.1). 
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Figure 1.7.1.1: Molecular structure of azaspiracid-1 
After the AZA-1 structure had been definitively characterised, four different analogs 
were identified, isolated and their structure determined using MS and NMR techniques 
(Ofuji et al., 1999; Ofuji et al., 2001). Three of these analogs differ only in the number 
of methyl groups. In comparison to AZA-1, AZA-3 is lacking the methyl group at C22 
and AZA-2 has an additional methyl group at C8 (Figure 1.7.1.1). The other two 
analogs of the toxin (AZA-4 and AZA-5) are hydroxyl analogs of AZA-3, having an 
additional OH group at either C3 (AZA-4) or at C23 (AZA-5). Only AZA 1-5 have 
been preparatively isolated, with their structure confirmed using NMR techniques. 
Structure elucidation of other analogs has relied on the analysis of fragmentation 
patterns of their respective MS/MS spectra. To date, 27 analogs to AZA have been 
identified, as reviewed by Rehmann et al. (2008).  
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1.7.1.3 Source organisms for AZP 
 
One of the major controversies surrounding AZP is the origin of the associated toxin. 
Studies on the seasonal and episode accumulation of azaspiracid in filter-feeding 
bivalve molluscs, especially the mussels Mytilus edulis, have always suggested a 
plankton source. Much research has gone into establishing a clear and definitive link 
between AZA toxins in shellfish and their planktonic source. Structural homology 
studies between AZA and other lipophilic phycotoxins indicated a dinoflagellate source 
(Satake et al., 1998). The heterotrophic dinoflagellate, Protoperidinium crassipes was 
proposed as the causative organism on the basis of micropipette isolation and pooling of 
cells, followed by confirmatory analysis by liquid chromatography coupled to mass 
spectrometry (LC–MS) (James et al., 2003). However, surveys carried out by the Irish 
Marine Institute failed to show any correlation between occurrence of AZA in shellfish 
and blooms of P. crassipes or other Protoperidinium species during a four year 
monitoring period along the Irish coast (Moran et al., 2005). Work in other countries, 
including Norway and the UK also has failed to support any clear association with this 
organism. Gribble et al. (2007) reported that little correlation between the occurrence of 
Protoperidinium spp. in plankton and azaspiracids in shellfish existed. Tillmann et al. 
(2009) definitively identified Azadinium spinosum spp. as the primary producer of 
azaspiracid toxins. 
 
1.7.1.4 Occurrence and accumulation of AZP in seafood 
 
Polyether toxins are known to concentrate in the digestive glands or hepatopancreas of 
shellfish. However, azaspiracid and its methyl- and demethyl-analogues, AZA2 and 
AZA3, respectively, are not confined to the hepatopancreas but are also distributed 
throughout shellfish tissues. Toxin profiles for AZA in different mussel tissues have 
been shown to differ significantly, with AZA-1 as the predominant toxin in digestive 
glands (James et al., 2002a). Mussel digestive glands initially contain most of the 
azaspiracid content due to grazing on toxic dinoflagellates. However, the transport of 
AZA to other tissues in the shellfish may cause a prolonged period of shellfish 
intoxication due to the low rate of natural depuration of AZA. Azaspiracids have shown 
an unusual solvent distribution during the extraction procedure, leading to the 
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suggestion that the polar amino acid and the non-polar polyether regions of the 
molecule confer unique properties to AZA (James et al., 2004). This may explain how 
azaspiracid moved though different polarities and how it can penetrate different tissues 
of shellfish and mammals. 
 
Detailed global surveys on the bio-geographical distribution of AZA toxins have not 
been conducted, but AZA contaminated mussels have been found on the east coast of 
England and along the Norwegian west coast (James et al., 2002b). Following its initial 
identification and confirmation of AZA-1 as the cause of human poisoning events, other 
cases of intoxication from consumption of mussels from Ireland, France and Italy were 
also attributed to AZP (Magdalena et al., 2003; James et al., 2004). The European 
Commission have set the maximum permitted level of AZP toxins in bivalve molluscs, 
echinoderms, tunicates and marine gastropods, to 160 µg/kg in 2002.  
 
1.7.1.5 Toxicological studies for AZP 
 
Human consumption of AZA-contaminated shellfish can result in severe acute 
symptoms that include nausea, vomiting, diarrhoea and stomach cramps. Due to a 
limited amount of data available for AZP events, most information on AZA toxicity has 
derived from in vitro and in vivo toxicological experiments. All symptoms appear 
within hours of ingestion and persist for 2-3 days. However, little is known about the 
effects of long term exposure to AZA, as all work has focused on acute effects. Also, 
given the EU regulatory limit of 160 µg/kg of shellfish meat, production sites have 
remained open where AZA contamination levels have remained below this level, 
resulting in marketing and consumption of contaminated produce throughout Europe.  
 
Considerable work was carried out to understand the mode of action of AZA in 
mammalian models from studies using purified toxin (Twiner et al., 2008). In vivo 
studies in mice showed that AZA-1 caused acute necrosis of the lamina propria of the 
small intestine and chronic damage to lymphoid tissues (Ito et al., 2002). Furthermore, 
AZA-1 decreases F-actin concentrations on a cellular level (Román et al., 2002) and 
causes teratogenic effects in Japanese rice fish (medaka) embryos (Colman et al., 2005). 
It has also been shown to be cytotoxic to several cell types (reviewed by Twiner et al., 
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2005) and it also modulates calcium concentrations in human lymphocytes (Alfonso et 
al., 2005). On the neuronal level, AZA-1 inhibits bioelectrical activity of spinal cord 
neuronal networks (Kulagina et al., 2006) and also decreases neuronal viability (Vale et 
al., 2007). 
 
1.7.2 Cyanobacterial poisoning 
 
Cyanobacteria (blue-green algae) are photo-autotrophic micro-organisms which are 
found in both terrestrial and aquatic environments. In many parts of the world, surface 
water is used as the drinking water supply and its quality can be variable. In developed 
countries, the water is treated by filtration in water treatment and purification plants. 
Conventional water treatment plants use flocculation, precipitation, sand filtration and 
chlorination, however, this is not enough to remove cyanobacterial toxins from water 
supplies with high levels of eutrophication. A key factor for cyanobacterial 
decontamination in water treatment plants is the removal of both cell-bound and 
dissolved toxins. Cyanotoxins can be released during water treatment processes as a 
result of mechanical and chemical stress factors (Schmidt et al., 2002). Removal or 
degradation of cyanotoxins can also occur naturally by the action of bacteria or sunlight 
(Shephard et al., 1998). However, in less developed areas, sophisticated water treatment 
plants are unavailable and people have to rely on untreated water. Cyanobacteria are a 
normal part of the phytoplankton of surface waters, but if they are present in sufficient 
quantities, they may pose a threat to consumers.  
 
Cyanotoxins are resistant to boiling and have the ability to pass through conventional 
water treatment facilities. In clean, oligotrophic lakes and rivers, the concentration of 
cyanobacteria is low and a range of species may be present at any given time. The 
cyanobacterial cell population is limited due to the lack of nutrients, particularly 
phosphates. As nutrient activity increases through human activity, including intensive 
agriculture and waste disposal, the cyanobacterial population rises rapidly. The 
condition of the freshwater is now described as eutrophic, where there are sufficient 
nutrients to support a large population of phytoplankton. The key factor which allows a 
particular species of cyanobacterium to become dominant is the ability to produce 
toxins. Cyanobacteria are the primary food source for organisms in freshwater. Toxin 
producers are given a competitive advantage by suppressing consumption, allowing the 
49 
 
toxic species to outgrow non-toxic phytoplankton. Globally, the most frequently found 
cyanobacterial toxins, in blooms from fresh and brackish waters, are the cyclic peptide 
toxins of the microcystin and nodularin family. They pose a major challenge for the 
production of safe drinking water from surface waters containing cyanobacteria with 
these toxins. 
 
1.7.2.1 Cases and outbreaks of cyanobacterial poisoning 
 
Microcystin contamination in water has led to fatalities in both wild and domestic 
animals worldwide and has been associated with human illness. There are several 
reports of animal and human deaths due to the consumption of water contaminated with 
cyanobacterial heptatoxins (Azevedo et al., 2002; Falconer and Humpage, 2005). 
Human poisoning associated with cyanobacterial poisoning in drinking water has been 
identified in Europe, Brazil, Africa, Australia and the US, although many cases remain 
unreported. This is due to the fact that cyanobacterial poisoning is primarily associated 
with vomiting, diarrhoea, a tender abdomen and headache, which are also the symptoms 
of common viral, bacterial and protozoal gastrointestinal illnesses. Therefore, poisoning 
events may often go unreported for medical diagnosis or treatment. Poisoning events are 
only reported when a substantial number of individuals are affected in a population and 
no infectious diseases have been found. Testing for cyanobacterial agents will only take 
place when other eventualities, such as heavy metal poisoning or industrial or 
agricultural chemicals, have been eliminated.  
 
In 1989, a direct case of poisoning from exposure to Microcystis aeruginosa scum was 
reported in the UK. Twenty army recruits who carried out exercises in a reservoir in 
Staffordshire became ill with malaise, vomiting, sore throat, dry cough and pneumonia. 
In 1996 in Brazil, a major disaster occurred in a dialysis clinic, affecting 131 patients, 
who had received dialysis over the course of one week. Dialysis patients are particularly 
vulnerable to soluble, low molecular weight chemicals in the water supply, as 120-150 
litres can be used in the treatment of one patient. Of the 131 patients, 76 died due to 
liver failure (Azevedo et al., 2002). The water supply originated from the Tabocas 
reservoir, which had a history of cyanobacterial poisoning. Most reported cases of 
human injury have been reported for drinking water supplies, therefore it is clear that 
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safe drinking water guidelines are essential. Another exposure route for microcystins is 
through contaminated food supplies, such as shellfish. Cyanobacterial toxins can 
accumulate in some species of mussel (Vasconcelos, 1995) and there is some evidence 
for the concentration of microcystin in fish (Carbis et al., 1997). 
 
1.7.2.2 Chemical structure and properties of the cyanobacterial toxin, microcystin 
 
Microcystins contain five constant amino acids, namely, ᴅ-alanine, ᴅ-methylaspartic 
acid, Adda, ᴅ-glutamic acid and N-methyldehydroalanine, as well as two variable L-
amino acids (Figure 1.7.2.1). The unique Adda or (2S,3S,8S,9S)-3-amino-9-methoxy-
2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid is a β-amino acid. Microcystins are 
named according to the variable amino acids at position X and Y. Microcystin-LR 
contains the amino acids leucine (L) and arginine (R) at these positions. Currently, over 
90 variants of microcystin have been identified and characterised and differ according to 
their toxicities (Falconer and Humpage, 2005). The different toxicities of the variants of 
microcystin provide some insights into the mechanism of their toxic effect. The most 
toxic of the microcystins are those with more hydrophobic L-amino acids, for example 
microcystin-LR, -LA, -YM and –YR, with the hydrophilic microcystin-RR being less 
toxic (Gupta et al., 2003). Loss of the methyl group from the ᴅ-methyl aspartic acid or 
from the methyldehydroalanine reduces toxicity roughly by half. The Adda group is 
also crucial for toxicity, as proven by removal or saturation of the group (Harada et al., 
1990). 
 
Microcystin-LR is the most common variant in cyanobacteria, although it is common to 
find more than one in a strain of cyanobacterium. The similar cyclic pentapeptide, 
nodularin contains arginine, glutamic acid, β-methyl aspartic acid, N-
methyldehydroalanine and Adda. Therefore, nodularins are structurally similar and 
exhibit similar toxicities to microcystin. The toxins act by inhibiting the serine and 
threonine protein phosphatases 1 and 2A, which are essential for many cell regulatory 
processes, such as growth, protein synthesis, glycogen metabolism and muscle 
contraction (Falconer and Humpage, 2005). The Adda group is essential for binding of 
the toxin to the phosphatase structure via highly specific, covalent bonding. Adda also 
provides microcystins and nodularins with a characteristic absorption wavelength at 238 
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nm due to the presence of a conjugated diene group in the long carbon chain. This 
special property provides a means of analysis for microcystin, especially for reverse 
phase chromatography.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Microcystin 
Variant  
X Y R1 R2 R3 
MC-LR  Leu Arg CH3 CH3 H 
MC-LW  Leu Trp CH3 CH3 H 
MC-LF  Leu Phe CH3 CH3 H 
MC-LA  Leu Ala CH3 CH3 H 
MC-RR  Arg Arg CH3 CH3 H 
MC-YR  Try Arg CH3 CH3 H 
 
Figure 1.7.2.1: Microcystin structure and derivatives: Microcystin-XY: X and Y 
represent the one-letter abbreviations of the variable amino acids 2 (X) and 4 (Y). R1 to 
R3 represent variations in the methyl group position. At least 80 microcystin variants 
have been identified and MC-LR, MC-LW, MC-LF, MC-LA, MC-RR and MC-YR 
represent the most abundant. Microcystins also consist of a ᴅ-alanine (Ala); ᴅ-erythro β-
methylaspartic acid (MeAsp); (2S,3S,8S,9S)-3-amino-9-methoxy-2,6,8-trimethyl-10-
phenyldeca-4,6-dienoic acid (Adda); iso-linked ᴅ-glutamic acid (Glu) and N-methyl 
dehydroalanine (Mdha).  
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1.7.2.3 Source organisms for the production of microcystin 
 
The cyanobacteria are ancient organisms, having been identified from rocks dating from 
the first thousand million years of the earth’s history. As colonies of cyanobacteria 
occur in shallow water, they appear in the fossil record in sedimentary rocks deposited 
in shallow seas and lakes. Cyanobacteria are photosynthetic prokaryotes, which possess 
a single circular chromosome, which has been completely sequenced in several species 
(Kaneko et al., 1996). Their photosynthetic membranes contain chlorophyll-a and the 
pigment phycocyanin, which produces the characteristic blue-green colour of many 
species. Nitrogen fixation is an important feature of many species of cyanobacteria. 
Cyanobacterial poisoning is caused by the hepatotoxins microcystin and nodularin, 
during bloom events. They are produced by several genera of cyanobacteria including 
Microcystis, Anabaena, Nostoc, Anabaenopsis, Hapalosiphon and Planktothrix 
(Oscillatoria) (Carmichael, 1997) (Figure 1.7.2.2). Toxin-producing species are also 
seen in other groups besides phytoplankton and cyanobacteria, including raphidophytes, 
diatoms and prymnesiophytes. 
 
 
Figure 1.7.2.2: Photomicrographs of toxic species of cyanobacteria. A.) Microcystis 
aeruginosa B.) Anabaena circinalis C.) Planktothrix species D.) Nodularia spumigena 
(Images courtesy of Google Images). 
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Toxic water blooms of Microcystis have been reported widely across the world, 
associated with livestock, pet and wildlife deaths, as well as human injury through 
drinking water and food sources. Bishop et al. (1959) first isolated the “fast-death 
factor” from M. aeruginosa in culture. The first structural determination for microcystin 
was carried out on toxin samples from South Africa and Australia, using Fast Atom 
Bombardment Mass Spectrometry (FABMS) and NMR techniques at Cambridge 
University. The toxins were purified by ammonium bicarbonate extraction of cell 
homogenates, followed by multi-step column fractionation using Sephadex G-50 and 
DEAE cellulose (Botes et al., 1984). Once the structure of microcystin was elucidated, 
the structures of four further variants were published (Botes et al., 1985). 
 
1.7.2.4 Occurrence and accumulation of microcystins in freshwater 
 
Incidences of animal and human fatalities resulting from microcystins have led to the 
implementation of guideline values for drinking water by the World Health 
Organisation (WHO, 1998). The threat of microcystins was examined in detail by an 
expert group, who determined a provisional “guideline value” for microcystin-LR at 1 
µg/L. This estimation was based on sub-chronic toxicity to rodents and pigs in the 
absence of sufficient data for carcinogenesis and teratogenesis. To minimise the danger 
to human health through exposure to microcystins, there is an urgent requirement for 
sensitive and reliable methods, capable of detecting these hepatopeptides in a wide 
variety of sample matrices. Increased awareness of the risks associated with 
microcystins has led to the development of a number of methods for their detection and 
quantification, ranging from biological-based screening methods to more sophisticated 
analytical techniques. Recently, routine sample screening using the mouse bioassay has 
been replaced with more sensitive and reliable assay methods such as enzyme-linked 
immunosorbent assay (ELISA; Nagata et al., 1995; Metcalf et al., 2000), and the 
protein phosphatase assay (Ward et al., 1997). Detection methodologies for microcystin 
are reviewed in detail in section 2.3.1 
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1.7.2.5 Toxicological studies for microcystins 
 
The toxicity of microcystins is caused by the inhibition of serine/threonine protein 
phosphatases 1 and 2A (MacKintosh et al., 1990), which leads to hepatocyte necrosis 
and hemorrhage (Bhattacharya et al., 1997). Hepatotoxins, such as microcystin, induce 
massive haemorrhage and disruption in the mammalian liver (Falconer et al., 1983) and 
they have also been known to affect the kidneys (Milutinovic et al., 2002). Microcystins 
induce apoptotic effects in mammals (Fladmark et al., 1999; Mankiewicz et al., 2001) 
and morphological changes include membrane budding, cell shrinkage and organelle 
redistribution in human and rat cells (McDermott et al., 1998; Mankiewicz et al., 2001). 
Microcystins promote tumour precursor production, particularly in the liver, and 
research from southern China has demonstrated a link to human liver carcinoma (Yu et 
al., 1995). Microcystin was also implicated in the occurrence of liver and colorectal 
cancer (Hernández et al., 2009). 
 
1.7.3 Mycotoxin poisoning 
 
Mycotoxins are secondary metabolites of moulds that exert toxic effects on animals and 
humans. The toxic effect of mycotoxins on animal and human health is referred to as 
mycotoxicosis, the severity of which depends on the toxicity of the mycotoxin, the 
extent of exposure, age and nutritional status of the individual and possible synergistic 
effects of other chemicals to which the individual is exposed. The chemical structures of 
mycotoxins vary considerably, but they are all relatively low molecular mass organic 
compounds. Mycotoxins have significant economic impacts in a number of crops, 
especially wheat, maize, peanuts and other nut crops, cottonseed, and coffee. The Food 
and Agriculture Organization has estimated that 25% of the world’s crops are affected 
by mycotoxins each year, with annual losses of around 1 billion metric tons of foods 
and food products. Aflatoxins are secondary fungal metabolites produced by strains of 
Aspergillus flavus and A. parasiticus. They are structurally related difuranocoumarin 
derivatives (Figure 1.7.6.1), incorporating the aflatoxin, trichothecenes, fumonisin and 
ochratoxin subgroups. 
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There are four major aflatoxin isoforms associated with food contamination: aflatoxin 
B1, B2, G1 and G2. Aflatoxin B1 (AFB1) and B2 (AFB2) are produced by A. flavus, while 
all four isoforms are produced by A. parasiticus (Creppy, 2002). Due to widespread 
incidence of Aspergillus contamination, aflatoxin can be found in a variety of 
foodstuffs, including cereals (maize, wheat, rice, sorghum, millet), nuts (pistachios, 
brazil, peanuts, walnuts, coconuts), spices (chili, turmeric, paprika, black pepper, 
ginger), dried fruit, and seeds (Pitt, 2000; Williams et al., 2004). Trichothecenes are a 
group of mycotoxins which represent a number of different entities, all containing the 
trichothecene nucleus and are produced primarily by the Fusarium genus and also 
Myrothecium, Trichothecium, Stachybotrys, and Cephalosporium.  
 
Toxicity generally occurs when a number of different trichothecene toxins are 
consumed simultaneously from mouldy cereal grains. Fumonisins are mycotoxins 
produced by Fusarium verticillioides (formerly known as F. moniliforme) and several 
other Fusarium species. Corn products contaminated with F. verticilliodes are 
responsible for agriculturally significant diseases in horses and swine (ICPS, 2000) and 
are currently being evaluated to determine the possible threat they pose to public health. 
Corn pests cause damage to the developing grain, which enables spores of the toxin-
producing fungi, Fusarium, to germinate. The fungus then proliferates, which leads to 
ear and kernel rot and the production of potentially hazardous levels of fumonisins. 
Another mycotoxin produced by some Fusarium species is zearalenone. Zearalenone 
can occur in corn, barley, wheat, hay, and oats as well as other agricultural 
commodities. Zearalenone consumption can decrease the reproductive potential of farm 
animals, especially swine. Ochratoxin A is primarily produced by Aspergillus 
ochraceous, A. carbonarius, and Penicillium verrucosum and human exposure occurs as 
the result of contamination of small grains (barley, wheat and corn), coffee beans and 
grapes. 
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1.7.3.1 Cases and outbreaks of mycotoxin poisoning 
 
Within the last decade, numerous outbreaks of mycotoxicoses have been reported 
worldwide. In 2004, 125 people died following a major outbreak of aflatoxicosis in the 
eastern and central provinces of Kenya. Three hundred and seventeen cases were 
reported, and most were linked to aflatoxin poisoning from contaminated maize. In 
2005, more than 75 dogs died in the United States after consuming pet food 
contaminated with aflatoxins, and hundreds more experienced severe liver problems 
associated with the intoxication. There have been many reported cases of trichothecene 
toxicity in farm animals and a few in humans. One of the well-known cases of 
presumed trichothecene human toxicity occurred in Russia during 1944 in Orenburg, 
Siberia. Disruption of agriculture caused by World War II resulted in millet, wheat, and 
barley being overwintered in the field. Consumption of these commodities resulted in 
vomiting, skin inflammation, diarrhoea, and multiple haemorrhages, among other 
symptoms. About 10% of the population was affected and mortality rates were high at 
60% in some countries. The causative agent was subsequently identified as alimentary 
toxic aleukia (ATA) (CAST, 2003). 
 
1.7.3.2 Chemical structure and properties of aflatoxins 
Four major aflatoxins: aflatoxin B1, B2, G1, G2 and two additional metabolic products, 
M1 and M2 are significant contaminants in foods and feed stocks. The aflatoxins M1 and 
M2 were first isolated from milk of lactating animals fed aflatoxin preparations; hence, 
the M designation. The B designation of aflatoxins B1 and B2 resulted from the 
exhibition of blue fluorescence under UV light and the G designation refers to the 
yellow-green fluorescence of the relevant structures under UV-light. These toxins have 
closely similar structures and form a unique group of highly oxygenated, naturally 
occurring heterocyclic compounds (Figure 1.7.6.1). Aflatoxins B2 and G2 were 
established as the dihydroxy derivatives of B1 and G1, respectively, whereas, aflatoxin 
M1 is 4-hydroxy aflatoxin B1 and aflatoxin M2 is 4-dihydroxy aflatoxin B2 (Fratamico et 
al., 2005).  
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                     Aflatoxin B1                                                Aflatoxin B2 
 
 
 
 
 
 
                       Aflatoxin G1                                              Aflatoxin G2 
 
 
 
 
 
 
                                                       
Fumonisin B1 
 
 
Figure 1.7.3.1: Structures of commonly-occurring aflatoxins: Aflatoxin B1,                        
Aflatoxin B2, Aflatoxin G1, Aflatoxin G2 and Fumonisin B1. 
 
1.7.3.3 Occurrence and accumulation of aflatoxins 
 
Mycotoxin contamination occurs during harvest time or during storage of food. 
Exposure to low levels of the mycotoxins through ingestion of the mouldy foods is 
common, depending on geographic location and type of food. Aflatoxins often occur in 
crops in the field prior to harvest. Postharvest contamination can occur if crop drying is 
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delayed and during storage of the crop if water is present. Insect or rodent infestations 
facilitate mould invasion in stored commodities. The most widely occurring 
contamination from aflatoxins is from Aspergillus species in stored grain, ochratoxin A, 
produced by Aspergillus and Penicillium in moulds, and zearalenone, a mycotoxin 
produced by Fusarium and Gibberella species (Al-Anati and Petzinger, 2006). 
Mycotoxins contamination can occur in a variety of plants used as food, including 
commodities such as cereal grains (barley, corn, rye and wheat), coffee, dairy products, 
fruits, nuts, peanuts, and spices. Contamination can also arise in animal products, in 
which animals consume contaminated feeds (e.g., milk). However, commodities such as 
cereal grains are eaten in the greatest quantities, therefore, the mycotoxins present in 
these foods represent the greatest risk (Cousins et al., 2005).  
 
Moulds can be divided into two main groups: field fungi and storage fungi. The field 
fungi group contains species that proliferate under field conditions and do not multiply 
readily once grain is in storage. Field fungi may be superseded by storage fungi if there 
is sufficient moisture and oxygen conditions. However, the presence of a toxigenic 
mould does not guarantee the presence of a mycotoxin, which occurs only under certain 
conditions. Furthermore, more than one mould can produce the same mycotoxin (e.g., 
both Aspergillus flavus and several Penicillium species produce the mycotoxin 
cyclopiazonic acid). Also, more than one mycotoxin may be present in an intoxication 
event (Fratamico et al., 2005). Among the various mycotoxins, the aflatoxins have been 
the most intensively researched because of their extremely potent 
hepatocarcinogenicity, especially for aflatoxins B1 and G1. Generally, aflatoxins occur 
in susceptible crops as mixtures of aflatoxins B1, B2, G1, and G2. 
 
 A carcinogenic hydroxylated metabolite of aflatoxin B1 (termed aflatoxin M1) can 
occur in the milk from dairy cows that consume contaminated feed. Aflatoxins may 
occur in a number of susceptible commodities derived from them, including edible nuts 
(peanuts, pistachios, almonds, walnuts, pecans, brazil nuts), oil seeds (cottonseed, 
copra), and grains (corn, grain sorghum, millet). Since the discovery of the threat of 
aflatoxins to human health, progress has been made in decreasing the level of aflatoxins 
in specific commodities in developed countries. For example, in the United States and 
Western European countries, control measures include ensuring adequate storage 
conditions and careful monitoring of susceptible commodities for aflatoxin level and the 
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banning of lots that exceed the action level for aflatoxin B1. Organic foods, produced 
without the use of insecticides and fungicides, may be more susceptible to mycotoxin 
contamination than foods produced using conventional agricultural practices. The UK 
Food Standards Agency found several organic maize meal products highly 
contaminated with fumonisin mycotoxins, whereas, conventional produced maize meal 
products analysed simultaneously had levels below recommended limits (UK Food 
Standards Agency, 2003). 
 
1.7.3.4 Toxicological studies for aflatoxins 
 
Aflatoxin exposure is detrimental to both human and animal health. AFB1, the 
predominant isoform, is a potent hepatocarcinogen, and aflatoxin exposure has been 
linked to development of hepatocellular carcinoma (HCC) (Kew, 2003). Based on the 
toxicological data, the naturally occurring aflatoxins (B1, B2, G1, and G2, including 
mixtures of isoforms) and the metabolic product aflatoxin M1 have been designated 
Group 1 carcinogens (carcinogenic to humans) by the International Agency for 
Research on Cancer (IARC) (IARC, 2002). Aflatoxins are also known to be teratogenic, 
mutagenic and immunosuppressive (Peraica et al., 1999; Kihara et al., 2000; Jiang et 
al., 2005). A number of mycotoxins produce nephrotoxicity such as aflatoxin B1, 
citrinin, ochratoxins, fumonisins, and patulin (O’Brien and Dietrich, 2005). Fumonisins 
B1 and B2 are commonly found on corn and corn products and produce nephrotoxicity 
in rats and rabbits (Bucci et al., 1998). There are few reports of acute intoxications 
caused by mycotoxins, however, prolonged exposure to small quantities of mycotoxin 
may lead to more dangerous effects including growth retardation, birth defects, 
impaired immunity, decreased disease resistance, and tumor formation in humans and 
decreased production in farm animals (CAST, 2003).  
 
Aflatoxins are products of species of the genus Aspergillus, particularly A. flavus, a 
common fungus found as a contaminant of grain, maize and peanuts. First implicated in 
poultry diseases such as Turkey-X disease, they were subsequently shown to cause 
cancer in experimental animals and from epidemiological studies in humans. Aflatoxin 
B1, the most toxic of the aflatoxins, must be activated enzymatically to exert its 
carcinogenic effect. Aflatoxin B1 is acutely toxic in all species studied, with an LD50 of 
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60 mg/kg for mice with death usually resulting from hepatotoxicity. Aflatoxin B1 is also 
highly mutagenic, hepatocarcinogenic, and possibly teratogenic. A problem in 
extrapolating animal data to humans is the extremely wide range of species 
susceptibility to aflatoxin B1. Aflatoxin B1 is an extremely reactive compound 
biologically, altering a number of biochemical systems. The hepatocarcinogenicity of 
aflatoxin B1 is associated with its biotransformation to a highly reactive electrophilic 
epoxide, which forms guanine adducts and induces apoptotic cell death in human 
hepatocytes (Reddy et al., 2006). Damage to DNA is thought to be the initial 
biochemical lesion resulting in the expression of the pathological tumour growth 
(IARC, 2002). Species differences in the response to aflatoxin may be due in part to 
differences in biotransformation and susceptibility to the initial biochemical lesion.  
 
Fumonisins are mycotoxins produced by the fungus Fusarium, primarily by Fusarium 
moniliforme and Fusarium proliferatum growing on corn. Ingestion by horses of corn 
contaminated with Fusarium mold causes “mouldy corn poisoning” or equine 
leukoencephalomalacia. In humans, an association with esophageal cancer has been 
suggested (Myburg et al., 2002). Trichothecenes are protein synthesis inhibitors which 
bind ribosomes. The extent of toxicity associated with the trichothecenes in humans and 
farm animals is poorly understood, owing in part to the number of entities in this group 
and the difficulty of assaying for these compounds. The acute LD50’s of the 
trichothecenes range from 0.5 to 70 mg/kg, and there has been reports of possible 
chronic toxicity associated with certain members of this group (Li et al., 2011). 
However more research is required to study the adverse human health effects of this 
toxin group. Fumonisins have been associated with cancer, reproductive toxicity, and 
acute disease outbreaks where low-quality corn is consumed on a regular basis (Cousins 
et al., 2005). Fumonisins target different organs in different species, but the underlying 
mechanism is a disruption of lipid metabolism by inhibition of ceramide synthetase, an 
enzyme integral to the formation of complex lipids in membranes (ICPS, 2000). 
Ochratoxin A is nephrotoxic and carcinogenic in mice and rats. Ochratoxin A is 
absorbed from the gastrointestinal tract and enters the enterohepatic circulation and it is 
also absorbed by the kidney. It binds tightly to albumin in the blood and can therefore 
have a very long serum half-life. Epidemiologic evidence indicates nearly half the 
European population is exposed to ochratoxin A and there is an association of endemic 
nephropathy and renal tumors in humans in parts of Eastern Europe (CAST, 2003).  
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1.8 Thesis Aims 
 
Intoxication events caused by consumption of seafood and water supplies with 
naturally-occurring marine toxins is becoming a worldwide problem. While 
phycotoxins and mycotoxins have been shown to modulate certain immune functions, 
their specific mechanisms of action remain unknown. Specifically, this work aims to 
elucidate mechanism involved in the effects of azaspiracid-1, microcystin-LR and the 
aflatoxins, B1, B2 and G1 on the murine macrophage, J774A.1, responses to LPS. 
Herein, a tailored approach is taken to examine the possible mechanisms of toxin-
mediated modulation of macrophage function by observing their effects on cellular 
function, cell surface marker expression and secreted cytokines. It is hoped to provide 
an insight into the mechanisms by which phycotoxins and mycotoxins modulate the 
host immune response to exert their immunosuppressive activity. 
 
The second purpose of this research was to generate recombinant antibodies to 
azaspiracid for incorporation into a specific and sensitive immunoassays. Currently, no 
recombinant antibodies exist to this target, but polyclonal and monoclonal azaspiracid-
specific antibodies have been generated (Forsyth et al., 2006; Fredrick et al., 2009) 
Immunoassays, incorporating novel recombinant antibodies, could potentially be 
incorporated into toxin detection systems in shellfish and water. Genetic material 
became available from an azaspiracid-immunised rabbit host. It was decided to harness 
this material to generate single chain antibody fragments (scFvs) to azaspiracid.  
 
A third goal of this research was to generate recombinant antibodies for detection of 
microcystin through generation of avian immune libraries. No previous reports of avian 
immune recombinant antibodies to this compound exist. However, scAb fragments have 
been isolated from non-immune libraries, but they lack sensitivity and their cross-
reactivity was shown to be variable (McElhiney et al., 2000; Strachen et al., 2002). 
Custom synthesised microcystin conjugate were generated for this purpose.  
 
A final aim was to produce a sensitive immunosensor for toxin detection, using the 
recombinant antibodies generated over the course of the research. Ideally, the 
immunosensor would be in a format applicable to future in situ device development and 
that could accurately and sensitively detect toxin outbreaks in an algal matrix. 
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CHAPTER 2 
Material and Methods 
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2.1 Media preparation 
 
All the components are prepared in distilled water and autoclaved at 120
o
C for 20 
minutes to remove contaminants. All components were purchased from Sigma-Aldrich 
Ltd. and Cruinn Diagnostics Ltd.  
 
Media  Components 
2x Tryptone Yeast extract (2xTY) 
 
Tryptone (16 g/L) 
Yeast extract (10 g/L) 
NaCl (5 g/L) 
 
Super Broth (SB) MOPS (10 g/L) 
Tryptone (30 g/L) 
Yeast extract (20 g/L)          
 
Super Optimal Catabolite (SOC) 
 
Tryptone (20 g/L) 
Yeast extract (5 g/L) 
NaCl (0.5 g/L) 
KCl (2.5 mM) 
MgCl2 (20 mM) 
Glucose (20 mM) 
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2.2 Buffer preparation 
 
2.2.1 General buffers 
 
The constituents of each buffer are dissolved in 990 mL distilled and deionised water 
and adjusted to a final pH of 7.4. The solution is made up to a final volume of 1 Litre. 
All components were analytical grade. 
 
Buffer Name Components 
Phosphate-buffered saline (PBS)  
150 mM (pH 7.4) 
NaCl (5.84 g/L) 
Na2HPO4 (4.72 g/L) 
NaH2PO4 (2.64 g/L)  
 
PBS Tween 20 (PBST) NaCl (5.84 g/L) 
Na2HPO4 (4.72 g/L) 
NaH2PO4 (2.64 g/L) 
Tween 20 (0.05 % (v/v)) 
 
HBS buffer HEPES (2.38 g/L) 
NaCl (8.77 g/L) 
EDTA (1.27 g/L)  
Tween 20 (0.05 % (v/v)) 
 
HBS was filter sterilised through a 0.2 µm 
filter and degassed.      
FACS Buffer 2 % (v/v) FCS 
0.05 % (w/v) sodium azide 
 
The buffer was prepared in sterile PBS (150 
mM, pH 7.4) and filter sterilised through a 0.2 
µm filter 
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2.2.2 Buffers for sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) 
 
Preparation of 12.5 % Separation Gel 1 gel/ 6 mL 
1 M TrisHCl (pH 8.8)     1.5 mL 
30 % (w/v) acrylamide (Acrylagel) 2.5 mL 
2 % (w/v) methylamine bisacrylamide (Bis-Acrylagel) 1.0 mL 
Water  934 μL 
10 % (w/v) sodium dodecyl sulfate (SDS)  30 μL 
10 % (w/v) Ammonium persulfate (APS) (Fresh)  30 μL 
N,N,N',N'-Tetramethylethylenediamine (TEMED) 6 μL 
 
Preparation of 4.5 % Stacking Gel 1 gel/ 2.6 mL 
1 M TrisHCl (pH 6.8)     300 μL 
30 % (w/v) acrylamide (Acrylagel) 375 μL 
2 % (w/v) methylamine bisacrylamide (Bis-Acrylagel) 150 μL 
Water  1.74 mL 
10 % (w/v) SDS      24 μL 
10 % (w/v) APS 24 μL 
TEMED      2.5 μL 
 
10X Electrophoresis Buffer Volume (1 L) 
196 mM Glycine  144 g 
50 mM Tris (pH 8.3) 30 g 
0.1 % (w/v) SDS 10 g 
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4X Loading Dye Volume (10 mL) 
Tris 0.5M (pH 6.8)  2.5 mL 
Glycerol   2 mL 
2-mercaptoethanol  0.5 mL 
20 % (w/v) SDS  2.5 mL 
Bromophenol blue  20 ppm 
Water    2.5 mL 
 
Coomassie Stain   Volume (500 mL) 
0.2 % (v/v) Coomassie blue R-250   1 g 
45 % (v/v) Methanol        225 mL 
45 % (v/v) Water            225 mL 
10 % (v/v) Acetic acid         50 mL 
 
Coomassie Destain Volume (1 L) 
10 % (v/v) Acetic acid      100 mL 
25 % (v/v) Methanol        250 mL 
65 % Water           650 mL 
 
2.2.3 Buffers for western blotting 
 
Transfer Buffer Volume (1 L) 
Tris 3.03 g 
Glycine 14.4 g 
Methanol 200 mL 
 Adjust to 1L with dH20 
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2.2.4 Buffers for immobilised-metal affinity chromatography (IMAC) 
 
Lysis Buffer                     Volume (100 mL) 
300 mM NaCl  1.754 g  
50 mM NaH2PO4 0.69 g 
10 mM Imidazole 0.068 g 
Adjust pH to 7.5, using 1 M NaOH 
 
Wash buffer A Volume (100 mL) 
50 mM NaH2PO4  0.69 g  
1 M NaCl  5.844 g 
10 % (v/v) glycerol  20 mL 50 % (v/v) solution 
20 mM Imidazole  0.136 g 
1 % (v/v) Triton X-100 1 mL 
Adjust pH to 7.5, using 1 M NaOH 
 
Wash buffer B Volume (100 mL) 
50 mM NaH2PO4  0.69 g  
300 mM NaCl 1.754 g 
20 mM Imidazole  0.136 g 
Adjust pH to 7.5, using 1 M NaOH  
 
Elution buffer Volume (100 mL) 
50 mM NaH2PO4  0.69 g 
300 mM NaCl 1.754 g 
250 mM Imidazole  1.7 g 
Adjust pH to 7.5, using 1 M NaOH  
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2.3 Reagents 
 
All reagents were of analytical grade and purchased from Sigma-Aldrich Ireland Ltd 
(Dublin, Ireland), unless otherwise specified. 
 
Reagent Supplier 
Biacore™ CM5 research grade sensor 
chips 
GE Healthcare Bio-Sciences AB,  
SE-751 84 Uppsala,  
Sweden. 
Bacteriological Agar 
Yeast extract 
  Tryptone 
Cruinn Diagnostics Ltd.,  
Hume Centre,  
Parkwest Business Park,  
Nangor Road,  
Dublin 12,  
Ireland. 
DNA Ligase 
Helper phage 
Restriction enzymes 
Phusion High-Fidelity DNA polymerase 
Antarctic Phosphatase 
ISIS Ltd., 
Unit 1 & 2, Ballywaltrim Business 
Centre,  
Boghall Road,  
Bray, Co. Wicklow,  
Ireland. 
dNTPs 
GoTaq
®
 DNA Polymerase 
RedTaq
®
 DNA Polymerase 
Medical Supply Company Ltd, 
Damastown,  
Mulhuddart,  
Dublin 15,  
Ireland. 
FPLC molecular protein standards Phenomenex Ltd.,  
Melville House,  
Cheshire SK10 2BN, 
 UK. 
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PageRuler™ Plus Prestained Protein 
Ladder 
 
AGB Scientific Limited - A VWR 
International Company, 
Orion Business Campus,  
Northwest Business Park,  
Ballycoolin, Dublin 15,  
Ireland. 
PCR primers Eurofins MWG Operon,  
318 Worple Road,  
Raynes Park, London, 
SW20 8QU,  
UK. 
Platinum
®
 Taq DNA Polymerase High 
Fidelity 
Trizol 
Bio-sciences,  
Crofton Road,  
Dun Laoghaire,  
Dublin,  
Ireland. 
RNaseZap™     
RNAlater™   
Glycogen (5 mg/mL)  
3M Sodium acetate   
Applied Biosystems/Ambion, 
2130 Woodward St., 
Austin,  
TX 78744-1832,  
USA. 
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2.4 Commercial antibodies and antigens 
 
Reagent Supplier 
Goat anti-rabbit,  
peroxidase conjugated pAb  
 
Rabbit anti-mouse,  
peroxidase conjugated pAb 
Sigma Aldrich,  
3050 Spruce Street, 
St. Louis, MO 63103,  
USA. 
Lipopolysaccharide (LPS) 
E. coli, serotype R515 
 
Microcystin-LR-BSA and OVA protein 
conjugates  
 
Microcystin-LR (MC-LR), MC-LW, MC-
LF, MC-LA, MC-RR and MC-YR 
Enzo Life Sciences Inc. 
10 Executive Boulevard 
Farmingdale, NY 11735,  
USA. 
Mouse anti- haemagglutinin (HA) mAb  Cambridge Bioscience,  
24-25 Signet Court,   
Newmarket Road,   
Cambridge CB5 8LA,  
UK. 
Mouse anti-M13 antibody, horseradish 
peroxidase conjugated 
 
GE Healthcare Bio-Sciences AB,  
SE-751 84 Uppsala,  
Sweden. 
Rabbit anti-chicken IgY (H+L), 
horseradish peroxidase conjugated 
Pierce, Thermo Fisher Scientific Inc., 
3747 N Meridian Rd,  
Rockford, IL  
USA 61101. 
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2.5 Commercial kits 
 
Reagent Supplier 
Cell proliferation reagent (WST-1) 
 
Cytotoxicity detection Kit (LDH) 
Roche Diagnostics GmbH, 
Sandhoferstrasse 116, 
DE-68305 Mannheim, 
Germany. 
DuoSet ELISA development kits R&D Systems, Inc., 
614 McKinley Place NE, 
Minneapolis,  
MN 55413, 
 USA. 
Perfectprep gel cleanup Kit 
 
 
  
Eppendorf AG,  
Barkhausenweg 1,  
Hamburg 22339,  
Germany. 
Superscript III reverse transcriptase kit Invitrogen Corporation, 
5791 Van Allen Way, 
Carlsbad, CA 92008,  
USA. 
Wizard Plus SV Miniprep™ kit Promega, 2800 Woods Hollow Road, 
Madison, WI 53711,  
USA. 
NucleoSpin
®
 Xtra Midi Plasmid 
Purification Kit 
Macherey-Nagel, 
Fisher Scientific Ireland Ltd., 
Suite 3, Plaza 212, 
Blanchardstown Corporate Park 2, 
Ballycoolin, 
Dublin 15. 
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2.6 Cell culture reagents 
 
Reagent Supplier 
RPMI-1640 liquid medium with ʟ-
Glutamine 
 
DMEM/high glucose with sodium pyruvate  
 
Fetal bovine serum 
 
ʟ-Glutamine 
 
Penicillin-Streptomycin solution (10,000 
unit/mL Penicillin and 10,000 μg/mL 
Streptomycin in 0.85 % (w/v) NaCl) 
 
Trypsin solution (0.05 % w/v) (1X) 
 
DPBS (1X) without calcium and 
magnesium 
 
Thermo Scientific Hyclone™, 
Fisher Scientific Ireland Ltd., 
Suite 3, Plaza 212, 
Blanchardstown Corporate Park 2, 
Ballycoolin, 
Dublin 15. 
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2.7 Equipment 
 
Equipment Name Supplier 
ÄKTA™ Explorer 100 system  GE Healthcare UK Ltd., 
Amersham Place, Little Chalfont, 
Buckinghamshire,  
England. 
Biacore™ 3000     
  
GE Healthcare Bio-Sciences AB, 
 SE-751 84 Uppsala, 
Sweden.  
Eppendorf™ Centrifuge 5810 R with 
swing-bucket rotor (A-4-62) and fixed-
angle rotor (F-45-30-11) 
 
AGB Scientific Ltd , 
VWR International, 
Co. Dublin,  
Ireland. 
FACSCalibur™ Flow Cytometer  
 
BD Biosciences, 
1 Becton Drive, Franklin Lakes, New 
Jersey, 07417,  
USA. 
Gene Pulser Xcell™ electroporator 
Biorad Gel electrophoresis system 
HERA Cell 100 CO2 incubator 
 
Bio-Rad Laboratories, Inc.,  
2000 Alfred Nobel Drive,  
Hercules, California 94547,  
USA. 
GeneSnap™ 2D Imaging System 
 
Syngene, 
5108 Pegasus Court, Suite M, 
Frederick, 
MD 21704, 
USA. 
MSC-Advantage Laminar Flow Cabinet 
PX2 thermal cycler  
 
 
Thermo Electron Corporation,  
81 Wyman Street, Waltham,  
Massachusetts (MA),  
02454, USA. 
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Sceptor Handheld Automated Cell 
Counter 
 
Millipore, 
290 Concord Road, 
Billerica, MA 01821,  
USA. 
Nanodrop™ ND-1000    NanoDrop Technologies, Inc., 
3411 Silverside Rd 100BC,  
Wilmington, DE19810-4803,  
USA. 
Perkin Elmer™ ScanArray Express 
Microarray Analysis System 
75 Nicholson Ln, 
San Jose, California, 
 95134-1366, USA 
Roller mixer SRT1    Sciencelab, Inc., 
14025 Smith Rd, 
Houston, Texas 77396, 
 USA 
Safire™ 2 plate reader    Tecan™ Group Ltd. 
Seestrasse 103, 
CH-8708 Männedorf,  
Switzerland 
Vibra Cell™ sonicator   Sonics and Materials Inc., 
53 Church Hill Road, 
Newtown,  
CT 06470-1614,  
USA 
 
2.8 Bacterial strains 
 
All strains were purchased from Stratagene, La Jolla, Calfornia, USA. 
 E. coli TOP10F strain: {lacIq, Tn10(TetR)} mcrA (mrr-hsdRMS-mcrBC) 
80lacZ M15 lacX74 recA1 araD139 (ara-leu)7697 galU galK rpsL (Str
R
) 
endA1 nupG 
 E. coli XL1-Blue strain: recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac 
[F′ proAB lacIqZ∆M15 Tn10 (TetR)]. 
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2.9 Safety precautions and protocols for handling toxin material and waste 
 
Azaspiracid, microcystin and aflatoxin are all highly toxic and hazardous substances. 
Therefore, for all experiments involving these compounds, the correct protocols for 
their safe storage, handling and disposal were carried out, in accordance with approval 
from the DCU Safety Committee and the Environmental Protection Agency (EPA). All 
cell culture work was carried out in a designated toxin laminar flow hood. All 
biopanning and ELISA experiments were also carried out in a designated toxin fume 
hood. Toxin-containing liquid waste, including coating, blocking, washing, assay and 
cell culture media solutions were decanted into designated glassware containing 
Virkon
®
. This liquid waste was collected and disposed of by Ecosafe Ltd. Personal 
protective equipment was worn at all stages, including lab coat, goggles and two pairs 
of gloves. 
 
2.10 Toxins and toxin conjugates 
 
Toxins and toxin conjugates were stored in single-use aliquots at - 20
o
C. Both aflatoxins 
(B1, B2 and G1; Sigma-Aldrich
 
Ireland Ltd.) and microcystin (MC-LR, M-RR, MC-LF, 
MC-LA, MC-YR and nodularin; Enzo Life Sciences Ltd.) were re-constituted, from 
lyophilised vials, according to manufacturer’s instructions in molecular-grade methanol 
(prepared in ‘endotoxin-free’ water). Azaspiracid was provided in PBS (150 mM, pH 
7.4).  
 
The use of plastic tubes and of plastic pipette tips in the manipulation of MC-LR 
solutions has been shown to influence dissolved toxin concentrations (Hyenstrand et al., 
2001). Therefore, microcystins were stored in glass vials and pipetting was minimised. 
In cases where multiple toxin dilutions in plastic microcentrifuge tubes were required, a 
stock solution of microcystin in 25 % (v/v) methanol was prepared, as the same study 
showed that MC-LR in a solution of above 25 % (v/v) methanol did not interact with 
plastics to any great extent (Hyenstrand et al., 2001). 
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2.11 Cell culture techniques 
 
2.11.1 Culture of cell lines 
 
The murine macrophage cell line J774A.1 was obtained from the European Collection 
of Cell Cultures (ECACC; Salisbury, UK). The cells were cultured in RPMI-1640 
medium supplemented with 10 % (v/v) foetal bovine serum, 2 mM ʟ-glutamine, 50 U 
penicillin and 50 μg streptomycin. The semi-adherent cell line, J774A.1 was sub-
cultured by gently tapped to dislodge the cells from the surface of the flask. Cells were 
recovered by centrifugation at 400 g for 5 minutes, diluted in fresh medium and then 
transferred to a sterile 75 cm
2
 tissue culture flasks for further growth.  
 
The human hepatocellular cell line, HepG2, was obtained from the European Collection 
of Cell Cultures (ECACC; Salisbury, UK). The cells were cultured in DMEM 
supplemented with 10 % (v/v) foetal bovine serum, 2 mM L-glutamine, 50 U penicillin 
and 50 μg streptomycin. For sub-culturing, the media was carefully removed, the cells 
were washed twice with sterile PBS and 2 mL of 0.05 % (w/v) trypsin (Hyclone) was 
added and incubated for 2-6 minutes in a CO2 incubator. Eight mL of fresh media was 
then added to deactivate trypsin, thus preventing cellular damage. The culture was 
centrifuged at 400 g for 5 minutes, resuspended in fresh media and transferred to a 
sterile 75 cm
2
 tissue culture flasks for further growth.  
 
All cultures were maintained in a 37°C, 5 % CO2 humidified atmosphere. All work was 
carried out in a LaminAir flow cabinet to ensure sterility. 
 
2.11.2 Long-term storage of cell lines 
 
Cells were prepared by aliquoting into 1 mL cryovials at a concentration of 5-10X 10
6 
cells/mL in freeze medium. Freeze medium consisted of 95 % of the appropriate 
medium and 5 % (v/v) dimethyl sulfoxide (DMSO). Once aliquoted, the vials were 
immediately transferred to a Nalgene
®
 Mr. Frosty and placed in a -80ºC freezer for slow 
freezing. Once frozen, the vials were transferred to liquid nitrogen, for long-term 
storage.  
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2.11.3 Resuscitation of frozen cell line stocks 
 
One aliquot of cells was thawed, when new cultures were required, or when the viability 
of the cells after cryopreservation needed to assessed. Ten mL of the appropriate 
medium was pre-warmed to 37C in a 25 cm2 sterile tissue culture flask. The cryovial 
was warmed briefly at room temperature before thawing in a 37ºC water bath. The 
contents of the vial were slowly transferred to the pre-warmed medium, which was then 
placed in the incubator. Cell growth was monitored by examining the cells, under a 
Nikon
®
 inverted microscope. After 72-96 hours, the regular subculture routine was 
initiated to ensure that the optimal cell concentration and conditions were maintained. 
 
2.11.4 Cell counting 
 
Cells were counted and their viability assessed using trypan blue exclusion. Trypan blue 
is negatively charged, so it is excluded from viable cells. Therefore, only the cells with 
damaged cell membranes (e.g. dead cells) will stain blue. To count the cells, 10 μL of 
cell suspension was added to 90 μL of 0.04 % (v/v) trypan blue solution. The sample 
was loaded into the chamber of an improved Neubauer haemocytometer. Using a light 
microscope, cells were counted in 5 squares of either side of the chamber (10 in total). 
The concentration of the cells in the suspension (cells/mL) was calculated by 
multiplying the total number of cells in all 10 squares x dilution factor x 1000. 
 
2.11.5 Mycoplasma testing 
 
Regular testing for mycoplasma was carried out using a MycoAlert
®
 Mycoplasma 
Detection Kit (Lonza), as per the manufacturer’s instructions. This luminescence-
technique was based on the measurement of ATP in a culture supernatant. Enzymes 
released from viable mycoplasma react with the kit substrate, catalysing the conversion 
of ADP to ATP. 
 
2.11.6 Endotoxin testing 
 
Regular testing for endotoxin contamination was carried out using an E-toxate™ kit 
(Sigma-Aldrich, Ireland), as per the manufacturer’s instructions. This test is dependent 
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on the viscosity of the test sample in the presence of circulating amebocytes of the 
horseshoe crab, Limulus polyphemus. 
 
2.12 Effects of marine toxin exposure on murine macrophage cell line  
 
2.12.1 Toxin treatments 
 
For cell culture analysis, all required toxin dilutions were prepared in cell culture media. 
For the toxins dissolved in methanol, including microcystin and aflatoxin, the final 
concentration of solvent exposed to cells was always less than 0.1 % (v/v) methanol. In 
all experiments, a control assay was prepared, in which cells were exposed to the 
equivalent vehicle concentration, to that used in the toxin treatment. 
 
2.12.2 Lactate dehydrogenase assay 
 
The lactate dehydrogenase (LDH) assay kit (Roche Applied Sciences) is a colorimetric 
assay for the quantification of cell death and cell lysis, based on the measurement of 
LDH activity released from the cytosol of damaged cells into the supernatant (Figure 
2.12.1). To calculate the percent cytotoxicity, a number of controls were included in the 
experimental set-up. The background control or media control provided information on 
the background LDH activity of the assay medium. The absorbance value obtained in 
this control has to be subtracted from all other values. The low control provided 
information about the LDH activity released from the untreated normal cells. The high 
control provided information about the maximum releasable LDH activity in the cells. 
For this experiment the low control was molecular grade methanol, at the same 
concentration as toxin solvent in the final cell preparation. The high control was 1 % 
(v/v) Triton-X100, a non-ionic surfactant, which is used for the solubilisation of 
membranes under non-denaturing conditions. The permeabilisation of the membrane 
leads to a fast cell death by necrosis (Weyermann et al., 2005). 
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Figure 2.12.2.1: Lactate dehydogenase (LDH) assay principle (Image from Roche 
Applied Sciences). LDH activity is determined in a coupled enzymatic reaction; during 
which, the tetrazolium salt (INT) is reduced to formazan salt. 
 
To determine the percentage cytotoxicity, the mean absorbance values of the triplicate 
experiments were calculated and the background measurement was subtracted from 
each. The resulting values are substituted in the following equation: 
 
 
   ytotoxicity   
 xperimental alue   Low  ontrol
High  ontrol   Low  ontrol
  100 
 
 
For the experiment, 200 µL of murine macrophage cells, at a concentration of 1x10
6
 
cells/mL in RPMI (with 10 % (v/v) FBS), was dispensed into each well of a 96 well cell 
culture plate (NUNC™). The plate was placed in a CO2 incubator at 37C, 5 % CO2 and 
the cells were allowed to adhere overnight. The next day, ‘serum-free’ RPMI was pre-
warmed to 37
o
C prior to experimental set-up. Dilutions of toxins and LPS were 
prepared in ‘serum-free’ media. The J774A.1 macrophage cells were checked under the 
inverted microscope to ensure that they adhered overnight and were viable. The toxins 
and controls were added to each well as appropriate. A positive and negative control 
was included each time the experiment was performed to both ensure that the cells are 
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behaving normally and to screen for contamination. In this situation, the negative 
control was medium alone and the positive control was 100 ng/mL LPS. The plate was 
incubated at 37C, 5 % CO2 for the predetermined time period. 
 
After treatment, the 96 well plate was centrifuged at 400g for 5 minutes to minimise the 
presence of cellular material in the supernatant, which may affect subsequent results. 
One hundred µL of supernatant was transferred to new plate for the LDH assay. One 
hundred µL of LDH assay solution was added to the supernatant plate and incubated for 
30 minutes at room temperature wrapped in tin foil to minimise exposure to light. The 
LDH assay solution was prepared immediately prior to use, according to manufacturer’s 
instructions, by mixing 250 µL ‘Bottle 1’ (Diaphorase/NAD+ mixture) with 11.25 mL 
‘Bottle 2’ (Iodotetrazolium chloride and sodium lactate). After incubation, the 
absorbance of the LDH assay plate wells was measured at 490 nm using a Tecan™ 
Safire II instrument. 
 
 
2.12.3 WST-1 cell death assay 
 
The WST-1 assay is designed for spectrophotometric quantification of cell growth, 
viability and proliferation, through determination of mitochondrial dehydrogenase 
activity. The stable tetrazolium salt, WST-1, is cleaved to a soluble formazan by a 
complex cellular mechanism which occurs primarily at the cell surface. This 
bioreduction is largely dependent on the glycolytic production of NAD(P)H in viable 
cells. Therefore, the amount of formazan dye formed directly correlates to the number 
of metabolically active cells in the culture. (Figure 2.12.3.1).  
 
Murine macrophages were prepared for analysis, as described in Section 2.12.1. After 
cells were treated for the pre-determined time period with controls and toxins, the 96 
well plate was removed from the incubator. Supernatant was removed for LDH 
analysis, WST-1 assay solution added in a volume of 10 µL and incubated at 37
o
C for 
time ranging from 0.5 to 4 hours. The WST-1 assay solution was thawed from a 1 mL 
frozen stock, immediately prior to use. Following incubation, the absorbance of the 
WST-1 assay plate was measured at 450 nm, using a Tecan™ Safire II instrument. 
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Figure 2.12.3.1: WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-
benzene disulfonate) cell death assay principle, based on the cleavage of WST-1 to 
formazan (dark red). EC = Electron coupling reagent, RS = Mitochondrial succinate-
tetrazolium-reductase system (Image from Roche Applied Sciences). 
 
2.12.4 Analysis of effects of toxin on cytokine (IL-6, IL-10, IL-12p40, IL-1β and 
TNF-α) release in the J774A.1 murine macrophage cell line 
 
TNF-α, IL-10, IL-6, IL-12p40, and IL-1β DuoSet ELISAs were performed according to 
the manufacturer’s instructions (R&D Systems, Ltd). Each sample was assayed in 
duplicate for each of the cytokines indicated. Sterile ‘serum-free’ RPMI (Fisher 
Scientific, Ireland) was pre-warmed to 37
o
C prior to the experimental set-up. Dilutions 
of toxin were prepared in a pre-determined assay range in ‘serum-free’ media. J774A.1 
murine macrophage cells at 70 % confluency were detached from a T75 (NUNC™) 
flask by gently tapping. The cells were transfered to a 25 mL sterilin tube and 
centrifuged at 400 g for 5 minutes (Sigma Centrifuge 2K15). The pelleted cells were re-
suspended in 10 mL fresh media, a sample was taken for trypan blue staining and a cell 
count was performed, as described in Section 2.22.4 The concentration was adjusted to 
1x10
6
 cells/mL in a 25 mL volume. Five hundred µL of this cell suspension was 
aliquoted into a 48 well tissue culture plate (NUNC™). The toxins were added to a final 
concentration (100 pg/mL AZA-1; 1 and 5 µg/mL MC-LR; 0.01 and 0.1 ng/mL 
aflatoxins B1, B2 and G1), with or without 100 ng/mL lipopolysaccharide (LPS) (Alexis 
Biochemicals), to induce an inflammatory response. Cells were incubated with an 
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equivalent methanol concentration, as a vehicle control for microcystin and aflatoxin 
toxicity analysis. The plates were placed in a 37
o
C incubator (Thermo Scientific), 5 % 
CO2, for the pre-determined time period. After the incubation period, the cell 
supernatant was harvested and aliquoted into sterile 1.5 mL tubes and used immediately 
or stored at -80
o
C until required. All experiments were performed in triplicate. 
 
2.12.5 Cell surface marker expression 
 
Cell surface expression of TLR2, TLR4, CD14 and CD40 on J774A.1 cells was 
assessed by flow cytometry. Following 72 hour exposure to AFB1, AFB2 or AFG1 alone 
or in combination (10 ng/mL), 1x10
6
 cells were stimulated with and without 100 ng/mL 
LPS for 24 hours. At the end of the 24 hour incubation, cells were labelled to determine 
cell surface expression of CD14, TLR4, TLR2 and CD40 (eBio). For this, cells were 
scraped from the bottom of the well with a sterile transfer pipette and collected in a 15 
mL falcon tube. Non-specific binding was blocked with an equal volume of foetal 
bovine serum (FBS) for 15 minutes at room temperature. After blocking, samples were 
centrifuged for 5 minutes at 400 g. Supernatant was discarded and the cells are washed 
once in 2 mL FACS buffer (See Section 2.13.2). The cell pellet was resuspended in 2 
mL FACS buffer and 200 μL of cell suspension was dispersed into a 96 well round 
bottom plate. The plate was centrifuged at 805 g for 5 minutes, in an Eppendorf 5018R 
centrifuge. The supernatant was discarded and the pellets were resuspended in 100 μL 
of appropriate antibody. The plate was incubated at 4°C for 30 minutes. At the end of 
incubation time, the cells were pelleted, as previously described, and washed 3 times in 
200 μL FACS buffer. The cells were fixed in 4 % (v/v) formaldehyde in a final volume 
of 500 μL per sample. The stained cells were transferred to a labelled FACS tube and 
stored at 4°C protected from light prior to analysis. Isotype controls for each cell surface 
marker included, respectively. A minimum of 10,000 events were acquired for each 
sample on a FACSCalibur flow cytometer (BD Biosciences). 
 
2.12.6 Statistical analysis 
 
Data was pooled and mean values ± 3SE was calculated. A one-way analysis of 
variance (ANOVA) was performed using JMP 7.0.1 (SAS Institute, Cary, NC). If the 
ANOVA table was significant (*P < 0.05; ** P < 0.01; *** P < 0.001), post-hoc 
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analysis was performed using Dunnett’s two-tailed test to evaluate the differences 
between treatment and control groups. 
2.13 Generation of immune library for azaspiracid (AZA) 
2.13.1 Immunisation of New Zealand white rabbit with azaspiracid-br-cBSA 
 
Immunisation of a New Zealand white rabbit was carried out by the Institute of Agri-
Food and Land Use, Queens University, Belfast. The rabbit was immunised with an 
AZA-br-cBSA conjugate produced in their laboratory. The immunogen was mixed in a 
1:1 ratio with montanide ISA 50V adjuvant (Seppic, France) by vortexing and then 
thickened by passing from one syringe to another connected by a narrow bore Pyrex 
cylinder. One mL of the resultant emulsion was administered to the rabbit sub-
cutaneously over four sites (250 µL each). The rabbit was primarily immunised with 50 
µg of immunogen and boosted at four weekly intervals with 50 and 100 µg 
concentrations. Bleeds were taken at intervals and analysed by direct ELISA. The rabbit 
was sacrificed and the spleen and two samples of bone marrow from two legs were 
removed with sterile surgical tools and stored in RNAlater
®
 (Ambion, Applied 
Biosystems, UK) for transport. 
 
2.13.2 Serum titre of AZA-cBSA –immunised Rabbit by ELISA 
 
In order to determine an immune response against AZA, a bleed was taken, left to 
coagulate and centrifuged at 18,514 g for 20 minutes to harvest serum. A NUN ™ 96 
well plate was coated with 10 µg/mL AZA-KLH conjugate, 10 µg/mL AZA-BTG 
conjugate, 10 µg/mL KLH and 10 µg/mL BTG, overnight at 4
o
C. The antigen solution 
was flicked out from the overnight plate, wells were blocked with 3 % (w/v) Milk 
Marvel/PBS (150 mM, pH 7.4) solution, 200 μL per well at 37˚  for 1 hour. Following 
blocking, the plate was washed three times with PBST (150 mM, pH 7.4) and three 
times with PBS (150 mM, pH 7.4). The immune serum was serially diluted from 10
-2
 to 
10
-7 
in 1 % (w/v) Milk Marvel/ 0.01 % (v/v) Tween 20/PBS (150 mM, pH 7.4) and 
added to the plate. This was incubated for 1 hour at 37
o
C; following this it was washed 
as above. 100 μL of a secondary HRP-labelled anti-rabbit polyclonal antibody (Sigma 
Aldrich, Ireland) at a 1/2,000 dilution in a 1 % (w/v) Milk Marvel/PBS (150 mM, pH 
7.4) solution was added to each well. The plate was incubated at 37˚  for 1 hour. 
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Following incubation, the plate was washed as above and 100 µL 3, 3', 5, 5' 
tetramethylbenzidine (TMB) substrate solution (Sigma Aldrich, Ireland) prepared in 
0.05 M phosphate-citrate buffer, pH 5.0, was added to each well. The plate was then 
incubated for approximately 20 minutes under tinfoil to allow for colour development 
after which the reaction was stopped by addition of 50 μL of 10 % (v/v) HCl. The 
absorbance was then determined at 450 nm with a Tecan™ Safire II plate reader 
(Tecan™, UK). 
 
2.13.3 Phenol-chloroform extraction of RNA 
 
The spleen and bone marrow were centrifuged for 10 minutes at 2,500 g (Eppendorf 
5810R, bucket rotor A-4-62) and all the RNAlater
®
 was removed. All excess fat was 
trimmed from the spleen. Both bone marrow and spleen were transferred to fresh 
‘RNase-free’ tubes. 10 mL of cold Trizol reagent (Invitrogen, Bio-Sciences) was 
immediately added and the samples was homogenised at 50 % output for 1 minute. A 
further 20 mL of Trizol was added after homogenisation. The samples were allowed to 
stand for 5 minutes at room temperature to allow for the total dissociation of 
nucleoprotein complexes, while maintaining the integrity of the RNA, before 
centrifuging at 2,500 g in an Eppendorf 5810R centrifuge (bucket rotor A-4-62) for 20 
minutes at 4
o
C. The supernatant was carefully removed and transferred to a 
polypropylene tube which had been pre-treated with RNaseZap and rinsed with ‘RNase-
free’ MG-water prior to use. 6 mL of MG-chloroform was added and the samples were 
vortexed for 15 seconds. This resulted in the separation of the homogenised spleen 
preparation into an upper aqueous phase (containing RNA) and a lower organic phase 
(containing DNA and protein). The spleen and bone marrow samples were incubated at 
room temperature for 15 minutes before centrifugation (fixed angle, pre-cooled Sorval 
SS34 rotor) at 17,500 g for 20 minutes at 4C.  
 
The centrifugation produced 3 layers; a lower red phenol/chloroform phase, a protein 
interphase and a colourless liquid-upper phase with the RNA. The upper aqueous layer 
was very carefully removed and transferred to a polycarbonate tube. Molecular grade 
(MG)-isopropanol (15 mL) was added, vortexed for 15 seconds and incubated at room 
temperature for 10 minutes. The isopropanol precipitated the RNA from solution. The 
samples were centrifuged for 25 minutes at 4
o
C and an RNA pellet was formed. The 
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supernatant was carefully removed and 30 mL of 75 % (v/v) MG-ethanol was added. 
The samples were centrifuged at 17,000 g for 20 minutes at 4
o
C and the supernatant was 
again removed. The pellet was air dried and 500 µL of ‘RNase-free’ water was used to 
gently re-suspend the pellet. The samples were stored on ice before immediately 
proceeding with cDNA synthesis. The spleen and bone marrow RNA samples were 
quantified using a Nanodrop
TM
 spectrophotometer. Bone marrow RNA (1.47 µg/µL) 
and spleen RNA (5.1 µg/µL) was sufficient for cDNA synthesis were obtained 
 
2.13.4 cDNA synthesis by reverse transcription  
 
For cDNA synthesis, a Superscript III First Strand Synthesis System for RT-PCR 
(Invitrogen, Biosciences) kit was used. A total of 5 μg RNA is required for each 
reaction. Two mixtures are prepared; mixture 1 and mixture 2, which each contain a 
20X reaction mixture. 
 
 The preparation of each mixture is outlined: 
 
Mixture 1                                          1X Reaction        20X Reaction 
RNA                                                        Y µL (to give 5 μg)             20X µL 
Oligo-(dT)20 (50 μM)   1 µL    20 µL 
dNTPs (10 mM)   1 µL    20 µL 
 
   Mixture 2                                             1X Reaction                                20X Reaction  
10X RT Buffer   2 µL    40 µL 
MgCl2 (25 mM)   4 µL    80 µL 
DTT (0.1 M)    2 µL    40 µL 
RNase OUT (40 U/μL)  1 µL    20 µL 
Superscript III RT (200 U/μL)  1 µL    20 µL 
 
Mixture 1 was divided into eight 25 μL aliquots and mixed by vortexing before Stage 1 
on the Thermocycler was run, as described below. The tubes were placed on ice for 1 
minute and 25 μL Mixture 2 was added and Stage 2 of the program was carried out. 
RNase H was added at a volume of 1 μL RNase H per 10 μL of reaction mixture. The 
purpose of RNase H was to digest template RNA from the RNA:cDNA hybrid mix 
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following cDNA synthesis. After, RNase H addition, Stage 3 of the program is 
followed. Following synthesis, the reaction mixture was aliquoted and stored at -80
o
C. 
cDNA synthesis was carried out using a PX2 thermal cycler using the following PCR 
program: 
Stage Temperature Time 
Stage 1 65
o
C 5 minutes 
  Pause 
Stage 2 50
o
C 50 minutes 
 85
o
C 5 minutes 
  Pause 
Stage 3 37
o
C 20 minutes 
  4
o
C Hold 
 
2.13.5 Amplification of antibody variable domain sequences using PCR 
 
Bone marrow and spleen cDNA obtained from reverse transcription was used in the first 
round of polymerase chain reaction (PCR) to amplify the variable heavy and variable 
light chain genes. The primers were obtained from Eurofins-MWG-Operon. 
pComb3XSS series primer sequences were obtained from Barbas et al. (2001). The 
various primer combinations for the heavy and light variable chains were assigned 
abbreviations for convenience. 
 
Variable kappa light chain combinations: 
Abbreviation:  Forward:  Reverse: 
VK1   RSCVK1   RKB9J10-BL 
VK2   RSCVK1  RKB9J0-BL 
VK3   RSCVK1  RKB42J0-BL 
VK4   RSCVK2  RKB9J10-BL 
VK5   RSCVK2  RKB9J0-BL 
VK6   RSCVK2  RKB42J0-BL 
VK7   RSCVK3  RKB9J10-BL 
VK8   RSCVK3  RKB9J0-BL 
VK9   RSCVK3  RKB42J0-BL 
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Variable lambda light chain combinations 
Abbreviation:  Forward:  Reverse: 
 Lλ   RS λ1   RJλo-BL 
 
Variable Heavy chain combinations 
Abbreviation:  Forward:  Reverse: 
VH1   RSCVH1  RSCG-B 
VH2   RSCVH2  RSCG-B 
VH3   RSCVH3  RSCG-B 
VH4   RSCVH4  RSCG-B 
 
PCR reactions were carried out using a PX2 thermal cycler using the following PCR 
program: 
 
Stage Temperature Time No. of Cycles 
Stage 1 94
o
C 10 minutes 1 cycle 
Stage 2 94
o
C 15 seconds  
30 cycles  56
o
C 30 seconds 
 72
o
C 60 seconds 
Stage 3 72
o
C 10 minutes 1 cycle 
 4
o
C Hold  
 
The PCR reaction mixture was prepared: 
 
Component Concentration 50 µL Volume 
GoTaq Buffer (5x) 1X   10.0 µL 
VL/VH Forward Primer 60 pM   0.5 µL 
VH/VL Back Primer 60 pM   0.5 µL 
MgCl2 1.5 mM   3.0 µL 
cDNA 0.5 µg   1.0 µL 
dNTP 0.2 mM   1.0 µL 
H2O -   33.75 µL 
GoTaq Polymerase 5 U/µL   0.25 µL 
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2.13.6 PCR optimisation using Phusion® Taq DNA polymerase 
 
For PCR optimisation of variable light chain kappa regions, the high fidelity Phusion
®
 
Taq polymerase was required. The PCR program was set up: 
 
Step Temperature Time No. of Cycles 
Stage 1 98
o
C 6 minutes 1 cycle 
Stage 2 98
o
C 15 seconds  
30 cycles  56
o
C 30 seconds 
 72
o
C 90 seconds 
Stage 3 72
o
C 10 minutes 1 cycle 
 4
o
C Hold  
 
The PCR reaction mixture was prepared: 
 
Component Concentration 50 µL Volume 
HF Buffer (5x) 1X 10.0 µL 
VL/VH Forward Primer 60 pM 0.5 µL 
VH/VL Back Primer 60 pM 0.5 µL 
cDNA  0.5 µg 1.0 µL 
dNTP  0.2 mM 1.0 µL 
H2O - 36.8 µL 
Phusion
®
 Taq Polymerase 1 U/µL 0.2 µL 
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2.13.7 SOE-PCR using Platinum® Taq DNA polymerase (High Fidelity) 
 
The variable heavy and variable light (both kappa and lambda) were combined in 
eqimolar concentrations and used for SOE-PCR. The following overlap PCR primers 
were used: 
 
RSC-F (sense): 5´ GAG GAG GAG GAG GAG GAG GCG GGG CCC AGG CGG 
CCG AGC TC 3´ 
RSC-B (reverse): 5´ GAG GAG GAG GAG GAG GAG CCT GGC CGG CCT GGC 
CAC TAG TG 3´ 
 
The PCR program was set up: 
Step Temperature Time No. of Cycles 
Stage 1 94
o
C 2 minutes 1 cycle 
Stage 2 94
o
C 15 seconds  
30 cycles  56
o
C 30 seconds 
 72
o
C 2 minutes 
Stage 3 72
o
C 10 minutes 1 cycle 
 4
o
C Hold  
 
The PCR reaction mixture was prepared: 
Component Concentration 50 µL Volume 
Buffer (10x) 1X 10.0 µL 
MgSO4 2mM 2.0 µL 
VH  100 µg 1.9 µL 
VL  100 µg 2.4 µL 
Forward Primer RSC-F 60 pM 0.5 µL 
Back Primer RSC-B 60 pM 0.5 µL 
dNTP  0.2 mM 1.0 µL 
H2O - 30.0 µL 
Platinum
®
 Taq Polymerase 1 U/µL 0.2 µL 
DMSO 3 % 1.5 µL 
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2.13.8 Plasmid purification using Wizard® Plus SV Miniprep DNA purification 
system 
 
The Escherichia coli strain, ER2925, containing the pComb3XSS plasmid was cultured 
on a 2xTY agar plate containing carbenicillin (100 µg/mL) and kanamycin (50 µg/mL). 
A single colony was then taken and inoculated into 10 mL of 2xTY also containing 
carbenicillin and propagated at 37
o
C overnight in an orbital shaker. The Wizard
®
 Plus 
Miniprep DNA purification system (Promega, US) was then used to isolate the 
pComb3XSS plasmid. A 5 mL of overnight culture was used in the miniprep. Once 
completed, the product was quantified using the Nanodrop
TM
 and stored at -20
o
C. 
 
2.13.9 Agarose gel electrophoresis   
 
A 1 % (w/v) agarose gel was prepared by adding 0.5 g of agarose to 50 mL of Tris-
Acetate-EDTA (TAE) buffer and heating to 100
o
C for 2-3 minutes. When the agarose 
was dissolved and partially cooled, 5 µL of SYBR
®
Safe DNA gel stain (Invitrogen) was 
added and poured into a prepared gel mold. DNA loading dye was added to the samples 
prior to loading along with a 1kb Plus DNA molecular weight ladder (Invitrogen) for 
size quantification. The gel was run at a voltage of 100V for approximately 40 minutes, 
viewed using a UV transilluminator Image Master VDS system (Amersham Pharmacia 
Biotech) and imaged using a Fujifilm Thermal Imaging System FT1-500.  
  
2.13.10 DNA agarose Gel purification using QIAquick ™ gel extraction kit   
 
All the DNA samples were gel-purified using the QIAquick Gel Extraction Kit 
(Qiagen). DNA was electrophoresed on a 1 % (w/v) agarose gel. The gel was visualised 
using a Darkreader transilluminator (Clare Chemical Research) and the required bands 
were excised from the gel with a sterile, sharp scalpel. The QIAquick protocol was 
followed and concentrations were obtained by measuring the absorbance at 260nm 
using the Nanodrop
TM
. Samples were stored at -20
o
C.   
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2.13.11 Digestion of scFv insert and pComb3XSS vector using the restriction 
enzyme SfiI  
  
The plasmid DNA and the scFv insert were digested using the SfiI restriction enzyme. 
Absorbances were measured at 260 nm using the Nanodrop
TM
. For the SOE insert, 
digestion was carried at 50
o
C for 5 hours. The digested product was electrophoresed on 
a 1.5 % (w/v) agarose gel and subsequently gel-purified, using the QIAquick gel 
extraction kit. The pComb3XSS vector was digested with SfiI for 5 hours at 50
o
C. After 
digestion, the pComb3XSS vector was treated with Antarctic phosphatase (NEB, ISIS) 
to prevent re-annealing of the vector. The product was electrophoresed on a 0.8 % (w/v) 
agarose gel and gel-purified. 
 
2.13.12 Ligation of SOE insert into pComb3XSS vector   
 
For ligation of the scFv fragment, T4 DNA Ligase (NEB) was incubated with 
pComb3XSS and SOE insert in a 2:1 (insert:vector) ratio at room temperature 
overnight. In addition, ligation controls to check for stuffer contamination and empty 
vectors were also carried out. 
 
2.13.13 Transformation of XL-1 Blue E.coli cells with library ligation 
 
Library ligations were transformed using a Gene Pulser X-cell electroporation system 
(Bio-Rad, USA). Fifty µL of XL-1 Blue electrocompetent cells (Technopath), which 
had been previously thawed on ice, was mixed with 5 µL of ligation mix and stored on 
ice for 1 minute. The samples were then transferred to a pre-chilled electophorator 
cuvette and electophorated at a voltage of 2.5 kV, a capacitance of 2S µF, a resistance 
of 200 Ω and in a 2 mm cuvette. The cuvette was immediately rinsed with 1 mL of SOC 
medium and mixed well. The cells were transferred to a sterile tube containing 2 mL of 
SOC medium. This was incubated for 1 hour at 37
o
C and 100 µL of each ligation was 
plated onto 2xTY agar plates containing carbenicillin (100 µg/mL). The library titre was 
approximately 1X 10
7
 cfu/mL. The plates were incubated overnight at 37
o
C and 
colonies are then analysed using colony-pick PCR. For colony-pick PCR, a single 
colony was taken and inoculated into 5 µL of molecular grade water.  
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The PCR amplification was carried out as per protocol in Section 2.6.8, and 
electrophoresed on a 1 % (w/v) agarose gel.  
   
2.13.14 Antibody selection from immune rabbit scFv library 
2.13.14.1 Rescue of rabbit anti-AZA scFv-displaying phage 
 
Five hundred µL of transformed library was inoculated into 400 mL of 2xTY medium 
(100 µg/mL carbenicillin). The culture was grown at 37
o
C in and orbital incubator until 
an OD600 of 0.4 was reached. The scFv library was rescued by addition of 400 µL of 
commercial M13K07 helper phage (NEB), left static at 37°C for 20 minutes and then 
transferred to a 37
o
C orbital shaker for 2 hours. Next, kanamycin was added, to a final 
concentration of 70 µg/mL, before propogating the culture overnight at 37°C.  
 
2.13.14.2 Enrichment of rabbit phage library via bio-panning against 
immobilised-antigens 
 
A NUNC
TM
 immunotube was coated overnight at 4°C with a 500 µL AZA-BTG in 
sterile-filtered PBS solution (150 mM, pH 7.4) see Table 2.6.19.1. The immunotube 
was blocked with 5 % (w/v) Milk Marvel-PBS (150 mM, pH 7.4) for 2 hours. The 
overnight phage induced scFv library was centrifuged at 3,220 g in a GSM rotor (brake-
on) for 15 minutes at 4
o
C. The phage were then precipitated with 4 % (w/v) PEG and 3 
% (w/v) NaCl for 1 hour at 4
o
C. The PEG-precipitated phage were harvested by 
centrifugation at 18,514 g in a GSM rotor (brake off) for 20 minutes at 4
o
C. The pellet 
was resuspended in 1.5 mL of BTG solution [1 % (w/v) BSA/PBS (150 mM, pH 7.4)] 
and centrifuged. Subsequently 400 µL of this BTG-phage solution was added to a 100 
µL 5 % (w/v) Milk Marvel to a final concentration of 1 % (w/v) milk. Four successive 
rounds of panning were performed (See Table 2.2.20.1).  
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Table 2.13.14.1: Panning Protocol for Azaspiracid Library Screening 
Variable PAN 1 PAN 2 PAN 3 PAN 4 
Coating 
concentration 
of AZA-BTG 
 
100 µg/mL 
 
50 µg/mL 
 
25 µg/mL 
 
12.5 µg/mL 
Number of 
Washes 
5 x PBST 
5 x PBS 
5 x PBST 
5 x PBS 
5 x PBST 
5 x PBS 
5 x PBST 
5 x PBS 
Culture Volume 400 mL 100 mL 100 mL 100 mL 
Phage Volume 400 µL 200 µL 200 µL 200 µL 
 
The coated and blocked immunotube was washed once with PBST (150 mM, pH 7.4) 
and once with PBS (150 mM, pH 7.4). The input is added to the immunotube and left to 
incubate at 37°C for 2 hours. The immunotube was decanted and washed several times 
with PBST and PBS (See Table 2.2.20.1) to remove weak-binding phage. Eight hundred 
μL of 100 mM glycine was added to the immunotube and allowed to stand for 8 
minutes. This eluted the phage-scFv antibodies from the surface antigen. After 8 
minutes, the contents of the immunotube were added to 66 μL 1 M Tris, to neutralise 
the antibodies. This was the output of the first round of panning. For re-infection, 200 
µL of output from the first round of panning was added into 4 mL of XL1-Blue cells 
(OD600 of approximately 0.5) and allowed to infect for 30 minutes at 37
o
C. This was 
plated onto 2xTY plates with 100 µg/mL carbenicillin and incubated overnight at 37
o
C. 
Input and output titres are determined by counting the number of colonies and 
calculating the number of transformants or colony forming units/mL (cfu/mL).  
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2.13.14.3 Polyclonal phage ELISA  
 
A polyclonal phage ELISA was performed with the output phage from the un-panned 
library, Pan 1, Pan 2, Pan 3 and Pan 4. A NUNC
TM
 immunosorbent 96 well plate was 
coated with 10 µg/mL AZA-BTG conjugate in PBS (150 mM, pH 7.4) overnight at 4
o
C. 
The antigen solution was flicked out from the plate, wells were blocked with 3 % (w/v) 
Milk Marvel/PBS (150 mM, pH 7.4) solution, 200 μL per well, at 37˚  for 1 hour. 
Following blocking, the plate was washed three times with PBST followed by three 
times with PBS. 100 μL of outputs from each round of panning was then added to the 
plate. The plate was incubated at 37˚  for 1 hour, following this it was washed as 
above. One hundred μL of a horse-radish peroxidase (HRP)-labelled anti-M13 antibody 
was added to each well, diluted 1/1,000 in a 1 % (w/v) Milk Marvel/PBS (150 mM, pH 
7.4) solution. The plate was incubated at 37˚  for 1 hour. Following incubation, the 
plate was washed as above and 100 µL TMB substrate solution (Sigma-Aldrich, 
Ireland) prepared in 0.05M phosphate-citrate buffer, pH 5.0, was added to each well. 
The 0.05M phosphate-citrate buffer (Sigma-Aldrich, Ireland) solution was prepared by 
dissolving one tablet in 100 mL deionised water. The plate was then incubated for 
approximately 20 minutes under tinfoil to allow for colour development after which the 
reaction was stopped with 50 μL of 10 % (v/v) HCl. The absorbance was then 
determined at 450 nm with a Tecan™ Safire plate reader (Tecan™, UK).  
 
2.13.14.4 Re-infection into Top10F' cells and scFv check via colony-pick PCR 
 
For soluble expression, the output phage from Pan 4 was re-infected into E. coli 
Top10F′. For re-infection, 200 µL of Pan 4 output was added into 4 mL of Top10F′ 
cells (OD600 of approximately 0.5) and allowed to infect for 30 minutes at 37
o
C. This 
was plated onto 2xTY plates with 100 µg/mL carbenicillin and incubated overnight at 
37
o
C. Individual colonies were selected from pan 4 agar plates, inoculated in 50 µL 
sterile water and incubated for 10 minutes at 95
o
C to facilitate cell lysis. This mixture 
was then used as template DNA in the PCR protocol outlined in Section 2.6.8. The 
product was electrophoresed on a 1 % (w/v) agarose gel to check for the presence of 
scFv insert fragments.  
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2.13.14.5 Direct monoclonal ELISA of solubly-expressed scFv fragments 
 
Single colonies, with one colony per well, from pan 4 Top10F′ re-infection plates, were 
inoculated into sterile non-absorbent 96 well plates, containing 200 µL of 2xTY and 
100 μg/mL carbenicillin. These plates were grown at 37oC in an orbital incubator 
overnight. Sixty µL of 50 % (v/v) glycerol was added to each well, to give a final 
concentration of 20 % (v/v) and this plate was stored at -80
o
C as stock. A fresh 96 well 
plate was prepared by adding 170 μL of super broth (SB) with 100 μg/mL carbenicillin 
to each well. A 30 μL culture taken from the stock plate was aseptically transferred to 
inoculate the fresh plate. This was incubated at 37˚  in an orbital incubator and once 
growth was observed, 50 µL of a 5 mM IPTG solution was added, to give a final 
concentration of 1 mM IPTG, and incubated at 30˚  overnight in an orbital incubator. 
The next day, the plates were removed from the incubator and centrifuged at 3,220 g 
(Eppendorf centrifuge 5018R) for 10 minutes. The pellets were resuspended in 100 µL 
sterile MG water. The plate was freeze-thawed to facilitate cell lysis, by incubating at -
80
o
C for 15 minutes, then 37
o
C for 15 minutes and this was repeated 3 times. The plate 
was centrifuged (Eppendorf centrifuge 5018R) at 3,220 g for 10 minutes and 100 µL of 
the supernatant was used for ELISA analysis.  
 
Simultaneously, 96 well  LISA plates (Maxisorp™, NUN ™) were coated with AZA-
BTG and AZA-KLH conjugates in PBS solution (150 mM, pH 7.4) (50 μL per well) 
and incubated overnight at 4°C. The following day, the antigen-coated plate was 
blocked with a 3 % (w/v) Milk Marvel-PBS (150 mM, pH 7.4) solution (200 μL per 
well) for 1 hour at 37°C. The culture supernatant was then added, at 100 μL per well, to 
the coated and blocked ELISA plate and incubated at 37°C for 1 hour. Following 
incubation, the plates were washed three times with PBST (150 mM, pH 7.4) and three 
times with PBS (150 mM, pH 7.4), to remove any unbound scFv. Binding was detected 
using a 1/2,000 dilution of an anti-rabbit, HRP-labelled, secondary antibody (Sigma 
Aldrich, Ireland). After 1 hour at 37° , 100 μL of TMB was added and the reaction was 
left to develop for 20 minutes at 37° . The reaction was stopped with 50 μL per well of 
10 % (v/v) HCl, after which the plate was measured at 450 nm on a Safire II plate 
reader (Tecan™). 
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2.13.15 Conjugation of AZA-2 to protein carriers, BTG and KLH 
 
For the conjugation of AZA-2 to Haemocyanin from Megathura crenulata (keyhole 
limpet) (KLH) (Sigma-Aldrich, Ireland), 0.05 mg toxin material was reacted with 8.5 
mg of KLH protein via reactive amine group coupling. The N-hydroxysuccinimide 
(NHS) ester group reacts with the amine of lysine (κ) residues to produce a stable amide 
bond. Firstly, DCC (dicyclohexylcarbodiimide) was used to activate the amine groups 
on the KLH protein. Subsequently 50 µL DMSO and 50 µL pyridine were added to 50 
µg AZA-2 on ice. After which 1.22 µL of 15 mg/mL DCC was prepared in pyridine, 
was added to the AZA-2 mixture and incubated further for 10 minutes, while stirring on 
ice. Next, a 0.7 µL solution of 15 mg/mL NHS (N-hydroxysuccinimide) that was 
prepared in pyridine, was added and stirred for 30 minutes. The process of DCC and 
NHS addition was then repeated and incubated for 30 minutes. The reaction was 
incubated overnight at 4
o
C, while stirring. The next day, the reaction was stirred for 4 
hours at room temperature, followed by removal of all solvents, except DMSO, using a 
Speedvac for 1 hour. A 28 mg/mL KLH solution was prepared with 0.05M potassium 
phosphatase di-basic (pH 8.2) in a final volume of 300 µL. The reaction was stirred 
slowly on ice, followed by the addition of 50 µg of the toxin ester. The reaction was 
stirred overnight at 4
o
C. A Vivaspin molecular weight cut-off (MWCO) 5,000 column 
(Sartorius, Sarstedt) was used for buffer exchange and to concentrate the final product 
to a final volume of 2 mL in sterile-filtered PBS (150 mM, pH 7.4). The estimated 
concentration of this product was 4 mg/mL. This was stored at 4
o
C.  
 
For the conjugation of AZA-2 to bovine thyroglobulin (BTG) (Sigma Aldrich, Ireland), 
0.15 mg toxin material was reacted with 2 mg of KLH protein via amine group 
coupling. Firstly, 15 mg/mL solutions of NHS and DCC were prepared in pyridine and 
sequentially added to the AZA-2 as before, this time with volumes of 2.1 µL NHS and 
3.66 µL DCC. The reaction was incubated for 30 minutes and stirred overnight at 4
o
C. 
The following day, the reaction was stirred at room temperature for 4 hours. A 
Speedvac was used for 1 hour to remove the solvents. A 10 mg/mL solution of BTG 
was prepared in 200 µL 0.05M potassium phosphate di-basic (pH 8.2). This was added 
to the toxin ester and stirred on ice for 2 hours. The reaction was again stirred overnight 
at 4
o
C.  
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A Vivaspin MWCO 5,000 column (Sartorius, Sarstedt) was used for buffer exchange 
and to concentrate the final product to a final volume of 2 mL in sterile-filtered PBS 
(150 mM, pH 7.4). The estimated concentration of the conjugated product was 1 
mg/mL.  
 
2.13.16 Immunisations of Leghorn chicken with AZA-KLH conjugate 
 
Prior to immunisation, a pre-bleed was taken from a female Leghorn chicken. The 
immunogen, AZA-KLH, was prepared in a final volume of 1 mL in a 1:1 ratio with 
Freund’s complete adjuvant (Sigma Aldrich, Ireland) for the primary immunisation and 
Freund’s incomplete adjuvant (Sigma Aldrich, Ireland) for subsequent immunisations. 
The immunogen was vortexed for 1 hour before immunisation to create a stable 
emulsion. 1 mL of the emulsion was administered to the chicken subcutaneously over 
four sites (250 µL each). For the primary immunisation, the animal was injected with 
100 µg AZA-KLH and for subsequent boosts, 50 µg AZA-KLH was used. A period of 
three weeks was left between each immunisation. A bleed was taken only after the third 
boost to determine the level of immune response. 
 
2.13.17 Pre-concentration and immobilisation of AZA-transferrin onto a CM5 
chip  
 
An AZA-transferrin conjugate (100 µL) was obtained from QUB at a 1 mg/ml 
concentration. Before immobilisation, a pre-concentration study was carried out to 
determine the optimal pH at which to immobilise the conjugate on the negatively 
charged dextran surface of a CM5 sensor chip surface. A pre-concentration study was 
performed using 10mM sodium acetate solution ranging from pH 3.8 to 5. The solutions 
were pH adjusted using 10 % (v/v) acetic acid solution. The AZA-transferrin conjugate 
was diluted at each respective pH to a final concentration of 20 µg/mL and sequentially 
passed over an un-activated carboxymethylated dextran sensor chip surface at a flow 
rate of 5 μL/minute. The pH showing the greatest degree of pre-concentration, shown 
by the highest response unit (RU) value and the sharpest slope was chosen as the buffer 
for immobilisation. The optimal condition was at a pH of approximately 4.0. An attempt 
was also made to immobilise the AZA-BTG conjugate (Prepared by QUB) on a CM5 
chip but change in response was observed at the pre-concentration stage. 
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The carboxymethylated dextran matrix on the sensor chip was activated by mixing 
equal volumes of 100 mM NHS and 400 mM EDC (N-ethyl-N-(dimethyl-aminopropyl) 
carbodiimide hydrochloride) and injecting the mixture over the sensor chip surface at a 
flow rate of 5 μL/minute. The AZA-transferrin conjugate was diluted in 10 mM sodium 
acetate, pH 4.0, to a concentration of 20 µg/mL. This solution was then injected over the 
activated chip surface at a flow rate of 5 μl/minute. A 1M ethanolamine hydrochloride 
solution (pH 8.5) was injected, resulting in both capping of any un-reacted active groups 
and removal of loose non-covalently attached proteins. Finally, loosely bound material 
was further removed using two pulses of 5 mM NaOH. 
 
2.13.18 Direct binding analysis on BiacoreTM 3000 using an AZA-transferrin chip 
 
Dilutions of serum from rabbit R922 (AZA-cBSA-immunised) were prepared in sterile 
HBS buffer, ranging from 1 in 2 to 1 in 1,000. There dilutions were passed over the 
AZA-transferrin-immobilised surface at a flow rate of 5 μL/minute for 20 minutes. A 20 
% (v/v) acetonitrile solution was used for regeneration of the sensor chip surface. 
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2.14 Generation, screening and selection of chicken scFv library for 
microcystin 
2.14.1 Derivatisation and protein conjugation of microcystin-LR  
2.14.1.1 Preparation of aminoethanethiol‐microcystin‐LR 
 
Derivatisation of microcystin‐LR was carried out according to Moorhead et al. (1994). 
Microcystin‐LR (2 mg) was dissolved in ethanol (500 μL) and added to a degassed 
solution of water (750 μL), DMSO (1 mL), 5 N NaOH (335 μL) and aminoethanethiol 
(500 μL, 1 mg/mL). The reaction mixture was incubated at 50ºC for 30 minutes under 
argon. The solution was cooled and glacial acetic acid (3 mL) was added. 0.1 % (v/v) 
TFA in water (24 mL) was added and the pH adjusted to 1.5 with TFA (approximately 
250 μL). The resultant solution was applied to a solid‐phase C18 cartridge (Supelco, 
52606‐U, DSC‐18) previously equilibrated with 0.1 % TFA (v/v) /H2O according to the 
supplier’s instructions. The column was washed with 10 % (v/v) acetonitrile/0.1 % (v/v) 
TFA water and the aminoethanethiol‐Microcystin‐LR eluted with 100 % (v/v) 
acetonitrile/0.1 % (v/v) TFA. Volatile solvent was removed by rotary evaporation and 
the remaining aqueous solution lyophilised overnight to give a glassy solid.  
 
2.14.1.2  HPLC analysis of aminoethanethiol‐microcystin‐LR  
 
At the end of the above reaction period and prior to work up, the reaction mixture was 
analysed by reverse‐phase high-performance liquid chromatography (HPLC) (Vydac 
218TP54, 4.6 mm x 250 mm) employing a helium‐degassed acetonitrile gradient of 
5‐95 % (v/v) acetonitrile (containing 0.1 % (v/v) TFA: water) run at 1.5 mL/minute and 
monitored spectrophotometrically at 230 nm (Figure 2.14.1.1 A). Consistent with 
Moorhead G., et al (1994), the reaction mixture showed conversion of starting material 
to >95 % of a single product peak, which did not co‐elute with a spiked sample of 
MC‐LR (Figure 2.14.1.1 B). 
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Figure 2.14.1.1: Reverse Phase HPLC analysis carried out by Enzo Life Sciences Ltd. 
A.) Analysis to verify presence of derivitised aminoethanethiol-MC-LR. The eluted 
peak at 10.23 minutes demonstrated the aminoethanethiol-derivatised MC-LR. The 
additional peaks are by-products of the derivitisation reaction B.) Analysis of 
aminoethanethiol-MC-LR with a spiked sample of un-derivatised microcystin-LR. The 
derivative at 10.23 minutes remained, with an additional peak at 11.67 minutes, 
corresponding to un-derivatised MC-LR. Conditions: Vydac 218TP54, (4.6 mm x 250 
mm), helium-degassed acetonitrile gradient of 5-95 (v/v) % acetonitrile: water (with 0.1 
(v/v) % TFA). The run was carried out at 1.5 mL/minute and monitored 
spectrophotometrically at 230 nm. 
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2.14.1.3 Preparation of microcystin‐LR‐aminoethanethiol‐BSA conjugate 
 
Aminoethanethiol‐derivatised Microcystin‐LR (~1 mg), as prepared in Section 3.2.1.1, 
was conjugated to bovine serum albumin (BSA) (~3 mg) using a one step 
glutaraldehyde coupling procedure 
 as outlined by Metcalf et al. (2000). The resultant conjugate was dialysed against 0.9 % 
(w/v) saline and supplied in a quantity of 1.2 mL at a concentration of ~2.5 mg BSA per 
mL.  
 
2.14.1.4 Preparation of microcystin‐LR‐aminoethanethiol‐OVA conjugate 
 
Aminoethanethiol‐derivatised Microcystin‐LR (~1 mg) was conjugated to ovalbumin 
(OVA) (~3 mg) using a one step glutaraldehyde coupling procedure as outlined by 
Metcalf et al. (2000). The resultant conjugate was dialysed against 0.9 % (w/v) saline 
and supplied (Enzo Life Sciences, USA) in a quantity of 1.2 mL at a concentration of 
~2.5 mg OVA per mL. 
 
2.14.2 Immunisation of Leghorn chicken with microcystin-LR BSA conjugate 
 
A female Leghorn chicken was immunised over a period of 12 weeks at 3 weekly 
intervals, with 500 µg microcystin–LR conjugated to bovine serum albumin (BSA). The 
injections were mixed and emulsified by vortexing in a 1:1 ratio with Freund’s 
 omplete Adjuvant (F A) for the primary immunisation and with Freund’s Incomplete 
Adjuvant (FIA) for each subsequent immunisation. The emulsions were administered to 
the chicken sub-cutaneously over four sites in a total volume of 1 mL. Bleeds were 
taken at three week intervals to determine the immune response of the animal. The 
chicken was sacrificed and the spleen and two samples of bone marrow from two legs 
were removed with sterile surgical tools in preparation for RNA extraction.  
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2.14.3 MC-LR-BSA chicken scFv library construction 
2.14.3.1 RNA extraction and cDNA synthesis 
 
Extraction from bone marrow and spleen samples was carried out, as described in 
Section 2.13.3, and cDNA was synthesised as described in Section 2.13.4. 
 
2.14.3.2 Amplification of antibody variable domain sequences using PCR 
 
To amplify the V gene rearrangements from the immunised chicken, one VH 
amplification and one VL (λ) amplification were performed. The following PCR primers 
were used: 
 
VH Primers 
CSCVHo-F (sense) 5´ GGT CAG TCC TCT AGA TCT TCC GCC GTG ACG TTG 
GAC GAG 3´ 
CSCG-B (reverse) 5´ CTG GCC GGC CTG GCC ACT AGT GGA GGA GAC GAT 
GAC TTC GGT CC 3´ 
 
VL Primers 
CSCVK (sense) 5´ GTG GCC CAG GCG GCC CTG ACT CAG CCG TCC TCG GTG 
TC 3´ 
CKJo-B (reverse) 5´ GGA AGA TCT AGA GGA CTG ACC TAG GAC GGT CAG G 
3´ 
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For PCR optimisation of the VH and VL regions, a MgCl2 concentration gradient was 
required. The PCR program was set up: 
 
Step Temperature Time No. of Cycles 
Stage 1 94
o
C 10 minutes 1 cycle 
Stage 2 94
o
C 15 seconds  
30 cycles  56
o
C 30 seconds 
 72
o
C 60 seconds 
Stage 3 72
o
C 10 minutes 1 cycle 
 4
o
C Hold  
 
 
The PCR reaction mixtures were prepared: 
 
Component Concentration 50 µL Volume 
GoTaq
®
 Flexi Reaction Buffer (5x) 1X 10.0 µL 
VL/VH Forward Primer 60 pM 0.5 µL 
VL/VH Back Primer 60 pM 0.5 µL 
cDNA  0.5 µg 1.0 µL 
dNTP (10 mM)  0.2 mM 1.0 µL 
MgCl2 and H2O Mix - 36.75 µL 
GoTaq
®
 Flexi DNA Polymerase 1 U/µL 0.25 µL 
 
 
Final MgCl2 conc./ 
per reaction 
1.5 mM 2 mM 3 mM 4 mM 
Volume of MgCl2 (µL) 3 4 6 8 
Volume H2O (µL) 33.75 32.75 30.75 28.75 
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The reaction was repeated in large-scale, using an optimised MgCl2 concentration of 3 
mM for both VH and VL fragments. The products were ethanol-precipitated by adding a 
0.1X volume of 3M sodium acetate, pH 5.2, a 10X volume of 100 % (v/v) ice-cold 
ethanol and 1 µL glycogen, and stored at -20
o
C overnight. The following day, the DNA 
was harvested by centrifuging at 18,514 g for 30 minutes. Subsequently, the ethanol 
supernatant was decanted and the pellet was washed with 70 % (v/v) ethanol and 
centrifuged for 10 minutes (18,514 g) at 4°C. The pellet was allowed to air-dry briefly 
and then gently dissolved in 5 µL of molecular grade H2O. This product was gel-
purified from a 1 % (w/v) agarose gel, using a QiaQuick Gel Extraction Kit (Qiagen) 
(See Section 2.13.10). 
 
2.14.3.3 SOE-PCR using High Fidelity Platinum® Taq DNA polymerase  
 
The purified VH and Vλ fragments were used for SOE-PCR. The following overlap PCR 
primers were used: 
 
CSC-F (sense) 5´ GAG GAG GAG GAG GAG GAG GTG GCC CAG GCG GCC CTG 
ACT CAG 3´ 
CSC-B (reverse) 5´ GAG GAG GAG GAG GAG GAG GAG CTG GCC GGC CTG 
GCC ACT AGT GGA GG 3´ 
 
The PCR program was set up: 
 
Step Temperature Time No. of Cycles 
Stage 1 94
o
C 2 minutes 1 cycle 
Stage 2 94
o
C 15 seconds  
30 cycles  56
o
C 30 seconds 
 72
o
C 2 minutes 
Stage 3 72
o
C 10 minutes 1 cycle 
 4
o
C Hold  
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The PCR reaction mixture was prepared: 
 
Component Concentration 50 µL Volume 
HF Buffer (10X) 1X 10 µL 
MgSO4 2 mM 2 µL 
VH 100 µg 0.34 µL 
VL 100 µg 0.23 µL 
CSC-F 60 pM 0.5 µL 
CSC-B 60 pM 0.5 µL 
10 mM dNTP 0.2 mM 1.0 µL 
H2O - 33.73 µL 
High Fidelity Platinum
®
 Taq 1 U/µL 0.2 µL 
DMSO 3 % 1.5 µL 
 
The approximately 750 bp fragment from this reaction was ethanol-precipitated and 
purified on a 1 % (w/v) agarose gel, using a QiaQuick gel extraction kit (Qiagen). 
 
2.14.3.4 Digestion of scFv insert and pComb3XSS vector using SfiI  
 
The SfiΙ restriction enzyme allows for unidirectional cloning of the scFv fragment 
library into the pComb3XSS vector. The enzyme recognises 8 bases which are 
interrupted by 5 random nucleotides (5′ ggccnnnnnggcc 3′), thus eliminating internal 
digestion in antibody sequences. 
 
Digests of the scFv insert and pComb3XSS vector were prepared as follow: 
 
Component 150 µL Volume 
SOE product (50 µg) 74.63 µL 
10X Buffer 2 15 µL 
100 X BSA 1.5 µL 
H20 43.87 µL 
SfiΙ (6 U/ µg) 15 µL 
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Component 50 µL Volume 
pCom3xSS vector (20 µg) 3.7 µL 
10X Buffer 2  5 µL 
100 X BSA 0.2 µL 
H20 25.1 µL 
SfiΙ (16 U/ µg) 16 µL 
 
Digestions were incubated for 5 hours at 50
o
C. Both digests were separated by 
electrophoresis on a 1 % (w/v) agarose gel and gel-purified, as described. 
 
2.14.3.5 Treatment of pComb3XSS vector with antarctic phosphatase  
 
In order to prevent pComb3XSS vector re-ligation without insert, the digested vector 
was treated with Antarctic phosphatase (NEB). Antarctic phosphatase (AP) causes the 
removal of 5´ phosphate groups from DNA. Since DNA fragments treated with AP lack 
the 5´ phosphate group needed by ligase, they cannot self-ligate. This would potentially 
decrease vector background in cloning. The reaction was prepared as follows: 
 
Reagent Volume 
Antarctic phosphatase buffer 20 µL 
Restricted pComb3XSS vector 200 µL 
Antarctic phosphatase  16 µL 
 
The reaction was incubated for 25 minutes at 15
o
C and the enzyme was de-activated for 
5 minutes at 65
o
C. 
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2.14.3.6 Ligation of SOE insert into pComb3XSS vector   
 
The restricted scFv fragment library was ligated into the pComb3XSS vector in a 2:1 
(insert:vector) ratio under the conditions below and incubated overnight at room 
temperature. 
 
Component 200 µL Volume 
10X Ligase buffer 20 
Digested pComb3XSS vector (1.4 µg) 3.4 
Digested SOE insert (700 ng) 7.5 
H2O 159.1 
T4 DNA Ligase (400 U/ µL) 10 
 
The ligations were ethanol-precipitated, as described in Section 3.2.3.2. 
 
2.14.4 Phage screening from a microcystin-specific immune library 
2.14.4.1 Library transformation and rescue of chicken scFv-displaying phage 
 
The ethanol-precipitated library ligations were centrifuged for 20 minutes at 4
o
C at 
18,514 g. The resulting pellets were washed twice with 1 mL 70 % (v/v) EtOH and 
dried briefly. The pellets were resuspended in 10 µL sterile MG H2O and stored on ice. 
Commercial electro-competent E.coli XL1-Blue cells (Stratagene) were thawed on ice. 
100 µL of cells were added to each library ligation and pipetted up and down. This was 
stored on ice for 1 minute. Electro-cuvettes (Bio-Rad
®
) were pre-chilled prior to 
transformations. The ligation:cell mixture was electroporated at 2.5 kV, 25 µF and 200 
Ω using a Bio-Rad® electrophorator. The electro-cuvette was washed with 1 mL pre-
warmed SOC media and transferred to 15 mL tubes, containing 3 mL SOC media. This 
was followed by incubated for 1 hour at 37
o
C in an orbital shaker. Serial dilutions of the 
transformed library were prepared, from 10
-1
 to 10
-8 
and 100 µL was plated onto LB 
agar plates, containing carbenicillin (100 µg/mL), which were incubated at 37
o
C 
overnight. The total transformants was the number of colonies, multiplied by the culture 
volume (25 mL) and divided by the plating volume (0.1 mL).   
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The library was transferred to a flask containing 600 mL 2xTY with 100 µg/mL 
carbenicillin and 20 µg/mL tetracycline and the cells were grown to an optical density 
(OD) of 0.6. 1 mL of 1X10
11 
pfu/mL M13KO7 helper phage (NEB) was added and the 
culture was incubated stationary at 37
o
C for 30 minutes. The culture was then 
propagated at 37
o
C for 2 hours in an orbital shaker. Subsequently, 50 µg/mL kanamycin 
was added and the culture was propagated overnight at 30
o
C. The overnight phage 
library was centrifuged at 10,414 g in a GSA rotor (brake off) for 20 minutes. The 
phage supernatant was transferred to 250 mL sorval tubes. Phage were precipitated by 
addition of PEG (4 % w/v) and NaCl (3 % w/v), dissolved in an orbital shaker for 20 
minutes at 37
o
C and placed on ice for 30 minutes. The precipitated phage were 
centrifuged at 10,414 g in a GSA rotor (brake off) for 15 minutes at 4
o
C. The 
supernatant was discarded and the phage pellet dried by inversion for 10 minutes. The 
pellet was resuspended thoroughly in 2 mL 1 % (w/v) BSA/PBS (150 mM, pH 7.4) and 
transferred to a 2 mL microcentrifuge tube. The solution was centrifuged (Herlme 
Microlitre centrifuge Z 233 M-2) at 15,000 g for 5 minutes to remove debris and 0.02 % 
(w/v) sodium azide was added before storage at 4
o
C.  
 
2.14.4.2 Enrichment of chicken phage library by bio-panning  
The overnight phage library was centrifuged at 10,414 g (brake off) for 20 minutes. The 
phage supernatant was transferred to an 85 mL Nalgene
®
 centrifuge tubes and PEG (4 
% w/v) and NaCl (3 % w/v) added. The tubes were shaken for 20 minutes at 37
o
C to 
dissolve the PEG and NaCl, after which the tubes were placed on ice for 30 minutes. 
Subsequently, phage were precipitated by centrifuging at 10,414 g (brake off) for 15 
minutes at 4
o
C. The supernatant was discarded and the resulting pellet dried on tissue. 
The pellet was re-suspended thoroughly in 2 mL of 1 % (w/v) BSA/PBS (150 mM, pH 
7.4) and transferred to a 2 mL micro-centrifuge tube. The solution was centrifuged 
(Herlme Microlitre centrifuge Z 233 M-2) at 15,000 g for 5 minutes at 4
o
C, after which 
the supernatant was transferred to a fresh micro-centrifuge tube with 0.02 % (w/v) 
sodium azide and the solution stored at 4
o
C. An immunotube (Nalgene
®
) was coated 
overnight with MC-LR-OVA, according to coating concentrations specified in Table 
3.2.3.1. The next day, the tube was blocked with 3 % (w/v) BSA/PBS (150 mM, pH 
7.4) for 1 hour at 37
o
C. The immunotube was washed in PBS / 0.05 % (v/v) Tween 20. 
1 mL of phage library, as prepared in Section 2.14.4.1, was placed in the immunotube 
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and incubated, rotating, for 2 hours at room temperature. The unbound phage were then 
carefully removed and the immunotube was washed, as specified in Table 2.14.4.1. One 
mL of 10 mg/mL trypsin, prepared in PBS (150 mM, pH 7.4) was added in the 
immunotube for 30 minutes at 37
o
C, followed by vigorous pipetting. A total of 800 µL 
of output phage were re-infected into a 5 mL XL-1 Blue culture, with an OD600 of 0.6, 
and incubated static for 15 minutes at room temperature. The phage-infected culture 
was added to 6 mL of warm SB media containing 1.6 µL 100 mg/mL carbenicillin and 
12 µL 5 mg/mL tetracycline, and incubated for 1 hour at 37
o
C in and orbital shaker. A 
further 4 µL of 100 mg/ml carbenicillin was added and incubated for an additional 1 
hour at 37
o
C. M13K07 helper phage (800 µL, NEB) was added to the culture and this 
helper phage-infected culture was then added to 88 mL warm SB media, containing 46 
µL carbenicillin and 184 µL tetracycline. The culture was propagated for 2 hours at 
37
o
C. Subsequently, 140 µL 50 mg/ml kanamycin was added and incubated overnight at 
37
o
C in an orbital shaker. 
 
Output titres were prepared by preparing dilutions of the phage output in XL-1 Blue and 
plating on 2xTY agar plates, containing 100 µg/mL carbenicillin. Input titres were made 
by preparing dilutions of input phage in SB media and re-infecting into XL1-Blue cells 
(OD600 of 0.6) for 15 minutes at room temperature. These re-infected cultures were then 
plated and all plates were incubated at 37C overnight. 
 
Table 2.14.4.1: Panning Protocol for Microcystin Library Screening 
Variable PAN 1 PAN 2 PAN 3 PAN 4 PAN 5 
Coating 
Concentration 
 
100 µg/mL 50 µg/mL 25 µg/mL 10 µg/mL 5 µg/mL 
Number of 
Washes 
 
5 x PBST 
5 x PBS 
5 x PBST 
5 x PBS 
10 x PBST 
10 x PBS 
15 x PBST 
15 x PBS 
15 x PBST 
15 x PBS 
Culture 
Volume 
600 mL 100 mL 100 mL 100 mL 100 mL 
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2.14.4.3 Analysis of anti-microcystin scFvs by soluble monoclonal ELISA 
 
For re-infection and soluble expression, 200 µL of Pan 5 output was added into 4 mL of 
E. coli Top10F′ cells (OD600 of approximately 0.5) and allowed to infect for 30 minutes 
at 37
o
C. This was plated onto 2xTY plates with 100 µg/mL carbenicillin and incubated 
overnight at 37
o
C. Individual colonies were picked from these plates and analysed by 
colony-pick PCR, as described in Section 2.13.14.4. A large number of single colonies 
(384) were picked, solubly expressed and incorporated into a direct ELISA to identify 
scFv fragment binding. The picked clones were grown overnight in an orbital incubator 
at 37°C in 96 well plates, containing 100 μL 2xTY media with 100 μg/mL carbenicillin. 
These stock plates were then sub-cultured into 180 μL SB media, containing 100 μg/mL 
carbenicillin and glycerol was added to the stock plates to a final concentration of 15 % 
(v/v) and stored at -80°C 
 
The sub-cultured plates were incubated at 37°C in an orbital incubator until an OD600 of 
~0.6 was reached. Expression was then induced by addition of IPTG at a final 
concentration of 1 mM and incubating at 30°C in an orbital incubator. In addition, 96 
well ELISA plates (Maxisorp™, NUN ™) were coated with 5 μg/mL microcystin-OVA 
in PBS solution (150 mM, pH 7.4) (50 μL per well) and incubated overnight at 4° . The 
following day, the antigen-coated plate was blocked with a 3 % (w/v) Milk Marvel-PBS 
(150 mM, pH 7.4) solution (200 μL per well) for 1 hour at 37° . Meanwhile, the 
overnight expression plates were freeze-thawed for the production of scFv-enriched 
lysate. The plates were placed at -80°C until frozen and then thawed at 37°C. This step 
was repeated a total of 3 times. The plates were then centrifuged at 3,220 g 
( ppendorf™  entrifuge 5810 R) for 15 minutes to isolate the scFv-enriched lysate 
supernatant. The resulting supernatant was then added, at 100 μL per well, to the coated 
and blocked ELISA plate, and incubated at 37°C for 1 hour. Following incubation, the 
plates were washed three times with PBST (150 mM, pH 7.4) and three times with PBS 
(150 mM, pH 7.4), to remove any unbound scFv. Binding was detected using a 1/2,000 
dilution of an anti-chicken, HRP-labelled, secondary antibody (Sigma Aldrich, Ireland). 
After a one hour incubation at 37° , 100 μL of TMB was added and the reaction was 
left to develop for 20 minutes at 37° . The reaction was stopped with 50 μL per well of 
10 % (v/v) HCl, after which the absorbance of the wells was measured at 450 nm on a 
Safire II plate reader (Tecan™). 
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2.14.4.4 Analysis of anti-microcystin scFvs by competition ELISA 
 
Fresh ‘scFv-rich’ lysate was prepared from 10 mL cultures, as described in Section 
3.2.5. A 96 well ELISA plate was coated overnight at 4
o
C with 5 µg/mL microcystin 
conjugate or carrier alone (50 μL per well). The plate was blocked with 3 % (w/v) Milk 
Marvel-PBS (150 mM, pH 7.4) solution (200 μL per well) for 1 hour at 37° . The scFv-
enriched lysate from each clone was incubated on the coated plate with varying 
concentrations of free microcystin-LR (1,000 to 3.9 ng/mL) for 1 hour at 37
o  (100 μL 
per well). The scFvs ability to bind free microcystin was then determined by 
comparison of the absorbance response (A) to A0. The A0 represents the absorbance of 
the same lysate without free toxin. The captured avian scFv was detected using an anti-
HA monoclonal antibody (HRP-labelled). After each stage, the ELISA plate was 
washed three times with PBST (150 mM, pH 7.4) and three times with PBS (150 mM, 
pH 7.4). Binding was detected using TMB substrate, stopped with 10 % (v/v) HCl and 
measured at 450 nm with a Safire II plate reader. 
 
2.14.5 Restriction digestion profiling 
 
Restriction digestion was carried out on the amplified SOE product with the enzyme, 
AluI. The amplified SOE products were obtained by carrying out a colony-pick PCR, as 
described in Section 2.13.14.4, using the chicken overlap extension primers (CSC-F and 
CSC-B). The PCR amplified SOE product was digested with the frequent cutting 
enzyme, AluI for 2 hours at 37
o
C, using the following conditions: 
 
Components Total 20 µL volume 
10x buffer 2 2 µL 
SOE product 8 µL 
AluI enzyme 0.5 µL 
100 X BSA 0.2 µL 
Water 9.3 µL 
 
The digestion products were electrophoresed on a 1 % (w/v) agarose gel and visualised 
using a UV light box.  
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2.14.6 Large-scale production of anti-microcystin scFvs and purification using 
immobilised metal affinity chromatography  
 
Overnight cultures of the 2 selected clones, 2H1 and 2G1, were grown in 10 mL SB 
media, containing 100 μg/mL carbenicillin, by inoculating a single colony from a stock 
plate and growing overnight at 37°C in an orbital shaker. Five mL of this overnight 
culture was then inoculated into 500 mL fresh SB media containing 100 μg/mL 
carbenicillin. The sub-cultured clones were incubated at 37°C in and orbital incubator 
until an OD600 of approximately 0.6 to 0.8 was reached. The cultures were then induced 
by addition of IPTG to a final concentration of 1 mM and incubating at 30°C before 
propagating overnight. The overnight-expressed culture was transferred into sterile 50 
mL tubes and centrifuged at 3,220 g for 30 minutes (Eppendorf 3810R), to pellet the 
bacterial cells. The supernatant was discarded and the excess media removed by 
inversion of the 50 mL tube onto a paper towel. The cell pellet was thoroughly 
resuspended in 5 mL of lysis buffer (Table 4.2.1.1) and put on ice. The sample was kept 
on ice and sonicated at an amplitude of 40 % for 6 second pulses for 3 minutes using a 
microtip Vibra Cell
TM
 sonicator. The cell extract was centrifuged (Herlme Microlitre 
centrifuge Z 233 M-2) at 15,000 g for 20 minutes at 4
o
C, in order to remove cell debris. 
The lysate supernatant was then passed through a 0.2 μM filter to remove any residual 
cell debris.  
 
Purification of scFv fragments using immobilised metal affinity chromatography 
(IMAC) was carried out using Ni
+
-NTA agarose resin (Novagen). Two mL of Ni
+
-NTA 
agarose resin was added to a 20 mL column and allowed to settle for 10 minutes. The 
column was equilibrated using 4 mL of lysis buffer (Section 2.2.4). The filtered lysate 
was passed through the column. The ‘flow-through’ was collected and passed through 
the column twice more. A 100 µL sample of this flow-through was kept for analysis on 
SDS-PAGE gel. The column was washed once with 8 mL wash buffer A (Section 2.2.4) 
and twice with 8 mL wash buffer B (Section 2.2.4) to remove any loosely bound non-
specific proteins. The wash fractions were collected for SDS-PAGE analysis. The 
protein was eluted with 10 mL of elution buffer (Section 2.2.4) and twenty 0.5 mL 
fractions were collected in 1.5 mL tubes. The protein concentration of each fraction was 
measured at 280 nm using the Nanodrop™ ND-1000. The fractions containing a 
sufficient quantity of protein were pooled and thoroughly buffer exchanged against 20 
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mL filter-sterilised PBS (150 mM, pH 7.4) using a 5 kDa molecular weight ‘cut-off’ 
 ivaspin™ 6 column (AGB). The buffer exchanged scFv was again quantified using 
the Nanodrop™ ND-1000, aliquoted and stored at -20°C. 
 
2.14.7 Size-exclusion chromatography of IMAC-purified scFvs  
 
To separate affinity-purified scFv molecules from dimers and higher aggregates, and to 
control stability of separated monomers, size exclusion chromatography was performed. 
A HiLoad™ Superdex 200 16/60 column (GE Healthcare Ltd) was equilibrated with 
three column volumes of PBS (150 mM, pH 7.4) at a flow rate of 2 mL/minute. A 1 mL 
sample of concentrated antibody was passed through a 0.2 µm filter and manually 
injected onto the 2 mL loop. Size exclusion was carried out on a AKTA™ FPL  system 
(GE Healthcare Ltd) using an pre-programmed method running on UNI ORN™ 
control software. A typical scFv size exclusion run was carried out at a flow rate of 0.5 
mL/minute with sterile filtered (0.2 µM), degassed PBS (150 mM, pH 7.4). Fractions of 
5 mL were automatically collected using a fraction collector (Frac-950). The system and 
column was cleaned between runs using distilled water and 20 % (v/v) ethanol.  
 
2.14.8 Size determination of scFv by size-exclusion chromatography 
 
A set of protein standards (Phenomenex Ltd.) was utilised to determine the exact 
molecular weight of the scFv molecule through comparison with the known molecular 
weights of the proteins used. The protein standard mixture contained; bovine 
thyroglobulin (670 kDa), human gamma globulin (150 kDa), ovalbumin (44 kDa), 
myoglobulin (17 kDa) and a separate vial containing uridine (244 Da). The protein 
standard kit consisted of 10 mg human gamma globulin, 5 mg bovine thyroglobulin, 5 
mg ovalbumin and 2 mg myoglobin. The uridine sample contained 2 mg in total. The 
standard mixture was reconstituted with 1 mL of 100mM phosphate buffer, 100 µL of 
protein mixture and 6 µL of uridine sample. Of this, 10 µL was injected in a total 
volume of 500 µL, resulting in a protein mixture in the approximate following final 
concentrations: human gamma globulin (100 µg/mL), bovine thyroglobulin (50 µg/mL), 
ovalbumin (50 µg/mL), myoglobin (20 µg/mL) and uridine (12 µg/mL). The standard 
run was carried out at a flow rate of 0.5 mL/minute in PBS running buffer (150 mM, pH 
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7.4). The protein for size determination was subsequently loaded, after cleaning of the 
column and system, as described. 
 
2.14.9  ScFv purification analysis by SDS-PAGE and western blotting 
 
The purified scFv fragments were analysed for their purity and to verify correct 
molecular weight by separation on a 12.5 % (w/v) SDS-PAGE gel, using a Bio-rad
®
 gel 
electrophoresis apparatus (Bio-Rad
®
). The preparation of all separation and stacking 
gels and buffers for SDS-PAGE was outlined in Section 2.2.3. The separation gel was 
prepared, cast between two clean glass plates and left to polymerise. After the gel 
polymerised, a stacking gel was prepared, poured and wells were formed using a 1mM 
plastic comb, for loading of protein samples. The samples were prepared by addit ion of 
appropriate volumes of 4X loading dye and deionised water and heated (to facilitate 
protein denaturation) for 5 minutes at 95
o
C. Each protein sample was added into each 
well in a total volume of 20 µL. The gels were placed in an electrophoresis apparatus 
and submerged in 1X electrophoresis buffer. The gel was run at 100V until the tracker 
dye had reached the bottom of the gel, taking approximately 1 hour. The gels were 
taken out and stained using Coomassie Blue for 1 hour and the de-stained for 3-4 hours, 
using Coomassie de-stain solution, until the protein band is clearly visible and the 
background was removed. 
 
Western blot analysis was also carried out to confirm the results obtained by SDS-
PAGE and ELISA. SDS-PAGE gels were prepared, as outlined above, loading 20 µg 
protein per well. Six sheets of Whatman
®
 Gel Blot paper (Sigma) and one sheet of 3 
mm Protran BA 85 Nitrocellulose membrane (Carl Stuart Ltd.) were cut to the same 
dimensions as the SDS-PAGE gel and soaked in ice-cold transfer buffer (Section 2.2.4) 
for 30 minutes. The SDS-PAGE gel was also soaked in transfer buffer. Three layers of 
the soaked blotting paper were placed between the electrodes of Trans-Blot
®
 Semi-Dry 
Transfer cell (Bio-Rad
®
) apparatus. The nitrocellulose membrane was placed over the 
blotting paper, followed by the SDS-PAGE gel containing the resolved proteins to be 
transferred. The gel was sandwiched by placing three more sheets of blotting paper on 
top. Any air bubbles were removed by carefully rolling each of the layers with a 
disposable 10 mL serological pipette. Proteins were transferred from the gel to the 
nitrocellulose by applying 15 V electric current for 15 minutes. The nitrocellulose 
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membrane was blocked with 20 mL of 5 % (w/v) Milk Marvel/PBS solution (150 mM, 
pH 7.4) overnight at 4°C. The blocked membrane was washed 3 times with PBST (150 
mM, pH 7.4) and three times with PBS (150 mM, pH 7.4), followed by incubation with 
20 mL of 1 % (w/v) milk/PBST solution containing a rat monoclonal anti-HA-HRP 
labelled antibody (1/2,000), for 1 hour at room temperature with gentle agitation. The 
membrane was then washed 3 times with PBST (150 mM, pH 7.4) and three times with 
PBS (150 mM, pH 7.4). The membrane was developed by the addition of TMB 
substrate for western blotting (Sigma). Once sufficient colour development had 
occurred, the reaction was stopped by repeatedly washing with distilled water. 
 
2.14.10 Inhibition ELISA for detection of MC-LR in solution 
 
A 96 well ELISA plate was coated overnight at 4
o
C with 500 ng/mL of MC-LR-OVA 
conjugate (50 μL per well). The plate was blocked with 3 % (w/v) Milk Marvel-PBS 
(150 mM, pH 7.4) solution (200 μL per well) for 1 hour at 37° . The purified scFv 
fragments, at an optimised dilution (1/20,000) was incubated on the coated plate with 
varying concentrations of free microcystin-LR (200 to 0.78 ng/mL) for 1 hour at 37
o
C 
(100 μL per well). The scFvs ability to bind free microcystin was then determined by 
comparison of the absorbance response (A) to A0. The A0 represents the absorbance of 
the scFv fragment without free toxin. The captured avian scFv was detected using an 
anti-HA monoclonal antibody (HRP-labelled). After each stage, the ELISA plate was 
washed three times with PBST (150 mM, pH 7.4) and three times with PBS (150 mM, 
pH 7.4). Binding was detected using TMB substrate, stopped with 10 % (v/v) HCl and 
measured at 450 nm with a Safire II plate reader. 
 
2.14.11 Inter- and Intra-day ELISA analysis of avian scFvs 
 
Inter-day and intra-day assay studies were performed to verify the accuracy and precision of 
the ELISA inhibition format. The standard curve was generated (n=3) on a single day (intra-
day) and on three consecutive days (inter-day) and the mean and standard error were 
calculated (n=3). The percentage coefficients of variation (% CV) were determined for each 
concentration and calibration curves were generated from the data with a four-parameter 
equation, using BIAevaluation™ software. The percentages accuracies were calculated for 
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each concentration of MC-LR from the curve, according to current assay validation 
techniques (DeSilva et al., 2003; Kelley and DeSilva, 2007) 
 
2.15 Mutagenesis of scFv clone, 2H1, by error-prone PCR and chain shuffling 
2.15.1 Amplification of variable heavy chain gene from 2H1 scFv clone  
 
The 2H1 wild type clone was chosen for mutagenesis studies. A stored plasmid 
preparation of the clone in the pComb3x phagemid vector was used for amplification of 
the VH region for chain shuffling with the light chain mutant library. For gene 
amplification of the VH region, the following PCR program was set up: 
 
Step Temperature Time No. of Cycles 
Stage 1 94
o
C 10 minutes 1 cycle 
Stage 2 94
o
C 15 seconds  
30 cycles  56
o
C 30 seconds 
 72
o
C 60 seconds 
Stage 3 72
o
C 10 minutes 1 cycle 
 4
o
C Hold  
 
The PCR reaction mixtures were prepared: 
 
Component Concentration 50 µL Volume 
GoTaq
®
 Flexi Reaction Buffer 
(5X) 
1X 10.0 µL 
VH Forward Primer 60 pM 0.5 µL 
VH Back Primer 60 pM 0.5 µL 
pComb3x (2H1) 0.5 µg 1.0 µL 
dNTP (10 mM)  0.2 mM 1.0 µL 
MgCl2 (25 mM) 1.5 mM 3.0 µL 
H2O - 33.75 µL 
GoTaq
®
 Flexi DNA Polymerase 
(5 U/µL) 
1 U/µL 0.25 µL 
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The product from this reaction was ethanol-precipitated and purified on a 1 % (w/v) 
agarose gel, using a QiaQuick gel extraction kit (Qiagen). 
 
2.15.2 Amplification of the avian light chain library using error-prone PCR and 
light chain shuffling 
 
Light chain shuffling of the 2H1 clone against the original, un-panned avian scFv 
library (microcystin-specific) was carried out. A total of 50 µL of the phage library (Pan 
1 Input-See Section 2.14.4.1), previously stored at -80
o
C, was infected into XL-1 Blue 
E.coli cells (OD 0.6 - 0.8) containing 20 µg/mL tetracycline. The culture was incubated 
at room temperature for 15 minutes and 5 µL of 100 mg/mL carbenicillin was 
subsequently added. The culture was shaken in an orbital shaker for 1 hour at 37
o
C. The 
phage library was titred at this stage to ensure phage infectivity and library was found to 
have 5 x 10
7
 cfu/mL, which was sufficient for further work. A further 45 µL 
carbenicillin was added to the culture in 45 mL of pre-warmed media and the culture 
was shaken overnight at 37
o
C. A large-scale plasmid purification was carried out the 
next day using a NucleoSpin
®
 Xtra Midi Plasmid Purification Kit (Macherey-Nagel).  
 
For error-prone PCR of the VL gene library, the following PCR program was set up 
using RedTaq
® 
DNA polymerase:  
 
Step Temperature Time No. of Cycles 
Stage 1 94
o
C 10 minutes 1 cycle 
Stage 2 94
o
C 1 minute  
30 cycles  55
o
C 2 minute 
 72
o
C 3 minute 
Stage 3 72
o
C 10 minutes 1 cycle 
 4
o
C Hold  
 
Error-prone PCR reactions were prepared with a higher concentration of MgCl2 (7 mM) 
compared to a basic PCR reaction (1.5 mM). The purpose of this was to stabilise non-
complementary nucleotide pairing. Manganese chloride (MnCl2) can also be added to 
increase the error-rate of amplification and the mutation rate was also modified by 
varying the ratios of nucleotides in the reaction. The optimal MnCl2 concentration for 
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the PCR reaction was empirically determined using an initial concentration gradient of 
10 to 40 µM. This concentration range was chosen as DNA polymerases are often 
inhibited at high MnCl2 concentrations. The PCR reaction mixtures were prepared as 
follows: 
 
Component Stock 
Concentration 
Final 
Concentration 
50 µL Volume 
RedTaq
®
 Reaction 
Buffer  
10X 1X 5.0 µL 
VL Forward Primer 100 µM 0.4 µM 0.2 µL 
VL Back Primer 100 µM 0.4 µM 0.2 µL 
Plasmid Prep  100 mg/mL  100 ng  0.1 µL 
dGTP  100 mM  0.2 mM 0.1 µL 
dATP  100 mM  0.2 mM 0.1 µL 
dTTP  100 mM  1 mM 0.5 µL 
dCTP  100 mM  1 mM 0.5 µL 
dH2O - - 24.8-18.8 µL 
MgCl2  25 mM 7 mM 14 µL 
MnCl2 250 µM 10-40 µM  2-8 µL 
RedTaq
®
 DNA 
Polymerase 
1 U/µL 0.05 U/µL  2.5 µL 
 
The products from this reaction were pooled, ethanol-precipitated and purified on a 1 % 
(w/v) agarose gel, using a QiaQuick gel extraction kit (Qiagen). 
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In order to introduce further errors into the sequence, PCR reactions were set up with 
varying concentration of template (light chain of avian library in pComb3x vector). A 
high error rate was introduced by using a low concentration of template (6 ng total) and 
a low error rate was introduced by using a high concentration of template (600 ng total). 
A higher concentration of Red Taq
®
 polymerase was also incorporated:  
 
Component Stock 
Concentration 
Final 
Concentration 
50 µL Volume 
RedTaq
®
 Reaction 
Buffer  
10X 1X 5.0 µL 
VL Forward Primer 100 µM 0.4 µM 0.2 µL 
VL Back Primer 100 µM 0.4 µM 0.2 µL 
Plasmid Prep  100 mg/mL  6/ 600 ng 0.06/ 6 µL 
dGTP  100 mM  0.2 mM 0.1 µL 
dATP  100 mM  0.2 mM 0.1 µL 
dTTP  100 mM  1 mM 0.5 µL 
dCTP  100 mM  1 mM 0.5 µL 
dH2O - -  22.34/ 16.4 µL 
MgCl2  25 mM 7 mM 14 µL 
MnCl2 250 µM 10 µM 2 µL 
RedTaq
®
 DNA 
Polymerase 
1 U/µL 0.1 U/µL 5 µL 
 
The products from this reaction were pooled, ethanol-precipitated and purified on a 1 % 
(w/v) agarose gel, using a QiaQuick gel extraction kit (Qiagen). 
 
2.15.3 SOE PCR for mutant library construction 
 
The purified VH (2H1) and VL error-prone amplification products were used for SOE-
PCR using Phusion
® 
Taq DNA polymerase. The overlap PCR primers, CSC-F and CSF-
B, as described, were used for amplification. 
 
120 
 
The PCR program was set up: 
 
Step Temperature Time No. of Cycles 
Stage 1 98
o
C 6 minutes 1 cycle 
Stage 2 98
o
C 15 seconds  
30 cycles  56
o
C 30 seconds 
 72
o
C 90 seconds 
Stage 3 72
o
C 10 minutes 1 cycle 
 4
o
C Hold  
 
The PCR reaction mixture was prepared: 
 
Component Concentration 50 µL Volume 
HF Buffer (10X) 1X 10 µL 
MgSO4 2 mM 2 µL 
VH (2H1) 100 µg 0.34 µL 
VL (EP) 100 µg 0.23 µL 
CSC-F 60 pM 0.5 µL 
CSC-B 60 pM 0.5 µL 
10 mM dNTP 0.2 mM 1.0 µL 
H2O - 33.73 µL 
High Fidelity Platinum
®
 Taq 1 U/µL 0.2 µL 
DMSO 3 % 1.5 µL 
 
The approximately 750 bp fragment from this reaction was ethanol-precipitated and 
purified on a 1 % (w/v) agarose gel, using a QiaQuick gel extraction kit (Qiagen). 
 
Re-cloning of the mutated scFv library into the pComb3XSS vector was carried out as 
described. The scFv insert and the pComb3X vector were first digested using SfiI 
(Section 2.14.3.4). In order to prevent pComb3XSS vector re-ligation, the digested 
vector was treated with Antarctic phosphatase (NEB) (Section 2.14.3.5). Library 
ligation and transformation were carried out according to Section 2.14.3.6 and Section 
2.14.4.1, respectively. 
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2.16 Selection and characterisation of mutant clones 
2.16.1 Enrichment of the mutagenised avian phage library by biopanning, 
against immobilised MC-OVA. 
 
Bio-panning was carried out, as described in Section 2.14.4.2, with a number of 
modifications. Phage rescue was carried out from overnight phage culture (600 mL) 
(Section 2.14.4.1). For the first three rounds of panning, trypsin elution was used to 
isolate phage from the immunotube. In subsequent rounds, the phage were split so that 
both trypsin elution and competitive elution were carried out simultaneously (Table 
2.16.1.1 ). The washing steps were increased in stringency over the successive rounds of 
biopanning. 
 
For bio-panning rounds 4 and 5, a competitive elution strategy was employed. After the 
phage had been incubated for two hours at room temperature on the immunotube, the 
unbound phage were removed and the tube was washed the required number of times 
(See Table 2.27.1) with PBST. The bound phage were eluted from the immunotube with 
1 mL of free MC-LR toxin for 2.5 hours at room temperature. The competitively-eluted 
output phage were re-infected into 5 mL XL-1 Blue culture (O.D.600 of 0.6) and 
incubated static at room temperature for 15 minutes. After phage re-infection, bio-
panning was carried out as described in Section 2.14.4.2. A library size of 2.14 x 10
7
 
cfu/mL was obtained for the light chain shuffle library. 
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Table 2.16.1.1: Bio-panning strategy for enrichment of mutagenised avian MC library 
 PAN 1 PAN 2 PAN 3 PAN 4 PAN 5 
Coating 
Concentration 
(Trypsin 
Elution) 
50 µg/mL 2 µg/mL 100 ng/mL 5 ng/mL 0.25 ng/mL 
Coating 
Concentration 
(Competitive 
Elution) 
50 µg/mL 2 µg/mL 100 ng/mL 100 ng/mL 100 ng/mL 
Competitive 
Elution 
Solution 
- - - 500 ng/mL  5 ng/mL 
Number of 
Washes 
5 x PBST 
5 x PBS 
5 x PBST 
5 x PBS 
10 x PBST 
10 x PBS 
15 x PBST 
15 x PBS 
15 x PBST 
15 x PBS 
Culture 
Volume 
400 mL 100 mL 100 mL 100 mL 100 mL 
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2.16.2 Selection and screening from light chain-shuffled library 
2.16.2.1 Polyclonal phage ELISA of mutant library 
 
The outputs from each round of bio-panning was analysed by direct ELISA using HRP-
labelled anti-M13 antibody. This procedure is described in detail in Section 2.24.4.3.  
2.16.2.2 Soluble monoclonal and inhibition ELISA of mutant avian scFvs 
 
Soluble monoclonal ELISA was carried out on clones from round 4 and round 5 from 
the light-chain shuffled mutant scFv library. Both competitively and trypsin-eluted 
phage were re-infected into Top10F' E. coli cells and soluble-expressed scFvs were 
analysed by direct ELISA, as described in Section 2.14.4.3. Inhibition analysis of the 
resulting clones was performed by ELISA with free MC-LR (See Section 2.14.4.4). 
 
2.17 Development of Biacore™ inhibition assay for microcystin and 
microcystin congeners 
2.17.1 Immobilisation of MC–LR onto a CM5 sensor chip for BiacoreTM 
inhibition analysis 
 
For immobilisation of MC-LR onto the sensor chip surface, a direct conjugation 
strategy was undertaken on the laboratory bench. This procedure was carried out in 
Queen’s University, Belfast, as part of a collaborative project, by a Ph.D student, 
Shauna Devlin. Firstly, equal volumes of EDC (N-ethyl-N'-(dimethylaminopropyl) 
carbodiimide) and NHS (N-hydroxysuccinimide) were pre-mixed and applied to a CM5 
chip surface in a 50 µL volume. This was incubated at room temperature for 30 minutes, 
protected from light. MC-LR (0.5 mg, Enzo) was dissolved in 25 µL 100 % (v/v) EtOH 
and made up to 100 µL with 75 µL dH2O, which was added dropwise. One hundred µL 
0.6mM CTAB, 0.10 mM HEPES, pH 7.4, was mixed with 100 µL 5 mg/mL of prepared 
MC-LR in 25 % (v/v) EtOH. The EDC/NHS mixture was removed from the chip 
surface and 50 µL MC-LR/CTAB/HEPES mixture was applied. This was incubated at 
room temperature overnight, protected from light. The mixture was removed from the 
chip surface the next day and 50 µL 1M ethanolamine-HCl, pH 8.5, was applied. This 
was incubated at room temperature for 20 minutes, protected from light. The chip was 
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washed with 2-3 drops of dH2O and dried under N2. The chip was stored at 4
o
C until 
required.  
 
2.17.2 Optimisation of assay parameters 
 
To determine the optimal flow rate and contact time for use on the immobilised MC-LR 
chip, a range of different flow rates and contact times were investigated. Contact times 
of 4 minutes, 2 minutes and 48 seconds, each at flow rates of 5, 10 and 25 μL/minute 
were evaluated. This was to determine what parameters gave the highest response 
change with respect to analyte concentration. To assess the stability of the immobilised 
surface, regeneration scouting was performed. A known concentration of antibody was 
passed over the chip surface, and the surface regenerated using a panel of different 
regeneration solutions. The solutions used included 10 mM glycine at pH of 1.5, 2.5 and 
3.0, 1 M NaCl, 10 mM HCl, pH 1.3, 50 mM HCl, pH 1.3, 20 mM NaOH, pH 12, 20 
mM NaOH/ 1 % (v/v) Acetonitrile, pH 12, and 200 mM NaOH, pH 12. The 
regeneration studies demonstrated that two pulses of 200 mM NaOH for 1 minute was 
the most effective regeneration buffer.  
 
2.17.3 SPR inhibition analysis of scFv clones 
 
Analysis was performed using a Biacore™ 3000 instrument and data analysis was 
performed using BIAevaluation™ 3.0 (BIAcore™, Uppsala, Sweden). The binding 
ability of the scFvs was assessed with the microcystin-LR-immobilised sensor chip 
surface. A dilution of the IMAC-purified scFv clones in HBS buffer was passed over 
the sensor chip at a flow rate of 5 µL/minute for 4 minutes. Bound scFvs were 
dissociated with a pulse of 200 mM NaOH and the baseline was restored with the 
injection of HBS running buffer over the chip surface. For the inhibition studies, an 
optimal scFv dilution was mixed with free microcystin toxin, MC-LR in an optimal 
1:10 ratio, at concentrations ranging from 300 to 0.69 ng/mL. These were analysed 
using a flow rate of 25 µL/minute with 2 minute injections. The surface was regenerated 
with two pulses of 200 mM NaOH for 1 minute. 
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2.17.4 Cross-reactivity studies of 2H1 and 2G1 clones on Biacore™ 3000 
 
For the cross-reactivity analysis using Biacore™ inhibition, an optimal scFv dilution 
was mixed with free microcystin toxins, MC-LR, MC-LW, MC-LF, MC-LA, MC-RR 
and MC-YR, at concentrations ranging from 300 to 0.69 ng/mL in HBS assay buffer. 
Toxin: antibody dilutions were pre-incubated for 30 minutes at room temperature prior 
to analysis. Samples were analysed using a flow rate of 25 µL/minute with 2 minute 
injections. The surface was regenerated with two pulses of 200 mM NaOH for 1 minute. 
The inhibition analysis for each toxin cogener was performed in triplicate. The IC50 
values of the calibration curve, for each respective toxin cogener, was directly compared 
to that of MC-LR to determine the degree of cross reactivity. 
 
2.17.5 Inter- and intra-day for Biacore™ assay development 
 
Inter-day and intra-day assay studies were performed to verify the accuracy and precision of 
the Biacore™ inhibition format. The standard curve was generated (n=3) on a single day 
(intra-day) and on three consecutive days (inter-day) and the mean and standard error were 
calculated (n=3). The percentage coefficients of variation ( % CV) were determined for 
each concentration and calibration curves were generated from the data with a four-
parameter equation, using BIAevaluation™ software. The percentages accuracies were 
calculated for each concentration of MC-LR from the curve.  
 
2.18 Fluorescence immunoassay development 
2.18.1 Generation of an antibody response to microcystin in a leporine host 
 
A New Zealand white rabbit was immunised over a period of 12 weeks at 3 weekly 
intervals, with 500 µg microcystin–LR conjugated to ovalbumin (OVA) in 1 mL. The 
injections were mixed and emulsified by vortexing in a 1:1 ratio with Freund’s 
 omplete Adjuvant (F A) for the primary immunisation and with Freund’s Incomplete 
Adjuvant (FIA) for each subsequent immunisation. The emulsion was administered to 
the rabbit sub-cutaneously over four sites (250 µL at each site). Bleeds were taken at 
three week intervals to determine the immune response of the animal. The rabbit was 
sacrificed and approximately 100 mL of blood was harvested. The blood was allowed to 
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clot at 4
o
C and was centrifuged at 18,514 g for 30 minutes to remove all cellular 
content. The serum was aliquoted into 2 mL volumes and stored at -20
o
C.  
 
2.18.2 Protein-G purification of anti-microcystin immunoglobulin G (IgG) from 
leporine serum 
 
A 2 mL suspension of immobilised protein G (immobilised on Sepharose 4B, stored in 
sterile-filtered PBS containing 20 % (v/v) ethanol) was equilibrated in a column with 30 
mL of sterile-filtered PBS (150 mM, pH 7.4). Five mL of serum from the sacrificed 
rabbit was thawed on ice and pooled and made up to a final volume of 10 mL with 
sterile-filtered PBS (150 mM, pH 7.4). The diluted pAb-rich serum was then passed 
through the column and the eluant collected and passed through the column twice more. 
A total of 30 mL of wash buffer (sterile-filtered PBS, 150 mM, pH 7.4) was passed 
through the column and the bound IgG was eluted with 0.1 M glycine-HCl buffer (pH 
2.5). Protein G binds the Fc portion of IgG. Fractions of eluate were collected in micro-
centrifuge tubes containing 150 μL of neutralisation buffer (2 M Tris-HCl, pH 8.5). This 
step allowed for the neutralisation of the highly acidic environment of the elution 
buffer, thus preventing denaturation of the eluted IgG. The fractions were quantified 
using the NanoDrop™ ND-1000 spectrophotometer employing an extinction coefficient 
of 13.7 at 280 nm. The fractions containing high concentrations of IgG were pooled, 
buffer-exhanged on a  ivaspin™ 5,000 MW O column into sterile-filtered PBS (150 
mM, pH 7.4) and stored at -20°C. Verification of the purification was carried out by 
separating and visualising the purified IgG using SDS-PAGE (See Section 2.2.3). 
 
2.18.3 Labelling of scFvs and IgG antibodies with Alexa Fluor® 647 dye 
 
An Alexa Fluor
®
 647 protein labelling kit (Molecular Probes) was employed to directly 
label both IgG and scFv molecules with fluorescent dye. The reactive dye possesses a 
succinimidyl ester moiety which reacts with primary amines on the protein to form 
stable amide bond-linked dye:protein conjugates. Conjugates of Alexa Fluor
® 
647 have 
an absorption and emission fluorescence maxima of 650 nm and 668 nm, respectively. 
Each fluorescence labelling reaction contained 1 mg of scFv or 2 mg of IgG in a volume 
of 500 µL. Accurate protein quantification was carried out using a Modified Lowry 
protein assay kit (Pierce). A 1M solution of sodium bicarbonate was prepared, as per the 
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manufacturer’s instructions, and the antibody of interest was diluted to a concentration 
of 2 mg/mL in 500 µL sterile-filtered PBS (150 mM, pH 7.4). Fifty µL of 1M sodium 
bicarbonate was added to the antibody solution. Sodium bicarbonate (pH ~ 8.3) 
functions to raise the pH of the reaction mixture, as succinimidyl ester groups react 
efficiently at pH 7.5 to 8.5. A vial of reactive dye was allowed to warm to room 
temperature, the antibody solution was directly added and the dye was allowed to fully 
dissolve. The reaction was stirred for 1 hour at room temperature. 
 
 Purification of the labelled antibody from un-reacted antibody and free dye was carried 
out using size exclusion chromatography on a Bio-Rad
®
 BioGel P-30 purification resin. 
The resin was packed into a 10 mL chromatography column and allowed to settle. The 
sample was directly loaded and allowed to enter the resin bed. The reaction vial was 
rinsed with 100 µL of elution buffer (PBS, 150 mM, pH 7.4) and the solution was 
allowed to enter the column. Elution buffer was diluted from a 10X stock solution and 
contained 0.1M potassium phosphate, 1.5M NaCL pH 7.2, with 2 mM sodium azide. To 
separate and elute the antibody and dye components, elution buffer was added to the 
resin. The dye:antibody conjugate was distinguishable from the free dye, because two 
blue band fronts could be observed. The first band front representing labelled-protein 
and the latter front represented unincorporated dye. All eluted fractions were collected. 
 
To determine the degree of labelling, the absorbance of the dye:antibody conjugate 
fractions were calculated at 280 nm and 650 nm (A280 and A650), using a Nanodrop™ 
ND-1000 spectrophotometer. The molar concentration of antibody and the number of 
moles of dye/ mole of antibody were calculated as follows: 
 
Antibody  oncentration  M    
 A280    A650  0.03     Dilution Factor
Molar  xtinction  oefficient of Antibody
 
 
Moles Dye per mole antibody   
A650  Dilution Factor
239,000   Antibody  oncentration (M)
 
 
A correction factor of 0.03 was incorporated to account for the absorption of dye at 280 
nm. The molar extinction coefficient of the Alexa Fluor
®
 647 dye is 239,000 M
-1
 cm
-1 
at 
650 nm. The molar extinction coefficient of a typical IgG is 203,000 000 M
-1
 cm
-1
. The 
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molar extinction coefficient of the scFv molecule was calculated in three ways. Firstly, 
a value of 51,130 M
-1
 cm
-1 
was extracted from the literature (Pace et al., 1995; 
Grovender et al., 2004). The ProtParam Expasy Tool 
(http://web.expasy.org/protparam/) was utilised to calculate the extinction coefficient of 
the 2G1 scFv as 38,390 M
-1
 cm
-1
. The ProParam tool computes parameters including: 
molecular weight, theoretical pI, amino acid composition, atomic composition, 
extinction coefficient, estimated half-life, instability index, aliphatic index and grand 
average of hydropathicity (GRAVY), using the molecular sequence of the protein. Also, 
the molecular weight of the 2G1 scFv was extrapolated from a protein standard curve 
using size exclusion chromatography to give a value of 29,649 M
-1
 cm
-1
. It was clear 
that an average of 1 mole of dye was incorporated per mole of the 2G1 scFv (mean of 
three extrapolated values) and approximately 6 moles of dye was incorporated per mole 
of protein G purified-rabbit IgG. 
 
Antibody Molar extinction coefficient (M
-1
 cm
-1
) Moles dye/ Mole Antibody 
2G1 scFv clone 51,130 (Typical scFv) 
38,390 (Calculated from ProtParam) 
29,649 (Extrapolated by Size Exclusion) 
1.30 
0.96 
0.74 
Rabbit IgG 
 
203,000 (Typical IgG) 5.70 
 
2.18.4 Biotinylation of scFv and IgG antibodies 
 
The size exclusion chromatography-purified chicken anti-MC scFvs (2G1 and C12) and 
protein G-purified rabbit IgG were biotinylated using Sulfo-NHS-Long Chain (LC)-
Biotin (Pierce). Sulfo-NHS-LC-Biotin can be used for the efficient labelling of 
antibodies through conjugation to primary amino groups (-NH2) to form stable amide 
bonds. N-Hydroxysuccinimide (NHS)-activated biotins react with primary amines found 
in the side chain of lysine residues and the N-terminus of peptides that are available for 
labelling. Prior to conjugation the molar antibody concentration and amount of biotin to 
add to the reaction had to be calculated. A 100-fold molar excess of biotin reagent was 
incubated with the antibody to ensure a high ratio level of biotin per antibody molecule. 
Two milligram of antibody was used for each reaction. 
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The millimoles (mmol) of biotin reagent to add to the antibody to have a 100-fold molar 
excess were calculated using the equation: 
 
mmol Biotin   mL protein x 
mg protein
mL protein
 x 
1 mmol protein
mg protein
 x 
100 mmol Biotin
1 mmol protein
 
 
To calculate the microlitres of 10 mM biotin reagent solution required to add to the 
antibody conjugation reaction, the following equation was used:  
 
µL Biotin for reaction   mmol Biotin x 
1,000,000 µL
L
 x 
L
10 mmol
 
 
Directly prior to use, the sulfo-NHS-LC biotin was equilibrated at room temperature 
and a 10 mM biotin solution was prepared by dissolving the required amount of biotin 
in ultra pure H2O. The required volume of biotin was then incubated with the protein 
solution for 2 hours on ice. After the incubation period, the biotinylated antibody was 
buffer-exchanged to remove any un-reacted biotin. This was carried out using a 
 ivaspin™ 10,000 MWCO (molecular weight cut-off) spin column. The column was 
centrifuged at 3,220 g until all the solution was removed and the column was washed 
and centrifuged three times with 10 mL sterile-filtered PBS (150 mM, pH 7.4). The 
labelled antibody was then collected, adjusted to the required concentration and stored 
at -20
o
C in aliquots.  
 
2.18.5 Biotin quantification 
 
Successful labeling with biotin will depend on the number and distribution of available 
amino groups on the antibody, the protein concentration and the ratio of reagents used. 
The degree of biotin incorporation onto the scFv and IgG molecules was determined 
using the biotin quantification kit (Pierce). In this procedure, the biotinylated antibody 
was incubated with a mixture of HABA and avidin. The inherent high affinity of avidin 
for biotin resulted in the displacement of the HABA from avidin and the absorbance at 
500 nm decreased proportionately.  
 
The HABA/avidin mixture was warmed to room temperature and re-constituted by 
adding 100 µL of ultrapure water. One hundred and sixty µL of sterile-filtered PBS 
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(150 mM, pH 7.4) was pipetted into a NUNC™ microtitre plate and 20 µL of the 
HABA/ avidin mixture was added. This was mixed well by vortexing and the 
absorbance measured at 500 nm (A500 HABA/avidin). Twenty µL of the biotinylated 
protein were added to the well and the solution was mixed well again. Biotinylated HRP 
of a known biotin:HRP ration of 1:1.4, was used as a positive control for all reactions. 
The HABA/avidin/biotin absorbance at 500 nm was determined (A500 
HABA/avidin/biotin). The moles of biotin per mole of protein was calculated using the 
Beer Lambert Law: 
Aλ =ελbC 
 
A is the absorbance at a particular wavelength (λ), ε is the absorptivity or extinction 
coefficient at the wavelength (λ). b is the cell path length expressed in centimetres (cm). 
For the microtitre plate format the path length is 0.5 cm. C is the concentration of the 
protein sample expressed in molarity (= mol/L = mmol/mL). To calculate the number of 
moles of biotin per mole of antibody, the concentration of biotinylated antibody in 
mmol/mL needed to be calculated as: 
 
mmol antibody per mL   
Antibody  oncentration (mg/mL)
MW of Antibody (mg mmol )
 
 
The calculated molecular weight (MW) of the scFv was 29,648 grams/mole, as 
determined by size exclusion chromatography (See Section 2.14.7) and the typical MW 
of an IgG was 150,000 grams/mole. The change is absorbance at 500 nm between the 
HABA/avidin (H/A) alone and the HABA/avidin/biotin (H/A/B) mixture was calculated 
as: 
∆A500   A500 H/A    A500H A /B  
 
This change in absorbance value was then incorporated into an equation to calculate the 
concentration of biotin in mmol/mL: 
 
mmolBiotin mL  Reaction  
∆A500
 34,000 x b 
 
 
131 
 
b is the pathlength (cm) which is equal to 0.5 for a microtitre plate and the extinction 
coefficient of HABA/avidin at 500 nm is equal to 34,000 M
-1
cm
-1
. The number of moles 
of biotin per mole of antibody can then be calculated as: 
 
mmol Biotin mmol Antibody   
 mmol mL Biotin  10  Dilution Factor 
mmol mL Antibody
 
 
The biotinylated protein was diluted by a factor of 10 in the original reaction mixture 
(10) and an addition dilution factor was also incorporated if the sample was further 
diluted prior to the assay. 
 
Table 2.18.5.1: Quantification of biotin in reaction after antibody biotin-labelling with 
Sulfo-NHS-LC-Biotin 
Antibody format Biotin incorporation ratio 
(mmol biotin/mmol protein) 
IgG 6.70  
C12 2.00  
2G1 2.27  
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2.18.6 Optimisation of fluorescence immunoassay conditions 
2.18.6.1 Optimisation of fluorescence parameters for fluorescence immunoassay 
development 
 
Fluorescence parameters were established using a direct immunoassay format where 
100 µL of a 500 ng/mL MC-OVA solution was coated on a NUNC™ black Maxisorp® 
plate and a 1 in 100 dilution of Alexa Fluor
®
-labelled anti-MC IgG was incubated for 1 
hour at 37
o
C. The plate was washed three times with PBS (150 mM, pH 7.4) and three 
times with PBST (150 mM, pH 7.4) and 100 µL PBS was pipetted into each well before 
a fluorescence measurement was taken. A wavelength absorption scan was performed 
with an excitation wavelength between 550 nm and 750 nm and a fixed emission 
wavelength of 668 nm. The gain and Z position were calculated automatically from the 
wells and were 79 arbitrary units and 6000 µM, respectively. A wavelength emission 
scan was performed with a fixed excitation wavelength of 650 nm and an emission 
wavelength of between 550 nm and 750 nm. The gain and Z position were calculated 
automatically from the wells and were 72 arbitrary units and 9900 µM, respectively. 
The step size was set at 5 nm and the excitation and emission bandwidths were both set 
at 5 nm for each scan. For each experiment, the gain was set at 255 arbitrary units (in 
order to maximise the fluorescence signal) and the Z position was calculated 
individually for each plate on a Safire II plate reader (Tecan™). 
                           
2.18.6.2 Checkerboard immunoassay for Alexa Fluor® 647-labelled anti-
microcystin antibodies  
 
A 96 well black microtitre plate (Maxisorp™, NUN ™) was coated with varying 
concentrations of microcystin conjugate (0.5 to 16 µg/mL), in sterile-filtered (150 mM, 
pH 7.4) and incubated overnight at 4°C. The following day, the conjugate-coated plate 
was blocked with a 5 % (w/v) Milk Marvel/ PBS solution (200 μL per well) for 1 hour 
at 37°C. Either Alexa Fluor
®
-labelled polyclonal antibody or Alexa Fluor
® 
- labelled 
2G1 scFv, were serially diluted in 1 % (w/v) Milk Marvel in PBST (1/100 to 1/12,500) 
and 100 μL was added in triplicate to the coated and blocked wells and incubated at 
37°C for 1 hour. Following incubation, the plates were washed using three times with 
PBST (150 mM, pH 7.4) and three times with PBS (150 mM, pH 7.4) to remove any 
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unbound antibody. For detection, 100 μL PBS (150 mM, pH 7.4) was pipetted into each 
well before a fluorescence measurement was taken with an excitation and emission 
wavelength of 646 nm and 674 nm, respectively.  
2.18.6.3 Competitive immunoassay with Alexa Fluor® 647-labelled anti-
microcystin antibodies 
 
A 96 well black microtitre plate (Maxisorp™, NUN ™) was coated with microcystin-
OVA conjugate at an optimised concentration of 4 µg/mL and incubated overnight at 
4
o
C. The following day, the coated plate was blocked with a 5 % (w/v) Milk 
Marvel/PBS solution (200 μL per well) for 1 hour at 37° . Dilutions of MC-LR (10X 
concentrated) were prepared from a stock solution of 10 µg/mL in 50 % (v/v) 
methanol/dH20, ranging in concentration from 0.8 - 2000 ng/mL. Optimised antibody 
concentrations (1/500 for 2G1- Alexa Fluor
®
 647 and 1/2000 for IgG - Alexa Fluor
®
 
647) were prepared in 1 % (w/v) Milk Marvel/ PBST. Toxin preparations were diluted 
1/10 in the antibody solution and incubated for 30 minutes at room temperature. One 
hundred μL was added in triplicate to each well of the coated and blocked plate and 
incubated at 37°C for 1 hour. The plate was then washed three times with PBST (150 
mM, pH 7.4) and three times with PBS (150 mM, pH 7.4), to remove any unbound 
material. For detection, 100 μL PBS (150 mM, pH 7.4) was pipetted into each well 
before a fluorescence measurement was taken on a Tecan™ Safire II reader, using 
excitation and emission wavelengths of 646 nm and 674 nm, respectively.  
2.18.6.4 Checkerboard immunoassay for biotinylated anti-microcystin antibodies  
 
For the biotinylated antibodies, coating and blocking were carried out as described in 
Section 2.18.6.2, this time with an optimal coating concentration of 0.5 µg/mL. Either 
biotinylated polyclonal antibody or biotinylated 2G1 or C12 scFv, were serially diluted 
in 1 % (w/v) Milk Marvel in PBST and 100 μL was added in triplicate to the coated and 
blocked wells and incubated at 37°C for 1 hour. Following incubation, the plates were 
washed using three times with PBST (150 mM, pH 7.4) and three times with PBS (150 
mM, pH 7.4) to remove any unbound antibody. Serial dilutions of streptavidin-Alexa 
Fluor
®
 647 conjugate or streptavidin – HRP conjugate were prepared in 1 % (w/v) Milk 
Marvel in PBST and added to the plate. After a one hour incubation at 37°C, the plates 
were washed as before. For fluorescence detection, 100 μL PBS (150 mM, pH 7.4) was 
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pipetted into each well before a fluorescence measurement was taken with an excitation 
and emission wavelength of 646 nm and 674 nm respectively. For colorimetric 
detection, TMB substrate was then added (100 μL per well) and left to react for 15 
minutes at room temperature. The reaction was quenched by the addition of 100 μL per 
well of 10 % (v/v) HCl, after which the absorbance was determined at 450 nm on a 
Safire II plate reader (Tecan™). 
2.18.6.5 Competitive immunoassay with biotinylated anti-microcystin antibodies 
and streptavidin conjugates 
 
A 96 well black microtitre plate (Maxisorp™, NUN ™) was coated with microcystin-
OVA conjugate at an optimised concentration of 0.5 µg/mL and incubated overnight at 
4
o
C. The following day, the coated plate was blocked with a 5 % (w/v) Milk 
Marvel/PBS solution (200 μL per well) for 1 hour at 37° . Dilutions of MC-LR (10X 
concentrated) were prepared from a stock solution of 10 µg/mL in 50 % (v/v) methanol/ 
dH20, ranging in concentration from 2000 to 0.8 ng/mL. Optimised antibody 
concentrations (1/10,000 2G1-Biotin, 1/2,000 C12-Biotin and 1/2,000 IgG-Biotin) were 
prepared in 1 % (w/v) Milk Marvel/ PBST. Toxin preparations were diluted 1/10 in the 
antibody solution and incubated for 30 minutes at room temperature. One hundred μL 
was added in triplicate to each well of the coated and blocked plate and incubated at 
37°C for 1 hour. The plate was then washed three times with PBST and three times with 
PBS (150 mM, pH 7.4) to remove any unbound material. 
 
For fluorescence detection, a solution of streptavidin Alexa Fluor
®
 647 (1/1,000) was 
prepared in 1 % (w/v) Milk Marvel/ PBST and 100 μL was incubated in each well for 1 
hour at 37°C. After the incubation period, the wells were washed, as described, and 100 
μL PBS (150 mM, pH 7.4) was pipetted into each well before a fluorescence 
measurement was taken with an excitation and emission wavelength of 646 nm and 674 
nm, respectively. For colorimetric detection, solutions of streptavidin-HRP (IgG-Biotin 
1/2,000, C12-Biotin 1/2,600 and 2G1-Biotin 1/1,000) was prepared in 1 % (w/v) Milk 
Marvel/ PBST and 100 μL was incubated in each well for 1 hour at 37°C. After the 
incubation period, the wells were washed, as described, and TMB substrate was added 
(100 μL per well) and left to react for 15 minutes at room temperature. The reaction was 
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quenched by the addition of 100 μL per well of 10 % (v/v) HCl, after which the 
absorbance was determined at 450 nm on a Safire II plate reader (Tecan™). 
 
2.18.7 Functionalisation of glass substrates for fluorescence-based slide assay 
 
All glass slides (75 mm x 25 mm) are cleaned before silanisation, to remove any debris 
and to ensure a clean surface for functionalisation. The slides were cleaned by 
sonicating in a solution of 4 % (v/v) Hellmanex
®
 in distilled water for 1 hour. 
Hellmanex
®
 II is an alkaline liquid detergent which produces an effective cleaning 
solution for glass surfaces when mixed with water. The slides are rinsed with distilled 
water and subsequently silanised using a solution of 2 % (v/v) 
aminopropyltriethoxysilane (APTES) in 95 % (v/v) molecular grade ethanol. After 30 
minutes, the slides were rinsed with 95 % (v/v) absolute ethanol and cured at 60
o
C for at 
least 2 hours. After baking, functionalised slides were stored in a dessicator for up to 
two weeks until ready to use. Prolonged storage beyond one month could reduce the 
efficacy of the slides.  
 
2.18.8 Fluorescence-based slide immunoassay for sensitive microcystin detection 
 
Poly-ʟ-Lysine-coated slides (VWR international) and APTES-treated glass slides 
(Section 2.29.7) were both used for slide-based immunoassay development. Adhesive 
micro-well cartridges were prepared by Dr. Robert Gorkin, School of Physical 
Chemistry, DCU, using laser cutting technology. Briefly, the well structures were 
created by laser machining (Zing 16 Laser, Epilog) using a laminate of double-sided 
pressure sensitive adhesive (PSA, Adhesives Research) and poly(methylmethacrylate) 
(PMMA) sheets (Radionics). In the design, the depth of the well was determined by the 
thickness of the PMMA (1.5mm), while the tacky nature of the PSA allowed for easy 
assembly. Following production, the carrier layer of the PSA was removed and the top 
polymer assembly could then be adhered to the poly-ʟ-lysine and APTES-treated glass 
slides. For an immunoassay, the cartridges was attached to the slides and secured 
carefully with a hand-held roller to prevent leakage. 
 
All incubations were carried out in a simple humidity container to prevent drying. The 
wells were coated with microcystin-LR-OVA or BSA conjugate at an optimised 
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concentration in 60 μL and incubated overnight at 4oC. The following day, the coated 
slide was blocked with a 5 % (w/v) Milk Marvel/PBS solution (100 μL per well) for 1 
hour at 37°C. Dilutions of MC-LR (10X concentrated) were prepared from a stock 
solution (10 µg/mL) in 50 % (v/v) methanol/ dH2O. Optimised antibody concentrations 
were prepared in 1 % (w/v) Milk Marvel/ PBST. Toxin preparations were diluted 1/10 
in the antibody solution and incubated for 30 minutes at room temperature. Sixty μL of 
the antibody:toxin mixture was added in duplicate to each well of the coated and 
blocked slide and incubated at 37°C for 30 minutes. The slide was washed carefully 
twice with PBST (150 mM, pH 7.4) and twice with PBS (150 mM, pH 7.4) to remove 
any unbound material.  
 
Binding could now be directly quantified if the detection antibody was directly labelled 
with Alexa Fluor
®
 647. If the detection antibody was biotinylated, a secondary 
streptavidin- Alexa Fluor
®
 647 (1/1,000) was prepared in 1 % (w/v) Milk Marvel/ PBST 
and 100 μL was incubated in each well for 1 hour at 37°C. After the incubation period, 
the wells were washed, as described, and the slide divider was carefully removed. 
Fluorescence was quantified using a Perkin Elmer Scanarray Express fluorescence 
scanner with a 633 nm
 
excitation laser (Gain: 80 %, Resolution: 5 µM). The Alexa 
Fluor
® 
647 dye has maximum excitation and emission wavelength of 640 and 668 nm, 
respectively. Advanced Image Data Analysis (AIDA) software was employed to 
quantify fluorescence intensity. Square measurement
 
areas of identical size were placed 
over each fluorescent spot, and the
 
fluorescence intensities were quantified and 
compared. 
 
Figure 2.18.8.1: Adhesion of PMMA micro-well cartridge to functionalised-glass 
substrate, using attached PSA adhesive strip. Sixteen well were laser cut in total, with a 
maximum volume of 100 µL per well. 
Treated glass substrate
PMMA micro-well cartridge
Laser-cut mico-wells
PSA adhesive
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CHAPTER 3 
Effect of phycotoxin and mycotoxin 
exposure on murine macrophage cells 
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3.1 Introduction 
 
The work described in this chapter focused on how products of naturally-occurring 
microalgae and fungi may affect the signaling pathways and associated immune 
functions of macrophages. The immunomodulatory effect of the algal toxins, 
azaspiracid and microcystin, as well as the mycotoxins, aflatoxin B1, B2 and G1, were 
analysed on the basis of their ability to repress immune function in response to LPS, a 
bacterial cell wall component. This work may aid in the understanding of how toxins 
exert their toxic effects to suppress the immune system in humans and animals. 
 
The J774A.1 murine macrophage cell line was utilised in the course of this research. 
The J774A.1 cell line originating from cultured murine lymphoblastoid cells 
(Snyderman et al., 1977). The study of continuous cell line, such as murine cells with 
macrophage properties provides important information concerning biochemical 
parameters associates with certain macrophage functions. Macrophages isolated from 
murine peritoneal cavity are commonly used for studying the activation properties of 
this immunologically important cell type. However, the behaviour of the J775A.1 
murine model closely mimics the physiological behaviour of a human macrophage in 
vivo, making it an ideal candidate to study the effects of immunotoxicity in vitro. 
 
3.1.1 Effect of azaspiracid on immune cell function 
 
Early toxicological studies to analyse the effect of azaspiracid (AZA) on cultured cells 
demonstrated that AZA was cytotoxic to a hepatocellular carcinoma cell line (HepG2) 
and a human bladder carcinoma cell line (ECV-304), following a 24 hour exposure to 
crude mussel extracts (Flanagan et al., 2001). This cytotoxic effect was also confirmed 
using purified toxin with a number of human, mouse and rat cell lines (Twiner et al., 
2005). Twiner and colleagues showed that AZA-1 was cytotoxic to a number of 
different cell lines (kidney, lung, neuronal, pituitary and immune cell cultures), both in a 
concentration- and time-dependent manner. The Jurkat T-lymphocyte cell line was one 
found to be most sensitive to AZA-1, and significant contraction and elimination of 
actin-containing pseudopodia was observed. However, the cytotoxic effects of AZA 
appeared to be broad-spectrum in action overall, which correlated with previous 
pathological studies in mice (Ito et al., 2000; 2002). These studies in mice demonstrated 
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that AZA targeted the liver, lung, pancreas, thymus, spleen and especially the murine 
small intestine. In the later study, T- and B-cell necrosis occurred in the lymphoid 
tissues (thymus, spleen and Peyer’s patches) and in lamina propria of the small 
intestine. Chronic exposure to AZA was associated with the development of lung 
tumours in mice (Ito et al., 2002).  
 
Román et al. (2002) demonstrated that AZA had marked effects on cytosolic calcium 
(Ca
2+
), cAMP and F-actin in human T-cells and neuroblastoma cells. The actin 
cytoskeleton has a key role in signal transduction and regulatory pathways. F-actin 
depolymerisation or disruption results in reduced cell proliferation. A change in 
intracellular calcium concentration is one of the main pathways by which information 
from the extracellular environment is transferred into the cell. Calcium is generally 
maintained at low levels in the cytosol, through sequestering by the mitochondria and 
the smooth endoplasmic reticulum. Calcium release from intracellular stores leads to 
signalling protein activation, resulting in cell injury and cell death. It has been suggested 
that AZA-4, unlike any other AZA analogue, is a novel inhibitor of plasma membrane 
Ca
2+
 channels (Alfonso et al., 2005). In this report, it was demonstrated that AZA-4 
inhibited Ca
2+
 entry by membrane channels in human T-lymphocytes. Alteration in 
intracellular pH and cytosolic Ca
2+
 levels was also demonstrated in human lymphocytes 
in relation to AZA-1 to 5 (Alfonso et al., 2008). The variable effect of different AZA 
analogs on intracellular calcium modulation has been attributed to differences in 
chemical structure. This would indicate that the presence of a methyl or a hydroxyl 
group can significantly affect changes in calcium influx. To further investigate the 
significant effect of AZA-1 on T-lymphocytes, whole genome microarray analysis was 
employed to assess the differential expression of genes over a period of 24 hours 
(Twiner et al., 2008). This analysis revealed increased expression of the low-density 
lipoprotein receptor (LDLR), which is involved in cholesterol biosynthesis. Analysis 
revealed that a number of other gene expression pathways were also targeted, including 
the insulin/glucagon pathway, the WNT signaling pathway, and other pathways that are 
involved in inflammation, ion channel activities, the cytoskeleton, and cell 
growth/division. In a recent review, it was highlighted that azaspiracids are significantly 
different from other classes of toxins, as they possess unusual toxicity profiles, resulting 
in erratic and unpredictable intoxication patterns (Furey et al., 2010).  
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3.1.2 Effect of microcystin on immune cell function 
 
It was widely reported that microcystin toxicity is associated with the inhibition of the 
serine/threonine protein phosphatases (PP) 1 and 2A at the cellular level (MacKintosh et 
al., 1990). The PP1 and PP2A regulatory enzymes are critical for maintaining 
homeostasis in eukaryotic cells. Inhibition by microcsytin can lead to hepatocyte 
necrosis, affecting cell proliferation and differentiation, leading to tumour promotion 
(Falconer and Humpage, 2005). In hepatocytes, microcystin utilises the bile duct 
transporter system to penetrate into cells and inhibit protein phosphatase activity in the 
cytoplasm (Fischer et al., 2005). This inhibition generates a sustained 
hyperphosphorylation cascade, eventually leading to hepatocyte and liver toxicity. 
Microcystin can also exert their toxic effects through immunomodulation of a number 
of immune cell types, and it is this particular area, which is of relevance for human and 
livestock toxicity events (Hernández et al., 2000; Yea et al., 2001). 
 
In relation to the immunomodulatory activities, it was speculated that microcystin may 
rely on over-stimulation of the immune system for effectiveness. For many years, 
microcystin compounds have been known to regulate the production of IL-1, TNF-α and 
inducible nitric oxide synthase in macrophages (Nakano et al., 1989; Nakano et al., 
1991; Pahan et al., 1998). Investigation into the immunosuppressive effects of 
microcystin on mice peritoneal macrophages showed that both short term (6 hour) and 
long term (24 hour) exposure had a significant inhibitory effect on iNOS (inductible 
nitric oxide synthase) and the macrophage-related cytokines, IL-1β, TNF-α, GM-CSF 
and IFN- γ (Chen et al., 2004, 2005). Another study employing mouse peritoneal 
macrophages demonstrated that supernatant from microcystin-treated macrophages 
induced electrogenic intestinal effects in rabbit ileum in a time-dependent manner 
(Rocha et al., 2000). In contrast to the studies by Chen and colleagues, the toxin-treated 
macrophages increased the secretion of TNF-α and IL-1β into the supernatant, but the 
authors speculate that these cytokines were not involved in the intestinal secretory 
effect. 
 
Interestingly, a study on the effects of MC on a number of mammalian cell lines, 
including human colon adenocarcinoma (Caco-2), astrocytoma (IPDD-A2) and 
lymphoblastoid (NCNC), showed that microcystin exposure in the NCNC cells (which 
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originate from an established cell line of peripheral blood lymphocytes), had very little 
effect on ROS production or DNA damage at concentrations of up to 10 µg/mL. This 
insensitivity to MC-LR exposure in human lymphoblastoid cell line (TK6) was also 
observed at low concentrations (< 80 µg/mL) by Zhan and co-workers (2004). In 
contrast, an investigation into the effect of MC-LR on peripheral human and chicken 
blood lymphyocytes, showed that toxin exposure significantly affected cytokine 
secretion and down-regulated B- and T-cell function by inducing apoptosis and 
necrosis, at low concentrations (Lankoff et al., 2004). For example, human lymphocytes 
increased production of IL-6 and decreased production of IL-2 following MC-LR 
exposure at concentrations of less than 2 µg/mL. 
 
In addition, microcystin can affect the spontaneous adherence properties of human 
peripheral polymorphonuclear leukocytes (PMN) (Hernández et al., 2000). It has also 
been reported that concentrations of microcystin below the recommended WHO limit 
affect human PMNs (Kujbida et al., 2006). Two microcystins (MC-LR and [Asp
3
]-MC-
LR) induced the production of reactive oxygen species (ROS), which enhanced 
neutrophil migration and increased phagocytosis and killing of Candida albicans. 
Interestingly, Yea and colleagues demonstrated that microcystin down-regulated the 
production of IL-2 mRNA in splenocytes and thymocytes (Yea et al., 2001). Their 
analysis revealed that microcystin decreased lymphocyte responsiveness to LPS, and 
produced a dose-dependent inhibition of the in vitro polyclonal antibody response. 
Moreover, MC-LR induced DNA damage in rat lymphocytes and inhibited natural killer 
(NK) cell activity (Zhang et al., 2001). Kujbida et al., (2009) investigated the ability of 
three structurally distinct microcystin toxins (MC-LA, MC-LR and MC-YR) to increase 
intracellular calcium and to affect neutrophil migration, especially in response to the 
chemoattractant, fMLP (formyl-Met-Leu-Phe). They demonstrated that toxins are 
chemoattractants for neutrophils, which may be linked to the interaction of microcystin 
with membrane components and their penetration into the cell.  
 
In many of these studies it is speculated that the immunotoxicity of microcystin is 
caused by an over-stimulation of the immune system (Pahan et al., 1998; Yea et al., 
2001). One of the unique approaches taken to assess the immunotoxic potential of 
microcystins was to analyse the apoptotic effects, induced by algal bloom extracts on rat 
hepatocytes and human lymphocytes (Mankiewicz et al., 2001). This was followed by a 
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study of DNA damage in human lymphocytes that demonstrated the genotoxic potential 
of these extracts (Mankiewicz et al., 2002). Shen et al. (2003) subsequently 
demonstrated the effect of cyanobacterial bloom extract (CBE) on immune functions, 
including phagocytosis of peritoneal phagocytes, inhibition of LPS-induced lymphocyte 
proliferation, and a dose-dependent decrease in the number of antibody-producing cells 
in mice.  
 
3.1.3 Effect of aflatoxin on immune cell function 
 
Mycotoxins, as secondary metabolites of fungi that grow on various food stuffs and 
feeds, have the potential to elicit a wide variety of toxicological effects, including 
immune-suppression and immune-stimulation. For the trichothecene family of 
mycotoxins, exposure to sublethal doses has the potential to either stimulate or suppress 
immune functions, such as lymphocyte proliferation, cell-mediated immunity and 
humoral immunity, depending on dose and exposure time (Pestka and Bondy, 1994). 
Production of cytokines by monocytes and macrophages in response to inflammatory 
stimuli and microbial products is well established (Bendtzen et al., 1988). Several 
studies have shown that aflatoxins can affect macrophages, both in vitro (Cusumano et 
al., 1990, Moon et al., 1998, Moon et al., 1999a and Moon et al., 2000) and in vivo 
(Moon et al., 1999b). Liu et al., (2002) showed that fumonisin B and aflatoxin B1 were 
immunotoxic to swine alveolar macrophages, employing techniques such as DNA 
laddering, nuclear fragmentation and phagocytosis and by analysis of apoptosis-related 
heat shock protein 72 (hsp72) and cytokines IL-1β and TNF-α.  
 
Numerous animal studies have demonstrated that aflatoxins have immunosuppressive 
activity. Poultry (chickens and turkeys), pigs and lambs in particular, are susceptible to 
aflatoxin-induced immunosuppression (Smith et al., 1995; Devegowda and Murthy, 
2005). Furthermore, cell-mediated immunity is affected by aflatoxin exposure. Murine 
macrophages exposed to aflatoxins in vivo (Dugyala and Sharma, 1996) and in vitro 
(Moon et al., 1999a; Moon et al., 1999c) exhibited decreased cytokine secretion. Other 
macrophage functions, such as release of reactive intermediates (Moon et al., 1999a; 
Moon et al., 1999b) and phagocytosis (Moon et al., 1999b; Liu et al., 2002) are 
decreased in macrophages exposed to AFB1. For example, human monocytes show 
decreased mRNA and protein secretion levels of pro-inflammatory cytokines (Rossano 
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et al., 1999), in addition to decreased phagocytosis and anti-microbial activity 
(Cusumano et al., 1996). 
 
The immunotoxicity of mycotoxins was extensively reviewed by Bondy and Pestka, 
2000. Mycotoxins can produce cellular depletion in lymphoid organs, cause alterations 
in T-cell and B-cell function, suppress antibody responses, suppress NK cell activity, 
decrease delayed-type hypersensitivity responses, and increase susceptibility to 
infectious disease. In addition, the T-2 mycotoxin has also been implicated as a 
developmental immunotoxicant, which targets fetal lymphocyte progenitors (Holladay 
et al., 2002). The dose, the route of administration, and the species type, are all critical 
factors in the immunotoxicity of the mycotoxin, ochratoxin (Al-Anati and Petzinger, 
2006). The effects of aflatoxins on the human immune system has not yet been fully 
characterised, but concerns have arisen, in countries such as West Africa, where 
widespread aflatoxin contamination has resulted in 99% of children in some areas 
possessing aflatoxin–albumin adducts in their blood (Gong et al., 2003).  
 
The effect of the tricothecene group of aflatoxins on immune function has shown that 
the mechanism of impairment is related to inhibition of protein synthesis. Interestingly, 
high doses of trichothecenes induce lymphocyte apoptosis along with immune 
suppression (Pestka and Bondy, 1994). In contrast, low dose trichothecene promotes 
expression of a diverse array of cytokines including IL-1, IL-2, IL-5, and IL-6. 
Tricothecenes also activate mitogen-activated protein kinases (MAPK’s) in vivo and in 
vitro, via the ribotoxic stress response (Zhou et al., 2003; Pestka et al., 2004). It was 
shown that LPS exposure can markedly increase the toxicity of deoxynivalenol by 
amplifying the pro-inflammatory cytokines: TNF-α, IL-6 and IL-1β (Zhou et al., 1999). 
Luyendyk et al. (2002) demonstrated that exposure to LPS increased liver injury and 
hepatotoxicity caused by AFB1. Similarly, Pestka and Zhou et al., (2006) showed that 
pre-exposure with LPS sensitised murine RAW264.7 macrophages and peritoneal 
murine macrophages to the pro-inflammatory effects of deoxynivalenol. Prolonged 
consumption of deoxynivalenol by mice was shown to induce elevation of IgA and IgA 
immune complex formation, in addition to kidney mesangial IgA deposition (Pestka, 
2003). Although the immunomodulatory effects of the aflatoxins have been 
demonstrated previously, the mechanism by which these compounds exert their 
immunosuppressive effects is still unknown. Previous investigations have shown that 
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AFB1 pretreatment, followed by LPS stimulation, decreases CD14 expression in murine 
peritoneal macrophages. However, CD14 expression was unaffected in cells that were 
pre-treated with AFB1, but not challenged with LPS (Moon and Pyo, 2000).  
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3.1.4 Chapter aims  
 
The purpose of this chapter was to study the effects of certain naturally-occurring toxins 
on the immune response to infection, using the murine macrophage cell line, J774A.1 as 
a model for host defence. This data provides further insight into the mechanisms by 
which phycotoxins and mycotoxins modulate the host immune response to exert their 
immunosuppressive activity. 
 
 This included analysis of the cytotoxic effect of the phycotoxin, azaspiracid, on 
murine macrophages, using end-point assays to examine cell viability and 
cytotoxicity. The expression of a number of pro- and anti- inflammatory 
cytokines, including TNF-α, IL-12p40, IL-6 and IL-10, after azaspiracid 
exposure, was studied. In addition, the effect of toxin exposure on cytokine 
expression after macrophage activation with the TLR4 ligand, 
lipopolysaccharide (LPS), was also examined. Importantly, this is the first report 
of the immunomodulatory effect of AZA on macrophages in vitro. 
 The anti-proliferative activity of the cyanobacterial toxin, MC-LR on the murine 
macrophage model was also studied using end-point assays to analyse 
cytotoxicity and viability. MC-LR was used to analyse the effect of toxin 
exposure on NLR3 inflammasome activation, a multi-protein complex 
responsible for activation of key inflammatory processes. The parameters under 
investigation included: inflammatory IL-1β and active caspase-1, which are both 
markers of inflammasome activation. The effects of microcystin exposure was 
studied following the exposure of J774A.1 cells to danger signals from 
adenosine triphosphate (ATP) and LPS endotoxin, which are know activators of 
the NLR3 inflammasome.  
 The effect of aflatoxin B1 (AFB1), aflatoxin B2 (AFB2) and aflatoxin G1 (AFG1) 
exposure, alone and in combination, on the secretion of TNF-α, IL-12p40, IL-6 
and IL-10 from murine macrophages, was investigated. In addition, the effect of 
aflatoxin exposure on the expression levels of key cell surface markers, involved 
in the inflammatory response, was also examined. Expression levels of ‘Toll-
like’ receptor 2 (TLR2), ‘Toll-like’ receptor 4 (TLR4) and Cluster of 
Differentiation 14 (CD14), along with the macrophage activation marker, CD40, 
were studied.  
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3.2 Results  
 
3.2.1 Cytotoxicity analysis of azaspiracid on murine macrophage and 
hepatocellular carcinoma cell lines 
3.2.1.1 WST-1 cell death assay 
 
The WST-1 assay (Roche) measures cell proliferation and viability through 
determination of mitochondrial dehydrogenase activity. An increase in enzyme activity 
leads to a increase in formazan dye formed, which is proportional to the number of 
metabolically-active cells. The growth rate of the J774A.1 murine macrophage cell line, 
in the presence of AZA-1 at concentrations, ranging from 0.01 to 100 pg/mL, was 
assessed using the WST-1 proliferation assay (Figure 3.2.1.1). A graph was plotted, 
which compared the percentage viability of the control groups (methanol control), with 
that of the toxin-treated cells. The results indicate AZA-1 has a potent cytotoxic activity 
on J774A.1 macrophages. The percentage viability decreased significantly (P < 0.01) at 
a concentration of 100 pg/mL AZA-1, compared to 0 pg/mL AZA-1. Certain 
experimental samples exceed 100 % viability, as they may have a higher mitochondrial 
dehydrogenase activity, compared with the methanol control (100 % viable). 
 
The inflammatory processes in the macrophage are activated by the endotoxin, LPS. 
Therefore, LPS was included in the WST-1 analysis, to analyse the effect of toxin 
exposure on macrophage activation and proliferation. LPS is a potent stimulator of the 
‘toll-like’ receptor 4 (TLR4) pathway in the immune response to infection, especially in 
macrophages and B-cells. With the inclusion of LPS stimulation, AZA-1 did not have 
any clear effect on cell viability, over a range of concentrations, compared with the LPS 
control (0 pg/mL AZA-1 and 100 ng/mL LPS) (Figure 3.2.1.1). 
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Figure 3.2.1.1: WST-1 proliferation assay to analyse the effect of AZA-1 on the 
J774A.1 macrophage cell line. J774A.1 cells were treated for 24 hours with AZA-1 
toxin, ranging in concentration from 0.01 to 100 pg/mL, with and without LPS (100 
pg/mL). The white bars (□) represent AZA-1 treatment alone and the black bars (■) 
represent AZA-1 treatment with LPS stimulation. Triton-X detergent (0.01% (v/v)) was 
included as a positive control of cytotoxicity (5.16 % viability, compared with vehicle 
(methanol) control). Results indicate a mean value from three independent experiments 
and error bars represent mean 3SE (standard error of mean) (n=3). AZA-1: P < 0.01** 
(100 pg/mL AZA-1, versus 0 pg/mL). 
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3.2.1.2 LDH proliferation assay 
 
The LDH cytotoxicity assay (Roche) assesses cell death and cell lysis, based on the 
measurement of lactate dehydrogenase (LDH) activity, released from the cytosol of 
damaged cells into the supernatant. The amount of colour formed, measured at an 
absorbance of 490 nm, is proportional to the number of lysed cells. Data was plotted as 
percent cytotoxicity, as a percent of the high control (Triton-X) versus toxin treatment 
concentration (pg/mL). The LDH activity in the high control is measured following 
solubilisation of the cells with 1 % (v/v) Triton-X. A significant decrease (P > 0.05) in 
cytotoxicity, from 34 % (negative control) to 22 %, was observed, at an AZA-1 
concentration of 0.01 ng/mL. A significant decrease (P > 0.01), from 34% to 19 %, also 
occurred after AZA-1 exposure, at a concentration of 0.1 ng/mL (Figure 3.2.1.2).  
 
However, significant alterations in cellular cytotoxicity were only observed at 
concentration of 0.01 and 0.1 ng/mL, respectively. At lower (0.001 pg/mL) and higher 
(1 - 100 pg/mL) AZA-1 concentrations, no discernable change in cytotoxicity was 
observed, relative to the control value. A very similar U-shaped graph was obtained 
when macrophages were co-treated with LPS (100 ng/mL) and AZA-1 (0 to 100 
pg/mL), with concentrations of 0.1 and 0.01 ng/mL displaying a significant decrease (P 
> 0.05) in % cytotoxicity, compared with the LPS control (no toxin). 
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Figure 3.2.1.2: LDH cytotoxicity assay to analyse the effect of exposure to AZA-1 on 
the J774A.1 macrophage cell line. J774A.1 cells were treated for 24 hours with AZA-1 
toxin, ranging in concentration from 0.001 to 100 pg/mL, with and without LPS (100 
pg/mL). The white bars (□) represent AZA-1 treatment alone and the black bars (■) 
represent AZA-1 treatment with LPS stimulation. Results indicate a mean value from 
three independent experiments and error bars represent the mean 3SE (n=3). - LPS: P < 
0.05* (0.01 pg/mL, versus 0 pg/mL), P < 0.01** (0.1 pg/mL, versus 0 pg/mL). + LPS: 
P < 0.05* (0.01 and 0.1 pg/mL, versus 0 pg/mL).  
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3.2.1.3 Effect of AZA-1 on cytokine secretion in J774A.1 murine macrophages 
 
Following the confirmation of the cytotoxic effects of AZA-1 on immune macrophage 
cells by WST-1 and LDH cell assays, it was decided to further investigate the effect of 
AZA-1 on the immune macrophage cell line, J774A.1. An approach was taken to 
analyse the cytokine secretion from macrophages after a 24 hour exposure to AZA-1 
(100 pg/mL). The concentration was selected from the cytotoxicity analysis as it 
significantly influenced cell viability, without causing a killing effect (See Section 
3.2.1.1 and 3.2.1.2). Cells were simultaneously challenged with LPS to analyse the 
ability of the cell to respond to endotoxin exposure.  
 
ELISA analysis was carried out on harvested supernatant in an antibody sandwich 
format. A capture antibody specific to the cytokine of interest (IL-6, IL-10, TNF-α and 
IL-12p40) was used for capture. Samples, standards (1,000 to 16 pg/mL) and controls 
were added to the capture surface, followed by a biotin-conjugated detection antibody. 
The biotinylated detection antibody bound to a different epitope of the cytokine being 
measured, thus completing the sandwich immunoassay. The detection reagent was 
streptavidin-labeled horse-radish peroxidase (HRP) and colour was developed using 
TMB substrate. A standard curve was prepared of concentration (pg/mL) versus 
absorbance (450 nm) and unknown values were extrapolated using linear regression 
analysis. 
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The cytokine response of J774A.1 macrophages to AZA-1 exposure varied, depending 
on the exposure time and the presence or absence of an LPS challenge. Incubation with 
AZA-1 (100 pg/mL) for 24 hours (no LPS) resulted in a statistically significant increase 
in IL-12p40 secretion (P < 0.001). In addition, a further increase was observed after 72 
hours of AZA-1 exposure, compared with the vehicle (methanol) control. Interestingly, 
IL-12p40 secretion also increased in a time-dependent manner following LPS exposure, 
but the results were not significant (Figure 3.2.1.3). There appeared to be a decrease in 
IL-12p40 after 72 hours of AZA-1 exposure, compared with the vehicle control. 
 
 
Figure 3.2.1.3: Analysis of IL-12p40 cytokine secretion from J774A.1 murine 
macrophages, treated for 24 and 72 hours with AZA-1 (100 pg/mL) and also stimulated 
with and without LPS (100 ng/mL). Results indicate a mean value from three 
independent experiments and error bars represent mean 3SE (n=3). Vehicle control 
(methanol) treatments are represented by the white bars (□) and toxin treatments are 
represented by the black bars (■). – LPS: P < 0.001*** for 24 hours AZA-1, versus 
vehicle control.  
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There was a very significant increase in TNF-α secretion (P < 0.001) with AZA-1 
treatment for 24 hours (Figure 3.2.1.4). In contrast, a significant decrease in TNF-α 
expression was observed when cells were exposed to AZA-1 for 24 hours and 
simultaneously stimulated with LPS for 24 hours (P < 0.001). No significant changes in 
TNF-α expression were observed for the 72 hour time point. Surprisingly, no TNF-α 
expression was observed for the control LPS-stimulated cells after the 72 hour 
treatment. It is postulated that this extended time point may have been too long to 
observe TNF-α expression and cells were unable to respond to LPS challenge. 
 
 
Figure 3.2.1.4: Analysis of TNF-α cytokine secretion from J774A.1 murine 
macrophages treated for 24 and 72 hours with AZA-1 (100 pg/mL) and also stimulated 
with and without LPS (100 ng/mL). Results indicate a mean value from three 
independent experiments and error bars represent mean 3SE (n=3). Vehicle control 
(methanol) treatments are represented by the white bars (□) and toxin treatments are 
represented by the black bars (■). - LPS: P < 0.001*** for 24 hours of AZA-1, versus 
vehicle control. + LPS: P < 0.001*** for 24 hours of AZA-1, versus vehicle control. 
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There was a significant decrease in the production of IL-10 by macrophages treated 
with AZA-1 for 24 hours, compared to the basal expression level (no LPS) (P < 0.05). 
However, there was no statistically significant change in IL-10 at 72 hours. No 
observable effects on IL-10 expression were observed for toxin-treated cells exposed to 
LPS challenge (Figure 3.2.1.5). 
 
 
Figure 3.2.1.5: Analysis of IL-10 cytokine secretion from J774A.1 murine 
macrophages treated for 24 and 72 hours with AZA-1 (100 pg/mL) and also stimulated 
with and without LPS (100 ng/mL). Results indicate a mean value from three 
experiments and error bars represent mean 3SE (n=3). Vehicle control (methanol) 
treatments are represented by the white bars (□) and toxin treatments are represented by 
the black bars (■). – LPS: P < 0.05* for 24 hours of AZA-1, versus vehicle control.  
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Closely mimicking the effect of AZA-1 exposure on TNF-α, levels of IL-6 expression 
by J774A.1 macrophages were significantly increased (P < 0.001) following 24 hours of 
AZA-1 exposure (Figure 3.2.1.6). In contrast, after LPS challenge, there was a decrease 
in anti-inflammatory IL-6 macrophage expression at 24 hours (P < 0.001). However, 
following 72 hours of exposure, no significant changes were observed. 
 
 
Figure 3.2.1.6: Analysis of IL-6 cytokine secretion from J774A.1 murine macrophages 
treated for 24 and 72 hours with AZA-1 (100 pg/mL) and also challenged with LPS 
(100 ng/mL). Results indicate a mean value from three experiments and error bars 
represent mean 3SE (n=3). Vehicle control (methanol) treatments are represented by the 
white bars (□) and toxin treatments are represented by the black bars (■). – LPS: P < 
0.001*** for 24 hours of AZA-1, versus vehicle control. + LPS: P < 0.001*** for 24 
hours of AZA-1, versus vehicle control. 
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3.2.2 Effect of cyanobacterial toxin, microcystin on J774A.1 macrophage 
function 
3.2.2.1 Cytotoxicity analysis of microcystin on the murine macrophage cell line 
 
The proliferation of the murine macrophage cells, J774A.1 exposed to microcystin-LR 
(MC-LR) for 12, 24 and 48 hours were compared on the basis of mitochondrial 
dehydrogenase activity, using the LDH assay. The toxins were incubated with the 
macrophages for the designated time points at two different MC-LR concentrations (10 
and 0.1 µg/mL) in media, both with and without LPS stimulation (100 ng/mL). The 
calculated cytotoxicity, expressed as a percentage of a high control (highly cytotoxic 
Triton-X detergent), increased in a time-dependent manner from 12 to 48 hours. The 
response of cells to microcystin did not appear to be dose-dependent when analysed 
over a range of MC-LR toxin concentrations (data not shown). In contrast, there was a 
significant increase in percent cytotoxicity from 12 to 48 hours, both in the presence and 
absence of LPS co-stimulation (P < 0.05) for the high MC-LR dose (10 µg/mL) (Figure 
3.2.2.1 A). A similar trend was observed for the lower MC-LR concentration (0.1 
µg/mL), where a significant effect (P < 0.05 with toxin; P < 0.01 with toxin and LPS) 
was observed from 12 to 48 hours (Figure 3.2.2.1 B). 
 
For the WST-1 cell death analysis for macrophages exposed to MC-LR (10 and 0.1 
µg/mL), the trend was less clear. For example, there was no statistically significant 
change in percent viability, compared with a vehicle control (methanol) for cells 
exposed to 10 µg/mL of MC-LR for 12, 24 and 48 hours. However, there was a notable 
decrease in viability at the 24 hour time point for MC-LR alone, followed by an 
increase in percent viability at 48 hours (Figure 3.2.2.2 A). Conversely, at the lower 
toxin concentration (0.1 µg/mL) there was a significant reduction in cell viability 
following MC-LR exposure from 12 to 24 hours (P < 0.01). This was followed by a 
significant cell recovery at 48 hours, compared with the 24 hour time point (P < 0.01). 
No significant effect was observed for cells co-stimulated with LPS after MC-LR 
exposure (0.1 µg/mL) (Figure 3.2.2.2 B).  
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Figure 3.2.2.1: LDH cytotoxicity assay to analyse effect of exposure of MC-LR on 
J774A.1. Macrophages were cultured in the presence of MC–LR (A. 10 and B. 0.1 
µg/mL MC-LR) for 12, 24 and 48 hours and stimulated simultaneously both with and 
without LPS. Toxin treatments alone are represented by the white bars (□) and toxin 
treatments with LPS challenge are represented by the black bars (■). A.) - LPS: P < 
0.05*, + LPS: P < 0.05* (12 to 48 hours, 10 µg/mL). B.) - LPS: P < 0.05*, + LPS: P < 
0.01** (12 to 48 hours, 0.1 µg/mL). 
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Figure 3.2.2.2: WST-1 proliferation assay to analyse the effect of MC-LR on J774A.1 
macrophage cell line. Macrophages were cultured in the presence of MC–LR (A. 10 and 
B. 0.1 µg/mL) for 12, 24 and 48 hours and simultaneously stimulated with and without 
LPS. Toxin treatments alone are represented by the white bars (□) and toxin treatments 
with LPS challenge are represented by the black bars (■). B.) - LPS: P < 0.05* (12 to 24 
hours, 10 µg/mL), P < 0.01** (24 to 48 hours, 10 µg/mL). 
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3.2.2.2 IL-1β cytokine release by J774A.1 murine macrophages following 
microcystin exposure and LPS challenge  
 
Interleukin-1β (IL-1β) production by murine macrophages was measured in cell culture 
supernatants. IL-1β is a pro-inflammatory cytokine generated at sites of injury as part of 
the innate immune response, following danger signals from ATP and inflammasome 
activation. Initially, a control experiment was prepared to assess the ability of ATP to 
propagate a danger signal in the macrophages. It was also relevant to assess the ability 
of the TLR4 ligand, LPS, to activate the TLR4 signalling pathway. Such activation 
would result in the production of pro-IL-1β. Following APT stimulation, NLRP3 
inflammasome activation would result in the cleavage of inactive pro-caspase-1 to 
active caspase-1, facilitating the conversion of pro-IL-1β to IL-1β, which would be 
released from the macrophage cell and subsequently detected in the supernatant, using 
ELISA.  
Two different concentrations of ATP (10 and 20 nM) were assessed for their ability to 
stimulate IL-1β production in the presence and absence of an optimised concentration of 
LPS (100 ng/mL) (Figure 3.2.2.3). Supernatants were harvested and analysed for IL-1β 
secretion by ELISA. It is clear that both LPS and ATP are required for active IL-1β 
production. A concentration of 20 mM ATP was sufficient for IL-1β production (P < 
0.001), whereas a concentration of 10 mM had no clear stimulatory effect. Glyburide 
(glybenclamide) is an inhibitor of ATP-sensitive K
+
 channels and blocks inflammasome 
activation in response to ATP. A concentration of 25 µg/mL glyburide was also added, 
as part of the control experiment, to assess whether IL-1β production could be inhibited 
in macrophages stimulated with both LPS and ATP (P < 0.001). It was apparent that 
glyburide decreased the production of IL-1β secreted from the LPS-stimulated 
macrophage in the presence of the ATP stress signalling molecule (Figure 3.2.2.3). This 
effect was only apparent when ATP was present at a concentration of 20 mM.  
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LPS  
(100 ng/mL) 
- + - + 
Glyburide 
(25 µg/mL) 
+ + - - 
 
Figure 3.2.2.3: Optimisation of ATP, glyburide and LPS concentrations for analysis of 
ATP- and LPS-dependent inflammasome activation and glyburide inhibition in a 
macrophage model. J774A.1 cells were stimulated with and without 100 ng/mL LPS for 
3 hours. Cells were subsequently exposed to varying concentrations of ATP (0, 10 and 
20 mM), along with glyburide (25 µg/mL) for 24 hours. Supernatants were analysed by 
ELISA for the presence of active IL-1β (pg/mL). Results indicate a mean value from 
three independent experiments and error bars represent mean 3SE (n=3). P < 0.001***  
(- / + glyburide, + LPS, + 20 mM ATP), P < 0.001*** (- / + LPS, + 20 mM ATP). 
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J774A.1 macrophages were exposed to MC-LR for 24 hours at two concentrations: 1 
and 5 µg/mL. The high dose of MC-LR, 5 µg/mL significantly reduced IL-1β basal 
expression after 24 hours, compared with the media control (P < 0.05). The lower MC-
LR concentration (1 µg/mL) also reduced IL-β basal expression but not in a statistically 
significant manner (Figure 3.2.2.4). The magnitude of IL-1β inhibition appeared to be 
significant and dose-dependent. 
 
 
 
Figure 3.2.2.4: Effect of MC-LR on IL-1β cytokine secretion in J774A.1 murine 
macrophages. J774A.1 cells were exposed to two concentrations of MC-LR (1 µg/mL 
and 5 µg/mL), along with a media control, for 24 hours. Supernatants were harvested 
and analysed for IL-1β secretion by ELISA. Results indicate a mean value from three 
independent experiments and error bars represent mean 3SE (n=3). P < 0.05* (5 µg/mL 
MC-LR, versus media control). 
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To further investigate the immunosuppressive effects of MC-LR on murine 
macrophages in vitro, cells were pre-stimulated in the presence or absence of LPS (100 
ng/mL) and exposed to extracellular ATP (20 mM) and MC-LR (5 µg/mL) for 3 hours. 
Supernatants were harvested and analysed for IL-1β secretion by ELISA. MC-LR 
exposure did not significantly alter LPS-stimulated or un-stimulated cells in the 
presence of ATP (Figure 3.2.2.5). However, MC-LR exposure did significantly reduce 
IL-1β expression in LPS-stimulated and un-stimulated cell in the absence of ATP (P < 
0.05).  
 
 
LPS  
(100 ng/mL) 
- + - + 
ATP  
(20 mM) 
+ + - - 
 
Figure 3.2.2.5: Effect of MC-LR on IL-1β cytokine secretion in J774A.1 murine 
macrophages, following NLRP3 inflammasome activation. J774A.1 cells were 
stimulated with and without LPS (100 ng/mL) and then exposed to ATP, a NLRP3 and 
caspase-1 activator, and MC-LR (5 µg/mL) for 3 hours. Results indicate a mean value 
from three independent experiments and error bars represent mean 3SE (n=3). Toxin 
treatments are represented by the white bars (□) and control treatments (media only) are 
represented by the black bars (■). P < 0.05* (- LPS/- ATP: 5 µg/mL MC-LR, versus 
media control), P < 0.05* (+ LPS/- ATP: 5 µg/mL MC-LR, versus media control). 
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3.2.2.3 Analysis of caspase-1 activity after microcystin exposure using FLICA™ 
(Fluorochrome-labelled inhibitors of caspases) analysis 
 
For sensitive detection of apoptotic cells in vitro, a fluorescence inhibitor probe, FAM-
YVAD-FMK was utilised to label active caspase-1 in the murine macrophages. 
FLICA™ (Fluorescent-labelled inhibitor of caspases) probes are comprised of three 
main components; an inhibitor peptide sequence that binds to active caspase enzymes, a 
fluoromethyl ketone (FMK) moiety which irreversibly binds the enzyme and a 
fluorescent reporter tag (carboxyfluorescein) (FAM). For caspase-1 inhibiton, the multi-
enzyme recognition sequence is tyrosine-valine-alanine-aspartic acid (YVAD). The 
FLICA™ FAM-YVAD-FMK probe interacts with the enzymatic reactive centre of 
activated caspase-1 via the YVAD recognition sequence, forming a covalent thioether 
adduct with the enzyme through the FMK moiety. The resulting fluorescence can be 
quantified using a fluorescence plate reader, giving an accurate indication of caspase-1 
activity in a cell population.  
 
In order to investigate the effect of MC-LR treatment on apoptosis in J774A.1 murine 
macrophages in vitro, cells were incubated with 5 µg/mL of MC-LR for 24 hours. Cells 
were incubated with FLICA solution and analysed for fluorescence activity on a Tecan
®
 
Safire II plate reader, using an excitation wavelength of 490 nm and an emission 
wavelength of 520 nm. The optimal gain and Z-Position were 255 AU and 3900 µM, 
respectively. The effects of non-specific binding were reduced by subtracting a 
background value of an un-stained cell population for each experiential parameter. 
Assessment of caspase-1 activation, via FLICA™ analysis, showed that MC-LR 
significantly increased the mean fluorescence intensity value and, thus, the amount of 
active caspase-1, in comparison with the media control (P < 0.001). This dramatic 
increase in active caspase-1 and, therefore, apoptotic cell number was only apparent 
when cells were exposed to MC-LR in the presence of two priming and stimulating 
signals from LPS and ATP, respectively. When the macrophages were subject to an 
LPS challenge alone, no significant increase in caspase-1 activity was observed (Figure 
3.2.2.6). 
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Figure 3.2.2.6: FAM-YVAD-FMK fluorescence detection of active caspase-1 in 
J774A.1 cells. Macrophages were stimulated with LPS (100 ng/mL), with and without 
ATP (20 mM) for 3 hours, followed by exposure to MC-LR (5 µg/mL) for 24 hours. 
Results indicate a mean value from three independent experiments and error bars 
represent mean 3SE (n=3). + LPS / + ATP: P < 0.001*** (5 µg/mL MC-LR, versus 
media control). 
 
3.2.3 Analysis of aflatoxin exposure on the murine macrophages  
3.2.3.1 Cytokine secretion by J774A.1 macrophages after exposure to aflatoxin 
G1, B1 and B2 following LPS challenge  
 
Initial cytokine analysis was carried out by Dr. Johanna Bruneau, as part of a 
collaborative publication. All subsequent data compilation and evaluation, for thesis 
work and publication, was carried out by Edwina Stack. The cytokine response of 
J774A.1 macrophages to LPS challenge varied depending on the aflatoxin isoform. 
Each graph shows concentration of cytokine released into supernatant compared to 
control, following high (0.1 ng/mL) and low (0.01 ng/mL) doses of AFB1, AFB2 or 
AFG1 toxin alone and toxin with LPS challenge. Data was expressed as the mean for 
each experiment (n=3), with error bars indicating 3 SE. Significant differences in 
cytokine secretion were observed for the basal expression levels of cytokine, however, 
the major focus of these experiments was the effect of aflatoxin exposure, following 
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LPS challenge. Incubation with AFB1 for 72 hours resulted in a statistically significant 
increase in IL-6 secretion with LPS stimulation at 0.1 ng/mL AFB1 (P < 0.01) (Figure 
3.2.3.1 A). Statistically, secretion of IL-12p40 and TNF-α were not significantly 
affected following LPS stimulation, but expression of IL-12p40 did decrease with an 
increasing AFB1 concentration (Figure 3.2.3.1 B and D, respectively). With LPS 
stimulation, there was a significant decrease in anti-inflammatory IL-10 at 0.01 ng/mL 
AFB1 and a significant increase at 0.1 ng/mL AFB1 (P < 0.001), compared with the LPS 
stimulation alone (Figure 3.2.3.1 C).  
 
Figure 3.2.3.1: Exposure of J774A.1 macrophages to AFB1 modulates cytokine 
secretion. Expression of IL-6, IL-10, IL12p40 and TNF-α in supernatants of J774A.1 
murine macrophage cells, cultured in the presence of AFB1 for 72 hours were 
stimulated with LPS for 24 hours. The 72 hour toxin treatments are represented by the 
white bars (□) and toxin treatments with 24 hour LPS challenge are represented by the 
black bars (■). A.) LPS: P < 0.05* (0.1 ng/mL AFB1, versus 0 ng/mL) C.) LPS: P < 
0.001*** (0.01 ng/mL AFB1, versus 0 ng/mL); P < 0.01** (0.1 ng/mL AFB1, versus 0 
ng/mL).  
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
0 ng/mL 0.01 ng/mL 0.1 ng/mL
IL
-
6
 C
o
n
ce
n
tr
a
ti
o
n
 (
p
g
/m
L
)
*
0
20
40
60
80
100
120
140
160
180
200
0 ng/mL 0.01 ng/mL 0.1 ng/mL
IL
-
1
0
 C
o
n
ce
n
tr
a
ti
o
n
 (
p
g
/m
L
)
***
**
0
20
40
60
80
100
120
140
160
180
200
0 ng/mL 0.01 ng/mL 0.1 ng/mL
IL
-
1
2
p
4
0
  
C
o
n
ce
n
tr
a
ti
o
n
 (
p
g
/m
L
)
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
0 ng/mL 0.01 ng/mL 0.1 ng/mL
T
N
F
-a
lp
h
a
 C
o
n
ce
n
tr
a
ti
o
n
 (
p
g
/m
L
)
A
C
B
D
AFB1 AFB1
AFB1 AFB1
LPS 100 ng/mL
LPS     0 ng/mL
165 
 
In comparison to AFB1, treatment with AFB2 (0.1 ng/mL), followed by stimulation with 
LPS, also resulted in a significant increase (P < 0.001) in IL-6 secretion (Figure 3.2.3.2 
A). There was a significant decrease (P < 0.05) in IL-10 at the lower dose of 0.01 
ng/mL AFB2 (Figure 3.2.3.2 C). Levels of IL-12p40 were also decreased significantly 
(P < 0.001) after AFB2 exposure, particularly at the lower dose (Figure 3.2.3.2 B). 
While TNF-α expression was inhibited by AFB2 treatment, the effect was not significant 
(Figure 3.2.3.2 D).  
 
 
Figure 3.2.3.2: Exposure of J774A.1 macrophages to AFB2 modulates cytokine 
secretion. Expression of IL-6, IL-10, IL12p40 and TNF-α in supernatants of J774A.1 
murine macrophage cells, cultured in the presence of AFB2 for 72 hours and stimulated 
with LPS for 24 hours. The 72 hour toxin treatments are represented by the white bars 
(□) and toxin treatments with 24 hour LPS challenge are represented by the black bars 
(■). A.) LPS: P < 0.001*** (0.1 ng/mL AFB2, versus 0 ng/mL) B.) LPS: P < 0.001*** 
(0.01 ng/mL AFB2, versus 0 ng/mL), P < 0.05* (0.1 ng/mL AFB2, versus 0 ng/mL) C.) 
LPS: P < 0.05* (0.01 ng/mL). 
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Of the three aflatoxin isoforms tested, AFG1 had the least effect on cytokine secretion in 
the presence of LPS. When the murine macrophages were exposed to 0.01 ng/mL AFG1 
for 72 hours, and stimulated with LPS, a decrease in TNF-α expression was observed 
(Figure 3.2.3.3 D). Secretion of IL-6, IL-10 and IL-12p40 by the macrophages was not 
affected by AFG1 at either dose tested (Figure 3.2.3.3 A-C). 
 
 
Figure 3.2.3.3: Effect of exposure of AFG1 on cytokine expression. Expression of IL-6, 
IL-10, IL12p40 and TNF-α in supernatant of J774A.1 murine macrophage cells, 
cultured in the presence of AFG1 for 72 hours were stimulated with LPS for 24 hours. 
The 72 hour toxin treatments are represented by the white bars (□) and toxin treatments 
with 24 hour LPS challenge are represented by the black bars (■).  D.) P < 0.05* (0.01 
ng/mL). 
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The effect of combining different aflatoxin isoforms on cytokine secretion, by J774A.1 
cells, varied depending on the isoform. Results for all isoform combinations are shown 
in Figures 3.2.3.4 and 3.2.4.5. Secretion of IL-6 was significantly increased (P < 0.001) 
following LPS exposure with a combination of AFB1 and AFB2, both at a concentration 
of 0.01 ng/mL (Figure 3.2.3.4 A). Significantly, there was no observable change in IL-6 
expression at this lower dose when the macrophages were exposed to AFB1 or AFB2 
alone. Although there was a significant decrease in LPS-induced IL-10 secretion from 
cells treated with 0.01 ng/mL AFB1 or AFB2 alone, IL-10 release was unaffected by any 
of the toxin combinations at either concentration (Figure 3.2.3.4 B). However, when 
AFB1 and AFB2 were combined at a concentration of 0.1 ng/mL, a significant increase 
in IL-10 basal expression levels was observed (P < 0.001). 
 
Incubation with every toxin combination, including AFB1 + AFB2, AFB1 + AFG1, and 
AFB2 + AFG1, significantly decreased (P < 0.001) IL-12p40 secretion in LPS-
stimulated macrophages (Figure 3.2.3.5 A). Previously, a significant decrease in IL-
12p40 had only been observed for treatment with AFB2 alone. Incubation with each 
toxin combination also inhibited the basal turnover of TNF-α expression across the 
board (P < 0.01 and P < 0.001). While there was little or no effect of single isoform 
treatment on TNF-α secretion observed, there was a significant (P < 0.01) decrease in 
LPS-induced TNF- secretion for 0.01 ng/mL AFB1 + AFG1 and 0.1 ng/mL AFB1 + 
AFB2, compared with the vehicle controls (Figure 3.2.3.5 B). 
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Figure 3.2.3.4: Expression of IL-6 and IL-10 in the supernatants of J774A.1 murine 
macrophage cells, cultured in the presence of different combinations of AFB1, AFB2 
and AFG1 for 72 hours, and stimulated with LPS for 24 hours. The 72 hour toxin 
treatments are represented by the white bars (□) and toxin treatments with 24 hour LPS 
challenge are represented by the black bars (■). Data was expressed as the mean for 
each experiment (n=3), with error bars indicating 3SE. Significance: P < 0.05*; P < 
0.01**; P < 0.001*** as illustrated, all relative to the LPS control (no toxins). 
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Figure 3.2.3.5: Expression of IL12p40 and TNF-α in supernatant of J774A.1 murine 
macrophage cells, cultured in the presence of different combinations of AFB1, AFB2 
and AFG1 for 72 hours, and stimulated with LPS for 24 hours. The 72 hour toxin 
treatments are represented by the white bars (□) and toxin treatments with 24 hour LPS 
challenge are represented by the black bars (■). Data was expressed as the mean for 
each experiment (n=3), with error bars indicating 3SE. Significance: P < 0.05*; P < 
0.01**; P < 0.001*** as illustrated, all relative to the LPS control (no toxins). 
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3.2.3.2 Cell surface marker expression on murine macrophage after exposure 
to Aflatoxin G1, B1 and B2 with LPS challenge 
 
Since cell surface markers play a critical role in the initiation of an inflammatory 
response, the effect of aflatoxin exposure on the expression of TLR2, TLR4, CD14 and 
CD40 in a murine macrophage cell line (J774A.1), was investigated. The results are 
summarised in Table 3.2.3.1. Treatments were performed at two concentrations, 0.1 
ng/mL and 0.01 ng/mL, but significant changes were only observed at the lower 
concentration (data not shown for 0.1 ng/ml). Data was analysed using mean 
fluorescence intensity (MFI) values. MFI is defined as the arithmetic mean of the data, 
in which the linear scaled fluorescence was averaged and the result is weighted by 
outliers at the high end of the distribution.  
 
A significant decrease was observed in expression of TLR2 on the murine macrophages, 
after treatment with AFB2 or AFG1 with endotoxin challenge (P < 0.01). With AFB1 
exposure alone, a slight increase in TLR2 expression was observed, compared with the 
solvent control (P < 0.05). Significantly, CD14 expression was significantly (P < 0.01) 
decreased following treatment with AFB1 + AFB2, both with and without LPS 
challenge. TLR4 and CD40 expression levels were not significantly affected by any of 
the toxin treatments, either in the presence or absence of LPS (data not included). For 
each experimental acquisition, the isotype-control antibody-stained cells indicated no 
non-specific binding of fluorophores. The isotype controls were rat anti-IgG2a 
(fluorescein (FITC)-labelled), rat anti-IgG2b (FITC-labelled) and rat anti-IgG2a 
(phycoerythrin (PE)-labelled). 
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Table 3.2.3.1: Cell surface marker analysis, following aflatoxin exposure. J774A.1 
murine macrophage cells were incubated with 0.01 ng/mL singly or in combination with 
aflatoxins, AFB1, AFB2 and AFG1 for 72 hours and subsequently stimulated with or 
without 100 ng/mL of LPS for 24 hours. Cells were stained with anti-TLR2 antibody, 
labelled with FITC (eBio), anti-TLR4 antibody, labelled with PE (eBio), anti-CD40 
antibody, labelled with PE (BD) and anti-CD14 antibody, labelled with FITC (eBio). 
Samples were analysed in three independent experiments using a FACSCalibur™ flow 
cytometer (BD). The data is represented as the mean value ± 3SE. TLR2 (- LPS): P < 
0.05* (AFB1 alone, versus control). TLR2 (+ LPS): P < 0.01** (AFB2, AFG1 alone, 
versus control), CD14 (- LPS): P < 0.01** (AFB1 + AFB2, versus control), CD14 (+ 
LPS): P < 0.01** (AFB1 + AFB2, versus control). 
Treatment    LPS   TLR2   CD14 
Solvent Control - 35.55 ± 2.16 
 
8.70 ± 0.03 
AFB1 - 44.43 ± 3.46 * 
 
9.80 ± 0.04 
AFB2 
 
- 33.68 ± 0.93 12.96 ± 3.86 
AFG1 
 
- 33.55 ± 1.65 7.69 ± 0.03 
Treatment LPS   TLR2   CD14 
Solvent Control + 81.50 ± 1.44 
 
16.20 ± 0.17 
AFB1 
 
+ 76.75 ± 2.88 16.17 ± 0.77 
AFB2 + 65.26 ± 2.42 ** 
 
12.07 ± 4.25 
AFG1 + 65.82 ± 4.36 ** 
 
17.20 ± 0.67 
Treatment LPS   TLR2   CD14 
Solvent Control - 45.75 ± 1.66 
 
43.11 ± 0.78 
AFB1 + AFB2 - 37.14 ± 2.51 
 
34.37 ± 1.07 ** 
AFB1 + AFG1 
 
- 37.59 ± 2.53 44.63 ± 1.23 
AFB2 + AFG1 
 
- 38.38 ± 0.47 46.51 ± 0.00 
Treatment LPS   TLR2   CD14 
Solvent Control + 70.87 ± 3.67 
 
88.78 ± 3.89 
AFB1 + AFB2 + 63.70 ± 3.54 
 
35.42 ± 1.08 ** 
AFB1 + AFG1 
 
+ 57.69 ± 4.74 105.40 ± 5.86 
AFB2 + AFG1 
 
+ 65.78 ± 0.18 97.91 ± 0.23 
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3.3 Discussion 
 
Under normal healthy circumstances, the immune system defends the host against 
pathogenic infections. However, certain environmental factors, including toxins, can 
alter the development and function of the immune response, leading to autoimmunity, 
hypersensitivity or immunosuppression. However, understanding of the biological 
processes underlying immune system dysfunction is incomplete. A functioning immune 
system is essential for survival as it defends the body against infection to foreign agents. 
A key element of immune function is the ability to distinguish ‘self’ from potentially 
harmful foreign components (‘non-self’). Failure to make this distinction results in 
autoimmune disease. Immunotoxicology is the study of undesired effects resulting from 
the interactions of xenobiotics, including toxins, with the immune system. There is 
evidence that certain xenobiotics cause immune suppression (Kaminski et al., 2008; 
Luster and Gerberick, 2010). It is clear that there are a vast number of cellular and 
molecular targets for xenobiotics that act as immunosuppressants, as reviewed by 
Grinyó et al. (2012).  
 
Xenobiotics, such as toxins, may interfere with receptor-ligand binding at the cell 
surface or with the cascade of signalling events that leads to transcription of genes 
responsible for generating and regulating the appropriate immune responses. One of the 
major adverse consequences of immunosuppression is that host resistance against 
microbial pathogens is impaired, leading to infection. Moreover, immunostimulation 
and immunosuppression can occur with the same xenobiotic depending on the exposure 
conditions, including dosage and time. Chemicals such as cadmium, lead and selenium 
have the ability to enhance immune function at very low exposure levels, although high 
exposure levels led to immunosuppression (Zelikoff and Thomas, 1998). Such 
experimental observations have given rise to the term ‘immunomodulation’ which 
accounts for this dual effect. It is important to stress that any deregulation of immune 
cell homeostasis can result in serious consequences for immune functions, increasing 
the susceptibility to infections and cancer, as well as favouring the development of 
autoimmune diseases. Therefore, any significant change in the functionality of immune 
cells must be considered as a hazard. 
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3.3.1 Azaspiracid 
 
Azaspiracid accumulation in shellfish and its ongoing risk to human health is a 
prevalent issue in the waters of Europe, Africa, and North and South America (James et 
al., 2002a; Taleb et al., 2006; Twiner et al., 2008; Álvarez et al., 2010). The lack of 
understanding of the molecular mechanisms of AZA toxicity has hindered researchers 
in identifying its acute and chronic effects on humans and other animals. To date, few 
studies have reported on the immunomodulatory effects of azaspiracid on macrophages 
in vitro. For example, Ito et al. (2000) is one of the few publications that demonstrated a 
decrease in the number of non-granulocyte cells, including monocytes, lymphocytes and 
macrophages in the spleen, following AZA exposure. According to Twiner and 
colleagues, AZA-1 was cytotoxic (EC50s as low as 1 nM) to a number of mammalian 
cell lines, including Jurkat, Raji, THP-1, HEK-293, A549, GH4C1 and Neuro-2A, with 
the Jurkat cell line (human T-lymphocyte) being particularly sensitive (Twiner et al., 
2005). Due to the lack of experimental evidence regarding molecular immunotoxicity of 
azaspiracid on cytotoxicity and cytokine production in macrophages, it was therefore 
important to investigate whether azaspiracid could regulate these pivotal parameters in a 
murine macrophage model. This investigation is the first to assess the in vitro effects of 
AZA on murine macrophages, although other phycotoxins including yessotoxin, have 
been shown to inhibit macrophage function (Orsi et al., 2010). 
 
In this study, two commonly used colorimetric, end-point cytotoxicity assays, the WST-
1 cell death assay and the LDH proliferation assay, were used to analysis azaspiracid 
toxicity in a J774A.1 murine model. The WST-1 assay provides a measurement of cell 
viability and proliferation, through determination of mitochondrial dehydrogenase, 
while the LDH assay is based on the measurement of lactate dehydrogenase activity in 
the cytosol of damaged cells. The J774A.1 murine macrophage cell line was exposed to 
various concentrations of AZA-1, and the WST-1 assay was used to analyse 
mitochondrial dehydrogenase activity. There was a significant change in the percentage 
viability of the macrophages, incubated with AZA-1 for 24 hours (0.001 to 100 pg/mL). 
Interestingly, no significant change in cell viability was observed when macrophages 
were co-stimulated with both LPS and AZA-1. It is clear that the presence of AZA-1 
affected the ability of the cells to proliferate, and this may have lead to cell death. 
However, this effect was negated through stimulation of the cell with LPS. For the LDH 
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cytotoxicity assay, the percentage cytotoxicity, relative to the vehicle control, showed 
an unexpected decrease in cytotoxicity at the lower AZA-1 concentration, followed by a 
subsequent increase in cytotoxic effect at higher concentrations. It is possible that a 
protection mechanism is preventing cellular injury at low toxin concentrations, perhaps 
though internalisation or secretory products. In biological investigations, the occurrence 
of U-shaped dose-response relationships is well-documented and is commonly known 
as hormesis (Calabrese and Baldwin, 2001). This effect is identifiable as a favourable 
biological response to low exposures to toxins and other stressors. Historically, this 
effect was characterised by the Arndt–Schulz rule or Schulz' law, which states that ‘for 
every substance, small doses stimulate, moderate doses inhibit, large doses kill’.  
 
The molecular mechanisms involved in AZA toxicity are still not well understood. This 
is despite numerous cytotoxicity experiments in which a variety of different 
morphological effects were observed (Román et al., 2002; Twiner et al., 2005; Ronzitti 
et al., 2007; Twiner et al., 2008). For instance, T-lymphocytes responded to AZA-1 
through reduction in membrane integrity, organelle protrusion and a retraction of 
pseudopodia, followed by protracted cell lysis (Twiner et al., 2005). In the study by 
Twiner et al., 2008, filamentous actin (F-actin) appeared to follow the retraction of the 
pseudopodia. AZA induced considerable morphological and cytoskeletal effects on 
human neuroblastoma cells, following 24 to 48 hour exposures (Vilariño et al., 2007).  
 
Macrophages are a major source of cytokines, including IL-1β, TNF-α, IL-6, IL-10 and 
IL-12 and participate as major effector cells in resistance to pathogens, including 
bacteria and viruses. In the current study, exposure to AZA-1 significantly suppressed 
the ability of macrophages to respond to LPS activation. LPS is a component of the 
outer membrane of the cell wall of Gram-negative bacteria. A notable inhibition in the 
abundance of TNF-α and IL-6 was achieved through AZA-1 exposure in LPS-
stimulated macrophages, which suggests that AZA-1 can antagonise the function and 
proliferation of macrophages through modulation of TNF-α and IL-6. TNF-α and IL-6 
are pro-inflammatory cytokines, secreted by activated macrophages. TNF-α is a multi-
functional cytokine, which serves to recruit and stimulate other cells to sites of 
microbial invasion and infection. These cytokines have important roles in host defence; 
however, their over-production or under-production can contribute to inflammatory 
diseases, including rheumatoid arthritis, cerebral malaria, and AIDS (McInnes and 
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Schett, 2007). IL-6 acts as both a pro-inflammatory and anti-inflammatory cytokine to 
stimulate the immune response to infection by promoting T- and B-cell proliferation. In 
addition, IL-6 functions as a mediator of the acute response to infection (Mosser and 
Edwards, 2008). 
 
In contrast, levels of IL-12p40 and IL-10 were increased by AZA-1 exposure in a time-
dependent manner; however, there was no significant effect on responsiveness to LPS 
stimulation. IL-12 is a regulator of cell-mediated immune responses. It is produced 
primarily by antigen-presenting cells, including activated B-cells, dendritic cells and 
macrophages. It is secreted as a 75 kD heterodimer glycoprotein, composed of a 40 kD 
and a 35 kD subunit, joined by a disulphide bond. Active IL-12 has multiple effects on 
T-cells and NK cells, including cytotoxicity stimulation, proliferation, cytokine 
production and TH1 cell development. As an anti-inflammatory molecule, IL-10 blocks 
cytokine production and the expression of membrane co-stimulatory receptors, therefore 
decreasing the ability of macrophages and dendritic cells to present antigens (Pestka et 
al., 2004). The work presented in this chapter shows that murine macrophages generate 
a significant immune response to toxin exposure, particularly through production of the 
regulatory cytokine, IL-12p40. Moreover, it is possible that AZA-1 exposure can negate 
the ability to mount a host response to invasion by Gram-negative bacteria, by 
inhibiting the secretion of pro-inflammatory TNF-α and IL-6.  
 
3.3.2 Microcystin 
 
It is clear that macrophage function was down-regulated by the cyanobacterial 
hepatotoxins, microcystin (MC). The potent anti-proliferative activity of MC on 
J774A.1 macrophages was significant, as this effect had not been demonstrated 
previously. Most studies on the cytotoxicity of cyanobacterial toxins to immune cells 
utilised peritoneal macrophages, as previously discussed (Rocha et al., 2000; Nobre et 
al., 2003; Chen et al., 2004; Chen et al., 2005). Therefore, J774A.1 murine 
macrophages were chosen to examine the effects of MC-LR on cell growth and 
apoptosis. Exposure to MC-LR generated a time-dependent increase of LPS-induced 
and un-induced cytotoxicity, as measured by the LDH assay in vitro. This data is 
consistent with the LDH data obtained by Chong et al. (2000). These authors 
demonstrated the toxic effect of MC on numerous mammalian cell lines. Significantly, 
176 
 
this effect was only observed after 48 hours, indicating the cytotoxicity may be chronic 
in nature. The selected doses (10 µg/mL and 0.1 µg/mL) showed similar toxicity 
profiles. The inhibition of J774A.1 cell proliferation provoked by MC-LR was also 
examined by WST-1 analysis, but only the lower concentration of 0.1 µg/mL MC-LR 
showed a significant response after 24 hours of exposure. Therefore, based on WST-1 
analysis, it appears that murine macrophage MC-LR-induced toxicity is both time-and 
dose-dependent. 
 
Members of the ‘nod-like’ receptor (NLR) family assemble into multi-protein 
complexes, termed inflammasomes (Tschopp et al., 2003). Inflammasomes activate 
caspase-1, a proteolytic enzyme, which cleaves and activates the secreted pro-
inflammatory cytokines, IL-1β and IL-18. Inflammasomes regulate pyroptosis, a 
caspase-1-dependent form of cell death that is highly inflammatory (Byrant and 
Fitzgerald, 2009). One of the most fully-characterised inflammasomes consists of 
NLRP3, ASC and caspase-1, and is termed the NLRP3 or NALP3 inflammasome. To 
test whether immunomodulation elicited by MC-LR was due to its influence on NLRP3 
inflammasome activation or de-activation, a number of key inflammasome mediators 
were examined, including active IL-1β and caspase-1. IL-1β was significantly 
modulated by MC-LR exposure at a concentration of 5 µg/mL (Figure 3.2.2.4). These 
results corroborated with data published by Chen and co-workers, who showed that 
mRNA levels of iNOS, IL-1β and TNF-α were decreased, in a dose-dependent manner, 
in murine peritoneal macrophages, which were exposed to MC-LR (Chen et al., 2004). 
It is well documented that the pro-inflammatory cytokine, IL-1β play a critical role in 
the initiation of the immune response to toxins and in resulting peripheral tissue 
destruction (Black et al., 2005; Church et al., 2008). The results of this study showed 
that MC-LR significantly inhibited expression of IL-1β, relative to the vehicle control. 
IL-1β has a wide range of action in many cells, including B-cells, T-cells and 
monocytes. Previously, microcystin has been shown to cause significant 
immunomodulation effects in macrophage models. High levels of TNF-α were secreted 
after 24 hours of exposure to microcystin (Chen et al., 2005). It was possible that this 
may represent an adaptive response of macrophages to the inhibitory effect of 
microcystin, since it is known that TNF-α also stimulates phagocytosis in macrophages. 
Similarly, a number of investigations have demonstrated a decrease in IL-2 production 
in immune cells, following MC-LR exposure (Yea et al, 2001; Lankoff et al., 2004). 
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Given the inhibitory effect of MC-LR in the basal level of IL-1β secretion in murine 
macrophages, it was important to investigate whether this effect was related to NLRP3 
inflammasome activation. The secretion of IL-1β is dependent on the levels of pro-IL-
1β induced at the transcriptional level by pro-inflammatory stimuli from TLR ligands, 
including LPS. A large number of microbial components have been shown to activate 
the NLRP3 inflammasome including Staphylococcus aureus, Listeria moncytogenes, 
Escherichia coli and Mycobacterium marinum (Mariathasan et al., 2006; Mariathasan 
and Monack, 2007). In addition to microbial stimulation, endogenous danger signals, 
including ATP, generally released from damaged tissues, are essential for triggering 
inflammasome activation. The requirement for two distinct stimuli in the regulation of 
IL-1β production ensures that it is not inappropriately released, which may cause 
deleterious effects in the host. Excessive production of IL-1β has been associated with 
hereditary periodic fever syndromes, autoimmune and inflammatory diseases, such as 
gout and rheumatoid arthritis (Masters et al., 2009).  
 
Through optimisation of the inflammasome activation in the J774A.1 macrophage 
model, it was clear that stimulation from both LPS and ATP was essential for the 
activation of IL-1β production, at a concentration of 100 ng/mL and 20 mM, 
respectively (Figure 3.2.2.3). The ATP-sensitive K
+
 channel inhibitor, glyburide was 
also effective in reducing IL-1β production, in response to ATP and LPS, proving that 
the inflammasome could be inhibited in the murine macrophage. Following microcystin 
exposure (5 µg/mL) in an ATP- and LPS- activated macrophage, it was clear that 
microcystin inhibited IL-1β production, independent of LPS or ATP stimulation (Figure 
3.2.2.5). Stimulation with ATP (both in the presence and absence of LPS) showed no 
significant effect on IL-1β production in response to microcystin. However, inhibition 
of IL-1β production was evident both in the presence and absence of LPS, with no ATP 
stimulation. It is clear that microcystin reduced the basal expression level of IL-1β, 
while also influencing the macrophages ability to respond to LPS stimulation. However, 
it is unknown whether this effect is influenced by inflammasome assembly or 
activation. 
 
Freche et al. highlighted the ability of toxins to activate the inflammasome (Freche et 
al., 2007). Furthermore, it was demonstrated that aerolysin from A. hydrophilia triggers 
178 
 
the activation of caspase-1 (McCoy et al., 2010). Aerolysin is also known to cause pore-
formation, which results in the permeabilisation of the plasma membrane to ions, 
particularly calcium and potassium. In response to pore formation, cells of the immune 
system, including lymphocytes, produce inflammatory molecules and undergo 
apoptosis. Potassium efflux can also be triggered by the purinergic receptor, P2X7, by 
ATP, which has long been used as an activator of caspase-1 (Perregaux and Gabel, 
1994). Opening of potassium-selective channels is followed by the opening of a larger 
pore, known as pannexin-1 (Pelegrin and Surprenant, 2006). Interestingly, pannexin-1 
was recently shown to also be crucial for maitotoxin-induced caspase-1 activation 
(Pelegrin and Surprenant, 2007). Maitotoxin is a potent marine phycotoxin isolated 
from the dinoflagellate, Gambierdiscus toxicus. Currently, the mode of action of both 
microcystin and maitotoxin remains unknown.  
 
In vivo and in vitro models demonstrated the stimulation of apoptosis, as a result of 
MC-LR exposure, via a mitochondrial pathway (Fladmark et al., 2002) and alternatively 
through expression of pro-apoptotic proteins (Fu et al., 2005). MC-LR induced reactive 
oxygen species formation, cytochrome-c and Ca
2+
 release, caspase activation and 
cytoskeletal damage, resulting in apoptosis (Ding et al., 2002; Ding and Ong, 2003; 
Weng et al., 2007). Analysis of caspase-1 activation in murine macrophages provides 
further insight into the mechanism by which microcystin induces apoptotic cell death. 
From the results, it is evident that MC-LR stimulated caspase-1 production in an ATP-
dependent manner (Figure 3.2.2.6). In LPS-stimulated macrophages, no effect on 
caspase-1 activity was observed when cells were exposed to MC-LR, compared with the 
vehicle control. However, in the presence of ATP, there was a distinct production of 
active caspase-1 in LPS-stimulated macrophages. It is unclear how microcystin inhibits 
the production of IL-1β, while simultaneously stimulating caspase-1 production. 
 
The immune system is highly susceptible to exposure and damage caused by toxic 
materials. It has previously been reported that MC can bind okadaic acid receptors in 
various cells, due to the similar tertiary structure between MC and okadaic acid (Bagu et 
al., 1997). Microcystin is transported into hepatocytes, as in intact molecule, via anion-
transporting polypeptides, OATP1B1 and OATP1B3. In both acute and chronic 
exposure, MC-LR induces immune suppression via inhibition of protein phosphatases 
(PP- 1 and PP-2A) leading to the formation of ROS and heat shock protein-70, which 
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contribute to decreased immune responsiveness (Jayaraj et al., 2006). However, there is 
still no evidence of a specific transporter molecule or receptors for aiding microcystins 
in their interaction with immune cells. It has been suggested that a similar mechanism to 
the hepatocyte transport system is utilised in immune cells, given the number of 
reported incidences of microcystin immune cell toxicity (Mankiewicz et al., 2001; Chen 
et al., 2004; Chen et al., 2005; Kujbida et al., 2006; Kujbida et al., 2009). The 
mechanism of immunomodulation in murine macrophages requires further 
investigation, especially in relation to toxin transport into the cell, which is currently 
unknown.  
 
3.3.3 Aflatoxins 
 
The effect of the various aflatoxins on the immune system has been widely investigated 
(Dugyala and Sharma, 1996; Moon et al., 1999a, b; Moon et al., 2000; Hinton, 2003; 
Minervini et al., 2005 and Ubagai et al., 2008). However, little is known about the 
effect of administering toxin mixtures at low concentrations for prolonged periods. It is 
well known that feed commodities can be contaminated with more than one mycotoxin, 
commonly produced by the same mould species. Therefore, exposure to different 
aflatoxins is highly probable, especially if co-infection occurs with Aspergillus and 
other aflatoxin-producing organisms. Also, if a food supply is contaminated with 
aflatoxin, a low level of consistent and prolonged exposure is possible. However, there 
is a limit in the amount of information available on the interactions between commonly 
occurring mycotoxins and their combined toxic effect (Speijers and Speijers, 2004). A 
number of recent studies have demonstrated synergistic effects of mycotoxins in vitro 
(Thuvander et al., 1999, Luongo et al., 2006 and Kouadio et al., 2007) and in vivo 
(Theumer et al., 2003). Bernhoft et al., (2004) used the Isobole method developed by 
Berenbaum (Berenbaum, 1989) to definitively characterise the combined influence of 
pairing Penicillium mycotoxins, by examining their effect on mitogen-induced 
lymphocyte proliferation. Ouyang et al., (1995) demonstrated that trichothecenes could 
have markedly different effects on cytokine secretion and gene expression in primary 
CD4+ T-cells from murine mice. Theumer et al., (2003) examined the effect of 
inducing mycotoxicoses in rats using toxin mixtures of aflatoxin B1 and fumonisin. In 
contrast to individual toxins, toxin mixtures had more pronounced affects on body 
180 
 
weight, mitogenic response, proliferation and cytokine production in spleen 
mononuclear cells (SMC’s). 
 
The aim of this study was to characterise the individual and combined effect of AFB1, 
AFB2 and AFG1 in order to improve the understanding of the molecular mechanism of 
aflatoxin cytotoxicity. From the cytokine expression study, it was clear aflatoxins have 
varying effects on the expression of IL-6, IL-10, IL-12p40 and TNF-α, which was 
dependent on toxin isoform, dosage and exposure to LPS stimulation. From these 
results, it may be said that differing structural isoforms of aflatoxins, have different 
effects on the macrophage function and cytokine secretion. For example, AFB1 and 
AFB2 both significantly increased IL-6 at the higher dose tested and decreased IL-10 at 
the lower dose. However, AFB2 also had a significant effect on the secretion of IL-
12p40 which was not observed with AFB1 treatment. These results demonstrate an 
isoform-specific effect on the modulation of cytokine secretion. Results obtained from 
experiments with AFG1 provide further evidence for this isoform-specific effect. AFG1 
significantly decreased TNF-α secretion, which was unaffected by either AFB1 or AFB2. 
These results demonstrate that although these compounds are structurally similar, due to 
the differences in the ring structure between the three isoforms, they exert variable 
effects on cytokine production. 
 
In addition to investigating the effect of single aflatoxin isoforms, the effect of exposure 
to multiple aflatoxins on the modulation of cytokine secretion was examined in murine 
macrophages. The results of these experiments show that the combination of toxin 
isoforms has a specific effect on cytokine secretion (Figures 3.2.3.4 and 3.2.3.5). 
Depending on the two isoforms used and the cytokine examined, the combinations had 
the ability to abrogate the effect observed in single treatments, or to act synergistically. 
For example, AFB1 + AFB2 acted synergistically at the lower dose to significantly 
increase IL-6 secretion (Figure 3.2.3.4 A), although neither isoform increased IL-6 at 
the 0.01 ng/ml dose independently (Figures 3.2.3.1 A and 3.2.3.2 A, respectively). 
However, IL-6 secretion did not change at the higher dose of AFB1 + AFB2 (Figure 
3.2.3.4 A), although both AFB1 and AFB2 significantly increased IL-6 secretion 
individually at this dose (Figures 3.2.3.1 A and 3.2.3.2 A, respectively). IL-6 is an 
important mediator of the acute phase response, and also induces B- and T-cell 
proliferation (Mosser and Edwards, 2008).  
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Of particular interest are the results obtained on the effect of toxin mixtures on IL-
12p40 and TNF-α secretion. All toxin combinations at both the low and high dose 
significantly decreased IL-12p40 expression (Figure 3.2.3.5 A) and exposure to AFB1 + 
AFG1 at a dose of 0.01 ng/mL and AFB1 + AFB2 at 0.1 ng/mL significantly reduced 
TNF-α expression (Figure 3.2.3.5 B), following LPS challenge. Such dramatic effects 
were not observed in IL-12p40 or TNF-α expression when macrophages were exposed 
to the aflatoxins individually. Individually, exposure to AFB2 did reduce IL-12p40 
expression and AFG1 did slightly reduce TNF-α expression, but the effects were not as 
significant as the results observed following combined exposure. IL-10 levels were 
increased compared to controls, but not significantly (Figure 3.2.3.4 C). The results 
presented in the current study show that aflatoxin inhibited the LPS-mediated activation 
of macrophages, and it is possible that this could alter the host response to infection. 
This is the first report of the effect of aflatoxin isoform combinations on cytokine 
secretion from murine macrophages. When the macrophages were exposed to mixtures 
of aflatoxins, it may be possible that one aflatoxin is modulating the effect of the other 
aflatoxin by some unknown mechanism. A possible explanation for the additive or 
antagonistic effects of the toxins is that they may have common binding sites in the cell 
or on a receptor.  
 
Macrophages express PRRs, which recognise conserved molecular patterns on the 
surface of the pathogen, known as PAMPs. PRRs expressed by macrophages include 
CD14 and TLRs. These cell surface markers play an important role in the ability of a 
host to respond to infection. Exposure of J774A.1 macrophages to low doses of AFB1 + 
AFB2 significantly decreased CD14 expression, both with and without LPS stimulation 
(Table 3.2.3.1). A decrease in the expression of CD14 on the cell surface impairs the 
ability of the cell to properly respond to LPS and mount a response to Gram-negative 
bacterial infection. Significantly, this effect was not observed when cells were exposed 
to AFB1 or AFB2 alone. Previous investigations of AFB1 exposure on CD14 expression 
found a decrease in CD14 levels on macrophages after LPS challenge (Moon and Pyo, 
2000). These indicate that aflatoxins inhibit the effectiveness of murine macrophages by 
decreasing their ability to respond to LPS stimulation, and to mount an inflammatory 
response. In addition to modulating CD14, TLR2 expression was also affected by 
aflatoxin exposure (Table 3.2.3.1). In the absence of LPS challenge, AFB1 significantly 
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decreased TLR2 expression. Interestingly, following LPS stimulation, treatment with 
AFB2 or AFG1 significantly decreased TLR2 expression. TLR2 is a receptor for Gram-
positive bacterial components, whereas, LPS is found in the outer membrane of the cell 
wall of Gram-negative bacteria. These results indicate that aflatoxins modulate the 
ability of macrophages to respond to both Gram-negative and Gram-positive bacteria. 
Overall, the results demonstrate that aflatoxins, both singly and in combination, have 
the ability to modulate the typical inflammatory response of macrophages to LPS 
stimulus. In particular, aflatoxins affected the secretion of cytokines and cell surface 
marker expression that are critical for normal host response to infection. Clearly, 
mycotoxins that are known to co-occur, and have proven to be interactive in causing 
immunomodulation, are highly significant. When considering implementation of limits 
of detection and risk assessments, toxin interactions, and whether they are antagonistic, 
synergistic or additive, should be taken into account.  
 
For this research, it is clear that certain toxins from natural sources, including the 
phycotoxin, azaspiracid, the cyanobacterial toxin, microcystin and the mycotoxins, 
aflatoxin B1, B2 and G1, have the ability to cause macrophage dysfunction. Some of the 
molecular processes of toxicity are still not fully understood. However, this report has 
shed further light on the mechanisms by which toxins inhibit macrophage functions and, 
therefore, host defence functions, through deregulation of cytokine profiles, cell surface 
marker expression and activation of apoptotic markers, including caspases. 
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CHAPTER 4 
Generation of recombinant antibody 
libraries to the phycotoxin, 
azaspiracid 
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4.1 Introduction 
4.1.1 Azaspiracid as a Target 
 
Outbreaks of phycotoxin contamination in shellfish are a major cause for concern in the 
Irish seafood industry. These toxins accumulate in the tissues of filter-feeding shellfish, 
which are consumed by humans. Although they are harmless to shellfish, they are toxic 
to humans. Azaspiracids (AZAs) are polyether phycotoxins associated with severe 
gastrointestinal intoxication in humans and other animals. Azaspiracid shellfish 
poisoning (AZP) was first reported in 1995 in the Netherlands, following the 
consumption of mussels cultivated in Killary Harbour, Ireland (Satake et al., 1998). 
Despite extensive research, little is known about azaspiracid, its toxicology or mode of 
action. Consumption of AZA-contaminated shellfish meat can cause severe acute 
symptoms, including nausea, vomiting, stomach cramps and diarrhoea. Toxin 
monitoring programmes have been implemented for AZA in Ireland and many other 
countries, to prevent the consumption of toxin-contaminated shellfish meat. Current 
detection methods include biological assays, such as the mouse bioassay, and chemical 
techniques, such as LC-MS and HPLC for regular AZA screening. Although they are 
the definitive methods for toxin detection, they require long extraction procedures and 
are not suitable for high throughput analysis. There is an ongoing requirement for the 
development of more sensitive, rapid and convenient testing for monitoring toxins such 
as AZA in shellfish.  
 
4.1.2 Detection Methodologies 
 
The European Commission have recognised the requirement for development of 
alternative methods to animal testing. One of the objectives of the EC’s Sixth 
Framework Programme (EC, 2003) was to develop cost-effective tools for analysis and 
detection of hazards associated with seafood from coastal waters, including azaspiracid 
shellfish poisoning (AZP). Thus, there is an urgent need for rapid and effective 
detection technologies in this area. Several types of analytical techniques have already 
been developed including; bioassays, chromatographic techniques, immunoassays and 
enzyme inhibition-based assays.  
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4.1.2.1 Mouse Bioassay 
 
Among the different bioassays, the in vivo mouse bioassay is the most commonly used, 
with the in vivo rat bioassay being an approved alternative. These bioassays involve the 
administration of potentially contaminated samples to mice or rats. The lethal dose and 
toxicity calculation are then determined, according to dose response curves established 
with reference material. Mussel extracts are intra-peritoneally injected into animal hosts 
and the azaspiracid response is characterised by hopping, scratching and progressive 
paralysis (Satake et al., 1998). This allows it to be distinguished from diarrheic shellfish 
poisoning (DSP), where these symptoms are atypical. Rodent death can range from 35 
minutes to 30 hours, depending on the dose present in the sample. Generally, polyether 
toxins are concentrated in the digestive glands of shellfish, however, azaspiracids do not 
show this pattern. In contrast, AZA toxins are distributed throughout shellfish tissue. If 
conventional mouse bioassay protocols are used for AZA analysis, where only the 
hepatopancreas is tested, only 0 to 40% of total AZA content is quantified, causing false 
negative results (James et al., 2002). The mouse and rat bioassay is currently the 
approved regulatory method for detection for AZA. However, ethical concerns have 
been raised regarding the use of animals for experimentation. Furthermore, the method 
suffers from unreliability and insensitivity and this has led the EU to search for 
alternative AZA detection methodologies, which are more reliable, cost-effective and 
ethical.  
 
4.1.2.2 Analytical Detection Methods 
 
The lack of confidence in the use of bioassays for the regulatory control of shellfish 
toxins has led to the development of analytical methods to quantify individual toxins. A 
number of analytical methods, such as liquid chromatography (LC) with fluorometric 
detection and liquid chromatography with mass spectrometry (LC-MS), can be used as 
alternatives to the animal testing methods. Unfortunately, fluorescent labelling of the 
carboxyl or amino group in the azaspiracid molecule is very slow, due to the reduced 
reactivity of the two groups. One of the first LC-MS quantitative detection methods for 
AZA was based on selected ion monitoring (SIM) detection (Ofuji et al., 1999). This 
LC-MS method had a detection limit of 50 pg for azaspiracid. A micro-liquid 
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chromatography-tandem mass spectrometry method (micro-LC-MS-MS) was also 
developed with a detection limit of 20 pg, using a triple quadrupole instrument (Draisci 
et al., 2000). Subsequently, a number of robust and sensitive methods for the 
determination of AZA1-5, using ion-trap multiple tandem electrospray MS were 
developed (James et al., 2002b; Lehane et al., 2002). Lehane et al. (2002) reported the 
development of an LC-ESI-MS method for the determination of three of the most 
prevalent AZA toxins (AZA1-3), as well as the isometric hyroxylated analogues 
(AZA4-5). Subsequently, James et al. (2003) developed a multiple tandem MS (LC–
MS
n
) method for azaspiracid, leading to the identification of five analogs, AZA-7 to 
AZA-11. LC-MS
n
 methods, such as LC-MS
3
, provide greater sensitivity than LC-
MS/MS, as well as providing full spectral data.  
 
However, when using techniques such as LC-MS for the analysis of a complex matrix, 
interferences can occur, especially with ion suppression (Suzuki and Yasumoto, 2000). 
One method to reduce interference and increase reliability is to introduce a clean-up 
step prior to analysis. Solid-phase extraction (SPE) was successfully employed for the 
analysis of AZA 1-3 using LC-MS (Ofuji et al., 1999). A comparison study using SPE 
methods for AZA determination in shellfish by LC-ESI-MS (Moroney et al., 2002) 
showed good recovery and reproducibility with a diol SPE cartridge and two octadecyl 
(C18) SPE cartridge types. SPE is not required for multiple tandem MS techniques, but 
still needs to be employed in the development of routine analytical methods for the 
determination of AZA in seafood. Recent advances have shown that it is now possible 
to purify up to five AZA analogs from mussels contaminated with both DSP toxins and 
AZA (Alfonso et al., 2008). This procedure involved three consecutive steps, in which 
the toxins are first extracted from the mussels, followed by a solid phase extraction 
(SPE) procedure, which cleaned the samples and separated DSP and AZA toxins. 
Finally, a preparative HPLC technique was utilised to isolate each analog. Significantly, 
large amounts of AZA-1, AZA-2, AZA-3, AZA-4 and AZA-5 were obtained using this 
procedure. This technique may have utility in other areas, for example, in the 
preparation of reference material, toxicological analysis or antibody development.  
 
However, for LC-MS
n
 detection purposes, complete chromatographic separation was 
not required for determination of AZA analogs. Lehane et al. (2004) demonstrated that 
LC-MS
3
 can be utilised to resolve isomers using prescribed mass selection, making it 
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possible to identify unique ion fragments for each azaspiracid. More recently, an ultra-
performance liquid chromatography (UPLC)–MS/MS method was capable of 
determining 21 individual marine toxins, including AZA-1, using predetermined 
precursor-product ion m/z combinations in 6.6 minutes (Fux et al., 2007). However, this 
analysis also resulted in signal suppression for AZA-1 analysis. A UPLC method 
coupled to quadrolope-time-of-flight (Q-TOF) MS/MS was employed to determine 20 
previously unknown analogs of azaspiracid with additional hydroxyl and carboxyl 
substituents in blue mussels (Rehmann et al., 2008). Currently, there is strong scientific 
evidence that supports the incorporation of a validated LC-MS-MS method into EU 
legislation for AZA detection in naturally-contaminated mussels. This would serve as a 
replacement for the current mouse bioassay reference method (Hess et al., 2009; 
McCarron et al., 2011). 
 
Despite the high sensitivity and reproducibility of these techniques, there is currently no 
means for performing rapid detection of azaspiracid toxin in algal blooms or in shellfish 
meat. Currently, LC-MS/MS-based methods have the greatest potential to replace bio-
assays. They have the capacity to detect AZAs at concentrations well below the current 
regulatory limit of 160 μg AZA1 equivalents/kg shellfish meat. The method can also 
detect and quantify multiple toxin group analogs simultaneously. However, LC-MS/MS 
requires costly equipment and highly trained personnel, as well as reference material for 
identification and quantification. Certified reference materials (CRMs) are essential for 
shellfish toxin monitoring programs as they facilitate method validation, ensure 
accuracy of results and maintain consistency between laboratories. Nevertheless, 
shellfish toxin CRM, particularly for AZA, is limited in availability due to insufficient 
toxin quantities. This is mainly due to the complex structure of marine toxins including 
AZA, which do not allow for synthetic approaches, making naturally-occurring sources 
essential for CRM production. The isolation of shellfish toxins from natural sources is 
labour-intensive and yields relatively low quantities of purified toxin, making analytical 
techniques very challenging and costly, thus limiting the availability of reference 
material. Significant research time has been invested to produce certified reference 
material (CRM) for AZA and its analogs (Canas et al., 2010; Perez et al., 2010). 
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4.1.2.3 Immunological Detection Methods 
 
Forsyth and co-workers developed polyclonal antibodies from sheep with broad 
specificity to the various forms of AZA. Their approach was to raise antibodies to 
synthetic haptens similar to the constant domain of the azaspiracid molecule, 
incorporating the common C28-C40 domain of AZA. The polyclonal antibodies 
detected natural AZA-1 in the range of 40 ng/mL (Forsyth et al, 2006). Moreover, 
Frederick et al. (2009) succeeded in generating a panel of monoclonal antibodies to 
synthetic AZA. This work was carried out with great difficulty, as the immunisation of 
mice with a synthetic azaspiracid-KLH conjugate resulted in the immediate death of the 
animals. It was postulated that the acute toxicity of the toxin-conjugate was attributed to 
the relative number of molecules immobilised on the surface of the KLH carrier. 
Immune response generation was achieved by reducing the conjugate dose by ten-fold, 
although an antibody response of only 1/ 3,200 to 6,400 was the highest achieved before 
sacrifice. The most sensitive clone had a limit of detection of 0.2 μM. No antibodies 
have yet been produced against naturally-occurring AZA. In addition, no recombinant 
antibodies have been developed.  
 
4.1.3 Chapter aims 
 
The purpose of this research was to generate a recombinant antibody to azaspiracid 
(AZA) for incorporation into a specific and sensitive immunoassay-based screening test. 
This immunoassay could potentially be incorporated into an AZA detection system in 
shellfish, for application in the seafood farming industry. In collaboration with Queen’s 
University Belfast (QUB), the AZA toxin was sourced from the EU Reference Library 
in Vigo, Spain and this material was used for antibody production. A rabbit single chain 
fragment (scFv) antibody library was constructed from the spleen and bone marrow of 
an AZA-cBSA-immunised rabbit. The polyclonal immune serum was screened for 
binders using two available AZA protein conjugates; AZA-BTG and AZA-KLH. Bio-
panning was carried out on the AZA scFv library using the AZA-BTG conjugate for the 
selection of high affinity clones. A chicken host was also immunised with AZA 
conjugates, generated ‘in-house’, and conjugate analysis was performed using surface 
plasmon resonance. 
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4.2 Results  
4.2.1  Immunisation of rabbit host with AZA-1-cBSA  
 
Immunisation of a New Zealand white rabbit took place in the Institute of Agri-Food 
and Land Use, Queen’s University. Serum samples were obtained from the AZA-1-
cBSA-immunised rabbit by Queen’s University Belfast (QUB) and transferred to DCU 
for analysis. The serum was tested by direct ELISA using two AZA conjugates; AZA-
BTG and AZA-KLH, synthesised at QUB (data not shown). Unfortunately, the immune 
serum displayed considerable non-specific background binding and it also appeared 
responsive to both the KLH and BTG protein carriers. It was apparent that the 
conjugates and resulting anti-sera were of poor quality. Moreover, the concentration of 
the conjugates appeared to be ambiguous, as a greater response was obtained to the 
carrier control, compared to the conjugates. 
 
 It was clear that there were major issues with conjugate quality and solubility, which 
made it difficult to establish a true titre value of the immune serum and, therefore, the 
responsiveness of the host animal to AZA. Unfortunately, due to the rarity of toxin 
material, no purified AZA toxin or AZA conjugates were available commercially and 
no definitive analytical methods were available for conjugate analysis. Despite these 
drawbacks, it was decided to generate an recombinant library with the immunised 
rabbit, which may potentially have generated an immune response for azaspiracid. 
 
4.2.2 Construction and screening of the azaspiracid scFv rabbit library 
4.2.2.1 Amplification of rabbit antibody heavy and light chains and PCR 
optimisation  
 
Bone marrow and spleen were extracted from the immunised rabbit and phenol-
chloroform extraction was carried out for isolation of RNA material, as described in 
Section 2.13.3. The cDNA from both the bone marrow and spleen were synthesised by 
reverse transcription and subsequently quantified and pooled in a 1:1 ratio. PCR 
amplifications for the four variable heavy (VH) chain primer combinations were carried 
out, as outlined in Section 2.13.4.  
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Figure 4.2.2.1: Amplification of rabbit heavy chain regions. The 4 combinations for the 
heavy chain regions were amplified successfully, utilising the primer combinations; 
RSCVH1 and RSCG-B (VH1), RCSVH2 and RSCG-B (VH2), RSCVH3 and RSCG-B 
(VH3), and RSCVH4 and RSCG-B (VH4). The amplifications are shown in duplicate 
along with a negative control (Neg.), which did not contain DNA template. The M lanes 
represent a 1 kb Plus DNA molecular weight ladder (Invitrogen).  
 
The amplifications for the variable heavy chains were performed using GoTaq™ 
polymerase and all four reactions amplified successfully (Figure 4.2.2.1). A band of 
approximately 400 base pairs (bp) was obtained for the variable heavy chain, which 
represented the correct amplicon size for that chain fragment. No optimisation for 
amplification of the variable heavy chains was required.  
 
  
M     VH1              VH2              VH3              VH4       Neg. M
400 bp
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PCR amplifications were carried out for the variable light (kappa) regions, using the 
primers sets RSCVK3 and RKB9J10-BL (VK7), and RSCVK3 and RKB9Jo-BL (VK8) 
(Figure 4.2.2.2). All the variable kappa chains amplified successfully at 400 bp with 
GoTaq™ polymerase, except for the VK7 and VK8 primer sets, which required further 
optimisation. This optimisation of the VK7 and VK8 PCRs included; MgCl2 
concentration gradients, temperature gradients, DMSO addition, asymmetric PCR and 
use of alternative polymerases including Phusion
®
 Taq DNA Polymerase (NEB) and 
Platinum
®
 Taq (Hi-Fi) DNA Polymerase (Invitrogen).  
 
 
 
Figure 4.2.2.2: PCR amplifications for the variable light (kappa) regions. The single 
variable light (lambda) chain products amplified successfully at 400 base pairs and are 
represented as VK1 to VK9. M represents the 1 kb Plus DNA ladder.  
 
 
 
  
M    VK1  VK2   VK3  VK4  VK5   VK6   VK7   VK9   VK8   M
400 bp
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A DMSO concentration gradient was performed to optimise the VK7 and VK8 primer 
combinations using the VK9 primer combination as a positive control. The 
concentrations used in the reaction mixtures were 2%, 4%, 6% and 8% (v/v) DMSO, 
respectively. The same reaction conditions and PCR program was used for GoTaq™ 
polymerase amplification, as outlined in Section 2.13.5. The addition of DMSO resulted 
in the successful amplification of the VK8 primer combination (Figure 4.2.2.3). For all 
further VK8 and VK9 PCR reactions, a concentration of 2% (v/v) DMSO was used. 
 
 
 
Figure 4.2.2.3: PCR amplifications of VK7, VK8 and VK9 variable light chain kappa 
with varying concentrations of DMSO, ranging from 2% to 8% (v/v). A band of 400 bp 
was observed for the variable light chain kappa gene fragment. A negative control was 
also included (Neg.), which did not contain DNA template. M represents the 1 kb Plus 
DNA ladder. 
 
 
 
 
 
 
 
 
 
 
 
VK7                      VK8                     VK9
400 bp
M  2% 4% 6% 8%  2% 4% 6% 8%  2% 4% 6% 8% Neg.  M
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To optimise the VK7 variable light kappa primer combination, high-fidelity Phusion
®
 
Taq DNA polymerase (NEB) was employed. The reaction conditions for this PCR are 
outlined in Section 2.13.6. There are two possible reaction buffers for PCR reactions 
using Phusion
® 
Taq polymerase, 5X Phusion
®
 GC buffer and 5X Phusion
®
 HF buffer. 
The error rate of HF buffer (4.4 x 10
-7
) is lower than that in GC buffer (9.5 x 10
-7
). The 
GC buffer can improve performance on difficult or longer templates. A hot start 
reaction was carried out for this PCR to aid in amplification efficiency. When a minute 
was left in Stage 1 of the PCR program, the machine was paused and the Phusion
®
 Taq 
was added before proceeding with the program. As illustrated in Figure 4.2.2.4, the 
correct band was obtained for amplification of VK7 and VK8 with the inclusion of HF 
buffer. A smaller band was obtained for VK7 with the inclusion of GC buffer.  
 
 
 
Figure 4.2.2.4: PCR optimisation of VK7 variable light chain primer combination using 
Phusion
®
 Taq polymerase and a hot start reaction. The VK8 primer combination was 
used as a positive control. The GC and HF reaction buffers were both used for 
comparison and optimisation. M represents the 1 kb Plus DNA ladder, in addition, a 
negative control was included (Neg.), which did not contain DNA template. ‘B’ denotes 
a blank well. 
 
 
 
400 bp
M      GC     HF       GC       HF      Neg.    B          M
VK8 VK7
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Further optimisation was carried out on the VK7 variable light kappa primer 
combination, for the purpose of obtaining a sufficient quantity of DNA material for 
library construction. A MgCl2 concentration gradient from 2 to 5 mM was prepared. The 
reaction buffer for this optimisation was 5X GC buffer. Phusion
®
 Taq DNA polymerase 
was utilised in the PCR reaction, as described in Section 2.13.6. The clearest band with 
the least amount of smearing was obtained with a MgCl2 concentration of 2 mM (Figure 
4.2.2.5). An additional band at 250 bp was also obtained due to non-specific 
amplification. The correct band of 400 bp was isolated using gel electrophoresis 
(Section 2.13.9) and purified using QIAquick gel extraction (Section 2.13.10). 
 
 
 
Figure 4.2.2.5: PCR optimisation of VK7 variable kappa light chain primer 
combination, with a gradient of MgCl2 concentration and Phusion
®
 Taq DNA 
polymerase. The MgCl2 concentration, ranged from 2 to 5 mM. M represents the 1 kb 
Plus DNA ladder. A negative control was also included (Neg.), which did not contain 
DNA template.  
 
 
 
 
 
 
 
 
MgCl2 (mM)
M     2.0   2.4   2.8    3.2 3.6   4.0    4.8   5.0    Neg.   M 
400 bp
250 bp
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M     1       2       3       4      5       N      M 
The variable light chain lambda (VLλ) primer combination was amplified using 
GoTaq™ polymerase. A number of reactions were carried out and subsequently pooled 
to have sufficient quantities for library construction. No optimisation for amplification 
of the variable light chain lambda region was required. The PCR was performed using 
the method described in Section 2.13.6. The amplifications are shown in Figure 4.2.2.6. 
The bands amplified at a molecular weight of 400 bp, which is the correct size for the 
variable λ light chain fragments. 
 
 
 
Figure 4.2.2.6: Amplification of light chain lambda (VLλ) primer combination 
including a negative control. Five of the same reactions (lanes 1-5) were carried out and 
the PCR products pooled. M represents the 1 kb Plus DNA ladder. A negative control 
(N) was also included, which did not contain DNA template. 
 
Following successful small-scale amplification of the variable heavy and light chain 
domains and PCR optimisation using methods described, large-scale PCR reactions 
(10X) were performed for all combinations. The large-scale PCR products were 
individually ethanol-precipitated, analysed via agarose gel electrophoresis (Section 
2.13.9) and purified by gel extraction (Section 2.13.10). The purified products were 
combined in equimolar amounts for each of the 3 variable chains (heavy, kappa and 
lambda). This master mix was subsequently used for splice-by-extension overlap PCR 
(SOE-PCR).  
 
 
400 bp
M        1         2         3         4        5       Neg.    M
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M      1      2      3      M 
4.2.2.2 SOE-PCR of the variable heavy and light chains of the rabbit library 
 
Construction of the rabbit scFv library proceeded by fusing of equimolar concentrations 
of the variable heavy and variable light chain mixtures using the overlap primers, RSC-
F and RSC-B (See Section 2.13.7). These primers were utilised to amplify a fusion 
product with a long serine-glycine linker (SSGGGGSGGGGGGSSRSS). The reaction 
was carried out both in the presence and absence of 2% (v/v) DMSO. No optimisation 
of the PCR was required; a sufficient band was obtained at approximately 750 bp 
(Figure 4.2.2.7). 
 
 
 
Figure 4.2.2.7: Splice by extension overlap PCR (SOE-PCR) of variable heavy and 
variable light chain fragment to form complete scFv fragment. The expected molecular 
weight of this fragment was 750 base pairs. A negative control was included (lane 3) 
which excluded DNA template and M represented the 1 kb Plus DNA ladder. 
 
The Platinum
®
 Taq High Fidelity DNA polymerase, which has proof-reading capacity, 
was chosen for the SOE-PCR. This enzyme was used to ensure that minimal mutations 
were incorporated into the scFv gene product. A 12X SOE-PCR was performed using 
the conditions outlined in Section 2.13.7. The scFv gene product was purified by gel 
extraction, as described in Section 2.13.10. 
 
 
 
 
1000 bp
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4.2.2.3 Library transformation and bio-panning of the AZA immune rabbit 
library 
 
The scFv SOE product was cloned into the pComb3XSS vector using an SfiΙ restriction 
enzyme. The SfiI digests were prepared as outlined in Section 2.13.11. Before the 
ligation reaction was carried out, the SfiI-digested pComb3XSS vector was treated with 
the enzyme, antarctic phosphatase (NEB). This enzyme was added to prevent self-
ligation of the vector. Following SOE vector ligation (Section 2.13.12), the rabbit scFv 
library was electroporated into commercial E. coli. XL-1 Blue cells (Section 2.13.13). 
The size of the transformed rabbit scFv library was determined to be 1.02 x 10
7
 cfu/mL. 
 
The library was ‘rescued’ with M13K07 helper phage (NEB) and enriched via phage 
display bio-panning using the immobilised-AZA-BTG conjugate (Sections 2.13.14.1 
and 2.13.14.2). Four rounds of bio-panning were carried out using decreasing 
concentrations of conjugate, which was coated onto an immunotube. Conjugate 
concentrations ranged from 100 to 12.5 µg/mL. During bio-panning the number of wash 
steps was kept constant at 5 washes of PBS-T and 5 washes of PBS. The objective was 
to use a low stringency bio-panning approach in order to enhance the selection of 
binding clones. The inputs and outputs from each bio-panning round are presented 
(Table 4.2.2.1). The AZA-BTG conjugate was chosen for bio-panning, as it showed a 
greater response to the immune serum compared with an alternative AZA-KLH 
conjugate (Data not shown). However, this analysis also indicated a high level of BTG 
carrier-binders. For this reason, a negative selection strategy was employed during the 
bio-panning process, whereby the phage were re-suspended in a solution of BTG and 
BSA, prior to incubation on the AZA-BTG conjugate-immobilised immunotube. The 
goal was to eliminate any phage specific for BTG alone by capturing them in solution 
and then discarding these binders, as this would aid the selection of AZA-specific 
clones. However, no enrichment was observed by polyclonal phage ELISA or by 
monoclonal soluble ELISA.  
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Table 4.2.2.1: Bio-panning inputs and outputs of the rabbit AZA phage library 
Pan Number Input (cfu/mL) Output (cfu/mL) 
Pan 1 1.28 x 10
11
 4.46 x 10
5
 
Pan 2 1.88 x 10
11
 2.38 x 10
4
 
Pan 3 3.13 x 10
11
 2.28 x 10
4
 
Pan 4 2.51 x 10
11
 2.30 x 10
5
 
 
4.2.2.4 Polyclonal phage ELISA and scFv check via ‘colony-pick’ PCR 
 
A polyclonal phage ELISA was carried out on the pre-pan, pan 1, pan 2, pan 3 and pan 
4 output phage, as outlined in Section 2.13.14.3. Commercial M13K07 helper phage 
was also incorporated as a negative control. However, no discernable response or 
change in response was observed after each round of bio-panning. To ensure that the 
antibody library contained scFv inserts, a colony-pick PCR was carried out. Ten 
colonies were picked from the pan 4 transformation plate. The colonies were used to 
amplify the SOE insert from the transformed library using PCR (See Section 2.13.14.4). 
The extension primers, RSC-F and RSC-B, were used for SOE PCR amplification and 
the PCR products analysed on a 1% (w/v) agarose gel. In total 8 out of 10 colonies were 
positive for the PCR insert check (Figure 4.2.2.8 A). All colonies were grown in small-
scale (10 mL) cultures and the plasmid was purified using the Wizard
®
 plasmid 
purification kit. The PCR was repeated and all 10 colonies amplified a PCR product of 
750 bp, as illustrated in Figure 4.2.2.8 B. 
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Figure 4.2.2.8: PCR insert check for successful cloning of SOE products into the 
pComb3XSS vector system. A.) Ten random colonies were studied (colony 1-10) by 
colony-pick PCR using the cloned phagemid as the template for PCR amplification. B.) 
The plasmids were purified from the isolated colonies and the same PCR was 
performed. A negative control was incorporated into each PCR (N). A 1 kb Plus DNA 
ladder was used for size confirmation of the SOE insert at 750 base pairs (M).  
4.2.2.5 Direct monoclonal ELISA of solubly-expressed scFv fragments 
 
The phage output from the final round of bio-panning round 4 (pan 4), were infected 
into Top10F′ cells for soluble expression (Section 2.13.14.4). The Top10F′ bacterial 
strain is a non-suppressor strain and is used for production of soluble protein. Single 
colonies (96) were selected from the transformed library and scFvs were solubly 
expressed using IPTG induction. The cells were freeze-thawed to facilitate cell lysis, 
and the supernatant was used for direct monoclonal ELISA, as described in Section 
2.13.14.5. 
750 bp
750 bp
M    1    2     3     4     5     6     7     8    9    10     N    M
M     1       2       3  4       5      6      7       8       9     10      N    M
M     1       2      3      4       5       6       7      8       9      10     N       MA
B
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A 
 
B 
 
Figure 4.2.2.9: Direct monoclonal ELISA of solubly-expressed scFv fragments in 
lysate from transformed scFv clones from pan 4. A.) Binding response to the AZA-KLH 
conjugate. B.) Binding response to the AZA-BTG conjugate. The black horizontal line 
indicates background signal. Binding was detected using an anti-HA monoclonal 
antibody, labelled with HRP. 
 
A number of positive clones were identified, however, the signal was very low (Figure 
4.2.2.9). After repeating this monoclonal ELISA analysis using the same 96 clones, it 
was observed that the results were not reproducible and no AZA binding clones were 
isolated. 
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4.2.3 Analysis of AZA toxin conjugate using BiacoreTM 3000 
 
An alternative approach was employed to further analyse the serum from the AZA-
immunised rabbit and to determine whether an alternative bio-panning conjugate could 
be successfully utilised for clonal isolation. An AZA-transferrin conjugate (QUB) was 
pre-concentrated and immobilised onto the surface of a CM5 sensor chip (GE 
Healthcare, Life Sciences) using EDC-NHS coupling chemistry, as outlined in Section 
2.13.17. The pre-concentration of AZA-transferrin on to the surface is shown in Figure 
4.2.3.1. A pH of 4.0 was chosen for immobilisation, as it showed the highest and 
steepest peak in the pre-concentration analysis. AZA-transferrin was successfully 
immobilised onto the surface of a CM5 dextran chip surface (Figure 4.2.3.2). Several 
dilutions of immune serum from the AZA-cBSA immunised-rabbit (R922) diluted in 
HBS buffer, were injected over the chip surface (Section 2.13.18). No change in 
response units was observed (data not shown).  
 
 
 
Figure 4.2.3.1: Pre-concentration study of AZA-transferrin conjugate on a CM5 sensor 
chip surface. AZA-transferrin (25 µg/mL) was diluted in sodium acetate buffers, with a 
pH range of 3.8 to 5.0. Each buffer solution was injected over the sensor surface at a 
flow rate of 5 µL/min for 1 minute. A pH of 4.0 was chosen for subsequent 
immobilisation. 
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Figure 4.2.3.2: Immobilisation of AZA-transferrin onto a sensor surface. The CM5 chip 
was activated using EDC/NHS chemistry and immobilised with 25 µg/mL AZA-
transferrin. The flow rate was 5 µL/min and the antigen contact time of 20 minutes. The 
non-reacted groups were capped using ethanolamine-HCl and the surface was 
regenerated using two pulses of 5 mM NaOH. 
 
These results indicated that the AZA-transferrin conjugate was un-suitable for bio-
panning of the R922 rabbit library, as no binding occurred between the rabbit immune 
serum and the immobilised AZA-transferrin. No clones were isolated from the R922 
rabbit library using the AZA-KLH or AZA-BTG screening conjugates. Therefore, it 
was decided to generate new conjugates and repeat the immunisation process. 
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4.2.4 Production of a recombinant antibody library from an AZA-immunised 
chicken 
4.2.4.1 Conjugation of AZA-2 to BTG and KLH 
 
Conjugation reactions were carried out, in which a molar excess of AZA-2 was 
chemically linked to a protein carrier through an amide linkage (Section 2.13.15). This 
amide linkage was created using the NHS-ester method. The protein carriers were 
bovine thyroglobulin (BTG), with a molecular weight of 660,000 Da and keyhole 
limpet haemocyanin (KLH), with a molecular weight of 4.5 x 10
5
 to 1.3 x 10
7 
Da.
 
A 
scheme of the conjugation is illustrated in Figure 4.2.3.1. No methods of analysis were 
available for these conjugates, as the size of the KLH and BTG molecules are too large 
for HPLC or MS determination and no AZA-specific antibodies were obtainable for 
immunological determination. 
 
 
Figure 4.2.4.1: Illustration of the conjugation reaction of AZA-2 ester to either KLH or 
BTG carrier proteins using the NHS-ester method for conjugation. The image was 
created using ChemDraw Ultra software (Version 9.0).  
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4.2.4.2 Immunisation of AZA-KLH-immunised chicken and serum titre  
 
A female leghorn chicken was immunised with the synthesized AZA-KLH conjugate 
(See Section 4.2.3.1). A pre-bleed was taken from the chicken prior to immunisation. 
For the primary immunisation, the chicken was injected with 100 µg of conjugate mixed 
with complete Freund’s adjuvant. All subsequent boosts (50 µg of conjugate mixed with 
Freund’s incomplete adjuvant) were administered subcutaneously at four sites and at 
three weekly intervals. After the third boost a serum bleed was taken and analysed by 
direct ELISA using a HRP-labeled anti-chicken (IgY) antibody.  
 
The immune serum was screened using the AZA-BTG ‘in-house’ conjugate, using a 
direct titre ELISA format. A control included the un-conjugated carrier, BTG. The 
results show that no significant immune response was generated to AZA. A very low 
response to AZA-BTG was generated (approximately 1/1,000). However, the chicken 
immune serum also bound significantly to the BTG carrier alone. It was unknown how 
the serum was responsive to BTG. It is possible that the animal may have consumed a 
number of bovine products in feed. This may have caused a response to the bovine 
protein (BTG).  
 
Screening with AZA-KLH and KLH carrier showed that there was a significant 
response to both proteins was generated (approximately 1/10,000) (data not shown). It 
cannot be determined whether this response was specific for AZA, as the AZA-KLH 
conjugate was used as the immunogen and the response may be solely KLH-specific. A 
negligible response was obtained when the conjugates and carriers were tested for 
binding to pre-immune serum from the chicken host (data not shown). 
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4.3 Discussion 
 
Azaspiracid has previously been identified as a key target for establishment of 
alternative detection methodologies to animal toxicity assays and analytical techniques. 
Development of rapid testing methodologies, such as those incorporating immune 
recognition elements, would serve to support existing techniques, such as HPLC and 
mass spectral analysis, by providing a rapid warning mechanism for toxin outbreaks. 
Both monoclonal (Frederick et al., 2009) and polyclonal (Forsyth et al., 2006) 
antibodies have been generated to date, but no reported recombinant antibodies exists to 
azaspiracid. Recombinant antibodies have potential for incorporation of tags for 
functionalisation, immobilisation, purification and detection. They can be expressed in 
large quantities in bacterial systems. Additionally, they can be further improved using in 
vitro affinity maturation. In this work, an immune AZA single chain antibody fragment 
(scFv) library was constructed from an immunised rabbit host. A rabbit was chosen as 
the host animal because of its suitability for antibody generation to small-molecular 
weight targets and because of its unique diversification and gene rearrangement 
capabilities (See Section 4.1.3). 
 
A rabbit host was immunised through successive injections with AZA, conjugated to 
BSA, to boost the immune system. Both genetic starting material and toxin conjugates 
were supplied from a different laboratory and no effective means was available to 
characterise or quantify these conjugates. As discussed, it was difficult to establish a 
true titre value, as there were significant and unexpected responses to the BTG and 
KLH carrier molecules, as well as significant background binding. The genetic material 
was extracted from the rabbit and the library was constructed using the polymerase 
chain reaction (PCR). The VH and VL (κ and λ) sequences were amplified, although 
some optimisation, using alternative high fidelity Phusion
®
 Taq polymerase, DMSO 
and MgCl2, was required. Genetic combinations of VH and VL sequences were spliced 
together via a short amino acid linker sequence (SOE-PCR), thereby creating a full 
length scFv gene fragment. An scFv fragment phage library was generated by cloning 
the gene fragment library into the pComb3XSS phagemid vector and transforming into 
E. coli cells. The phage library was rescued by infection with helper phage and screened 
against immobilised AZA-BTG conjugate.  
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Failure to isolate a recombinant antibody to AZA can be attributed to a number of 
factors, including ineffective immune response generation, the toxic nature of the 
immunogen, the size of the hapten and the quality of conjugation. Barbas et al. (2001) 
has specified that ideally recombinant antibody libraries should be built from animals 
that display a high serum titre to the antigen of interest. A high serum titre reflects a 
high level of antibody production and, therefore, a high level of specific mRNA for 
library construction. However, recombinant antibodies have been isolated from immune 
libraries with titres as low as 1/100 (Burton and Barbas, 1994; Barbas et al, 2001). In 
this work, considerable difficulty was encountered in generating a response in the AZA-
conjugate–immunised rabbit. During the course of immunisation, the animal displayed 
poor health and this may have negatively impacted on the quality of the AZA-antibody 
response. The poor health of the animal may also have been attributed to the 
immunotoxic nature of azaspiracid (See Section 3.2.1). Despite the poor response to the 
AZA-conjugate, it was decided to construct a recombinant library from the genetic 
material of the rabbit.  
 
A further challenge in this work was the inefficiency of toxin-protein conjugates. In an 
ideal situation, conjugates would be fully characterised with comprehensive analytical 
techniques, such as matrix-assisted laser desorption/ionization, with time of flight 
(MALDI-TOF), before immunisation or screening. This analysis would provide 
invaluable information regarding molecular mass of the conjugate and hapten 
incorporation ratios. However, in this project these systems were not available and the 
large size of the protein carriers would have made any analysis extremely complex and 
difficult to analyse. Furthermore, not enough conjugate material was available for this 
type of analysis.  
 
In an attempt to further characterise the rabbit immune serum, an alternative AZA-
transferrin conjugate was immobilised on a CM5 chip surface and binding to the 
immune serum was analysed by SPR. However, no serum antibody-conjugate binding 
was observed. In order to continue this work, new conjugates were required. Therefore, 
two new conjugates were generated for immunisation and screening using purified 
AZA-2 toxin; AZA-bovine thyroglobulin (BTG) and AZA-keyhole limpet haemocyanin 
(KLH) molecule. The AZA-KLH produced ‘in-house’ was employed for avian 
immunisations. In addition, attempts were made to characterise the ‘in-house’ 
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conjugates through HPLC analysis, scanning absorbance spectrum analysis and surface 
plasmon resonance (data not shown). However, none of these techniques provided any 
definitive information about the quality of the conjugation, the number of toxin 
molecules bound or the concentration of the conjugate. Such information can only be 
elucidated by extensive and complex analytical analysis. It was not possible at this time 
to produce a recombinant avian AZA library, as the immunised chicken generated a 
greater response to the carrier molecules compared to the ‘in-house’ AZA-conjugates.  
 
Frederick et al. (2009) encountered similar issues with immune response generation to 
AZA-conjugates in mice for monoclonal antibody development. Major problems were 
observed with mice immunisations, most resulting in death within 24 hours. The 
author’s postulated that an unknown toxicity to the conjugate material, or the presence 
of un-conjugated material in the immunogen preparation was the cause of the deaths. 
Interestingly, it was discovered that a 10-fold reduction in the immunisation conjugate 
concentration had less harmful side effects in the mice. This positive effect was due to a 
decrease in the relative amount of toxin in the context of the carrier. Overall, this led to 
the successful production of polyclonal antibodies.  
 
AZA is a problematic molecule. For instance, there are a number of ongoing issues 
surrounding its structural analysis, epidemiological analysis, toxicity analysis and 
isolation. Problems were encountered by the Yasumoto and Satake group who worked 
with minute quantities of purified toxin material in the structural elucidation of the 
molecule (Satake et al., 1998). Interestingly, total synthesis of the azaspiracid structure 
by Nicolaou et al. (2003a, b) found that the previous proposed structure was incorrect. 
Nicolaou et al. (2006a, b and c) employed a combination of degradation studies and 
synthetic approaches to revise the structure of AZA. Also, little epidemiological data is 
available for AZA, as only a small number of AZA-poisoning events have been 
rigorously documented. This limitation has made the determination of a safety level 
very difficult.  
 
The currently employed detection methodologies for AZA include HLPC, mass spectral 
analysis and the mouse toxicity assay. However, these methods are impractical due to 
their requirement for purified reference material, which is a rarity. Moreover, the in-
humane use of animals in toxicology testing should be avoided (Twiner et al., 2008). 
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Certified reference material is vital for shellfish toxin monitoring programs to facilitate 
method validation and to ensure accuracy of results. AZA CRM is notoriously limited 
due to insufficient quantities of toxin, as previously discussed. The complex structure of 
marine toxins, such as AZA, do not allow for efficient synthetic approaches, so 
naturally-occurring sources are generally required. Isolation from natural sources is 
labour-intensive and the yields of purified material are very low.  
 
The main limitation of this project work was the scarcity and high price of purified 
toxin material, as well as the immunotoxic nature of the immunogen, as reported 
previously in this thesis. Antibody generation does not require an excessively large 
amount of AZA material, however, a combination of factors, including inability to 
generate effective immune responses in two species of animal and the lack of 
characterisation capabilities, have made recombinant antibody production unattainable 
at this time. However, this is the first reported attempt to generate an immune 
recombinant library for AZA using naturally-sourced material. If a reliable, purified 
source of toxin material becomes available in the future, or if a more efficient 
purification process is established, it may be possible to isolate the first novel 
recombinant antibody to AZA from the existing immune libraries. 
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CHAPTER 5 
Generation and characterisation of 
avian anti-microcystin antibodies  
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5.1 Introduction 
 
This chapter outlines the process of generating a recombinant phage antibody library to the 
cyanobacterial toxin, microcystin-LR (MC-LR), and the isolation of specific clones via bio-
panning. The development of a recombinant antibody to MC-LR would allow unlimited 
expression of the antibody in a bacterial host, greatly reducing cost and increasing 
availability of the antibody. Although, a number of recombinant antibodies were generated 
to microcystin (McElhiney et al., 2000; Strachen et al., 2002; McElhiney et al., 2002), 
these antibodies were from non-immune sources that included; a naïve human semi-
synthetic phage display library, Griffin I, and the synthetic naïve library, Tomlinson I.  
 
However, a major advantage of using immune libraries, over conventional naïve antibody 
libraries, is that the host animal immune system can refine and enhance antigen affinity and 
specificity. This increases the possibility of selecting higher affinity antibodies from a 
recombinant antibody fragment library, due to in vivo affinity maturation (Schmitz et al., 
2000; Hoogenboom, 2005). Although naïve libraries are becoming increasingly popular for 
recombinant antibody selection, they may not have the same diversity as that of the 
immune system, which uses somatic hypermutation and gene rearrangement to generate 
large panels of diverse antibodies. Moreover, the affinity of antibodies generated from non-
immune sources is frequently low, often requiring the use of antibody engineering for 
improved affinity (Gram et al., 1992). 
 
This chapter describes the characterisation of the selected antibodies to microcystin by 
sequence analysis, molecular modelling and three-dimensional in silico docking analysis. 
Chromatographic techniques, including immobilised-metal affinity chromatography 
(IMAC) and size-exclusion chromatography (SEC), were employed for scFv purification 
and molecular weight characterisation. An inhibition ELISA was developed for sensitive 
detection of MC-LR, with a limit of detection of 0.5 ng/mL, utilising both the 2H1 and 2G1 
anti-MC-LR scFv fragments. The MC assays were proven to be both accurate and precise 
following inter- and intra-day assay validation. 
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5.2 Microcystin as a target 
 
5.2.1 Microcystin as a public health risk 
 
The hepatotoxic cyclic peptides, including microcystin and nodularin, are part of the group 
of cyanobacterial toxins. Microcystins have been identified from species belonging to the 
genera Microcystis, Anabaena, Oscillatoria (Planktothrix), Nostoc, and Anabaenopsis. 
Nodularin is related to microcystin structurally and has a similar mode of toxicity. It was 
isolated from only a single species of cyanobacteria, Nodularia spumigena (Rinehart et al., 
1988). Concern involving the presence of microcystins in drinking water and their possible 
contamination of food, such as salad, fish and shellfish; have resulted in an urgent need for 
reliable and accurate means for the detection and quantification of this class of toxin. 
 
Although there is a lot of basic information available on the acute toxicity of microcystin, 
there are significant gaps in the understanding of chronic effects, caused by long term, low 
level exposure. The immunotoxicity of microcystins also remains an unresolved issue (see 
Chapter 3). Interestingly, there is strong evidence for tumour promotion in experimental 
animals (Nishiwaki-Matsushima et al., 1992), but the relevance of this in relation to human 
cancer has not yet been clearly demonstrated. As microcystin is taken up and excreted 
through the gut, there is the possibility of an increased rate of gastrointestinal tumours. In 
the mouse colon, tumour precursors were shown to grow faster with microcystin in the 
drinking water (Humpage et al., 2000). Until an exposure marker for cyanobacterial toxin 
intake in humans is clearly demonstrated, it is difficult to carry out effective human 
epidemiology. The implementation of appropriate regulatory limits for microcystin content 
requires the availability of suitable detection methods, which are sufficiently sensitive and 
reliable to detect the presence of microcystin at the stated levels. 
 
Microcystin toxic episodes also impact society at both ecological and economic levels. For 
example, at an ecological level, marine wild animals that have fed on microcystin-
contaminated material, such as marine mammals and birds may suffer intoxication and 
even death. Furthermore, the presence of microcystin blooms also generates economic 
losses to the aquaculture sector and fish industries. This is due to governmental regulations, 
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which determine the maximum acceptable limit of microcystins in freshwater. Breaches of 
such regulations and human poisoning events, often results in the closure of recreational 
and shellfish-handling areas. The growth of the world population and the subsequent 
increased demand on agricultural products has placed an increased demand on water 
supplies in recent years. Intensification of agricultural activity has also resulted in more 
water usage for irrigation, along with higher nutrient loads in water catchment areas. In 
circumstances where irrigation has depleted water flow in rivers, especially in the summer 
months, eutrophication often occurs. The use of eutrophic water for drinking supplies, 
which is prone to MC contamination, elevates the requirement for fast and effective MC 
detection and identification strategies. 
 
5.2.2 Detection methodologies for the cyanobacerial toxin, microcystin  
 
To protect the public from exposure to microcystin toxins, which may cause poisoning 
events, it is important to accurately quantify the identity and absolute quantity of the 
microcystin present in a sample. Potential sources of poisoning include; drinking water, 
dietary supplement and recreational swimming areas. The toxicity to humans is generally 
reported as acute poisoning and limits for the content of microcystin destined for human 
consumption have been set to protect human health. In 1998, the WHO published a 
guideline threshold for microcystin-LR in drinking water of 1 µg/L (WHO, 1998), leading 
to the requirement for a range of methodologies to detect, identify and quantify 
microcystins in natural and treated water (McElhiney and Lawton, 2005; Lawton and 
Edwards, 2008).  Current routine analysis for microcystin involves high-performance liquid 
chromatography, with photodiode array detection (HPLC-PDA). A number of biological 
assays, such as the mouse toxicity assay and enzyme inhibition assays, exist for microcystin 
detection (Metcalf and Codd, 2003; McElhiney and Lawton, 2005; Msagatu et al., 2006). 
ELISA-based detection is, however, the most widely utilised because of its sensitivity and 
selectivity. 
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5.2.2.1 Mouse Bioassay 
 
Until recently, the approved regulatory methods for most countries were based on 
laboratory animal bio-assays. The mouse bioassay plays an important role as a screening 
tool, as it gives the total toxic potential of the sample within a few hours and it can 
distinguish hepatotoxins from neurotoxins. The assay determines the minimum amount of 
microcystin required to kill a mouse and compares this value with lethal doses of a known 
amount of microcystin. The male swiss albino mouse is the most commonly used animal 
for toxicity testing for cyanotoxins. Toxicity is tested by intraperitoneal injection of 
cyanobacterial lysate prepared either by sonication or freeze-thawing of a cell suspension 
which has been sterilised by membrane ultra-filtration. The mice are observed for 24 hours 
and then sacrificed by an approved method. The observation time must be extended to 
seven days where cylindrospermopsin contamination is suspected. This toxin demonstrates 
protracted symptoms which result from progressive liver and kidney failure. Following 
animal sacrifice, the tissue injury is examined to determine which cyanotoxins are present. 
A disadvantage of this method is where more than one type of cyanotoxin is present, the 
more rapid-acting toxin may mask other symptoms. The final toxicity is expressed as LD50 
mg cell dry weight per kg mouse body weight.  
 
These assays raised a number of ethical issues, arising from the prolonged suffering and 
sacrifice of animals (Langley et al., 2007). Technical issues were also a key factor, 
including lack of specificity, duration of the assays and a high rate of false positives and 
negatives (Sauer et al., 2005). The assay does not detect toxins at low levels, especially in 
finished drinking-water, and it does not identify the specific toxic agent (Lambert et al., 
1994). In most countries, there is a desire to move away from the approved animal testing 
methods, as demonstrated by European Directive 86/609/EEC. A large number of 
alternative methods have been proposed. However, regulatory authorities have set strict 
criteria around the possible substitution of these methods. Such rigid criteria have been set 
in order to ensure consumer protection. Consequently, solid evidence must exist to prove 
that any new method is comparable to internationally validated methods, before the 
authorities will accept its use in toxin testing.  
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5.2.2.2 Analytical Detection Methods 
 
Analytical detection methods for microcystins are characterised based on their sensitivity 
and ability to detect the various toxin variants. Chemical analysis of microcystin is most 
commonly conducted on reversed-phase high-performance liquid chromatography (RP-
HPLC), with UV detection at 238 nm. Microcystins have characteristic spectra at this 
wavelength, due to the presence of a chromophore and a diene in the Adda residue 
(Meriluoto et al., 1997). The HPLC detection limit for microcystins, especially 
incorporating photo-diode array (PDA), is in the nanogram range (Meriluoto, 1997; 
Sangolkar et al., 2006). Using this technique, Lawton et al. (1994) detected microcystin in 
a spiked water sample at 250 ng/L. Separation of microcystin variants is dependent on the 
composition of the mobile and stationary phases used for analysis. Microcystins can be 
separated using gradient elution or isocratic mobile phases, although gradient elution has 
the potential to separate a wider range of toxin variants. 
 
C18 silica columns are the most widely used HLPC columns for separating toxins. They 
use a gradient of water and acetonitrile, both containing 0.05% (v/v) trifluoroacetic acid 
(TFA), which acts as an ion-pairing agent. This technique can separate up to 10 microcystin 
variants, but it is also necessary to analyse toxin standards in parallel, in order to accurately 
identify which variants are present (Lawton et al., 1995). The use of more than one mobile 
phase is often necessary to ensure separation and identification of the full range of 
microcystin variants. HPLC with PDA detection is one method that is often used to 
determine the microcystin content of a sample. However, it is limited in its ability to 
distinguish between different microcystin variants, as most variants have a similar 
absorption peak between 200 and 300 nm. A major limitation for analytical detection 
methods for microcystins is the lack of reference material. There are approximately 90 
different MC variants. However, commercial standards are available for only a few these 
variants (McElhiney and Lawton, 2005). In the absence of suitable standards, quantified 
microcystin variants are generally expressed as equivalents of MC-LR (McElhiney and 
Lawton, 2005). 
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More accurate identification of microcystins can be carried out using HPLC, followed by 
detection with mass spectrometry (LC/MS). In mass spectrometry, the molecules in a 
biological sample are converted to desolvated ions, which are resolved by mass analysers 
on the basis of mass and charge (Graves and Haystead, 2002). Different variations of this 
method have been developed for microcystin analysis, including fast atom bombardment 
(FAB) (Kondo et al.,1995), electrospray ionisation (ESI-MS) (Barco et al., 2002) and 
matrix-assisted laser desorption ionisation-time of flight (MALDI-TOF) (Welker et al., 
2002). The structural information provided by these methods allows for definitive 
differentiation between the toxin variants. Techniques, such as HPLC-ESI-MS, have 
become more popular and are extensively used in the monitoring and identification of a 
range of cyanobacterial toxins, which include microcystins (Dahlmann et al., 2003). ESI-
MS techniques provide molecular weight information, which can confirm the identity of 
toxin variants, previously detected by HPLC-PDA. When no mass data is available, in the 
case of unknown microcystin variants, the patterns obtained using tandem mass 
spectrometry (MS/MS) fragmentation are very useful for identification, especially for 
complex matrices (Lawton et al., 1995). Meriluoto et al. (1998) developed an 
electrochemical sensor for microcystin-LR, -RR and -YR, following HLPC analysis. In the 
study by Meriluoto and colleagues, measurement of the electrochemical response obtained 
by oxidation of arginine and tyrosine residues in the microcystin structure was carried out. 
 
5.2.2.3 Immunological Detection Methods 
 
Currently, the most promising techniques for the detection of microcystins involve the use 
of antibodies. Polyclonal, monoclonal and recombinant antibodies have been employed in a 
wide range of formats for toxin detection and quantification. These approaches have been 
reviewed according to conjugation strategies and carriers, used for immunogen preparation, 
as well as inhibitory concentration (IC50), assay format and cross-reactivity, in Tables 
5.2.3.1, 5.2.3.2 and 5.2.3.3, inclusively. The IC50 is defined as the inhibitory concentration 
of toxin required to cause half maximal binding. 
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Table 5.2.2.1: Strategies for polyclonal antibody development to microcystin. Antibodies were 
compared, according to their immunogen preparation (conjugation strategy and carrier molecule), 
IC50, immunoassay format and cross-reactivity to microcystin variants. (*RIA: radioimmunoassay; 
*CIPPIA: Colorimetric immuno-protein phosphatase inhibition assay. 
Toxin Conjugation strategy Carrier IC50 
(µg/L) 
Format Cross-
reactivity 
Reference 
MC-LR 
and 
Nodularin 
Aminoethylation of the 
N-methyldehydroalanine 
residue and one-step 
glutaraldehyde coupling  
KLH 2.50  Indirect 
competitive 
MC-LA, -LR, 
-LF, -LW,   -
D-Asp3-RR, 
-LY, NOD, 
MC-Asp (Z)-
Dhb7-HtyR 
Metcalf et 
al., 2000 
MC-LR Carbodiimide 
EDPC (1-(3 
dimethylaminopropyl)-3- 
ethylcarbodiimide)  
BSA 
Polyl-
lysine 
1.75  RIA*, direct 
and indirect 
competitive  
MC-RR, -LR 
and –YR, 
NOD 
Chu et al. 
1989 
MC-LR Aminoethylation of the 
N-methyldehydroalanine 
residue and 
glutaraldehyde coupling 
BSA 0.63  Direct 
competitive 
MC-LR, -RR, 
-YR, -LF,   -
LW, NOD 
Sheng et 
al., 2006 
MC-LR/RR            
Nodularin 
Carbodiimide  Polyl-
lysine 
10-50  Competitive 
inhibition 
MC- LR,-RR          
Nodularin 
Baier et 
al., 2000 
Adda Synthetic N-acetyl ᴅ-
alanyl Adda 
cBSA          
OVA 
0.61  Indirect 
competitive 
MC-LR, -RR, 
-YR,-LW,   -
LF, 3-dm-
MC-LR, 3-
dm-MC-RR, 
NOD 
Fischer et 
al., 2001 
MC-LR Carbodimide method 
using activated EDC, via 
carboxylic acid group                                                
(Mixed anhydride)                                                        
BSA                                   
OVA                                   
HRP
0.50 Indirect and                                  
direct 
competitive 
Abs with
similar cross-
reactivity 
pooled 
Mhadhbi et 
al., 2006 
MC-RR Aminoethylation of the 
N-methyldehydroalanine 
residue and 
glutaraldehyde coupling 
KLH 3.03  CIPPIA* MC-LR, -RR, 
nodularin 
Young et 
al., 2006 
217 
 
Table 5.2.2.2: Strategies for monoclonal antibody development to microcystin. Antibodies were 
compared, according to their immunogen preparation (conjugation strategy and carrier molecule), 
IC50, immunoassay format and cross-reactivity to microcystin variants (EIA*: Enzyme immunoassay). 
Toxin Conjugation Strategy Carrier IC50 
(µg/L) 
Format Cross-
reactivity 
Reference 
MC-LR Carbodiimide 
EDPC  
BSA  
OVA                                 
KLH 
0.13  Indirect 
competitive 
_ Nagata et 
al., 1995 
MC-LR Aminoethylation of the 
N-methyldehydroalanine 
residue and 
glutaraldehyde coupling 
BSA 1.8  Indirect 
competitive 
Very low 
level 
Sheng et 
al., 2007 
MC-LR Aminoethylation of  N-
methyldehydroalanine 
residue and 
glutaraldehyde coupling  
BSA 1.00  Direct 
competitive 
MC -RR, 
dmMC-
LR, 
dmMC-
RR, H2N-
etMC-LR, 
MC-YR, 
NOD 
Mikhailov 
et al., 2001 
Adda Amide (activated ester) 
between carboxylic acid 
of Adda and primary 
amino groups 
KLH           
BSA            
HRP 
0.33  Direct 
competitive 
All 
cogeners 
Zeck et al., 
2001 
MC-LA _ Polylysine 
Muramyl 
dipeptide 
- - 6 variants Kfir et al., 
1986 
MC-LR Carboxylic acid group 
via carbodimide 
HRP 0.22  Direct 
competitive 
All 
cogeners 
Weller et 
al., 2001 
MC-LR 
Nodularin 
Aminoethylation on N-
methyldehydroalanine  
BSA 0.01  EIA* MC-LR, -
YR, -LA, 
NOD 
Khreich et 
al., 2009 
MC-LR EDC/ NHS linkage via 
carboxylic acid groups 
Biotin 0.05  Indirect 
inhibition 
_ Lindner et 
al., 2004 
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Table 5.2.2.3: Strategies for recombinant antibody development to microcystin. Antibodies 
were compared, according to their immunogen preparation (conjugation strategy and carrier 
molecule), IC50, antibody format, immunoassay format and cross-reactivity to microcystin 
variants. 
 
Microcystin antibodies have also been incorporated into an immuno-protein 
phosphatase inhibition assay (Metcalf et al., 2001), immunoaffinity chromatography 
(McElhiney et al., 2002; Aranda-Rodriguez et al., 2003) and, most recently, a lateral 
flow ‘dipstick’ style assay (Kim et al., 2003). Such kits have proven useful for 
screening water and cyanobacterial samples, but they have shown poor cross-reactivity 
to toxin variants (Rapala et al., 2002). In general, the analytical capacity of any ELISA 
in routine sample screening is dependent on the antibody’s ability to recognise all 
microcystin variants. Polyclonal antibodies to microcystin have the advantage of being 
composed of a mixed pool of antibodies, which bind different sites on the microcystin 
molecule, including those that are common to all toxin variants. However, polyclonal 
antibody responses are highly variable and non-reproducible, especially when different 
batches of sera are used. A sheep polyclonal antibody was raised to the Adda moiety, 
which is found in 80 % of all microcystin and nodularin variants (Fischer et al., 2001). 
Toxin Conjugation 
Strategy 
Carri
er 
Antibody 
Format 
IC50 
(µg/L) 
Format Cross-
reactivi
ty 
Reference 
MC-LR Aminoethylation of 
the N-
methyldehydroalanine 
residue and one-step 
glutaraldehyde 
coupling 
KLH                
BSA 
scAb from 
Tomlinson I 
library 
4-9 Direct 
Competitive 
MC-RR, 
-LW, -
LF 
McElhiney 
et al., 2000 
MC-LR Aminoethylation of 
the N-
methyldehydroalanine 
residue and one-step 
glutaraldehyde 
coupling 
KLH                
BSA 
scAb from 
Griffin I 
library 
0.0045 Direct 
Competitive 
MC-RR, 
-LW, -
LF 
McElhiney 
et al., 2002 
MC-LR Aminoethylation of 
the N-
methyldehydroalanine 
residue and one-step 
glutaraldehyde 
coupling 
KLH                
BSA 
scAb from 
Tomlinson I 
 
scab from 
Griffin I  
0.013  
 
 
4  
Direct 
Competitive 
- Strachen et 
al., 2002 
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Immunisation with a common structural feature, such as Adda, restricts the number of 
sites available for binding, giving greater reproducibility. The sheep pAb cross-reacted 
with MC-LR, -RR, -YR, -LW, -LF, 3-desmethyl-MC-LR, 3-desmethyl-MC-RR and 
nodularin. ELISA formats have also been developed for microcystin using monoclonal 
and recombinant antibodies. Monoclonal antibodies from hybridoma cell lines are more 
reliable and reproducible than polyclonal antibodies, as they can be generated in 
uniform batches, with comparable specificities. Isolation of single-chain antibody 
fragments to MC-LR, from a synthetic Tomlinson human phage library, was reported 
by McElhiney et al. (2000). The most sensitive antibody clone selected from the library 
detected MC-LR with an IC50 of 4 μg/L. The suitability of two naïve antibody libraries; 
the synthetic Tomlinson and the semi-synthetic Griffin phage libraries for recombinant 
antibody generation to MC-LR, were compared by Strachan et al. (2002). The Griffin 
library consists of human VH and VL chain gene fragments, with CDR3 diversity 
generated using synthetic oligonucleotides. The Tomlinson library is based on a single 
human framework with side chain diversity incorporated at 18 amino acid positions in 
the antigen-binding site. Selected antibodies (single chain antibody fragment, scAb) 
from the Griffin library were found to be 300 times more sensitive than those isolated 
from the Tomlinson library. McElhiney and colleague also employed the Griffin library 
to isolate recombinant antibody fragments (scAb) to MC-LR. It was reported that the 
most sensitive scAb isolated, was capable of detecting microcystin-LR at levels below 
the World Health Organisation limit in drinking water (1 μg/L). In addition, the 
antibody fragment cross-reacted with three purified microcystin variants (MC-RR, -LW, 
and -LF) and a related cyanotoxin, nodularin. The quantification of microcystins in 
toxic samples assayed by ELISA showed good correlation with analysis by high-
performance liquid chromatography (McElhiney et al., 2002). 
5.2.2.4 Phosphatase inhibition assays 
 
Methods for detection of microcystin have been developed which exploit the 
biochemical properties of this hepatotoxin molecule. These assays are based on 
microcystins inherent ability to inhibit the catalytic subunit of protein phosphatases. 
There are a number of advantages to this approach; they provide a useful indication of 
the biochemical activity of the toxin sample, as a whole, and the assays are sensitive, 
rapid and inexpensive, due to the commercial availability of the enzymes. Protein 
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phosphatase inhibition assays (PPIAs) involve the ability of the catalytic subunit of 
protein phosphatase 1 (PP1) to dephosphorylate the chromogenic substrate p-
nitrophenylphosphate. However, a limitation of this method is that the reactivity of 
different microcystins to protein phosphatases may not be the same, and the assay may 
be sensitive to other protein phosphatase inhibitors (Metcalf et al., 2001). Therefore, 
Metcalf et al. (2001) developed a modification of the PPIA to make it specific for 
microcystins and to decrease its sensitivity to other protein phosphatase inhibitors, such 
as okadaic acid, calyculin and tautomycin. They successfully combined immunoassay 
detection with protein phosphatase inhibition in a colorimetric, immuno-protein 
phosphatase inhibition assay system. Assays have been developed using both protein 
phosphatase 1 (PP1) and protein phosphatase 2A (PP2A), although the reaction of 
microcystin with PP1 is approximately 50 times less sensitive than with PP2A 
(Honkanen et al., 1994).  
 
5.2.3 Detection Issues for Microcystin 
 
Overall, there are a number of key issues causing concern in the area of microcystin 
detection. There is some concern that analytical techniques used for the detection of 
microcystins may fail to recognise toxin variants and this may result in a significant 
number of false negatives. This applies to instrumental techniques, as well as 
immunochemical assays. Also, certain methods have been hindered due to the presence 
of over 90 different purified variants, most of which are not commercially available. 
This may lead to the under-estimation of total microcystin in a sample. For example, 
some methods only report microcystin-LR equivalence, regardless of what other 
variants are present (McElhiney and Lawton, 2005). The availability of HPLC, coupled 
to mass spectral analysis, can aid in more accurate estimation of toxin variants. 
However, many microcystins share the same molecular mass, making definitive 
identification difficult. Another difficulty in analysing microcystins is the requirements 
for sample processing, including solid-phase extraction (SPE), in order to enrich 
environmental concentrations of microcystin and to eliminate contaminating animal and 
plant tissue from complex samples. New techniques involving recombinant antibodies 
have been exploited to develop assays and biosensors for microcystins, with higher 
sensitivities and a greater potential for cross-reactivity to toxin variants than other 
methods (McElhiney et al., 2002; Strachen et al., 2002).  
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5.2.4 Chapter aims 
 
The purpose of this chapter is to give an overview of the successful generation of an 
avian scFv fragment to the cyanobacterial toxin, microcystin. An antibody is required 
that can detect microcystin and its variants with high sensitivity and specificity below 
the limit of detection of 1 µg/L. A chicken host was immunised, RNA extracted and 
cDNA synthesised. The antibody variable genes were amplified by PCR, gel-purified 
and cloned into a phagemid vector. Specific clones were isolated by bio-panning, which 
involved a selection process on MC-OVA-coated immunotubes, enrichment and affinity 
maturation. Five rounds of selection were performed on the avian anti-MC-LR single 
chain variable fragment (scFv) recombinant antibody library. 
 
In addition, this chapter provides an insight into the molecular structure and binding 
characteristics of the recombinant antibody fragments to microcystin, isolated from an 
immune scFv avian library. Two antibodies were selected, 2H1 and 2G1, based on their 
binding characteristics by direct and competitive ELISA. DNA sequence information 
from the microcystin-binding scFvs allowed for a comprehensive comparison between 
the genetic sequences of each antibody and the three-dimensional (3-D) in silico 
modelling, which employed the Deepview–Swiss PDB Viewer. Docking analysis was 
performed with the scFv fragments and the microcystin-LR molecule, using the PDB 
NMR sequence data for microcystin (1LCM). This provided information about the 
interactions between the scFvs and the MC-LR molecule and also predicted possible 
docking positions for MC-LR with the scFv structures.  
 
The availability of a hexa-histidine (His6) tag on the scFvs fragments allowed for 
purification using an immobilised-nickel resin. These antibodies were further purified 
and characterised by size exclusion chromatography on an Akta
™
 Explorer  FPLC 
instrument. An inhibition ELISA was optimised and preliminary assay validation was 
carried out, using the IMAC- and size exclusion-purified scFvs. The purpose of this 
chapter was to demonstrate the accuracy, precision and sensitivity of the isolated 
antibody fragments. The overall aim was to provide microcystin-binders for 
incorporation into a new immunosensor for microcystin that would be comparable or 
more effective than the detection technologies outlined in Section 5.2.2.  
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5.3 Results  
5.3.1 Production of an avian recombinant scFv library for microcystin 
5.3.1.1 Avian immune response generation to a microcystin conjugate  
 
Two bespoke conjugates were generated through modification of the N-
methyldehydroalanine residue to create an aminoethanethiol‐microcystin‐LR derivative 
(Section2.14.1). The derivatised microcystin‐LR was subsequently conjugated to OVA 
and BSA using one-step glutaraldehyde coupling. An immune response was generated 
in an avian host using the MC-LR-BSA conjugate, as described in Section 2.14.2. Prior 
to the sacrifice of the immunised chicken, a serum titre was performed to determine 
whether a sufficient immune response was generated. Similar dilutions of serum, taken 
from the chicken prior to immunisation (pre-bleed), were also prepared. In order to 
characterise the true response to the toxin, an alternative coating conjugate, MC-LR-
OVA was utilised.  
 
Figure 5.3.1.1: ELISA analysis of pre-bleed and immune serum from MC-LR-BSA-
immunised avian host. The ELISA plate was coated with MC-LR-OVA conjugate, at a 
concentration of 10 µg/mL. Binding was detected with an anti-chicken (IgY) antibody, 
conjugated to horseradish peroxidase (HRP). The ELISA was developed with TMB 
substrate and the absorbance was measured at 450 nm, using a Tecan™ Safire II plate 
reader. 
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A clear immune response was generated in the chicken by administering four boosts 
with 500 µg of microcystin-BSA conjugate, at four weekly intervals. The titre was 
approximately 1/20,000 (Figure 5.3.1.1), which was sufficient for recombinant antibody 
generation. The pre-bleed showed some response with the conjugate, but this was 
largely due to non-specific binding of serum to the ELISA plate, despite the use of 
extensive blocking steps. 
 
5.3.1.2 Extraction of RNA and reverse transcription to cDNA 
 
RNA was extracted from the bone marrow and spleen of the immunised-animal and 
complementary DNA (cDNA) was synthesised using the First Strand
®
 cDNA Synthesis 
Kit (Invitrogen). The cDNA from the bone marrow and spleen was electrophoresed on a 
1 % (w/v) agarose gel to confirm the presence of good quality templates for further gene 
amplification (Figure 5.3.1.2). 
 
 
Figure 5.3.1.2: Agarose gel demonstrating successful cDNA synthesis from 
microcystin-immunised avian host. 1.) Spleen cDNA (5.6 µg) and 2.) Bone marrow 
cDNA (4.8 µg) were loaded on the 1 % (v/v) agarose gel. The presence of cDNA is 
characterised as a continuous smear from approximately 400-1650 bp. Lanes ‘M’ 
represent a 1 kb Plus DNA ladder (Invitrogen). 
 
500 bp
1650 bp
M            1                2            M
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5.3.1.3 Amplification of avian heavy and light chains and PCR optimisation 
 
The long linker primers, CSCVHo-F and CSCG-B (Barbas et al., 2001) were used to 
amplify VH segments from the avian cDNA, as long linker scFv fragments have less 
tendency to dimerise and cause avidity effects. The sense primer has a sequence tail, 
which corresponds to the linker sequence that is used in the overlap extension PCR. The 
reverse primer has a sequence tail, containing an SfiI restriction site. This tail is 
recognised by the reverse extension primer used in the second-round PCR. The CSCVK 
sense primer is combined with the CKJo-B reverse primer to amplify VL gene segments 
from the avian cDNA. CSCVK has a 5´ sequence tail that contains an SfiI site and is 
recognised by the sense extension primer in the second-round PCR. The reverse primer 
has a linker sequence tail that is used in the overlap extension. It was neccessary to 
optimise the MgCl2 concentrations for both products. The PCR products were evaluated 
on 1 % (w/v) agarose gel (Figure 5.3.1.3).  
 
 
Figure 5.3.1.3: Optimisation of VH and VL PCR amplifications. MgCl2 concentrations 
for each reaction were prepared from 1.5 mM to 5 mM, for both the VH and VL chains. 
‘M’ represents a 1 kb Plus DNA ladder.  
 
A 400 bp product amplified for the VH reactions and a 350 bp amplicon was generated 
for the VL reactions. These results indicated that the optimal MgCl2 concentration for 
the VL and VH chain amplifications, were 3 mM and 1.5 mM, respectively. At 1.5 mM 
MgCl2, a non-specific band was observed in the VL reaction. Therefore, this 
concentration was not employed for further amplification. A large-scale PCR 
M   1.5mM 3mM 4mM 5mM       M   1.5mM 3mM 4mM 5mM   M 
~ 350 bp
~ 400 bp
VL VH
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amplification (10X reaction) was performed, using the optimised conditions, and the 
products were purified by gel extraction, using a QiaQuick gel extraction kit (Qiagen). 
5.3.1.4 SOE-PCR of variable heavy and light chains from the avian library 
 
Following purification of the VH and VL chains by gel extraction, SOE-PCR was carried 
out. SOE-PCR was performed, using the extension primers, CSC-F and CSC-R. This 
process joined the VL and VH regions, using the sequence tails introduced in the first 
round of PCR, to create a serine-glycine linker sequence. This second round of PCR 
produced a 750 bp product (Figure 5.3.1.4). An annealing temperature of 56
o
C and a 
magnesium sulphate (MgSO4) concentration of 2 mM were found to be optimal for the 
PCR, using the high fidelity Platinum
®
 Taq DNA polymerase (Invitrogen). 
 
 
Figure 5.3.1.4: Large-scale amplification of SOE-PCR product. The approximate 
molecular weight of this fragment was 750 base pairs (bp). A negative control (no 
template) was included (1), and ‘M’ represents a 1 kb Plus DNA ladder. Lanes 2-6 
contains repeat amplifications of the SOE product, employing the same PCR conditions. 
 
Some non-specific bands were observed for the large-scale amplification (Figure 
5.3.1.4), which were subsequently removed through gel purification. The purified SOE 
product, with a molecular weight of approximately 750 bp, was isolated, ethanol-
precipitated and stored at -20
o
C. 
 
  
~ 750 bp
M       1       2        3       4          5           6         M   
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5.3.1.5 Antibody library construction and bio-panning 
 
The SOE product was harvested, quantified (using a Nanodrop ND-1000™), and cloned 
into a pComb3xSS vector, using the restriction enzyme, SfiΙ (see Section 2.14.3.4). SfiI 
was used for cloning, as the sites at which it cuts are rare in antibody sequences and, 
therefore, the use of this enzyme eliminates the possibility of internal digestion and 
incorrect sequence lengths. Antartic phosphatase treatment (see Section 2.14.3.5) 
ensured that self-ligation of the vector did not occur. The ligated product was 
transformed into electro-competent E. coli XL1-Blue cells (Strategene), by 
electroporation. The transformed avian anti-microcystin scFv library had a size of 3.47 
x 10
7
 cfu/mL, which was sufficient for immune phage-displayed libraries.  
 
5.3.1.6 Screening of microcystin chicken library using phage display  
 
The library was ‘rescued’ using M13K07 helper phage, as outlined in Section 2.14.4.1. 
The immune library was subsequently enriched, via phage display bio-panning, against 
immobilised MC-LR-OVA conjugate (100 to 10 µg/mL). Five rounds of bio-panning 
were carried out, with decreasing concentrations of conjugate coated onto the 
immunotube for each round. The number of washes was increased to facilitate high 
stringency panning to select for all available binding clones (Table 2.14.4.1). The inputs 
and outputs from each round of bio-panning give an indication of panning efficiency 
and were optimal for each round (Table 5.3.1.1).  
 
Table 5.3.1.1: Bio-panning inputs and outputs for the avian immune library 
Pan Number Input (cfu/mL) Output (cfu/mL) 
Pan 1 4.3 x 10
11
 9.0 x 10
7
 
Pan 2 4.1 x 10
10
 4.7 x 10
7
 
Pan 3 6.4 x 10
10
 1.1 x 10
5
 
Pan 4 2.9 x 10
8
 1.1 x 10
6
 
Pan 5 1.2 x 10
11
 2.9 x 10
6
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5.3.1.7 Polyclonal phage ELISA  
 
The precipitated input phage from each round of bio-panning was analysed by 
polyclonal phage ELISA, as described in Section 2.13.14.3, to test for enrichment to the 
immobilised-MC-LR-OVA conjugate. The phage input contains a mixture of 
microcystin binders, with varying specificities and affinities, which are selectively 
enriched against the toxin-conjugate with each round of bio-panning. The polyclonal 
phage response is, therefore, an indication of bio-panning efficiency. An increase in the 
absorbance signal to MC-LR-OVA, in bio-panning rounds 4 and 5, is illustrated in 
Figure 5.3.1.5. A high signal of MC-OVA-specific scFv-phage can be observed in bio-
panning round 1, which subsequently decreased, due to increased panning stringency. 
There is also an increase in selection to M13K07 helper phage in rounds 2 and 3, which 
subsequently decreased in rounds 4 and 5. 
 
 
 Figure 5.3.1.5: Polyclonal phage ELISA for the avian library. Input phage from each 
round of bio-panning was incubated with immobilised-MC-LR-OVA conjugate (10 
µg/mL) and binding was detected using a HRP-labelled anti-M13 commercial antibody 
(GE Healthcare). Non-specific binding controls were included for the carrier 
immunogen, BSA (10 µg/mL) the screening carrier, OVA (10 µg/mL) and M13KO7 
helper phage (1/100). Errors bars represent the standard error of the mean. 
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5.3.1.8 Direct soluble monoclonal ELISA and colony-pick PCR 
 
It is possible to perform monoclonal phage ELISA from bio-panning outputs. However, 
it has been shown that the multivalent nature of display on the phage particle may cause 
avidity effects, resulting in selection of antibodies with lower affinities (Kwasnikowski 
et al., 2005). Therefore, phage outputs from panning rounds 4 and 5 were re-infected 
into E.coli Top10F' bacterial cells. Single colonies (150) were picked and sub-cultured 
overnight in 200 µL SB media, containing 100 µg/mL carbenicillin. The cultures were 
induced with 1 mM IPTG, for soluble expression, and subjected to three ‘freeze-thaw’ 
cycles. The scFv-enriched lysate was clarified by centrifugation and tested in a direct 
ELISA format for binding to immobilised MC-LR-OVA conjugate (5 µg/mL) (Figure 
5.3.1.6). Ten of the best clones, selected on the basis of their absorbance values, were 
taken forward for cross-reactivity and inhibition analysis to assess their ability to bind 
MC-LR in solution. 
 
Figure 5.3.1.6: Soluble monoclonal ELISA of the anti-microcystin scFvs. One hundred 
and fifty clones were selected from panning rounds 4 and 5, for soluble expression 
analysis. Supernatant, containing solubly-expressed scFv, was incubated on MC-LR-
OVA–coated plates (5 µg/mL) and binding was detected using HRP-labelled anti-HA 
commercial monoclonal antibody. All clones tested had an absorbance signal 
significantly above background. The ELISA background (three times the blank value) is 
marked with a horizontal line. 
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A ‘colony-pick’ PCR was performed on ten randomly selected individual colonies from 
the bio-panning rounds 4 and 5 of the avian scFv library. The bacterial colonies were 
inoculated into 50 µL of sterile, molecular-grade water and lysed at 94°C for 10 
minutes. The amplified scFv products were analysed via gel electrophoresis on a 1% 
(w/v) agarose gel. An insert of approximately 750 bp was observed for every colony 
(data not shown). 
5.3.1.9 Restriction digestion of the anti-microcystin scFvs 
 
Ten of the scFv clones, identified by monoclonal soluble ELISA, were digested with 
AluI restriction enzyme. The aim of this analysis was to characterise the antibodies, 
based on their characteristic restriction profiles, which may give an indication of library 
diversity (Figure 5.3.1.7). Four different digestion profiles were observed, based on the 
nucleotides identified by the AluI enzyme (AG/CT), indicating that there was at least 
four distinct clones. Profile 1 is shown in lanes 1 and 7, resulting in four distinct bands. 
Profile 2 is shown in lanes 2 and 9, resulting in three distinct bands. Profile 3 is shown 
in lane 5, resulting in 2 distinct bands. Profile 4 is shown in lane 3, also resulting in two 
distinct bands. Some banding patterns may have resulted from partial enzymatic 
digestion. A number of clones remained un-digested, including lanes 4, 6, 8, 10, 11 and 
12 (Figure 5.3.1.7). 
 
Figure 5.3.1.7: Restriction digestion analysis, utilising AluI restriction enzyme. Lane 1: 
2C3, Lane 2:2H1; Lane 3:1F11; Lane 4:5C9; Lane 5:2C5; Lane 6:2G1; Lane 7: 5A9; 
Lane 8: 2C1; Lane 9: 2C4; Lane 10: 1E11; Lane 11: 2G1; Lane 12: Un-digested control 
vector; Lane 13: Negative control (no colony). Lane ‘M’ represents a 100 bp DNA 
ladder (Invitrogen). 
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5.3.2 Characterisation of the microcystin-specific scFv fragments 
5.3.2.1 Carrier cross-reactivity analysis of the anti-MC-LR clones 
 
It was established that the ten clones, selected by soluble, monoclonal ELISA, were 
capable of binding microcystin in the context of a protein conjugate and that they 
possessed some genetic diversity, as illustrated by restriction analysis. It was, therefore, 
important to establish that the clones were not specific for the screening conjugate 
alone, and that they bound MC-LR in the context of other protein conjugates. The MC-
LR-KLH (obtained from Queen’s University) and the MC-LR-OVA (Enzo Life 
Sciences Ltd.) conjugates were utilised for screening. The screening protein carrier, 
ovalbumin (OVA), the immunogen carrier, bovine serum albumin (BSA) and the 
alternative conjugate protein, keyhole limpet haemocyanin (KLH) were included in the 
analysis (Figure 5.3.2.1).  
Figure 5.3.2.1: Direct ELISA analysis of crude lysate from cultures of ten selected 
clones. The clones were tested for reactivity to two microcystin conjugate, including 
MC-LR-KLH and MC-LR-OVA (5 µg/mL) and the carrier proteins, BSA, OVA and 
KLH (5 µg/mL). Ten mL cultures were grown, induced with IPTG and lysed using 
successive freeze-thaw cycles. Lysates were clarified by centrifugation and diluted (1/5) 
in 1 % (w/v) Milk Marvel/ PBS, containing 0.05 % (v/v) Tween 20.  
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The clones displayed some cross-reactivity to the MC-LR-KLH conjugate, which was 
not comparable to the binding of the MC-LR-OVA conjugate. The conjugates may have 
been synthesised using different techniques. Derivitisation and two-stage glutaraldehyde 
coupling were employed for the generation of the MC-LR-OVA conjugate. The 
conjugation technique employed for the functionalisation of MC-LR with KLH, remains 
unknown (undisclosed information). The conjugates may have different sites for 
conjugation and have different toxin:carrier ratios. Little or no binding was observed for 
the protein carriers, BSA, KLH and OVA.  
 
5.3.2.2 Indirect inhibition ELISA of microcystin-binding clones in lysate 
 
The MC-LR-specific scFvs were analysed for their capacity to bind free MC-LR in 
solution. Inhibition analysis was carried out by pre-incubating with free MC-LR for 30 
minutes and adding the mixture to the pre-coated microplate. In total, ten scFvs were 
analysed for inhibition with MC-LR, ranging in concentration from 10 to 0.03 µg/mL of 
free microcystin in solution. The ability of the scFvs to bind the toxin in solution, 
relative to the immobilised conjugate on plate (A) was determined by analysing the 
same clone without any inhibition by the free antigen (A0). The results were normalised 
by subtracting the absorbance at an excess of analyte (Aexcess) from both A and A0. The 
resulting normalised absorbance (A-Aexcess/A0-Aexcess) was plotted as A/A0, versus MC-
LR concentration (ng/mL). This analysis showed that all of the scFvs selected were 
inhibited from binding the immobilised conjugate, for a given concentration of the free 
toxin in solution (Figure 5.3.2.2). It was observed that depletion of the free toxin was 
evident down to the low ng/mL range. This was important in relation to antibody 
characterisation and assay development, as the antibodies need to be able to recognise 
free toxin in solution. 
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Figure 5.3.2.2: Crude inhibition ELISA of ten solubly-expressed MC-LR scFv clones. 
The ELISA plate was coated with 500 ng/mL MC-LR-OVA conjugate and inhibition 
occurred between free MC-LR, ranging in concentration from 10 to 0.03 µg/mL, and 
crude, induced lysate, diluted to a final concentration of 1/2,000 in 1 % (w/v) Milk 
Marvel/ PBS contain 0.05 % (v/v) Tween 20. The normalised absorbance (A/A0) versus 
the free toxin concentration (µg/mL) was plotted. 
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5.3.2.3 Sequence analysis of four selected soluble microcystin-binding clones 
 
Purified plasmids from four of the inhibitive clones, 2H1, 2G1, 2C1 and 5C9, were 
prepared using the Wizard
® 
Plus SV Miniprep DNA purification system, as described in 
Section 2.13.8. The plasmids were sequenced by MWG-Operon, using the splice by 
extension overlap (SOE) primers. The light and heavy chain variable regions were 
identified using the Kabat numbering system and subsequently aligned (Figure 5.3.2.3). 
ClustalW is widely used for multiple alignments and for preparing phylogenetic trees 
(Thompson et al., 1994). It is the third generation of the Clustal series of programs, 
where ‘W’ stands for weighting, which refers to the programs use of sequence 
weighting and position-specific gap penalties.  
 
Considerable sequence diversity was evident between the 2H1 and 2G1 clones. The 
2G1, 2C1 and 5C9 sequences were found to be genetically identical (Figure 5.3.2.3). 
CDRL1 and CRDL2 each have three amino acid differences and CDRH1 only has one 
difference, where alanine (Ala) in the 2H1 sequence was substituted to asparagine (Asp) 
in the 2G1 sequence. CDRL3, CDRH2 and CDRH3 are markedly different in 2H1 and 
2G1, with 9, 6 and 9 amino acid differences between them, respectively. CDRL3 is 
shorter by two amino acids and CDRH3 is shorter by three amino in the 2G1 clone, 
compared to the related sequences in the 2H1 clone. The linker region is highlighted in 
blue, while the hexahistidine (His) tag is highlighted in yellow and the haemagglutinin 
(HA) tag is highlighted in green. The framework regions of the scFvs show high 
sequence similarity, with only 19 differences between the two molecules. There are a 
number of hydrophobic proline residues in the framework regions and in the CDRL2 
region. Despite being hydrophobic, proline residues are frequently found on protein 
surfaces and play an important role in molecular recognition (Kay et al., 2000). 
Tyrosine residues are present in CDRH1, CDRH2 and CDRL1 of both scFv fragments. 
Tyrosines are important in the formation of protein-protein interactions and, therefore,  
have an important role in molecular recognition (Koide and Sidhu, 2009).The most 
specific antibodies were those with the highest tyrosine content. In contrast, arginine 
content is associated with increased non-specific binding (Birtalan et al., 2008).  
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Figure 5.3.2.3: ClustalW sequence alignment for four MC-LR clones. CDR regions and 
tags, including His and HA, are highlighted in colour. Sequences 2G1, 2C1, 5C9 are 
identical. Key: CDRL1 = Red, CDRL2 = Green, CDRL3 = Purple, Linker = Blue, 
CDRH1 = Orange, CDRH2 = Red, CDRH3 = Pink, His Tag = yellow and HA Tag = 
Light Green. 
5.3.2.4 Structural analysis of scFv clones using 3-D computer modelling 
 
A murine scFv against IL-1β (2KH2, 2B chain) was found in the protein databank 
(PDB) that had a good homology to the 2H1 and 2G1 gene sequences using EMBL’s T-
Coffee alignment program. There is no current crystallographic structure for avian 
scFvs available. This ClustalW alignment was submitted to the Swiss Expasy protein 
structure homology-modelling server. The results from structural modelling studies for 
the two clones are illustrated in Figure 5.3.2.4. The hypervariable CDR domains were 
subsequently identified, from the Kabat numbering scheme for identification of residues 
belonging to CDR regions in the antibody structure. The 2H1 and 2G1 sequences have a 
high degree of homology. However, 2H1 has a longer CDRH3 and CDRL3 compared 
with 2G1 and residue differences can also be observed in all CDR regions. 
                                             L1 
2H1     METKKTAIAIAVALAGFATVAQAALTQPSSVSANPGETVKITCSGSSGRYGWYQQKSPGS 
2G1     METKKTAIAIAVALAGFATVAQAALTQPSSVSANLGGTVEITCSGGSNNYGWYQQKSPGS 
2C1     METKKTAIAIAVALAGFATVAQAALTQPSSVSANLGGTVEITCSGGSNNYGWYQQKSPGS 
5C9     METKKTAIAIAVALAGFATVAQAALTQPSSVSANLGGTVEITCSGGSNNYGWYQQKSPGS 
        ********************************** * **:*****.*..*********** 
                     L2                             L3 
2H1     APVTVIYSNNQRPSDIPSRFSGSKSGSAHTLTITGVQADDEAVYYCGSYDTNLRSDDMFG 
2G1     APVTVIYQNTKRPSDIPSRFSGALSGSTVTLTITGVQAEDEAVYFCAKFDG--STDDLFG 
2C1     APVTVIYQNTKRPSDIPSRFSGALSGSTVTLTITGVQAEDEAVYFCAKFDG--STDDLFG 
5C9     APVTVIYQNTKRPSDIPSRFSGALSGSTVTLTITGVQAEDEAVYFCAKFDG--STDDLFG 
        *******.*.:***********: ***: *********:*****:*..:*    :**:** 
                 LINKER                                   H1 
2H1     AGTTLTVLGGSSRSSGGGGSGGGGSSALTLDESGGGLQTPGRTLSLVCKASGFTFSSYA 
2G1     AGTTLTVLGGSSGSSGGGGSGGGGSSALTLDESGGGLQTPGGALSLVCKGSGFTFSSYN 
2C1     AGTTLTVLGGSSGSSGGGGSGGGGSSALTLDESGGGLQTPGGALSLVCKGSGFTFSSYN 
5C9     AGTTLTVLGGSSGSSGGGGSGGGGSSALTLDESGGGLQTPGGALSLVCKGSGFTFSSYN 
        ************ **************************** :******.********  
                         H2 
2H1     METGWVRQAPGKGLEYVAGINNDGSFTHYESAVKGRATISRDNGQSTVRLQLNNLRAEDT 
2G1     METGWVRQAPGKGLEFVASIDKTGSRTWYGAAVKGRATISRDNGQSTVRLHLNNLRPEDT 
2C1     METGWVRQAPGKGLEFVASIDKTGSRTWYGAAVKGRATISRDNGQSTVRLHLNNLRPEDT 
5C9     METGWVRQAPGKGLEFVASIDKTGSRTWYGAAVKGRATISRDNGQSTVRLHLNNLRPEDT 
        ***************:**.*:: ** * * :*******************:*****.*** 
                   H3                    HIS      HA 
2H1      ATYYCARSLSSIGDIDAWGHGTEVIVSSTSGQAGQHHHHHHGAYPYDVPDYASSTOP 
2G1      AIYYCAK--GNIN-IEEWGHGTEVIVSSTSGQAGQHHHHHHGAYPYDVPDYASSTOP 
2C1      AIYYCAK--GNIN-IEEWGHGTEVIVSSTSGQAGQHHHHHHGAYPYDVPDYASSTOP 
5C9      AIYYCAK--GNIN-IEEWGHGTEVIVSSTSGQAGQHHHHHHGAYPYDVPDYASSTOP 
         * ****:  ..*. *: **************************************** 
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Figure 5.3.2.4: Three-dimensional (3D) structural models of the 2H1 and 2G1 scFv 
fragments, modelled to the known crystallographic structure of the scFv for the IL-1β 
complex (2KH2, 2B chain). CDRL1 = Green, CDRL2 = Orange, CDRL3 = Light Blue, 
Linker = Red, CDRH1 = Purple, CDRH2 = Pink and CDRH3 = Dark blue.  
 
5.3.2.5 In silico docking of scFv clones to microcystin–LR  
 
Once the protein structures of the scFv clones were known and the MC-LR peptide 
toxin were accessible through the Protein Data Bank (PBD), it was possible to carry out 
molecular docking, using Gramm-X software analysis. The aim of this analysis was to 
determine how the antigen-antibody interaction was occurring, thereby obtaining highly 
useful structural information. The MC-LR sequence was obtained from the PDB 
(Designation: 1LCM) and modelled using the Swiss-Model software programme 
(Kiefer et al., 2009) (Figure 5.3.2.5).  
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Figure 5.3.2.5: Structure of microcystin-LR (ILCM) created using the ExPASy 
homology-modelling server, SwissModel. Microcystin is characterised by the ᴅ-amino 
acids; ᴅ-Glutamic acid (ᴅ-Glu), ᴅ-Alanine (ᴅ-Ala) and ᴅ-erythro-methylaspartic acid (ᴅ-
MeAsp) and the ʟ-amino acids; ʟ-Arginine (ʟ-Arg) and ʟ-Leucine (ʟ-Leu). N-
methyldehydroalanine (Mdha) and ß-amino acid side-group, 3-amino-9-methoxy-2-6, 8-
trymethyl-10-phenyldeca-4, 6-dienoic acid (Adda) are also unique.  
 
The Adda and arginine (Arg) side chains protrude from the ring structure distal from 
one another caused by the repulsion between the guanido function of Arg and the 
hydrophobic Adda (Rudolph-Böhner et al., 1994). Underlying the heterogeneity in MC 
variants is their common cyclic structure and possession of several rare, highly 
conserved amino acid moieties. The microcystin isoforms differ primarily at the two ʟ-
amino acids, and secondarily, by the presence or absence of the methyl groups on ᴅ-
MeAsp and N-Mdha. 
 
The purpose of the Gramm-X program is to add layers of possible docking protein sites, 
starting with the most probable prediction candidates (Tovchigrechko and Vakser, 
2006).The input for modelling programs, such as Gramm-X, can be two molecules of 
any type: proteins, DNA, peptides or drugs. The output can be a list of potential 
complexes, sorted by shape complementarity criteria. Given two molecules, their 
surfaces are divided into patches according to the surface shape. Once the patches are 
ʟ-Arg
ʟ-Leu
Adda
ᴅ-Ala
Mdha
ᴅ-Glu
ᴅ-Me-Asp
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identified, they can be superimposed using shape matching algorithms. The best results 
can be re-scored using more advanced criteria, including energetic considerations, 
which should be more accurate in identifying the correct structural positions. Docking 
involves finding the most favourable binding modes of the ligand to the target. All 
docking methods require a scoring function to rank the various binding modes available 
and search methods to explore the variables.  
 
Virtual screening on the basis of molecular distribution and physiochemical properties 
of ligands is very useful in proving leads for library mutagenesis and screening (Collis 
et al., 2003; Fellouse et al., 2004). Overall, it provides a three-dimensional structural 
hypothesis of how a ligand interacts with its target. Success of docking can be measured 
as the root mean square deviation (RMSD) of the Cartesian coordinates of the atoms of 
the ligand of the docked molecule in comparison to the actual crystallographic 
coordinates. A docking is seen as successful if the RMSD is less than the arbitrary 
threshold of 2 Å. Using the Gramm-X docking server, sequences for the 2H1 and 2G1 
clones were submitted, along with the sequence for MC-LR (1LCM). The server 
provides the option of viewing multiple possible binding sites between the MC-LR 
molecule and the scFv. One possible binding combination of MC-LR with 2H1 and 2G1 
is illustrated in Figures 5.3.2.6 A and D, respectively. Fifty possible MC-LR binding 
combinations are illustrated as layers of super-imposed molecules on the images for 
2H1 and 2G1 (Figures 5.3.2.6 B and E, respectively). Figures 5.3.2.6 C and F illustrate 
the scFv structures, as red and green ribbon diagrams, with 50 possible microcystin 
positions super-imposed.  
 
The green ribbon is representative of β-pleated sheet structures. For the 2H1 clone, the 
probable points of contact for MC-LR are characterised by the clustering of possible 
MC-LR binding sites (white circle) in Figure 5.3.2.6 B. These binding sites are in close 
proximity to the CDRL3, CDRH1, CDRH2 and CDRH3 regions of the 2H1 sequence 
and may be involved in recognition of the MC-LR peptide structure. For the 2G1 clone, 
the binding site is more ambiguous, with three possible points of contact identified 
(Figure 5.3.2.6 E). In this case, it is more difficult to determine which CDR regions may 
be involved in antibody:antigen recognition. All the RMSD values were below the 
arbitrary threshold of 2 Å. 
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Figure 5.3.2.6: In silico docking prediction analysis, using Gramm-X software. A.) 2H1 
clone docked with MC-LR (1LCM), with one visible layer B.) 2H1 clone docked with 
MC-LR (1LCM), 50 visible layers of possible docking sites C.) 2H1 clone ribbon 
structure (green indicating β-sheets and red strand), with 50 layers of possible MC-LR 
structures overlaid D.) 2G1 clone docked with MC-LR (1LCM), one visible layer E.) 
2G1 clone docked with MC-LR (1LCM), 50 visible layers of possible docking sites F.) 
2G1 clone ribbon structure, with 50 layers of possible MC-LR structures overlaid. 
 
  
A B C
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5.3.2.6 Recombinant antibody expression and purification using IMAC 
 
Large-scale expression of the avian anti-MC scFvs, 2H1 and 2G1, was carried out in 
500 mL culture volumes, as outlined in Section 2.14.6. Three culture media were 
compared for expression, including super broth (SB), terrific broth (TB) and auto-
induction media (ZY). SB and TB are highly enriched media and contain high 
concentrations of tryptone and yeast. TB is a rich nutrient media for propagation of 
E.coli for the purpose of strain maintenance, plasmid propagation and protein 
expression. TB is also a phosphate-buffered rich medium and contains an additional 0.4 
% (v/v) glycerol as an extra carbon source. SB is richer in peptone and yeast extract, 
compared with TB, and is used in high yield plasmid and protein production. This 
method of growth and induction relies on media components that are metabolised 
differentially to promote high-density growth and automatic induction of protein 
expression from lac-based promoters. The ZY auto-induction media contains carbon 
sources, which are optimised for tightly regulated un-induced growth to high cell 
density, followed by induction with lactose for continued growth and protein 
expression.  
 
The antibody was extracted from both the IPTG-induced and auto-induced cultures by 
sonication and the bacterial pellets were isolated by centrifugation. The protein lysate 
was passed through a 0.2 µm filter, to reduce clogging of the nickel resin. Through 
application of the scFv-containing lysate, any expressed proteins containing a histidine-
tag, were captured by the Ni
+
-NTA agarose resin. Non-specific protein binding on the 
column was minimised by washing with 20 mL of wash buffer (containing 20 mM 
imidazole) and the protein was successfully eluted in fractions, using 250 mM 
imidazole. The IMAC-purified scFv fractions were quantified using a NanoDrop ND-
1000™ and the fractions containing pure protein were pooled. The antibody was buffer-
exchanged, to remove any residual elution buffer, and concentrated using Vivaspin™ 6 
columns. Column ultra-filtration is a common technique used to separate proteins in 
size-graded fractions. The fractions for the 2H1 avian scFv clone (crude lysate and 
concentrated pure scFv) were analysed by SDS-PAGE to determine the degree of 
purity. The SDS-PAGE gel (Figure 5.3.2.7 A) verified that the scFvs were all of the 
correct molecular weight, at approximately 27 kDa. However, a number of impurities 
were present in the ‘pure’ SB and TB expression fractions. It was initially thought that 
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these products were as a result of protein degradation, so a suitable protease inhibitor 
cocktail (Sigma-Aldrich) was added and protein samples were handled and stored with 
the utmost care. However, this did not eliminate the impurities from the scFv 
preparation. Interestingly, a markedly pure band was observed for the ZY auto-
induction media, which was verified by western blotting (Figure 5.3.2.7 B).The proteins 
were transferred to a nitrocellulose membrane and the blot was probed with anti-HA 
monoclonal antibody, labelled with HRP, which bound the HA tag of the scFv.  
 
 
 
Figure 5.3.2.7: Analysis of avian scFv expression profiles A.) SDS-PAGE analysis for 
2H1 growth media optimisation. Lanes ‘M’ contain the molecular weight marker, Page-
Ruler™ Plus Ladder (Fermentas). Lanes 1, 3 and 5 contain crude lysate from 20 mL 
sonicated cultures. Lanes 2, 4, and 6 contain concentrated IMAC-purified 2H1 scFv. B.) 
Western Blot of purified 2H1 scFv (A) using ZY auto-induction as the growth medium. 
Fifty µg of protein were loaded for all samples. 
5.3.2.7 Size exclusion chromatography of scFv fragments 
 
The 2H1 scFv clone was expressed using ZY auto-induction media and purified by 
IMAC (Section 5.3.2.6). However, the protein yield from this expression was not 
sufficient for immunoassay development. In contrast, a high yield was obtained when 
the scFv was expressed in either SB or TB media and induced with IPTG, but SDS-
PAGE analysis revealed a number of contaminating protein bands (Figure 5.3.2.7 A). 
Therefore, further purification of the scFv from the IMAC-pure material was performed, 
using size exclusion chromatography (SEC) on an ÄKTA
™
 Explorer 100 system (GE 
Healthcare, USA).  
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Figure 5.3.2.8: Size exclusion chromatography of avian scFv fragments. A.) 
Purification of 2H1 scFv clone on a HiLoad™ 16/60 Superdex™ 200 16/60 size-
exclusion column. A graph of absorbance, measured as mAu, versus time (minutes) was 
plotted. B.) Selected fractions from the 2H1 analysis were compared to the IMAC-
purified 2H1 fraction, by SDS-PAGE analysis. Fifty µg of protein was loaded for each 
fraction. ‘M’ represents a molecular weight marker, Page-Ruler™ Plus Ladder 
(Fermentas). ‘ FPLC-Peak 1’ and ‘ FPLC-Peak 2’ correspond to the peaks observed in 
the  FPLC chromatogram in A. C.) Purification of 2G1 scFv clone on a Sephradex™ 
200 16/60 size-exclusion column. D.) The protein content of the two 2G1 peaks was 
also compared to the IMAC-purified 2G1 fraction, by SDS-PAGE analysis. ‘ FPLC-
Peak 1’ and ‘ FPLC-Peak 2’ correspond to the peaks observed in the  FPLC 
chromatogram in C.   
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A HiLoad™ 16/60 Superdex™ 200 Prep-grade FPLC column was used with PBS (pH 
7.2) mobile phase at a flow rate of 0.5 mL/min and monitored by UV absorbance 
spectroscopy, at 280 nm. Superdex™ is a composite matrix of dextran and agarose. The 
PBS buffer showed an expected conductivity of approximately 17.2 mS/cm. In this 
study, gel filtration was used as a final ‘polishing’ step to remove minor contaminants 
from the partially purified 2H1 and 2G1 scFv fragments. For each size exclusion run, 
the proteins were eluted and collected. Two major peaks were observed for the FPLC-
purified 2H1 scFv size exclusion chromatogram (Figure 5.3.2.8 A). Peak locations for 
the separated fractions are indicated by arrows (Peak 1 and Peak 2). It was unknown, at 
this stage, whether each peak was representative of pure scFv, contaminants or 
aggregates.  
 
Fractions (5 mL), corresponding to Peak 1 and Peak 2 were collected at approximately 
154 and 174 minutes, respectively. The fractions were analysed by denaturing protein 
gel electrophoresis. The fractions from the 2H1 scFv gel filtration (FPLC-Peak 1 and 
FPLC-Peak 2) were compared to the pre-column, IMAC-pure 2H1 antibody fragment 
(Figure 5.3.2.8 B). It was clear that the ‘FPLC-Peak 2’ fraction contained the majority 
of the pure 2H1 scFv and the purity was significantly improved following gel filtration, 
compared to the IMAC-pure 2H1 scFv. The purified 2H1 scFv had an apparent 
molecular weight of approximately 29 kDa, which is the approximate size for a 
monomeric scFv fragment. There was a slight double band present on the SDS-PAGE 
gel (FPLC-Peak 2, Figure 5.3.2.8 B), which may be a result of the large amount of 
protein loaded on the gel. The fraction was re-analysed, with less protein, and 
demonstrated a clear single band (data not shown).  
 
The size exclusion purification process was repeated for the 2G1 scFv fragment. Two 
peaks were also obtained (Peak A and B), but it is clear that these peaks are 
overlapping, indicating that the separation was not complete. Fractions, corresponding 
to the peak positions at 154 and 174 seconds were isolated for Peak A and Peak B, 
respectively. For the SDS-PAGE analysis of the 2G1 scFv FPLC fractions (FPLC-Peak 
A and FPLC-Peak B), it was clear that the majority of the 2G1 scFv was present in the 
FPLC-Peak A fraction, along with a number of concentrated impurities (Figure 5.3.2.8 
D). The FPLC-Peak B fraction contained less 2G1 scFv, but no impurities were present. 
The purified 2H1 and 2G1 scFv fractions (Peak 2 and Peak B, respectively) were 
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analysed for the presence of functional antibodies by direct ELISA, using a HRP-
labelled antibody, specific for the HA tag on the carboxyl terminus of the scFv fragment 
(data not shown). Functional scFv, denoted by high ELISA signals, were obtained for 
both fractions. The IMAC-SEC-purified 2H1 and 2G1 fractions were stored at -80
o
C, 
with a protease inhibitor cocktail (Sigma-Aldrich) and subsequently used for 
immunoassay development.  
 
Size exclusion chromatography was also applied to the determination of the native 
molecular weight of the monomer fraction of the scFv fragment, 2H1. Fifty µL of the 
monomer fraction of the 2H1 scFv was applied to a HiLoad™ 16/60 Superdex™ 200 
FPLC column, using filtered and degassed PBS (pH 7.4), at a flow rate of 0.5 mL/min. 
A molecular weight standard preparation (Phenomenex), containing bovine 
thyroglobulin (670 kDa), human gamma globulin (150 kDa), ovalbumin (44 kDa), and 
myoglobin (17 kDa), was then directly analysed, under identical conditions. The FPLC 
chromatogram illustrated four main peaks with retention times of 60.67 minutes, 127.47 
minutes, 163.60 minutes and 209.65 minutes, respectively, which represent the four 
protein constituents of the molecular weight standards (Figure 5.3.2.9 A). Some small, 
unknown peaks were also observed, which may be representative of degradation 
products, aggregates or small, UV active substances from the sample buffer.  
 
The molecular weight of the scFv could be estimated from the peak position of the 
elution fraction, by comparing the retention time with that from the protein standards. 
The retention time of the 2H1 scFv fraction was 88.79 minutes (data not shown). The 
estimated molecular mass for the monomeric scFv fraction was extrapolated from the 
best fit line of the molecular weight standards (y = - 0.0109x + 6.5042, R
2
 = 0.99), as 
29,649 kDa. The data points should lie on a straight best fit line, as illustrated. If not, 
the column either has a separation range not suited or the gel-bed is not correctly packed 
and the column should be repacked or discarded. 
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Figure 5.3.2.9:  FPLC analysis of molecular weight standards A.) FPLC chromatogram 
of molecular weight standards, plotted as absorbance versus retention time. The 
retention time (rt) of the molecular weight standards are indicated: Bovine thyroglobulin 
(670 kDa), 60.67 minutes; human gamma globulin (150 kDa), 127.47 minutes; 
ovalbumin (44 kDa), 163.60 minutes and myoglobin (17 kDa), 209.65 minutes. B.) The 
retention time was plotted on the x axis, versus the log of the corresponding molecular 
weight on the y axis and the best-fit equation of the line was calculated as y = - 0.0109x 
+ 6.5042) with an R
2 
value of 0.99.  
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5.3.3 Validation of an inhibition ELISA for microcystin detection 
5.3.3.1 Optimisation of the coating concentration and antibody dilution for 
inhibition ELISA development  
 
Checkerboard ELISAs were carried out to determine the optimal coating concentration 
and optimal antibody dilution for use in an inhibition ELISA format. The sensitivity is 
significantly influenced by the coating concentration. High conjugate concentrations can 
result in binding bias towards the immobilised conjugate, thereby reducing sensitivity to 
free toxin in solution. Similarly, higher concentrations of free antibody will require a 
higher concentration of free toxin to inhibit binding to the immobilised conjugate, 
resulting in decreased sensitivity. Therefore, an important parameter in inhibition assay 
development is the optimisation of the conjugate and antibody concentrations. The 
accuracy and precision of any immunoassay are critical parameters and require the 
utmost attention for determining the sensitivity of the assay.  
 
The optimal conjugate coating concentration and antibody dilution were determined by 
preparing serial dilutions of the MC-LR-OVA conjugate (1.25 to 4,000 ng/mL) and the  
scFvs, 2H1 and 2G1 (1/5,000 to 1/640,000). Analysis was carried out in a direct ELISA 
format (Figure 5.3.3.1). For the 2H1 and 2G1 scFv fragments tested, a coating 
concentration of 500 ng/mL was sufficient for signal generation, using the most 
economical amount of conjugate. The optimal 2H1 and 2G1 scFv concentration for 
immunoassay development, which gave the greatest change in absorbance per change in 
antibody dilution, was 1/20,000.  
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Figure 5.3.3.1: Checkerboard ELISA for inhibition assay development. A.) 2H1 scFv 
fragment. B.) 2G1 scFv fragment. To optimise the coating concentration, ELISA plates 
were coated with MC-LR-OVA conjugate, ranging in concentration from 4,000 to 1.25 
ng/mL, in PBS (pH 7.4, 150 mM). Dilutions of scFv, ranging from 5,000 to 640,000 
were prepared, using 1 % (w/v) Milk Marvel/ PBS (150 mM, pH 7.4), with 0.05 % (v/v) 
Tween 20. The serially-diluted scFvs was added to the ELISA plates. Binding was 
detected using a HRP-labelled anti-HA monoclonal antibody (Pierce). 
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5.3.3.2 Intra- and inter-day inhibition assay variability studies 
 
Intra-day assay (variation within a day) and inter-day assay (variation between days) 
variability studies were performed to demonstrate the reproducibility of the inhibition 
ELISA for MC-LR detection. The % coefficient of variation (CV) was calculated, by 
expressing the standard deviation as a percentage of the mean values. To determine 
whether the measured concentrations agreed with the theoretical values, the % relative 
error (RE) was calculated, by expressing the measured concentration as a percentage of 
the back-calculated concentration. The limit of detection (LOD) was determined by 
selecting the mean normalised response for the negative standard (no MC-LR) and 
subtracting three standard deviations. This value was used to calculate an unknown 
value from the four-parameter fit equation, using BIAevaluation™. 
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Figure 5.3.3.3 illustrates the inter-day calibration curve using the 2G1 scFv fragment. 
As described previously, the A/A0 value was plotted against the logarithm of the MC-
LR concentration. The IC50 was calculated as 8.1 ng/mL.  
 
 
Figure 5.3.3.2: Inter-day assay calibration curve for the determination of MC-LR in 
PBS, for the 2G1 scFv. MC-LR concentrations, ranging from 200 to 0.39 ng/mL, were 
pre-incubated with an optimised dilution of the chicken 2G1 anti-MC-LR scFv 
(1/20,000) and added to the plate. Using BIAevaluation™ software (Version 3.1), the 
data was fitted using a 4-parameter equation. The error bars represent the standard 
deviation for each concentration. 
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Table 5.3.3.1: Inter-day and intra-day inhibition assay validation to determine the % 
coefficient of variation (CV) and % relative error (RE) for 2G1 scFv fragment. 
 
 
Inter-day Assay Validation Intra-day Assay Validation 
MC-LR 
(ng/mL) 
% CV Back Calculated 
Concentration 
(ng/mL) 
% RE % CV Back Calculated 
Concentration 
(ng/mL) 
% RE 
50.0 3.4 46.2 108.3 10.2 36.3 137.7 
25.0 5.9 27.9 89.7 12.6 23.7 105.3 
12.5 3.9 12.2 102.3 7.3 12.8 97.6 
6.3 3.5 6.3 99.7 8.9 6.2 101.3 
3.1 13.3 3.1 99.6 5.4 3.2 98.9 
1.6 6.1 1.7 93.8 2.5 0.9 173.0 
0.8 5.8 0.9 82.5 4.7 1.3 60.9 
 
Both the inter-day and intra-day assays for the 2G1 scFv fragment displayed acceptable 
reproducibility (Table 5.3.3.1), as they were below the recommended precision level of 
20 % (Findlay et al., 2000). The % RE values for the 2G1 scFv fragment were in the 
acceptable limits (80 to 120 %) (Findlay et al., 2000) from 3.1 to 25 ng/mL of MC-LR. 
Therefore, the 2G1 scFv assay had a useable assay range of 3.1 to 25 ng/mL for MC-
LR. The overall LOD was calculated as 4.4 ng/mL. 
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Figure 5.3.3.5 illustrates the inter-day calibration curve using the 2H1 scFv fragment. 
As previously described, the A/A0 value was plotted against the logarithm of the MC-
LR concentration. The IC50 was calculated as 11.5 ng/mL. 
 
Figure 5.3.3.3: Inter-day assay calibration curve for the determination of MC-LR in 
PBS, for the 2H1 scFv. MC-LR concentrations, ranging from 200 to 0.39 ng/mL, were 
pre-incubated with an optimised dilution of the chicken 2H1 anti-MC-LR scFv 
(1/20,000) and added to the plate. Using BIAevaluation™ software (Version 3.1), the 
data was fitted using a 4-parameter equation. The error bars represent the standard 
deviation for each concentration. 
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Table 5.3.3.2: Inter-day and intra-day inhibition assay validation to determine the % 
CV and % RE for the 2H1 scFv fragment. 
 
 
Inter-day Assay Validation Intra-day Assay Validation 
MC-LR 
(ng/mL) 
% CV Back Calculated 
Concentration 
(ng/mL) 
% RE % CV Back Calculated 
Concentration 
(ng/mL) 
% RE 
100.0 2.0 73.2 136.6 32.3 89.5 111.7 
50.0 1.5 67.2 74.4 24.7 57.6 86.9 
25.0 14.8 26.5 94.4 14.6 25.6 97.8 
12.5 8.2 11.7 107.1 9.5 11.6 108.0 
6.3 6.8 6.4 97.7 13.4 6.7 93.9 
3.1 1.5 3.5 90.3 9.4 3.1 99.6 
1.6 2.4 2.0 77.4 9.9 1.4 109.0 
 
The 2H1 assay had acceptable %CV values between 1.6 and 25 ng/mL.The intra-day 
CV values for high concentrations (50 and 100 ng/mL) were outside the acceptable 
range of 20 % (Table 5.3.3.2). The % RE values for the 2H1 scFv fragment were in the 
acceptable limits from 3.1 to 25 ng/mL. Therefore, for the 2H1 scFv fragment, the range 
of assay sensitivity was between 3.1 to 25 ng/mL MC-LR. The overall LOD was 
calculated as 3.2 ng/mL. 
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5.4 Discussion 
 
The aim of this research was to generate a high affinity recombinant antibody to 
microcystin. An approach was taken to conjugate microcystin through its N-
methyldehydroalanine residue for maximal exposure to the common Adda moiety. This 
seventh amino acid residue is located on the opposite side of the molecule from the two 
variable amino acid residues and the Adda moiety. This strategy increased the 
possibility of generating an antibody that was microcystin-specific and cross-reactive 
with other microcystin variants. Two MC-LR conjugates were generated commercially 
and the MC-LR-BSA conjugate was chosen for immunisation. The spleen, a rich source 
of antibody-producing B-lymphyocytes, was isolated from an avian host, after 
confirming anti-MC-LR-specific antibodies were present in the serum by ELISA. The 
RNA was extracted, using a phenol-chloroform method, and reversed transcribed to 
cDNA. The variable antibody genes (VH and VL) were successfully amplified, using 
PCR, and the desired single chain Fv fragments were assembled, with a glycine-serine 
linker in a VL-(G4S)4-VH orientation. The flexible linker region (20 amino acids) 
allowed for correct folding of the generated scFvs. While being considerably smaller in 
size compared with a full IgG antibody, scFv fragments consisting of linked antibody 
heavy and light chains, still retain their specificity and affinity to their cognate antigen. 
This recombinant phage display library was cloned into the pComb3XSS vector. The 
pComb3XSS phagemid vector contains an amber stop codon (TAG) between the scFv 
and g3p, which is suppressed in E. coli XL-1 Blue cells. A library size of 3.47 x 10
7
 
transformants per mL was obtained.  
 
Phage display technology has facilitated the selection and enrichment of recombinant 
antibodies against a range of different haptens, including microcystin, from large 
antibody libraries (McCafferty, 1990). In order to select from the avian scFv library, 
five rounds of bio-panning were carried out, and stringency was introduced by 
increasing the number of washes for each round of bio-panning and decreasing the 
conjugate coating concentration on the immunotube. After five rounds of selection, on 
MC-LR-OVA-coated immunotubes, a polyclonal ELISA revealed the presence of 
positively binding anti-MC-LR-OVA phage-scFv clones. The selected soluble binders 
from phage selection were transformed into the non-suppressor TOP10F' E. coli cells 
and the soluble scFv fragments were transcribed, without any g3p fusion tag.  
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A panel of scFvs were selected, based on their diverse and inhibitive nature, as proven 
by restriction analysis and ELISA, respectively. These antibodies have the potential to 
be incorporated into an immunoassay for microcystin analysis. The most widely used 
format for microcystin immunoassays is the direct competitive format (Zeck et al., 
2001; Weller et al., 2001; Sheng et al., 2006), although a number of other formats were 
also employed (Nagata et al., 1999; Metcalf et al., 2000; Mhadhbi et al., 2006). 
However, none of these immunoassays are in widespread use, most likely due to their 
poor sensitivity, unfavourable cross-reactivity and lack of commercial availability. In 
contrast, an immunoassay that has broad specificity to all microcystin variants would be 
extremely useful, especially for regulatory purposes. Interestingly, an scFv fragment 
from an immune source has not previously been generated to microcystin, although 
recombinant single chain antibody fragments (scAbs) have been developed from non-
immune sources (McElhiney et al., 2002; Strachen et al., 2002). 
 
Protein modelling technology was used to predict possible three-dimensional structures 
of the anti-MC-LR scFvs, which aided in the prediction of possible microcystin-binding 
sites. The sequencing data generated for the 2H1 and 2G1 scFvs were used to create a 
computer-generated model of the structure of the scFv. As no crystallographic structure 
was available for a chicken scFv molecule, the scFvs were modelled against an IL-1β 
murine scFv (Wilkinson et al., 2009). This murine scFv had a high sequence homology 
to the microcystin clones. A structure that is sequentially most homologous to the 
antibody of interest is the preferred template for framework modelling. The modelling 
procedure was started at the variable domain framework region (FW), which is well 
conserved in structure among different antibodies. In the case of antibody sequences, 
structural variability is restricted to the hypervariable regions. CDRs are described as 
CDR-L1, L2 and L3 in the light chain and CDR-H1, H2 and H3 for the heavy chain. All 
CDRs, except for CDRH3, are classified to the structural canonical classes, which 
facilitates modelling of their structures (Decanniere et al., 2000). From the Gramm-X 
MC-LR docking site analysis, it can be hypothesised that the 2H1 and 2G1 scFv 
molecules bind microcystin through different interaction sites. For the 2H1 scFv 
fragment, a large concentration of possible binding-sites were localised at one location. 
However, the 2G1 scFv had three different locations where binding was highly 
probable. Docking programs, such as Gramm-X, provide a good indication of binding 
site position and hapten orientation. This information may be useful in the design of 
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site-directed mutagenesis approaches for antibody improvement and in future modelling 
studies. However, docking analysis using a best-fit approach only provides an 
estimation of antibody-antigen binding, based on a mathematical prediction model. 
Therefore, crystallographic analysis is essential to definitively verify binding sites and 
interaction residues. 
 
The 2H1 and 2G1 clones were grown in large-scale cultures and antibody fragment 
expression was induced, using IPTG. An auto-induction media was also utilised. Auto-
induction is more convenient than IPTG induction because the bacterial stock is simply 
inoculated into the auto-inducing medium and grown to saturation, eliminating the need 
to follow culture growth and to add inducer (IPTG) at the correct time. Furthermore, the 
culture density and concentration of the expressed protein, per volume of culture, are 
generally higher than IPTG induction. In this report, a larger protein yield was obtained 
when the bacterial clones were cultured in enriched growth media, including SB and 
TB, compared with auto-induction media. Interestingly, a highly pure fraction was 
obtained after IMAC purification of the auto-induced culture. It is possible that 
expression in the auto-induced culture is tightly-controlled by the inducible T7 system, 
preventing transcription of contaminating protein products. However, the protein yield 
for the auto-induced cultures was insufficient for immunoassay development. Therefore, 
further purification or ‘polishing’ of the IPTG-induced cultures was carried out, using 
size-exclusion chromatography. 
 
The 2H1 and 2G1 scFv fragments were successfully purified by fast protein liquid 
chromatography (FPLC), and subsequently analysed by ELISA and gel electrophoresis. 
FPLC protein purification produced a high yield of pure scFv fragments. These scFv 
fragments were used to further develop the microcystin immunoassay. FPLC size 
exclusion also allowed for the successful determination of the native molecular weight 
of the 2H1 scFv (29 kDa). A large number of chromatographic separation techniques 
are applicable to FPLC, including; ion exchange (Easton et al., 2010), 
chromatofocusing (Rausell et al., 1997), gel filtration (Madadlou et al., 2011), 
hydrophobic interaction (Zera et al., 2002), and reverse phase (Gerber et al., 2004). Gel 
filtration has proven to be a useful technique for the analysis of antibody fragments, 
including scFv fragments, which have a tendency to form large multimeric aggregates 
(Kortt et al., 1997; Laroche-Traineau et al., 2000). A single peak, in the purification of 
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the 2H1 scFv fragment, was identified as a large molecular weight aggregate. The 
formation of aggregates often depends on the specific antibody fragment, the linker 
design (Schmiedl et al., 2006), and the concentration of the antibody fragments (Arndt 
et al., 1998). The tendency of scFv antibody fragments to form aggregates is also an 
indicator for their stability, because high aggregation levels lead to lower long-term 
stability of the scFvs. By using SEC, antibody fragments can be isolated from 
aggregates, including dimers. For this reason, it has become a standard technique to 
purify and characterise antibody fragments (Voedisch and Thie, 2004). 
 
Following the successful expression and purification of the anti-MC antibody 
fragments, 2H1 and 2G1, ELISA inter- and intra-day analysis was carried out to 
determine the assay ranges and limits of detection of the scFvs. ELISA conditions, 
including coating concentration and antibody dilution, were optimised. Assay 
performance, including detection range, % precision and % relative error, were 
investigated. The 2H1 scFv fragment was found to have a range of detection of 3.1 to 
25 ng/mL and a limit of detection of 3.2 ng/mL. When compared to the 2H1 scFv, the 
2G1 scFv fragment displayed the same MC-LR range of 3.1 to 25 ng/mL and an LOD 
of 4.4 ng/mL. The MC-LR ELISA-based assays proved to be reasonably sensitive and 
precise, with the majority of analysis within 20 % of the acceptable range.  
In summary, two novel avian scFv fragments were generated to the cyanobacterial toxin 
MC-LR. This is the first known report of recombinant microcystin antibodies in an scFv 
format, generated from an immune source. These antibodies are not sensitive enough for 
the required detection limit of 1 µg/L (WHO, 1998). The most sensitive antibody 
fragment (scAb) generated to microcystin cross-reacts with MC-RR, MC-LW, MC-LF, 
and nodularin and had a limit of detection of 0.8 nM (0.8 ng/L) (McElhiney et al., 
2002). A major advantage of recombinant antibody technology for microcystin 
detection is that it provides a means to manipulate sensitivity, specificity and affinity at 
a molecular level at the molecular level (McElhiney et al., 2000), making them ideal for 
incorporation into immunosensor formats. Ideally, assay sensitivity well below the limit 
of detection is required for the immunoassay to be accepted as a validated technique for 
toxin detection. Therefore, it was necessary to employ affinity maturation strategies for 
the improvement of the selected MC-LR clones. A number of assay formats, including 
an SPR-based immunosensor and fluorescence-based immunoassay techniques will also 
be employed to reach the required detection limit. 
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CHAPTER 6  
Random mutagenesis of the anti-
microcystin scFv and subsequent 
immunoassay development 
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6.1 Introduction 
 
In the work described in this chapter, maturation techniques were exploited to improve 
the binding potential of a previously isolated anti-microcystin scFv fragment. The light 
chain sequence of the 2H1 scFv was diversified by error-prone PCR. Subsequently, this 
error-prone light chain library was shuffled with the original heavy chain of the 2H1 
clone. The mutant gene repertoire was displayed on the surface of filamentous phage 
and alternative binders were selected using both trypsin and competitive elution 
strategies. The major focus of this work was the development of sensitive 
immunoassays for the detection of MC-LR and its variants, MC-LW, MC-RR, MC-YR, 
MC-LA and MC-LF. Biacore™ inhibition assays were developed and validated for the 
scFv fragments, with an MC-LR-immobilised sensor chip surface. The immunosensor-
based assays displayed good accuracy and precision in the low ng/mL range. 
 
The wild-type scFv fragment (2H1) were compared to the mutant antibody using 
ELISA and Biacore™ analysis. The C12 mutant clone displayed a 2.3-fold 
improvement in the limit of detection, when compared by ELISA. Surprisingly, the 2G1 
scFv fragment displayed excellent sensitive and reproducibility using SPR bio-sensing, 
compared to the 2H1 and C12 scFvs, with a limit of detection of 1.7 ng/mL. The limits 
of detection for the 2H1 and C12 scFvs were 13.8 and 14.8 ng/mL, respectively. 
Significantly, the C12 scFv displayed a better cross-reactivity profile, compared with 
the 2H1 parental scFv.  
 
High assay sensitivity was achieved through development of fluorescence-linked 
immunosorbent assays (FLISAs), particularly using a poly-ʟ-lysine functionalised slide-
based format. The avian anti-microcystin scFvs, 2G1 and C12, were successfully 
biotinylated and incorporated into an indirect FLISA, using a streptavidin-Alexa Fluor
®
 
647 conjugate (LODs of 1.4 and 0.6 ng/mL, respectively). The 2G1 scFv-Alexa Fluor
®
 
647 and C12-biotin conjugates were incorporated into slide-based inhibition formats for 
rapid microcystin detection (IC50 of 6 and 1 ng/mL, respectively). A rabbit polyclonal 
microcystin-specific antibody was purified using immobilised-protein G 
chromatography. This antibody was incorporated into an alternative, highly-sensitive 
FLISA for MC-LR detection, on a functionalised glass substrate (IC50 = 0.4 ng/mL).   
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6.1.1 Antibody mutagenesis strategies for affinity improvement 
 
In the human immune system, high affinity antibodies are generated in two stages. 
Firstly, a diverse primary repertoire of antibodies is produced through the combinatorial 
rearrangement of germline V-gene segments, followed by clonal selection of B-cells 
that produce higher affinity antibodies. Subsequently, antibody affinities are further 
improved by somatic hypermutation and further rounds of selection. Advances in 
phage-displayed antibody technology have enabled the affinity maturation process to be 
mimicked in vitro. It is now possible to improve the antigen-binding affinity and alter 
the binding specificity of recombinant antibodies (Barbas et al., 1992; Jackson et al., 
1995). In the process of in vitro affinity maturation, the V-gene sequences are generally 
targeted, thus mimicking the in vivo process of somatic hypermutation.  
 
During in vivo somatic hypermutation, mutations are preferentially targeted to the CDR 
regions, over the framework regions. The location of these CDR mutations generally 
mimics the locations where diversity is generated in the primary antibody repertoire 
(Tomlinson et al. 1996). Many CDR residues, particularly CDRH3 and CDRL3, are 
responsible for high energy interactions with the antigen. The mutation of residues 
within these regions may eliminate or reduce antigen-binding. Alternatively, the 
mutation of residues within the CDR regions may also increase affinity by introducing 
new contact residues, or by replacing low affinity or “repulsive” contact residues with 
more favourable energetics. It has been observed that many mutations, introduced both 
in vivo and in vitro by directed evolution, exert their effect on affinity indirectly. This 
may occur when insertions or deletions cause a shift in the position of the CDR regions, 
relative to one another, or by altering the side chains of contact residues for optimal 
interaction with the antigen (Foote and Winter, 1992).  
 
Mutations have been introduced by chain-shuffling (Marks et al., 2004; Lou et al., 
2010), error-prone PCR (Pritchard et al., 2005; Cirino et al., 2003), DNA-shuffling 
(Crameri et al., 1996), or by propagation of phage in mutator strains of E. coli. (Low et 
al., 1996). These approaches have yielded large increases in affinity for hapten targets 
(up to 300-fold) (Irving et al., 1996; Low et al., 1996). In site-directed mutagenesis 
approaches, sequence analysis of binding clones can result in the identification of both 
conserved structural and functional residues which may modulate affinity (Schier et al. 
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1996). These sequences can guide subsequent mutagenic efforts to further improve 
affinity. 
 
Random introduction of mutations is the simplest approach, as it makes no assumptions 
as to which sites are the best to mutate in order to increase affinity, and more closely 
mimics the in vivo process of somatic hypermutation (Lou and Marks, 2010). This can 
be achieved by error-prone PCR, in which a low-fidelity DNA polymerase is utilised to 
introduce random point mutations into a selected V-region. Mutational error may be 
further increased, using suboptimal PCR conditions during DNA amplification. In 
another approach, synthetic oligonucleotides can be used to focus mutations on residues 
involved in antigen-binding, whilst avoiding key structural residues. The repertoire of 
mutant antibody sequences is then displayed on phage, and mutant antibodies with 
improved affinities are selected under stringent selection conditions (Rajpal et al., 
2005).  
 
Chain-shuffling and site-directed mutagenesis have been employed to increase the 
affinity of an anti-ErbB2 single chain antibody by 1,200-fold (Marks et al., 1992). 
These workers reported that mutagenesis of the CDR3 regions of the antibody were the 
most effective in improving affinity, using phage display. Similarly, Yang and co-
workers increased the affinity of an anti-gp120 Fab by 420-fold. This was achieved by 
generating mutations in the CDR regions of five separate mutagenised libraries, which 
were subsequently combined (Yang et al., 1995). Interestingly, they observed that the 
largest affinity gain occurred when the CDR3 regions were mutated. In addition, light-
chain shuffling of an anti-halofuginone-specific scFv fragment resulted in a 185-fold 
improvement in antibody affinity (Fitzgerald et al., 2011). 
 
Selection of high affinity antibodies from mutant libraries is often achieved in phage 
display bio-panning by using increasingly harsh conditions in each successive round. 
For example, decreasing the antigen concentration, increasing the number of washing 
steps and reducing incubation times (Hust et al., 2008). A drawback of this approach is 
that bio-panning on immobilised surfaces can increase the tendency to isolate binders 
that are prone to dimerisation, particularly when using the scFv format. Dimerisation 
issues can be reduced by bio-panning with the antigen in solution (Schier et al., 1996). 
This can be achieved by utilising a biotinylated antigen, in combination with 
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streptavidin-coated beads. Moreover, it is possible to use un-biotinylated antigen after 
antibody phage binding has occurred, to introduce competition and to improve selection 
for better ‘off-rates’. Monoclonal soluble binders can be assessed and affinity ranked 
through analysis of crude cell supernatants by competitive ELISA. In recent years, 
alternative techniques for affinity and specificity ranking have been employed, 
including SPR and flow cytometry (Geuijen et al., 2005; Leonard et al. 2007). 
 
6.1.2 Immunosensors for toxins from marine microalgae  
 
Chromatographic techniques have been widely employed for the sensitive detection of 
toxins produced by marine microalgae. Chromatography allows for separation, highly 
selective identification and sensitive quantification of the various toxin mixtures present 
in a sample. Moreover, limits of detection are generally one order of magnitude lower 
than those obtained with the mouse bioassay. However, toxin chromatographic 
techniques require expensive equipment and trained personnel. Furthermore these 
methods are laborious and time-consuming. The lack of standards is also a key concern, 
since non-certified or unknown toxins cannot be evaluated. Other reported issues 
include peak spreading, poor resolution and the need for continuous calibration (Botana, 
2008) The versatility of biosensor-based analytical platforms for pharmacological, 
environmental and food safety detection has been extensively reviewed (Ivnitski et al., 
1999; Baeumner, 2003; Amine et al., 2006; Rodriguez-Mozaz et al., 2006; Byrne et al., 
2009; Van Dorst et al., 2010). Biosensors provide a cost-effective alternative for marine 
toxin detection, as well as, group specificity, sensitivity, portability, repeatability and 
robustness. However, a key issue in the analysis of marine toxins is the lack of 
uniformity between analytical techniques in different laboratories.  
 
Biosensors have the potential to fulfil increasing demand for certification and 
traceability of seafood products. A biosensor is an analytical device incorporating a bio-
recognition element which is associated with or integrated within a transducer that 
converts a biological response into an electrical signal. A large number of detection 
techniques can be incorporated into a biosensor format. The biological response can 
include enzymatic activity, antibody binding, receptor binding or cell responses. 
Biosensor technologies include transduction platforms based on electrochemical 
(potentiometric, amperometric, impedance), piezoelectric, thermal or optical methods 
261 
 
(reflectrometric interference spectroscopy, interferometry, optical waveguide lightmode 
spectroscopy, total internal reflection fluorescence, surface plasmon resonance). The 
sensitivity and the portability of a biosensor will depend on the signal transducer used. 
Recently, micro-fabrication tools have made it possible to manufacture micro-
biosensors and nano-biosensors (Pumera et al., 2007; Jaffrezic-Renault et al., 2008). An 
immunosensor is a biosensor, incorporating an antibody as its biological detection 
element. Immunosensors can also be applied to the detection of small molecular weight 
toxins produced by toxic marine microalgae. A summary of electrochemical 
immunosensors for phycotoxin detection is presented in Table 6.1.2.1.  
 
An electrochemical biosensor was developed for the detection of a number of marine 
toxins with disposable screen printed electrodes (SPEs), using a monoclonal antibody to 
okadaic acid and polyclonal antibodies to domoic acid and saxitoxin, as the recognition 
elements (Kreuzer et al., 2002). The assay was based on the detection of p-aminophenol 
and alkaline phosphatase-labelled antibodies. P-nitrophenol can be detected 
electrochemically at a low working potential of +300mV, versus Ag/AgCl. The sensors 
all achieved detection limits in the µg/L range, well within the limits of detection for 
each target. Micheli et al. (2004) also developed a disposable immunosensor for domoic 
acid, with a 5 µg/L detection limit. The assay was bases on an electrochemical 
immunosensor, using screen-printed electrodes coated with a domoic acid-BSA 
conjugate, as a transducer for differential pulse voltammetry (DPV). The assay format 
had a good percentage recovery making it suitable for accurate determination of domoic 
acid in real shellfish samples.  
 
A novel electrochemical immunosensor was developed for detection of microcystin, 
employing functionalised single-walled carbon nanohorns (SWNHs) and HRP-labelled 
polyclonal antibodies (Zhang et al., 2010). The numerous carboxylic acid groups on the 
cone-shaped tips of the SWNHs enhanced the immobilisation capacity of MC-LR, 
resulting in an accurate, precise and reproducible assay. The same antibodies were 
employed to develop a technique for determination of microcystin residues in water, 
based on the magnetic relaxation of super paramagnetic nanoparticles, using nuclear 
magnetic resonance technology (Ma et al., 2009). Hayat et al. (2011) developed a 
competitive immunosensor, based on superparamagnetic nanobeads, for the detection of 
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okadaic acid. The electrochemical sensing was carried out using DPV and a limit of 
detection of 0.38 µg/L was achieved. 
 
Table 6.1.2.1: Electrochemical immunosensors for the detection of marine toxins  
Toxin Antibodies LOD Reference 
Okadaic acid 
Brevetoxin 
Domoic acid 
Tetrodotoxin 
Anti-OA monoclonal-AP; Anti-
BTX-AP; anti-DA sheep 
polyclonal; anti-sheep IgG-AP 
labelled 
1.5 g/L 
1 g/L 
2 g/L 
0.016 g/L 
Kreuzer et al., 2002 
Brevetoxin 
Saxitoxin 
Goat polyclonal anti-PTX-
glucose oxidase; Donkey 
polyclonal anti-STX-glucose 
oxidase; Rabbit anti-STX 
15 g/L Carter et al., 1993 
Okadaic acid Monoclonal (on quartz crystal 
microbalance) 
3.6 µg/L Tang et al., 2002 
Okadaic acid Monoclonal (on super 
paramagnetic nanobeads) 
0.38 µg/L Hayat et al., 2011 
Domoic acid Polyclonal anti-DA; Anti-goat 
IgG-AP labelled 
5 g/L Micheli et al. 2004 
Domoic acid Rabbit polyclonal; goat anti-
rabbit IgG- biotin; Strep-HRP 
conjugate 
0.6 g/L Kania et al.,2003 
Microcystin Monoclonal  
(on silver nanoparticles) 
7.0 x 10
-6
 g/L Loyprasert et al., 2008 
Microcystin Rabbit polyclonal (on magnetic 
nanoparticles) 
0.6 ng/g Ma et al., 2009 
Microcystin Rabbit polyclonal (SWNHs) 0.03 µg/L Zhang et al., 2010 
Microcystin Monoclonal (MC10E7) and 
polyclonal (undisclosed source) 
0.10 g/L 
(mAb)/ 1.73 
g/L (pAb) 
Campàs and Marty, 
2007 
Okadaic acid Monoclonal: AP-labelled OA 2 g/L Tang et al., 2003 
Okadaic acid Monoclonal; goat anti-mouse-
HRP or AP 
0.03 g/L Campàs et al., 2008 
263 
 
Carter et al. (1993) described one of the first amperometric immunosensors for the 
detection of saxitoxin and brevetoxin. The biosensor utilised solid support membranes 
for immobilisation of toxin conjugates. Detection was based on a glucose oxidase-
labelled antibody in a competitive format with immobilised and free toxin. The glucose 
oxidase label caused the conversion of a β-D-glucose substrate to its product with the 
release of H2O2, which was detected using a platinum electrode. The limit of detection 
for this assay format was 15 µg/L. Campàs and Marty (2007) utilised both anti-
microcystin monoclonal and polyclonal antibodies to develop a competitive ELISA on 
screen-printed graphite electrodes. Tang et al. (2003) also produced a disposable 
immunosensor based on screen-printed electrodes for okadaic acid with a commercial 
monoclonal antibody, with a 2 ng/ml detection limit. 
Optical-based immunosensors for toxin detection, particularly those that incorporate 
SPR, are widely used (Table 6.1.2.2). Kreuzer et al. (1999) developed a highly 
sensitive, optical immunosensor for okadaic acid using commercial murine monoclonal 
antibodies. They discovered that changing from a competitive to a displacement ELISA 
format affected the selectivity of the assay for okadaic acid and dinophysis-1. This work 
highlights the importance of assay format on overall specificity. A semi-automated 
membrane-based chemiluminescent biosensor was also developed for the detection of 
okadaic acid in mussels by Marquette et al. (1999). An okadaic acid-BSA conjugate 
was immobilised onto a pre-activated membrane connected to a fibre optic-based 
chemiluminescent flow injection configuration. The membranes minimised non-specific 
protein adsorption and showed good regeneration potential. Anti-okadaic acid 
monoclonal antibodies were mixed with spiked samples and antibody binding onto the 
membrane was monitored. The combination of the membranes and sensitive 
chemiluminescent detection resulted in a high sensitivity of 0.1 ng/ml in spiked mussel 
extracts. 
 
A number of surface plasmon resonance (SPR)-based methods for paralytic shellfish 
poisoning (PST) toxins were developed. The aim was to develop methods that could 
detect saxitoxin below the regulatory limit. In addition, another goal was to assess if 
these SPR-based methods were comparable to the mouse bioassay and current HPLC 
techniques. Significantly, cross-reactivity to PST congeners was also evaluated 
(Campbell et al., 2007; Fonfria et al., 2007). Both these SPR methods utilised an anti-
GTX2/3 monoclonal antibody and were capable of detection saxitoxin (STX) and its 
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congeners below the required regulatory limit. In addition, Campbell et al., (2007) also 
employed a rabbit polyclonal antibody raised to saxitoxin, along with a saxitoxin-
binding sodium channel receptor. Haughey et al., (2011) also compared the same 
polyclonal and monoclonal antibodies using two SPR instruments; a Biacore™ Q 
biosensor and a Biacore™ T100. A novel approach was used for the detection of 
saxitoxin by Chen and co-workers (Chen et al., 2007). This group employed self-
assembled monolayers (SAMs) of a calix[4]arene derivative to sensitively detect 
saxitoxin, using SPR. STX, a bis-guanidinium structure, binds calix[4]arene, based on 
its guanidinium ion selectivity. In addition, Yakes and co-workers developed an 
improved SPR immunoassay for saxitoxin detection, by optimisation of the sensor chip 
surface chemistry and determination of optimal antibody:analyte mixing ratios and 
incubation times (Yakes et al., 2011). 
 
Table 6.1.2.2: Optical immunosensors for the detection of marine toxins 
Toxin Competition 
Format 
Antibodies LOD Reference 
Okadaic acid Direct Monoclonal-AP; OA-
AP 
5 x 10
-4
 to  
4 g/L 
Kreuzer et al., 
1999 
Okadaic acid Direct Monoclonal-HRP  0.1 g/L Marquette et 
al., 1999 
Domoic acid Indirect Monoclonal  1.8 g/L Lotierzo et al., 
2004 
Domoic acid Indirect Monoclonal  
 
0.1 g/L Yu et al., 
2005 
Domoic acid Indirect Rabbit polyclonal  3.0 g/L Stevens et al., 
2007 
Microcystin Direct Monoclonal; Cy5 –
labelled  
0.03 g/L Long et al., 
2009 
Saxitoxin Direct  Donkey polyclonal  0.5 g/L Yakes et al., 
2011 
 
Surface plasmon resonance has also been applied to the detection of domoic acid by Yu 
et al. (2005). In this biosensor format, the toxin was linked covalently to a mixed SAM-
modified chip. The assay used a competition format between free domoic acid in 
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solution, and anti-domoic acid monoclonal antibodies. The detection limit achieved was 
0.1 ng/mL, which was superior to that of a conventional colorimetric ELISA. This 
improvement was due to the lack of non-specific antibody adsorption on the SAM and 
the high sensitivity of the SPR instrument. Le Berre and Kane, (2006) developed 
Biacore™-based assays for detection of domoic acid, using polyclonal, monoclonal and 
recombinant antibodies. Interestingly, they demonstrated that the polyclonal antibody 
was the most sensitive for domoic acid analysis. A sensitive toxin inhibition SPR assay 
was also developed, using a monoclonal antibody, which detected MC-LR below the 
regulatory limit of 1 µg/L (Hu et al., 2009). In addition, monoclonal antibodies were 
also employed to detect MC-LR in Spirulina and Aphanizomenon flos-aquae blue-green 
algae food supplements, using SPR (Vinogradova et al., 2011). 
 
Increased awareness has lead to the development of a diverse range of sensor techniques 
for phycotoxin and hepatotoxin monitoring, as reviewed by Byrne et al. (2009). 
Unfortunately, very few antibody-based sensors for phycotoxins have been approved as 
regulatory methods. This is due to the scarcity of sufficient quantities of pure toxin for 
the development of anti-toxin antibodies and assay validation (Hirama, 2005). Also, a 
poor supply of reference materials and cross-reactivities with non-target molecules pose 
significant problems. To reduce the risk to human health of exposure to marine bio-
toxins, there is a requirement for more sensitive and reliable detection methods. An 
important aspect for immuno-detection of marine algal toxins is the structural similarity 
between toxin cogeners, therefore, care must be taken to characterise the toxin antibody 
for cross-reactivity to structurally similar molecules of the same phycotoxin grouping. If 
a mixture of toxin cogeners is analysed in an immuno-sensor format, underestimation or 
overestimation of toxicity may occur, due to the inability of the antibody to recognise 
one or multiple isomers of the toxin molecule. Ideally, biosensors for marine toxins 
should also be capable of detecting mixtures of toxins in complex matrices, such as 
shellfish meat. The described biosensor formats for marine toxins were all created in an 
attempt to replace the current regulated methods of detection, including the mouse 
bioassay and physiochemical analysis, including HPLC-MS. However, it remains to be 
seen whether they will be incorporated into legislation or routine monitoring 
programmes in the future. 
 
  
266 
 
6.1.3 Chapter aims 
 
This chapter describes the application of random mutagenesis strategies for the 
generation of improved anti-microcystin binding recombinant antibody fragments. The 
light chain of the 2H1 scFv fragment was shuffled and a library of mutagenised clones 
with alternative VH-VL chain combinations were screened for improved microcystin 
binding and specificity. Random errors were introduced into the light chain sequences 
by error-prone PCR. Subsequently, phage display was used to isolate novel microcystin 
binders. An alternative, competitive elution strategy was also employed in the bio-
panning process to select for scFv-phage particles that had an increased affinity for free 
toxin in solution. The amplified antibody variable genes were assembled by SOE-PCR 
and ligated into the Barbas pComb3XSS vector (Barbas et al., 2001).  
 
An alternative mutant scFv (C12) was isolated using random mutagenesis techniques. 
The major aim of this research was to assess whether the mutations introduced into the 
amino acid sequence of the new clone, caused an improvement in assay sensitivity. The 
parent and mutant clones were compared by ELISA and Biacore™ inhibition analysis. 
This chapter also investigated the potential of different immunoassay formats to 
produce a robust and sensitive assay for microcystin. The parental, 2H1, and 2G1 and 
mutant C12 scFvs were biotinylated and functionalised with the fluorophore, Alexa 
Fluor
®
 647. The potential of a functionalised glass slide-base detection format was also 
investigated with some ‘proof-of-concept’ studies. 
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6.2 Results 
6.2.1 Random mutagenesis of the 2H1 scFv fragment 
 
To improve the binding characteristics of the 2H1 scFv, a random mutagenesis 
approach was employed, in which the un-panned variable light chain library, from the 
MC-LR-BSA immunised avian host, was mutagensied using error-prone PCR. 
Mutations were introduced using sub-optimal PCR reaction conditions, including 
unbalanced concentrations of template, dNTPs, MnCl2 ions and MgCl2 and a low-
fidelity DNA polymerase (RedTaq
®
). This was then re-shuffled with the variable heavy 
chain of the parental, 2H1, scFv. The overall aim was to increase the sequence diversity 
of the light chain pool. 
6.2.1.1 PCR amplification of the variable heavy chain (VH) from the 2H1 scFv 
clone  
 
Initially, the variable heavy (VH) gene sequence was amplified from a plasmid 
preparation of the anti-microcystin scFv clone, using GoTaq
®
 polymerase. The CSCHo-
FL and CSCG-B primers were utilised for amplification. Successful amplification of the 
heavy chain fragment was achieved, at approximately 400 base pairs (bps) (Figure 
6.2.1.1). 
 
Figure 6.2.1.1: PCR amplification of variable heavy (VH) sequence from the 2H1 
plasmid DNA preparation. Lanes 1-5 contain amplifications of the same heavy chain 
product. A control amplification, with no primer (C1) and a control with no template 
(C2), were also included. ‘M’ represents the 1 kb Plus DNA ladder. 
M       1        2       3       4       5      C1    C2
650 bp
500 bp
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The pComb3XSS vector was also visible on the 1 % agarose gel (Figure 6.2.1.1). A 
non-specific band at approximately 2,500 bp was also observed (Lane 2-5). This band 
was eliminated in the process of gel extraction, using a QiaQuick gel extraction kit 
(Qiagen). The band in Lane 1 appeared to be faint, which may have resulted from a gel 
loading error. 
6.2.1.2 Amplification of the light chain regions using error-prone PCR 
 
Error-prone PCR is based on the lack of fidelity of the Taq polymerase in the presence 
of an unbalanced mixture of deoxyribonucelotides. The low-fidelity DNA polymerase 
RedTaq
®
 lacks a 3' to 5' exonuclease activity. The error rate of RedTaq
® 
is 
approximated at 1x10
-4
 bps/kb under normal amplification conditions. However, under 
certain error-prone amplification conditions, a higher error rate, of between 1-20 
nucleotides in 1000, can be achieved (Vanhercke et al., 2005). 
 
 
 
Figure 6.2.1.2: Optimisation of variable light (VL) error-prone PCR amplification 
conditions. Manganese chloride (MnCl2) concentrations were prepared from 1 to 40 µM 
for each reaction, along with 7 mM MgCl2. Deoxyribonucleotide concentrations 
included 0.2 mM dATP and dGTP, and 1 mM dCTP and dTTP. The PCR reaction 
contained 0.5 U/μL of RedTaq® DNA polymerase. ‘M’ represents 1 kb Plus DNA 
ladder.  
 
MnCl2 Concentration
M    0 µM  10 µM  20 µM  30 µM  40 µM      M
500 bp
400 bp
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The addition of MnCl2 stabilised non-complementary base-pairing and promotes the 
introduction of random mutations throughout the amplified product (Cadwell and Joyce, 
1992). It was necessary to optimise the concentration of MnCl2, as too high a 
concentration can result in a substantial reduction in PCR amplification. Concentrations 
of MnCl2, ranging from 10 to 40 µM, were investigated. In order to increase the 
potential mutation rate, a higher concentration of MgCl2 was also included in the PCR 
reaction buffer (Cirino et al., 2003).  
 
Additionally, in error-prone PCR, A and T residues are more likely to be mutated, 
compared with G and C residues. This type of bias could potentially alter the type of 
mutations observed in the mutant library. Therefore, to eliminate this possibility, an 
unbalanced mixture of dNTPs was used in the PCR mix (Cirino et al., 2003; Pritchard et 
al., 2005). The PCR reaction contained an increased concentration of dTTP and dCTP 
(1 mM) and a decreased concentration of dGTP and dATP (0.2 mM). A 350 bp product 
was amplified, for the VL chain library mutagenesis reaction (Figure 6.2.1.2). All the 
MnCl2 concentrations tested resulted in successful PCR amplification. Each of the 
error-prone PCR products were pooled and subsequently purified by gel extraction.  
 
To ensure a sufficient level of mutation, a low (6 ng) and high (600 ng) concentration of 
the light chain library was used as the input DNA template for error-prone PCR. The 
template concentration can influence the potential error rate, with lower template 
concentrations resulting in higher mutation frequencies. Therefore, the low and high 
template concentrations were included to amplify genes with both high and low 
mutation frequencies. The successful amplification of the VL library under these 
conditions using RedTaq
®
 DNA polymerase, 10 µM MnCl2 and 7 mM MgCl2 is shown 
in Figure 6.2.1.3. All the products from the MnCl2 amplification and the template 
concentration reactions were pooled, to achieve maximum VL mutant library diversity. 
PCR products were subsequently purified by gel extraction. 
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Figure 6.2.1.3: Optimisation of light chain library template concentrations. 
Concentrations of 600 and 6 ng of DNA template (three lanes each) were used in the 
amplification of the light chain library. A high RedTaq
®
 polymerase concentration (0.1 
unit/µL) was also used in the amplification reaction. Deoxyribonucleotide 
concentrations included 0.2 mM dATP and dGTP, and 1 mM dCTP and dTTP. ‘M’ 
represents 1 kb Plus DNA ladder. 
 
6.2.2 Construction of mutant light chain-shuffled library 
6.2.2.1 SOE-PCR of variable heavy and mutant light chain regions 
 
Following purification of the VH and VL chains by gel extraction, SOE-PCR was carried 
out, using the extension primers, CSC-F and CSC-R. This process joined the VL and VH 
regions, using the sequence tails introduced in the first round of PCR to create a serine-
glycine linker sequence. This second round of PCR produced a 750 bp product (Figure 
6.2.2.1). The high fidelity Phusion
®
 Taq DNA polymerase (Fermentas) was employed 
for further PCR amplification, in order to minimise the possibility of introducing mis-
sense or non-sense mutations in the linker or cloning regions. 
 
M M
600 ng                      6 ng
Template Concentration
500 bp
400 bp
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Figure 6.2.2.1: Large-scale amplification of the SOE-PCR product from the light chain-
shuffled library. The approximate molecular weight of this fragment was 750 base pairs 
(bp). A negative control (no template) was included (Neg.), and ‘M’ represents the 1 kb 
Plus DNA ladder. Lanes 1 and 2 contain the same PCR amplicon. 
 
The purified SOE product was amplified by large-scale PCR, purified by gel extraction, 
ethanol-precipitated and stored at -20
o
C. 
 
6.2.2.2 Mutant library construction and bio-panning 
 
The SOE product was harvested, quantified using a Nanodrop ND-1000™ and cloned 
into the pComb3XSS vector, using the restriction enzyme, SfiΙ. Antartic phosphatase 
treatment ensured that self-ligation of the vector did not occur. The ligated product was 
transformed into electro-competent E. coli XL1-Blue cells (Strategene), by 
electroporation. The transformed mutant avian anti-microcystin scFv library had a size 
of 2.14 x 10
7
 cfu/mL. The library was ‘rescued’ using M13K07 helper phage.  
 
In order to isolate the most sensitive clones from the mutant library, two different 
selection strategies were employed. Using the standard bio-panning strategy, the library 
was initially enriched against an immobilised MC-LR-OVA conjugate (50 to 0.25 
µg/mL) and eluted using trypsin (Rounds 1-3). Bio-panning were carried out with 
M          Neg.          1            2
~ 750 bp
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decreasing concentrations of conjugate coated onto the immunotube for each round. The 
number of washes were increased, in order to facilitate high stringency bio-panning 
(Table 2.16.1.1). For rounds 4 and 5, the library was split and trypsin and competitive 
elution was carried out simultaneously. The inputs and outputs from each round of bio-
panning give an indication of bio-panning efficiency. Table 6.2.2.1 shows that the 
inputs and outputs were optimal for rounds 1-4. However, bio-panning round 5 did not 
result in any input or outputs as the panning stringency was too severe. 
 
Table 6.2.2.1: Bio-panning inputs and outputs for the mutant avian immune library 
Round Input (cfu/mL) Output (cfu/mL) 
1 1.4 x 10
10
 5.7 x 10
5 
(Trypsin Elution) 
2 1.3 x 10
12
 1.5 x 10
6 
(Trypsin Elution) 
3 5.0 x 10
10
 7.4 x 10
4 
(Trypsin Elution) 
4 8.4 x 10
11
 
1.2 x 10
6
 (Competitive Elution) 
6.9 x 10
4
 (Trypsin Elution) 
 
For the competitive elution strategy in the final rounds of bio-panning (round 4 and 5), 
the phage library was incubated on the immunotube with immobilised MC-LR-OVA 
conjugate, and subsequently eluted with a decreasing concentration of MC-LR toxin in 
solution (500 ng/mL and 5 ng/mL). The aim of this strategy was to elute phage-scFv 
binders from the immunotube, which showed a high sensitivity for free toxin in 
solution. This should result in the isolation of mutant clones that bound MC-LR in its 
free form, and not in the context of a protein conjugate. A high affinity for the toxin 
attached to the conjugate is generally undesirable, because such antibodies do not 
dissociate readily, resulting in a reduction in assay sensitivity. Care must also be taken 
to avoid selection of ‘interface binders’ (Tuomola et al., 2000). These antibodies 
recognise haptens in the context of the conjugate and bind to some extent to the linker 
or carrier protein close to the point of conjugation. Hence, they often show higher 
affinity for conjugate than for free hapten (Charlton and Porter, 2002). Selection and 
characterisation of mutant clones 
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6.2.2.3 Polyclonal phage ELISA of a light chain-shuffled and error-prone mutant 
library 
 
The precipitated input phage, from each bio-panning round of the mutant library, was 
analysed by polyclonal phage ELISA. A high signal from the MC-OVA-specific scFv-
phage can be observed in bio-panning round 2, which subsequently decreased, due to 
increased panning stringency. Enrichment was observed for panning round 4, from the 
trypsin-eluted (TE) phage only (Figure 6.2.2.2). No enrichment was observed for the 
competitively-eluted (CE) outputs. 
 
 
Figure 6.2.2.2: Polyclonal phage ELISA for the avian mutant library. Output phage 
from each round of bio-panning were incubated with immobilised MC-LR-OVA 
conjugate (10 µg/mL) and binding was detected using a HRP-labelled, anti-M13 
commercial antibody (GE Healthcare). Non-specific binding controls were included; 
BSA (10 µg/mL) and OVA (10 µg/mL). Errors bars represent the standard deviation 
above the mean value. 
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6.2.2.4 Direct soluble ELISA of the light chain-shuffled avian library 
 
Soluble monoclonal ELISA was performed on clones selected from rounds 4 and 5 of 
the trypsin-eluted and competitively-eluted bio-panning methods. No enrichment was 
detected for round 5, but it was decided to check for any positive binders. The quantity 
of phage may have been too small to generate a positive signal by polyclonal phage 
ELISA. Initially, phage outputs from bio-panning rounds 4 and 5 were re-infected into 
E.coli Top10F' bacterial cells for soluble expression. The scFv-enriched lysates were 
tested by monoclonal soluble ELISA for binding to immobilised MC-LR-OVA 
conjugate (5 µg/mL).  
 
All clones were tested in parallel for cross-reactivity to the OVA and BSA carrier 
protein. No cross-reactivity pattterns were observed (data not shown). The majority of 
clones, from both the trypsin and competitively-eluted methods, had ELISA signals 
which were more than three-fold higher than that of the control proteins, BSA and 
OVA. The monoclonal ELISA screening results, from bio-panning round 4, are 
illustrated in Figure 6.2.2.3. The trypsin and competitively-elute clones displayed a 
percentage binding, above background, of 94 % and 72 %, respectively. It was clear that 
highest-binding clones were obtained from the trypsin-eluted library in this round.  
 
The mean background value for all clones analysed was 0.359 AU. Similarly, the 
trypsin and competitively-eluted clones from bio-panning round 5 displayed a 
percentage binding, above background, of 95.8 % and 99 %, respectively (Figure 
6.2.2.4). Thirty randomly-selected clones from rounds 4 and 5 (both trypsin and 
competitive elution) were taken forward for cross-reactivity and inhibition analysis to 
assess their ability to bind MC-LR in solution.  
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A. 
 
B. 
 
 
Figure 6.2.2.3: Soluble monoclonal ELISA of mutant, solubly-expressed scFvs from 
bio-panning round 4. Ninety six clones each were selected from the trypsin-eluted (A) 
and competitively-eluted (B) round 4 of bio-panning. Supernatant, containing solubly-
expressed scFv was incubated on MC-LR-OVA–coated plates (5 µg/mL) and binding 
was detected using a HRP-labelled anti-HA monoclonal antibody.  
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A. 
 
B. 
 
Figure 6.2.2.4: Soluble monoclonal ELISA of mutant, solubly-expressed scFvs from 
bio-panning round 5. Ninety six clones each were selected from the trypsin-eluted (A) 
and competitively-eluted (B) round 5 of bio-panning. Supernatant, containing solubly-
expressed scFv, was incubated on MC-LR-OVA–coated plates (5 µg/mL) and binding 
was detected using a HRP-labelled anti-HA monoclonal antibody.  
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6.2.3 Sequence analysis of wild-type and mutant clones 
 
The clones, 2H1, 3BA1, 4CF8, 4TC2 and 5TC12, which demonstrated the best 
inhibition ELISA profiles (data not shown) were sequenced by MWG-Operon, using the 
splice by extension overlap (SOE) primers. The light and heavy chain variable regions 
were identified using the Kabat numbering system (Johnson and Wu, 2000) and 
subsequently aligned using ClustalW (Figure 6.2.3.1).  
 
                       CDRL1                      CDRL2  
2H1   AALTQPSSVSANPGETVKITCSGSSGRYGWYQQKSPGSAPVTVIYSNNQRPSDIPSRFSGSKSGSAHTLTITGVQADDEA 
3BA1  AALTXPSSVSANPGETVKITCSGSSGRYGWYQQKSPGSAPVTVIYSNNQRPSDIPSRFSGSKSGSAHTLTITGVQADDEA 
4CF8  AALTXPSSVSANPGGTVKITCSGSSGRYGWYQQKSPGSAPVTVIYSNNQRPSDIPSRFSGSKSGSAHTLTITGVQADDEA 
4TC2  AALXXPSSVSANPGETVKITCSGSSGRYGWYQQKSPGSAPVTVIYSNNQRPSDIPSRFSGSKSGSAHTLTITGVQADDEA 
5TC12 AALTXPSSVSANPGETVKITCSGSSGRYSWHQQKSPGSAPVTVIYSNNQRPSDIPSRFSGSKSGSAHTLTITGVQVDDEA 
      **  **** **** *************.* :********************************************.**** 
             CDRL3                      LINKER                                    CDRH1  
2H1   VYYCGSYDTNLRSDDM--FGAGTTLTVLGGSSRSSGGGGSGGGGS-SALTLDESGGGLQTPGRTLSLVCKASGFTFSSYAMETG 
3BA1  VYYCGSYDTNLRSDDMETFGAGTTLTVLGQSSRSSGGGGSSGGGG-SAVTLDESGGGLQTPGRTLSLVCKASGFTFSSYAMETG 
4CF8  VYYCGSYDTNLRSDDMETFGAGTTLTVLGQSSRSSGGGGSSGGGGSSAVTLDESGGGLQTPGRTLSLVCKASGFTFSSYAMETG 
4TC2  VYYCGSYDTNLRSDDMETFGAGTTLTVLGQSSRSSVGGGSSGGGG-SAVTLDESGGGLQTPGRTLSLVCKASGFTFSSYAMETG 
5TC12 VYFCGSYDTNLRSDDMETFGAGTTLTVLGQSSRSSGGGGSSGGGG-SAVTLDESGGGLQTPGRTLSLVCKASGFTFSSYAMETG 
      **:*************  *********** ***** ****.***.  *:*********************************** 
                       CDRH2                                            CDRH3  
2H1   WVRQAPGKGLEYVAGINNDGSFTHYESAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCARSLSSIGDIDAWGHGTEVIV   
3BA1  WVRQAPGKGLEYVAGINNDGSFTHYESAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCARSLSSIGDIDAWGHGTEVIV 
4CF8  WVRQAPGKGLEYVAGINNDGSFTHYESAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCARSLSSIGDIDAWGHGTEVIV 
4TC2  WVRQAPGKGLEYVAGINNDGSFAHYESAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCARSLSSIGDIDAWGHRTEVIV 
5TC12 WVRQAPGKGLEYVAGINNDGSFTHYESAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCARSLSSIGDIDAWGHGTEVIV 
      **********************:********************************************************** 
 
Figure 6.2.3.1: ClustalW sequence alignment for four MC-LR clones, compared to the 
2H1 parent scFv clone (Top). CDR regions are highlighted with colour. Regions of 
sequence diversity are highlighted in yellow. Key: CDRL1 = Blue, CDRL2 = Pink, 
CDRL3 = Red, Linker = Turquoise, CDRH1 = Light Blue, CDRH2 = Green, CDRH3 = 
Purple. 
The sequence comparison between the wild-type scFv (2H1) and the error-prone PCR, 
light chain-shuffled clones (2BA1, 4CF8, 4TC2 and 5TC12) clearly illustrates that the 
majority of sequence substitutions were located in the framework regions. Significantly, 
no alternative light chains were incorporated into the mutant clones. However, one 
substitution from threonine (T) to alanine (A) in the CDRH2 region was evident in the 
4TC2 clone. The clone displaying the best inhibition profile by ELISA, 5TC12 
(shortened to C12) was also the clone with the most amino acid substitutions (5), most 
likely caused by point mutations in the error-prone PCR replication process. In this 
process, the point mutations introduced a mis-sense error in the reading frame, caused 
by a malfunction in DNA replication. These changes are classified as either transitions 
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or transversions. Most common mis-sense mutations include the exchange of a purine 
for a purine (A ↔ G) or a pyrimidine for a pyrimidine, (C ↔ T). The threonine to 
alanine substitution in the CDRH2 region was most likely an A → G substitution. 
Notably, all the mutant clones had an insertion mutation (ET) close to the CDRL3 
region (glutamic acid, E and threonine, T). Insertions and substitutions of nucleotides in 
the antibody-encoding genes are natural components of the hypermutation process, 
which may expand the possible interaction sites and conformations for antibody:antigen 
binding. Although mutations of amino acids have also been widely utilised in antibody 
engineering, little is known about the functional consequences of such modifications.  
 
6.2.4 ELISA comparison of wild-type and mutant clones 
 
The MC-LR-specific wild-type (2H1) and mutant (C12) scFvs were analysed for their 
capacity to bind free MC-LR in solution. The C12 clone was chosen for comparison, as 
it displayed the best inhibition profile in preliminary ELISA analysis, performed in 
crude lysate (data not shown). In addition, the C12 scFv displayed the most amino acid 
substitution, compared with the 2H1 clone. Inhibition analysis was carried out by pre-
incubating the scFv fragments with MC-LR for 30 minutes before adding the mixture to 
the microplate, coated with MC-LR-OVA conjugate. Inter- and intra-day variability 
analysis was also performed, using the light chain-shuffled scFv fragment, C12. 
Satisfactory % CV and RE values were obtained in the validation studies, and the assay 
had a range of 0.8 to 50 ng/mL (Table 6.2.4.1).  
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The current ELISA analysis showed that the C12 scFv fragment was marginally more 
sensitive, in comparison to the 2H1 parent clone. The limit of detection (LOD) of the 
C12 mutant scFv was 1.4 ng/mL, while the LOD of the parental 2H1 was calculated as 
3.2 ng/mL. Therefore, the mutagenesis strategy resulted in a 2.3-fold improvement in 
the limit of detection value of the 2H1 scFv fragment. The ELISA inhibition curves are 
compared in Figure 6.2.4.1.  
 
 
Figure 6.2.4.1: Comparison of 2H1 wild-type and C12 mutant scFv fragments by 
inhibition ELISA. The ELISA plate was coated with 500 ng/mL MC-LR-OVA 
conjugate. Inhibition between MC-LR (200 to 0.78 ng/mL) and purified scFv, diluted to 
a final concentration of 1/20,000, was observed. The normalised absorbance for a given 
MC-LR concentration (A-Aexcess), divided by the normalised absorbance for negative 
sample (A0-Aexcess), was expressed as a percentage (% A/A0) and plotted versus the MC-
LR concentration (ng/mL). 
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Table 6.2.4.1: Inter- and intra-day variability studies for the C12 mutant scFv fragment 
  Inter-day Assay Validation Intra-day Assay Validation 
MC-LR 
(ng/mL) 
% CV Back Calculated 
Concentration 
(ng/mL) 
% RE % CV Back Calculated 
Concentration 
(ng/mL) 
% RE 
100.0 6.0 57.3 174.6 1.7 70.1 142.7 
50.0 2.1 60.4 82.8 10.8 48.2 103.8 
25.0 2.5 25.9 96.5 2.9 29.1 85.9 
12.5 3.7 12.4 100.7 18.4 12.3 101.3 
6.3 12.1 6.2 101.2 19.9 6.0 103.5 
3.1 5.7 3.5 88.8 12.2 3.3 95.4 
1.6 5.8 1.4 115.4 5.7 1.5 104.5 
0.8 6.5 0.7 118.2 6.9 0.9 90.6 
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6.2.5 Development of a Biacore™ inhibition assay for microcystin and 
microcystin congeners 
 
Inhibition assays for the detection of MC-LR were developed by employing a CM5 
dextran chip surface, immobilised with the heptapeptide toxin, MC-LR. For successful 
assay development, optimisation of a number of parameters was required. Inter-day and 
intra-day analysis was carried out for the 2H1 and 2G1 wild-type scFv fragments, as 
well as the C12 mutant clone, which was a product of mutagenesis and light chain 
shuffling of the 2H1 scFv clone. The three scFv fragments were compared in terms of 
their sensitivity and cross-reactivity to the microcystin variants; MC-LW, MC-RR, MC-
YR, MC-LA and MC-LF. 
 
6.2.5.1 Immobilisation of MC-LR onto a CM5 chip surface for Biacore™ analysis 
 
MC-LR was directly conjugated to a CM5 dextran chip surface using EDC-NHS 
coupling chemistry (Queen’s University, Belfast). The chip was firstly activated by (N-
ethyl-N'-(dimethylaminopropyl) carbodiimide) (EDC) and (N-hydroxysuccinimide) 
(NHS), the toxin was subsequently incubated on the chip surface. The EDC solution in 
the presence of NHS, activates the CM dextran carboxyl groups, converting them into 
functional ester groups. The surface NHS esters react with primary amino groups, such 
as lysine residues on MC-LR, causing covalent binding of the toxin to the surface 
(Murphy et al., 2006; Vinogradova et al., 2011). Any remaining available unbound 
functional ester groups are deactivated by injecting a 1 M ethanolamine hydrochloride 
solution (pH 8.5) over the chip surface. Surface regeneration was optimised, as 
described in Section 2.17.2. The surface was regenerated using two pulses of 200 mM 
NaOH, to remove non-covalently attached proteins from the surface.  
 
6.2.5.2 Inhibition assay optimisation for wild-type and mutant scFv fragments 
 
In order to optimise the sensitivity of the standard curves for detection of MC-LR, 
various parameters, including the antibody dilution and contact time, were examined. 
The effect of antibody concentration on the standard curve was examined using 
dilutions of each scFv (1/900, 1/2,000, 1/3,000, 1/5,000 and 1/7,000) and the effect of 
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the flow rate was examined using three different rates (5, 10 and 25 µL/min) (data not 
shown). A flow rate of 5 µL/min was chosen for the generation of an inhibition assay 
for all three scFv fragments, as it produced the most stable and reproducible curve under 
the defined conditions. Overall, the flow rate did not affect the sensitivity of the assay 
over the range examined. However, in the current study, a longer contact time was 
chosen to generate a robust standard curve. Antibody dilution of 1/7,000, 1/2,000 and 
1/3,000 and a flow rate of 5 µL/min were found to be optimal for the generation of a 
sensitive and reproducible inhibition assay using the 2G1, 2H1 and C12 scFv fragments, 
respectively.  
 
6.2.5.3 Inter- and intra-day Biacore™ studies of wild-type and mutant clones 
 
Optimal antibody dilutions (2H1, 2G1 and C12) were prepared in HBS-EP buffer, and 
mixed with MC-LR, to give final concentrations of between 0.7 and 200 ng/mL MC-
LR. Samples were incubated for 30 minutes at room temperature, to allow equilibration, 
and subsequently injected over the MC-LR-immobilised chip surface, at a flow rate of 5 
µL/min for 4 minutes. This was followed by two 5 second pulses of 200 mM NaOH, 
which allowed complete regeneration of the chip surface. The antibody response values 
(R) for each concentration were normalised by the transformation to % R/R0, according 
to the equation:  
 R R0   
R   Rexcess
R0  Rexcess
  
 
where R is the relative response, R0 is the response at a zero concentration of analyte, 
and Rexcess is the response at an excess of analyte. The % R/R0 value was plotted against 
the logarithm of the MC-LR concentration (ng/mL). To demonstrate the reproducibility 
of the assays, both inter- and intra-day variability studies were performed. The results of 
the inter-day assay for the 2H1, 2G1 and C12 scFv fragments are presented in Figures 
6.2.5.1, 6.2.5.2 and 6.2.5.3, respectively.  
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The inter-day calibration curve for the 2H1 scFv fragment is illustrated in Figure 
6.2.6.1. The IC50 was calculated as 33.5 ng/mL. The limit of detection was calculated 
from the mean of the zero analyte concentration, minus three standard deviations, as 
13.8 ng/mL. 
 
 
Figure 6.2.5.1: Inter-day Biacore™ assay calibration curve for the determination of 
MC-LR in PBS, for the 2H1 (wild-type) scFv fragment. MC-LR concentrations, ranging 
from 200 to 7.8 ng/mL were pre-incubated with an optimised dilution of the avian 2H1 
anti-MC-LR scFv (1/2,000) and injected over the MC-LR-immobilised surface. Using 
BIAevaluation™ software (Version 3.1), the data was fitted using a 4-parameter 
equation. The error bars represent the standard deviation for each concentration.  
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Table 6.2.5.1: Inter-day and intra-day Biacore™ inhibition assay validation to 
determine the precision (% CV) and relative error (% RE) for the 2H1 (wild-type) scFv 
fragment. 
scFv: 2H1 Inter-day Assay Validation Intra-day Assay Validation 
MC-LR 
(ng/mL) 
% CV Back Calculated 
Concentration 
(ng/mL) 
% RE % CV Back Calculated 
Concentration 
(ng/mL) 
% RE 
200 1.9 156.1 128.1 65.75 172.34 116.05 
133.3 0.2 123.1 108.3 29.3 118.9 112.1 
88.9 2.2 69.2 128.5 17.9 102.9 86.4 
59.3 4.8 51.7 114.7 13.5 59.7 99.3 
39.5 1.8 46.6 84.7 17.2 37.8 104.6 
26.3 0.4 27.2 96.9 11.6 27.5 95.9 
17.6 4.0 15.1 116.7 8.8 17.1 102.7 
11.7 3.1 13.1 89.7 7.2 11.8 98.8 
7.8 2.5 7.1 110.0 9.6 7.7 102.0 
 
The precision and relative error of the inhibition analyses was evaluated by 
extrapolating the % CV and % RE. Inter- and intra-day assay CVs for the 2H1 scFv 
were all well below the acceptable limit of 20 %, indicating excellent reproducibility. 
The 2H1 inhibition assay was reproducible in the range of 7.8 to 59.3 ng/mL (Table 
6.2.5.1).  
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The inter-day calibration curve for the 2G1 scFv fragment is presented in Figure 6.2.6.2. 
The IC50 was calculated as 6.2 ng/mL. The limit of detection was calculated from the 
mean of the zero analyte concentration, minus three standard deviations, as 1.7 ng/mL. 
 
 
Figure 6.2.5.2: Inter-day Biacore™ assay calibration curve for the determination of 
MC-LR in PBS, for the 2G1 (wild-type) scFv fragment. MC-LR concentrations, ranging 
from 200 to 7.8 ng/mL were pre-incubated with an optimised dilution of the avian 2G1 
anti-MC-LR scFv (1/7,000) and injected over the MC-LR-immobilised surface. Using 
BIAevaluation™ software (Version 3.1), the data was fitted using a 4-parameter 
equation. The error bars represent the standard deviation for each concentration. 
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Table 6.2.5.2: Inter-day and intra-day Biacore™ inhibition assay validation to 
determine the precision (% CV) and relative error (% RE) for the 2G1 (wild-type) scFv 
fragment. 
scFv: 2G1 Inter-day Assay Validation Intra-day Assay Validation 
MC-LR 
(ng/mL) 
% CV Back Calculated 
Concentration 
(ng/mL) 
% RE % CV Back Calculated 
Concentration 
(ng/mL) 
% RE 
40.00 13.3 27.6 144.9 60.9 30.7 130.1 
26.67 15.9 27.2 98.0 79.9 25.9 102.9 
17.78 12.2 21.4 83.1 82.8 20.3 87.76 
11.85 9.8 13.3 89.0 28.9 13.3 89.0 
7.90 8.0 7.5 106.1 7.8 6.9 113.4 
5.27 5.8 4.9 108.3 12.6 5.5 96.3 
3.51 4.6 3.5 101.8 3.5 3.5 101.9 
2.34 3.44 2.5 92.8 6.8 2.4 96.9 
1.56 5.2 1.7 90.3 5.3 1.8 88.9 
1.04 3.9 1.2 87.0 1.9 0.9 107.9 
0.69 4.7 0.9 80.9 0.8 0.5 155.9 
 
For the 2G1 scFv intra-day analysis, the % CV values for the high MC-LR 
concentrations were outside the acceptable limit. Therefore, the assay was not 
reproducible within this range. The 2G1 scFv was reproducible in the range of 1 to 7.9 
ng/mL, for both inter-day and intra-day analysis (Table 6.2.5.2).   
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The inter-day calibration curve for the C12 scFv fragment is illustrated in Figure 
6.2.6.3. The IC50 was calculated as 28.2 ng/mL. The LOD was calculated from the mean 
of the zero analyte concentration, minus three standard deviations, as 14.8 ng/mL. 
 
 
Figure 6.2.5.3: Inter-day Biacore™ assay calibration curve for the determination of 
MC-LR in PBS for the C12 (mutant) scFv fragment. MC-LR concentrations ranging 
from 100 to 7.8 ng/mL were pre-incubated with an optimised dilution of the avian C12 
anti-MC-LR scFv (1/3,000) and injected over the MC-LR-immobilised surface. Using 
BIAevaluation™ software (Version 3.1), the data was fitted using a 4-parameter 
equation. The error bars represent the standard deviation for each concentration. 
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Table 6.2.5.3: Inter-day and intra-day Biacore™ inhibition assay validation to 
determine the precision (% CV) and relative error (% RE) for the C12 (mutant) scFv 
fragment. 
scFv: C12 Inter-day Assay Validation Intra-day Assay Validation 
MC-LR 
(ng/mL) 
% CV Back Calculated 
Concentration 
(ng/mL) 
% RE % CV Back Calculated 
Concentration 
(ng/mL) 
% RE 
88.9 0.9 97.1 91.5 15.4 72.0 123.4 
59.3 3.6 59.3 99.9 12.0 57.5 103.0 
39.5 2.2 38.2 103.3 9.3 40.9 96.7 
26.3 6.4 27.2 96.7 7.3 26.1 100.8 
17.6 3.0 16.8 104.3 6.7 16.1 108.9 
11.7 4.4 11.7 100.1 10.7 15.2 76.9 
7.8 3.7 8.6 90.6 4.4 6.8 114.4 
 
For the C12 inhibition analysis, the % RE indicated reasonable error, with the majority 
of values with 80 to 120 %. The % CV and % RE values for the mutant clone are 
outlined in Table 6.2.5.3. The C12 scFv fragment had an acceptable assay range, with 
good reproducibility between 7.8 and 59.3 ng/mL. 
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6.2.5.4 Comparison of wild type and mutant clones on Biacore™ 
 
The results of the Biacore™ inhibition assays, employing the wild-type scFv fragments, 
2H1 and 2G1, were compared to the light chain-shuffled C12 scFv fragment, in terms of 
assay sensitivity. The Biacore™ inhibition curves for the three antibody fragments are 
shown in Figure 6.2.5.4. 
  
 
Figure 6.2.5.4: Comparison of Biacore™ inhibition analysis for the detection of MC-
LR in HBS-EP buffer, using the 2H1, 2G1 and C12 scFv fragments. The mutant C12 
fragment was derived from the 2H1 clone by error-prone PCR and light-chain shuffling. 
The normalised responses (R), expressed as % R/Ro, were plotted against the logarithm 
of the MC-LR concentration (ng/mL).  
 
The range of detection, IC50 and limit of detection values are summarised in Table 
6.2.5.4. The 2H1 scFv fragment (LOD = 13.8 ng/mL) displayed a similar sensitivity to 
the C12 mutant clone (LOD = 14.8 ng/mL), from which it was derived by mutagenesis 
and light–chain shuffling. The 2G1 scFv fragment was approximately 2.6-fold more 
sensitive in an SPR format, compared with the original ELISA format (Section 6.2.5) 
(ELISA LOD = 4.4 ng/mL; Biacore LOD: 1.7 ng/mL). Moreover, the 2G1 scFv showed 
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an estimated 9-fold greater assay sensitivity, compared with the C12 and 2H1 scFv 
fragments, in the SPR assay. It was clear that the 2G1 scFv fragment displayed 
excellent sensitivity for MC-LR in an immunosensor format, which was extremely close 
to the WHO detection limit of 1 µg/L (1 ng/mL). 
 
Table 6.2.5.4: Comparison of assay range, IC50 and limit of detection (LOD) of the 
2H1, 2G1 (wild-type) and C12 (mutant) scFv fragments.  
scFv Fragment Range (ng/mL) IC50 (ng/mL) LOD (ng/mL) 
2H1 (Wild-Type) 7.8 – 59.3 33.5 13.8 
C12 (Mutant 2H1) 1 – 7.9 28.2 14.8 
2G1 (Wild-Type) 7.8 – 59.3 6.2 1.7 
 
6.2.5.5 Cross-reactivity studies of wild-type and mutant clones  
 
To determine the degree of cross-reactivity of the scFv fragments, 2H1, 2G1 and C12, 
with the five, structurally-related variants or ‘cogeners’ of microcystin, MC-LW, MC-
RR, MC-YR, MC-LA and MC-LF, a Biacore™ inhibition analysis was performed. All 
the assay conditions were consistent. Percentage cross-reactivities (% CR50) were 
extrapolated by comparing the relevant IC50 of the microcystin variants to the IC50 of 
the MC-LR toxin. The % CR50 was calculated using the equation: 
 
  Cross reactivity  0 (CR 0)  
IC 0 MC ariant
IC 0 MC LR
   100 
 
The cross-reactivity profiles for the 2G1 scFv clone for MC-YR, MC-LW and nodularin 
are illustrated in Figure 6.2.6.5 A, while the profiles for the MC-RR, MC-LF and MC-
LA variants are illustrated in Figure 6.2.6.5 B. Each microcystin variant IC50 is 
compared to the IC50 of the MC-LR variant in each four-parameter fit profile. Figure 
6.2.6.6 illustrates the cross-reactivities of the most commonly-occurring MC variants to 
the 2H1 scFv fragment. The IC50 and % CR50 for the 2G1, 2H1 and C12 scFv fragments 
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are shown in Table 6.2.6.5. It was not possible to generate four-parameter fit equations 
for the C12 mutant scFv cross-reactivity analysis, as the data was poor. This may have 
occurred due to the degradation of the chip surface with extended use over time. 
Therefore, the IC50 and CR50 values were estimated from a graph of normalised 
response (%R/R0) versus the logarithm of the MC variant concentration (ng/mL) (data 
not shown).  
 
The results, listed in Table 6.2.5.5, indicate that the 2G1 scFv fragment had lower 
percentage cross-reactivities, compared with the 2H1 and C12 scFvs. However, the 
overall reactivity of the 2G1 scFv for MC-LR toxin and its variants is still considerably 
more sensitive, in comparison with the 2H1 and C12 scFv fragments. The degree of 
cross-reactivity of the 2G1 scFv to the MC variants was variable, with MC-YR and 
MC-LA showing a high cross-reactivity relative to MC-LR (Table 6.2.5.5).  
 
The 2H1 scFv showed considerable cross-reactivity to the MC-LF variant, which 
contains leucine and phenylalanine, at the variable amino acid positions. However, the 
binding of the 2H1 scFv to the MC-LW and MC-RR were low, at 43.2 and 39.3 %, 
respectively. MC-LW is characterised by the presence of leucine and the bulky, 
aromatic-ring containing tryptophan, while MC-RR contains two long-chain arginine 
residues, at the variable positions. This may suggest that binding of the 2H1 scFv to the 
structurally-diverse MC variants is inhibited by the presence of bulky side chains.  
 
Preliminary cross-reactivity studies were also carried out on the mutant C12 scFv, 
revealing that that the antibody offered greater specificity towards certain MC variants, 
in comparison with the parent scFv, 2H1. Binding to the MC-LA, nodularin and MC-
RR variants were improved by approximately 190 %, 67 % and 47 %, respectively. 
However, binding to the C12 scFv mutant to the MC-LF variant was reduced by almost 
50 % and reactivity to MC-YR and MC-LW was also reduced, in comparison with the 
wild-type 2H1 scFv. 
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A. 
 
B. 
 
 
Figure 6.2.5.5: Cross-reactivity characterisation of the 2G1 scFv fragment, in HBS-EP 
buffer. A.) Comparison of MC-LR with the MC-YR, MC-LW variants and the related 
toxin, nodularin. B.) Comparison of MC-LR with the MC-LF, MC-RR and MC-LA 
variants. The normalised responses (R), expressed as % R/R0, were plotted against the 
logarithm of the MC variant concentration (ng/mL).  
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A. 
 
B. 
 
Figure 6.2.5.6: Cross-reactivity characterisation of the 2H1 scFv fragment, in HBS-EP 
buffer. A.) Comparison of MC-LR with the MC-YR, MC-LW variants and the related 
toxin, nodularin. B.) Comparison of MC-LR with the MC-LF, MC-RR and MC-LA 
variants. The normalised responses (R), expressed as % R/R0, were plotted against the 
logarithm of the MC variant concentration (ng/mL).  
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Table 6.2.5.5: Summary of cross-reactivity analysis of 2G1, 2H1 and C12 antibody 
fragments. The cross-reactivity values were extrapolated from the IC50 value, which was 
estimated as 50 % B/B0. The % CR50 values were determined as a percentage of the IC50 
values for the MC-LR variant. 
Cross-reactivity of MC toxins to 2G1 scFv fragment in HBS-EP buffer 
Analyte IC50 (ng/mL) % CR50 
MC-LR 4.8 100.0 
MC-YR 8.1 79.7 
MC-LA 6.4 74.8 
MC-LF 7.1 67.5 
MC-LW 10.1 63.7 
MC-RR 7.9 60.1 
Nodularin 9.3 69.3 
Cross-reactivity of MC toxins to 2H1 scFv fragment in HBS-EP buffer 
Analyte IC50 (ng/mL) % CR50 
MC-LR 21.9 100.0 
MC-YR 32.9 66.9 
MC-LA 37.0 59.4 
MC-LF 21.2 103.8 
MC-LW 50.9 43.2 
MC-RR 55.9 39.3 
Nodularin 31.9 68.7 
Preliminary cross-reactivity of MC toxins to C12 scFv fragment in HBS-EP buffer 
Analyte IC50 (ng/mL) % CR50 
MC-LR 25 100.0 
MC-YR 48 52.1 
MC-LA 22 113.6 
MC-LF 43 58.1 
MC-LW 80 31.3 
MC-RR 30 83.3 
Nodularin 25 100.0 
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6.2.6 Fluorescence immunoassay development for microcystin  
 
Fluorescence immunoassays were developed, in parallel, using two antibody formats, a 
purified ‘in house’ rabbit polyclonal anti-microcystin antibody, and the novel scFv 
fragments, 2G1 and C12. The 2G1 and C12 scFvs were selected based on their high 
sensitivity and cross-reactivity to microcystin variants. The performance of a number of 
fluorescence immunoassay formats were compared, including the use of biotinylated 
antibodies, which were detected with fluorescent-streptavidin conjugates, and 
fluorescently-labelled antibodies. The assays were also incorporated onto a convenient 
slide-based immunoassay system for sensitive detection of microcystin. 
 
6.2.6.1 Serum titration of MC-LR-OVA-immunised rabbit host  
 
Following successive rounds of immunisation of a rabbit host, with MC-LR-OVA 
conjugate, a serum titre was performed, using MC-LR-BSA as the screening conjugate. 
Serum from the immunised rabbit was diluted (1/10 to 1/2,000,000) in 1 % (w/v) Milk 
Marvel in PBS, containing 0.05 % (v/v) Tween 20. These dilutions were tested against 
immobilised MC-LR-BSA (10 µg/mL), in a direct ELISA format. The immune rabbit 
serum was compared to a pre-bleed serum, taken prior to immunisation. A graph of 
absorbance versus the logarithm of the rabbit serum dilution is shown in Figure 6.2.6.1. 
The rabbit serum displayed a high titre in excess of 1/300,000 to the microcystin 
conjugate, making it ideal for the production of polyclonal antibodies. 
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Figure 6.2.6.1: Titration of pre-bleed and immune serum from an MC-LR-OVA-
immunised rabbit host. The ELISA plate was coated with an MC-LR-BSA conjugate, at 
a concentration of 10 µg/mL. Binding was detected with an anti-rabbit (IgG) antibody, 
conjugated to horseradish peroxidase (HRP). The ELISA was developed with TMB 
substrate and the absorbance was measured at 4 0 nm, using a Tecan™ Safire II plate 
reader. 
6.2.6.2 Protein-G purification of rabbit IgG polyclonal antibody 
 
The polyclonal antibody from the microcystin-immunised rabbit was purified from the 
immunoglobulin-rich immune serum, using protein G chromatography. Protein G 
affinity chromatography is a well established and reliable method for purifying whole 
antibodies from serum. The protein G-purified polyclonal antibody was compared to the 
crude immune serum, using SDS-PAGE analysis (Figure 6.2.6.2). The SDS-PAGE gel 
clearly illustrates that the antibody was efficiently purified from the impure serum 
sample. The two bands in lane B represent the heavy chain (~55 kDa) and the light 
chain (~25 kDa) of the polyclonal antibody, which had a high level of purity.  
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Figure 6.2.6.2: SDS-PAGE gel of fractions of protein G purification of rabbit anti-
microcystin polyclonal antibody. The crude, unpurified serum (A), and the eluted 
purified polyclonal antibody (B), were analysed. A protein marker ladder (Sigma-
Aldrich) was also loaded (M), for estimation of the apparent molecular weights of each 
of the protein samples. 
6.2.6.3 Labelling of anti-microcystin scFv and polyclonal rabbit IgG with Alexa 
Fluor
®
 647 dye 
 
A protein labelling kit was employed to directly label the recombinant (2G1) and 
polyclonal antibodies with Alexa Fluor
®
 647 reactive dye, via a succinimidyl ester 
moiety on the dye molecules. This moiety reacted with the primary amino groups on the 
antibody molecules to form stable amide linkages. The labelled antibodies were purified 
from the reaction mixtures, using size exclusion chromatography, on a P-30 purification 
resin. Differences in the molecular weight of the dye:antibody conjugate and the free 
dye, were used to separate the two components. The larger protein-dye conjugate eluted 
from the column first and was captured. The degree of labelling was calculated, based 
on the relative absorbances of the dye:antibody conjugates at 280 and 650 nm, 
respectively. It was estimated that the 2G1 scFv fragment contained approximately 1 
mole of dye per mole of scFv and the rabbit IgG ratio was estimated at 6 moles dye per 
mole of IgG. The larger conjugation ratio for the IgG molecule was expected, as the full 
length antibody contains more primary amino groups for conjugation, in contrast to the 
single chain antibody fragment. 
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6.2.6.4 Biotinylation of anti-microcystin scFvs and polyclonal rabbit IgG 
 
For the development of an indirect inhibition ELISA for MC-LR, the scFv fragments, 
2G1 and C12 and the polyclonal antibody (IgG) were biotinylated, using a 100-fold 
excess of antibody (scFv or IgG) for efficient conjugation. A sulfo N-
hydroxysuccinimde-LC activated biotin was used for labelling of the primary amino 
groups on the antibody molecules. After completion of the conjugation reaction, the 
conjugate was purified from non-conjugated biotin and microcystin, using molecular 
weight cut-off  ivaspin™ columns (10,000 Da MWCO). Identification of biotin in the 
conjugation reaction was assessed using a HABA (4'-hydroxyazobenzene-2-carboxylic 
acid)/ avidin assay. The scFv molecules (2G1 and C12) possessed approximately 2 
millimoles of biotin per millimole scFv, and the IgG molecules contained 
approximately 7 millimoles of biotin per millimole of IgG. As expected, the IgG had a 
greater biotin incorporation ratio, compared to the smaller scFv fragments. 
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6.2.6.5 Optimisation of fluorescence immunoassay conditions 
 
Before carrying out extensive assay development, the Z position and the bandwidth for 
the Tecan Safire II instrument were optimised. The Z position is defined as the optimal 
position of the well, corresponding to the focus of the optics of the instrument. The 
bandwidth of a monochromator is defined as the span of monochromator settings 
needed to move the image of the entrance slit across the exit slit. The bandwidth of the 
spectrofluorometer is changed by adjusting the width of the excitation and emission 
slits. Empirical optimisation revealed that a bandwidth of 12 nm was optimal for robust 
signal generation and a low signal to noise ratio.  
 
The optimal plate coating concentration and antibody dilution was determined for the 
fluorescently-labelled 2G1 scFv fragment. Several concentrations of MC-LR-OVA (0.5 
to 16 µg/mL) conjugate were compared with dilutions of 2G1-Alexa Fluor
®
 647, 
ranging from 1,00 to 1/12,000, in 1 % (w/v) Milk Marvel in PBS, containing 0.05 % 
(v/v) Tween 20. A graph of fluorescence intensity, arbitrary units (AU), versus the 
reciprocal of the labelled 2G1 scFv dilution was plotted (Figure 6.2.6.4). The optimal 
scFv concentration and corresponding conjugate coating concentration, which gave an 
adequate fluorescence signal, were determined. A signal of 20,000 AU was considered 
optimal for all fluorescence optimisation experiments. Dilutions were chosen to 
minimise the use of both protein and antibody conjugates. The optimal coating 
concentration was 8 µg/mL of MC-LR-OVA conjugate and the optimal scFv-fluorphore 
dilution was 1/500. 
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Figure 6.2.6.3: Checkerboard FLISA to determine optimal conjugate coating 
concentration (MC-LR-OVA) and optimal dilution of 2G1 scFv fragment. The scFv 
was directly-labelled with Alexa Fluor
®
 fluorescent dye, using EDC-NHS conjugation. 
A graph of fluorescence intensity (AU) was plotted against the reciprocal of the 
conjugate concentration (ng/mL).  
 
A checkerboard ELISA was also performed to calculate the optimal conditions for 
detection of IgG-Alexa Fluor
®
 647 binding (Figure 6.2.6.5). Similiar to the 2G1 
scFv:fluorophore optimisation, different concentrations of MC-LR-OVA (0.5 to 16 
µg/mL) were compared with dilutions of IgG-Alexa Fluor
®
 647, ranging from 1,00 to 
1/12,000, in 1 % (w/v) Milk Marvel in PBS, containing 0.05 % (v/v) Tween 20. A graph 
of fluorescence intensity (AU), versus the reciprocal of the labelled IgG dilution was 
plotted (Figure 6.2.6.5). The optimal IgG concentration and corresponding conjugate 
coating concentration, which gave an adequate fluorescence signal, were calculated. 
The optimal coating concentration was 2 µg/mL of MC-LR-BSA conjugate and the 
optimal IgG-fluorphore dilution was 1/100. 
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Figure 6.2.6.4: Checkerboard FLISA to determine optimal conjugate coating 
concentration (MC-LR-BSA) and optimal dilution of the Protein-G purified, rabbit 
polyclonal antibody. The IgG was directly-labelled with Alexa Fluor
®
 fluorescent dye, 
using EDC-NHS conjugation. A graph of fluorescence intensity (AU) was plotted 
against the reciprocal of the conjugate concentration (ng/mL).  
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Optimisation experiments for fluorescence immunoassay development were also carried 
out for the biotinylated IgG, C12 and 2G1 antibodies. A number of parameters required 
optimisation, including the coating concentration, the dilution of biotinylated antibody 
and the dilution of streptavidin Alexa Fluor
®
 647 conjugate. The results of these 
optimisation experiments are summarised in Table 6.2.6.1. 
 
Table 6.2.6.1: Optimisation of the conjugate coating concentration, the biotinylated 
antibody (rabbit IgG, 2G1 and C12 avian scFvs) dilution and the streptavidin-Alexa 
Fluor
®
 647 conjugate. 
Biotinylated 
antibody 
Conjugate Conjugate 
coating 
concentration 
(ng/mL) 
Biotinylated 
antibody 
dilution 
Streptavidin 
Alexa Fluor
®
 
647 conjugate 
dilution 
Rabbit IgG-biotin MC-LR-BSA 500 ng/mL 1/2,000 1/1,000 
scFv 2G1-biotin MC-LR-OVA 500 ng/mL 1/2,500 1/1,000 
scFv C12-biotin MC-LR-OVA 500 ng/mL 1/2,000 1/1,000 
 
 
6.2.6.6 Fluorescence immunoassay development using the biotinylated mutant 
C12 scFv fragment 
 
The fluorescence assay calibration curve for the C12 scFv fragment is shown in Figure 
6.2.6.6. The normalised percentage fluorescence intensity (% F/F0) was plotted against 
the logarithm of the MC-LR concentration (ng/mL), using BIAevaluation™ software. F 
represents the fluorescence intensity, while F0 represents the fluorescence at a zero 
concentration of analyte. The data was normalised by expressing F as a percentage of F0 
(% F/F0). The IC50 was calculated as 6.04 ng/mL. The preliminary limit of detection 
was calculated, as the mean of the normalised response for the zero value (no MC-LR), 
minus three standard deviations, at 0.6 ng/mL.  
 
 
303 
 
 
Figure 6.2.6.5: Calibration curve of FLISA with biotinylated mutant C12 scFv 
fragment, at an optimised concentration (1/2,000 dilution). Binding was detected using 
a streptavidin- Alexa Fluor
®
 conjugate (1/1,000 dilution). Dilutions were prepared in 1 
% (w/v) Milk Marvel, in PBS (150 mM, pH 7.4), containing 0.05 % (v/v) Tween. The 
error bars represent the standard deviation for each concentration.  
 
6.2.6.7 Comparison of fluorescence immunoassay formats, using the labelled anti-
microcystin antibodies 
 
The fluorescence assay calibration curves for the labelled 2G1 scFv fragments are 
shown in Figure 6.2.6.7. The curves compare the sensitivity of the directly-labelled 2H1 
scFv to the biotinylated scFv, as the percentage normalised fluorescence intensity (% 
F/F0), versus the logarithm of the MC-LR concentration (ng/mL), using 
BIAevaluation™ software. The biotinylated scFv required a secondary detection 
fluorophore, in the form of a streptavidin Alexa Fluor
®
 647 conjugate. The use of 
biotin-streptavidin in the immunoassay resulted in a clear shift in assay sensitivity. This 
may be due to the presence of two millimoles of biotin, per millimole of scFv on the 
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2G1 scFv fragment. In contrast, the directly-labelled 2G1 scFv only contained 
approximately 1 mole of dye, per mole of scFv. Therefore, signal amplification may 
have occurred as a result of two-fold more biotin conjugated to the scFv, compared with 
the fluorophore-labelled  scFv fragment (1:1 fluorophore:dye ratio). The antibodies may 
be analysed at different dilutions, but the F0 values have been normalised (20,000 Au) 
to standardise the data. 
 
 
Figure 6.2.6.6: Comparison of calibration curves for FLISA with the 2G1 scFv-Alexa 
Flour
®
 conjugate and the biotinylated 2G1 scFv fragment. Binding of the biotinylated 
2G1 scFv fragment was detected with a streptavidin Alexa Fluor
®
 647 conjugate 
(1/1,000 dilution). Dilutions were prepared in 1% (w/v) Milk Marvel, in PBS (150 mM, 
pH 7.4), containing 0.05 % (v/v) Tween. The data was fitted into four-parameter fit 
equations, using BIAevaluation™ software.  
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The fluorescence assay calibration curves for the labelled IgG polyclonal antibody are 
illustrated in Figure 6.2.6.8. The curves compare the sensitivity of the directly-labelled 
IgG to the biotinylated IgG, as the percentage normalised fluorescence intensity (% 
F/F0) versus the logarithm of the MC-LR concentration (ng/mL), using 
BIAevaluation™ software. The biotinylated IgG required a secondary detection 
fluorophore, in the form of a streptavidin Alexa Fluor
®
 647 conjugate. As the assay was 
already highly sensitive, little improvement in sensitivity was seen when the two assay 
formats were compared (Figure 6.2.6.8). As before, the antibodies may be analysed at 
different dilutions, but the F0 values have been normalised (20,000 Au) to standardise 
the data. 
 
 
Figure 6.2.6.7: Comparison of calibration curves for FLISA with the IgG-Alexa Flour
®
 
conjugate and the biotinylated IgG polyclonal antibody. Binding of the biotinylated IgG 
was detected with a streptavidin Alexa Fluor
®
 647 conjugate (1/1,000 dilution). 
Dilutions were prepared in 1 % (w/v) Milk Marvel, in PBS (150 mM, pH 7.4), 
containing 0.05 % (v/v) Tween. The data was fitted into four-parameter fit equations, 
using BIAevaluation™ software.  
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A comparison of the assay sensitivities achieved using the fluorescence-immunoassay 
formats is summarised in Table 6.2.6.2. It is clear that the most sensitive antibody and 
assay formats were achieved using the fluorophore and biotin-labelled rabbit IgG 
antibodies, which resulted in limits of detection significantly lower than the regulatory 
limit of 1 ng/mL (0.3 and 0.2 ng/mL, respectively). Moreover, although the 
fluorescently-labelled 2G1 scFv did not reach the limit of detection (17.7 ng/mL), the 
biotin-labelled 2G1 scFv format achieved a limit of detection of 1.4 ng/mL. This change 
in fluorescence assay format resulted in an approximately 13-fold improvement in 
sensitivity. The biotinylated C12 mutant showed an excellent cross-reactivity below the 
limit of detection (0.6 ng/mL). Therefore, this fragment was used for further proof-of-
concept immunoassay studies. 
 
Table 6.2.6.2: Comparison of the IC50 and LOD values from the rabbit polyclonal and 
the 2G1 and C12 antibodies, using different immunoassay formats. Calibration curves 
were fitted, using a four parameter equation and the IC50 was calculated, as the MC-LR 
concentration, required to inhibit 50 % of antibody binding. The corresponding LOD 
was calculated from the equation, as the mean zero value, minus three standard 
deviations. 
Antibody Directly-labelled 
Alexa Fluor
®
 647 antibodies 
Biotinylated antibodies, 
detected, using streptavidin 
Alexa Fluor
® 
647 
Rabbit polyclonal (IgG)  IC50 = 0.6 ng/mL 
LOD = 0.3 ng/mL 
IC50 = 0.5 ng/mL 
LOD = 0.2 ng/mL 
2G1 scFv fragment  IC50 = 38.5 ng/mL 
LOD = 17.7 ng/mL 
IC50 = 13.7 ng/mL 
LOD = 1.4 ng/mL 
C12 scFv fragment 
- 
IC50 = 6.0 ng/mL 
LOD = 0.6 ng/mL 
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6.2.6.8 ‘Proof-of-concept’ slide-based fluorescence immunoassay development 
 
For ‘proof-of-concept’ a number of immunoassays were carried out on a poly-ʟ-lysine 
functionalised glass slide, separated using a slide divider, to create wells for 
immunoassay spots. Optimised concentrations of antibody were incubated with a range 
of MC-LR concentrations (0.032 to 20 ng/mL) at room temperature for 20 minutes. The 
inhibition assay was carried out on the functionalised-glass substrate, which was 
previously coated with 4 µg/mL MC-LR-OVA and blocked with 5 % (w/v) Milk 
Marvel, in PBS.  
 
Adhesive slide dividers were prepared, by the School of Physical Sciences, DCU, and 
all assay steps were carried out in the slide divider wells. After protein incubation and 
washing steps, the slide divider was removed and the fluorescence was quantified using 
a Perkin Elmer™ Scannarray Express scanner, under optimal conditions (see Section 
2.18.9). Image analysis software (AIDA) was employed to quantify the pixel intensity 
in each spot in a defined area (Figure 6.2.6.9). The pixel intensity values were 
normalised to the negative spot intensity value (no MC-LR) and expressed as F/F0. The 
F/F0 value was plotted against the logarithm of the MC-LR concentration. Preliminary 
results for the inhibition assay curves generated for IgG-Alexa Fluor
®
 647, 2G1-Alexa 
Fluor
®
 647 and C12-biotin, detected with streptavidin-Alexa Fluor
®
 647, are shown in 
Figure 6.2.6.9 B, C and D, respectively. A representation and comparison of the assay 
sensitivities achieved using the microplate and slide-based assay is summarised in Table 
6.2.6.3. 
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Figure 6.2.6.8 (previous page): Proof of concept analysis of fluorescence 
immunoassay for detection of MC-LR, on poly-ʟ-lysine functionalised glass slides. The 
inhibition immunoassay was carried out on individual conjugate-coated spots on the 
glass substrate, created using adhesive slide dividers. Fluorescence was quantified on a 
Perkin Elmer™ Scanarray Express instrument. Inhibition curves were generated as the 
normalised fluorescence (F/F0), versus the MC-LR concentration (ng/mL). A.) Image of 
spots from an inhibition assay, using the Alexa Fluor
®
 647- labelled rabbit polyclonal 
antibody. As the MC-LR concentration decreased, the signal or pixel intensity 
increased, as measured by an increase in the colour intensity. B.) Inhibition assay curve 
of IgG-Alexa Fluor
®
 647 C.) Inhibition assay curve of 2G1-Alexa Fluor
®
 647. D.) 
Inhibition assay curve of C12-biotin, detected with streptavidin-Alexa Fluor
®
 647. The 
error bars represent the standard deviation for each data point and the mean was 
calculated from three separate experiments. 
Table 6.2.6.3: Comparison of the IC50 values from the rabbit polyclonal and the 2G1 
and C12 antibodies, using the microplate and slide-based fluorescence immunoassays. 
The IC50 values for the slide assays were calculated, as the MC-LR concentration, 
required to inhibit 50 % of antibody binding. The corresponding LOD was calculated 
from the equation, as the mean zero value, minus 3 standard deviations. 
Antibody (Rabbit IgG) Directly-labelled Alexa Fluor
®
 647  
Plate Assay  IC50 = 0.55 ng/mL 
Slide Assay  IC50 = 0.40 ng/mL (approximate) 
Antibody (2G1 scFv)  Directly-labelled Alexa Fluor
®
 647 
Plate Assay  IC50 = 38.52 ng/mL 
Slide Assay  IC50 = 6.00 ng/mL (approximate) 
Antibody (C12 scFv) Biotinylated antibody with streptavidin Alexa 
Fluor
®
 647 detection 
Plate Assay  IC50 = 6.04 ng/mL 
Slide Assay  IC50 = 1.00 ng/mL (approximate) 
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6.3 Discussion 
 
Recombinant antibodies can be covalently attached to drugs (Schrama et al., 2006) or 
toxins (Schmidt et al., 1999) for targeted cancer therapies or engineered for different 
specificities and affinities (Korpimäki et al., 2004; Holliger et al., 2005; Maynard and 
Georgiou, 2000). Both random and site-directed mutagenesis strategies can be 
employed for recombinant antibody improvement. In this work, novel recombinant scFv 
molecules were isolated from an immune library by phage display, and subsequently 
these scFvs were improved though affinity mutagenesis. The ability to mutate 
antibodies at the genetic level is a powerful tool in the antibody engineering repertoire. 
Specific properties of these molecules, such as stability, specificity, and in some cases 
catalysis, can be enhanced using mutagenesis techniques (Marks, 2004). Error-prone 
PCR has become one of the most common techniques for random mutagenesis. Using 
error-prone PCR, mutations can be precisely targeted to specific sequences, including 
CDR regions. Furthermore, the error rate of this technique can be tightly controlled and 
unlike other methods it avoids the use of hazardous chemicals. Furthermore, 
mutagenesis results using error-prone PCR can be obtained in a relatively short period 
of time (Cirino et al., 2003; Pritchard et al., 2005). Moreover, the employment of both 
chain shuffling and error-prone PCR in combination has the advantage of more closely 
mimicking the in vivo antibody maturation process. 
 
The 2H1 avian scFv clone was chosen for affinity maturation. Following error-prone 
PCR amplification of the mutant light chain library, and non-error-prone PCR 
amplification of the parent heavy chain from the 2H1 scFv clone, the VL and VH gene 
fragments were joined by overlap extension PCR. The assembled single chain Fv 
fragments were cloned into the pComb3XSS phagemid vector. The library was 
subsequently transformed into electrocompetent E.coli XL-1 Blue cells. During the bio-
panning process, a competitive elution strategy was performed in parallel with a trypsin 
elution strategy in the last rounds of bio-panning, with the aim of selecting improved 
binders in solution. Polyclonal phage ELISA showed that a large increase in the output 
phage was observed in round 2. These binders were eliminated during subsequent 
stringent bio-panning rounds. Encouragingly, a second enrichment of phage binders was 
observed in the fourth round of phage bio-panning, from the trypsin-eluted phage 
population.  
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No enrichment was observed for the competitively-eluted rounds, or for the fifth round 
of bio-panning. This may be because the bio-panning strategy was too stringent or the 
number of positive binders was too small to create a discernable signal. Clones were 
selected and screened from both bio-panning rounds, for both bio-panning strategies, by 
monoclonal phage ELISA. Phage pools were infected into a non-suppressor strain of E. 
coli (TOP10F′) and 96 clones from rounds 4 and 5 (trypsin and competitive elution) 
were solubly expressed and screened, by indirect ELISA. The majority of randomly-
picked clones demonstrated significant binding reactivity to the MC-LR-OVA 
conjugate. A higher percentage of positive binders were evident in the trypsin-eluted 
clones, compared with the competitively-eluted clones. In addition, no significant 
binding was observed to the negative control proteins, BSA and OVA.  
 
It has been reported that certain single amino acid insertions and deletions are generally 
well-tolerated and permit the production of correctly-folded recombinant antibody 
molecules, which retain their antigen recognition properties (Lantto and Ohlin, 2002). 
Sequence analysis of the anti-microcystin scFvs from the mutant avian library showed 
that no alternative light chain combinations were selected. This data strongly suggests 
that the existing light chain is the best partner for the parent heavy gene sequence, as re-
selection from the light chain pool did not find a superior binding combination. A future 
avenue of research would be to reverse the chain shuffling process and perform heavy 
chain shuffling. It is possible that an alternative heavy chain combination could have 
yielded an improved anti-microcystin scFv with a higher sensitivity. In this research, the 
increased sensitivity of the C12 scFv most likely relates to its altered amino acid 
sequence. From the sequencing analysis, it is clear that the 2H1 and C12 clones are 
different, with five amino acid substitutions evident in the framework regions. Even 
though extensive PCR mutagenesis was carried out, only a small number of missense 
mutations occurred between the two sequences. It is possible that the mutant scFv 
library was highly diverse during the initial rounds of bio-panning. However, with 
subsequent rounds of harsh selection, the diversity of the scFv library was most likely 
reduced.  
 
Even with this small number of amino acid changes in the framework region of the 
antibody, the binding properties of the antibody were significantly affected. In the 
ELISA comparison of the 2H1 and C12 clones, a two-fold increase was seen in the 
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LOD values, compared to the wild-type clone. Biacore™ inhibition analysis showed 
that the cross-reactivity profiles of C12 for the microcystin variants, MC-LA, nodularin 
and MC-RR, were significantly increased. In comparison to the parental 2H1 scFv, the 
C12 mutant scFv had a 190 % (MC-LA), 67 % (nodularin) and 47 % (MC-RR) 
improvement in binding to these MC variants. However, C12 reactivity to MC-LF, MC-
YR and MC-LW were decreased. This is highly significant since a prerequisite for 
microcystin quantification is that the cognate antibody displays a good cross-reactivity 
profile for commonly-occurring microcystin variants. Therefore, the random 
mutagenesis approach resulted in an improved antibody specificity for some 
microcystin variants, which may aid in the accurate quantification of total toxin content 
in a sample. Importantly, this is the first report of an improved recombinant avian anti-
MC scFv fragment. 
 
The development of an easy-to-use, rapid, robust and non-expensive method for the 
measurement of low concentrations of microcystin has been recognised as a high 
priority (WHO, 1998). Biochemical methods for microcystin detection including 
immunoassay (Zeck et al., 2001; Sheng et al., 2007; Khreich et al., 2009) and enzyme 
assays (protein phosphatase inhibition assay) (Metcalf et al., 2001; Campàs et al., 
2005), are currently replacing un-ethical and inaccurate in vivo assays and expensive 
analytical detection systems. Although some of these methods are less qualitative, 
compared with the physiochemical methods, they are still equally sensitive. Moreover, 
some of these methods are more rapid, making them particularly useful for the 
screening of environmental samples (Carmichael and An, 1999).  
 
Strachen et al. (2002) demonstrated that a highly-sensitive recombinant scAb antibody 
to microcystin could be selected from the non-immune Griffin I library, with 
sensitivities that ranged from 13 to 2,000 nM. Recombinant fragments (scAbs) were 
subsequently isolated from the Griffin I library with LODs as low as 0.8 nM 
(McElhiney et al., 2002). Antibodies were previously isolated by the same group using 
the Tomlinson I library, however, these antibodies did not prove sensitive enough for 
detection below regulatory limits (4 µM) (McElhiney et al., 2000). The CDRH3 of the 
Tomlinson I library is conserved at seven amino acids, while the Griffin I library 
incorporates variable heavy-chain CDR3 lengths. This may explain how a more 
sensitive antibody to microcystin was isolated from the Griffin I source, which had 
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CDRH3 of 10 amino acids long. This group postulated that improved antibody:hapten 
recognition may be associated with the length of the complementary determining region 
(CDRH3) in the heavy chain variable domain. The CDRH3 is known to play a major 
role in antigen binding (Johnson and Wu, 1998). Studies have shown that long CDRH3 
regions are capable of forming anti-hapten binding pockets (Strachen et al., 2002).  
 
A Biacore™ surface plasmon resonance biosensor was used as an assay platform to 
analyse the interaction of novel recombinant antibodies with covalently immobilised-
microcystin-LR. The SPR detector monitors changes in resonance angle due to 
molecular interaction at the interface which is directly proportional to the change of 
mass at the surface. SPR biosensor techniques have proven to be versatile, robust and 
capable of producing rapid and reliable results, with minimum sample preparation 
(Baxter et al., 2001). Two of the clones from the original avian phage display library 
(2H1 and 2G1) were brought forward for SPR analysis, and their ability to bind 
microcystin was compared with the C12 mutant. The inhibition assays for the 2H1 and 
C12 scFv fragments had an IC50 value of 33.5 and 28.2 ng/mL, and LOD values of 13.8 
and 14.8 ng/mL, respectively. The range of detection for these clones, at which the 
assays were both accurate and precise, was 7.8 to 59.3 ng/mL. However, the 2G1 scFv 
displayed a dramatically increased sensitivity to MC-LR and its variants, using 
Biacore™ inhibition analysis, compared to the ELISA analysis. The 2G1 scFv 
displayed an IC50 and limit of detection of 6.2 and 1.7 ng/mL, respectively. This was 
unexpected as the 2G1 had previously displayed comparable sensitivity to 2H1 by 
ELISA. The 2H1 scFv clone was chosen for mutagenesis based on ELISA analysis. It 
was not known at the time of mutant library construction that the 2G1 clone was more 
sensitive in an SPR format. It was demonstrated previously in this laboratory 
(unpublished results) that the same recombinant antibody may display remarkable 
different sensitivities depending on the format of analysis (ELISA or Biacore™).  
 
Cross-reactivity analysis showed that the three antibodies were cross-reactive to varying 
extents with the microcystin variants MC-LW, MC-LF, MC-LA, MC-RR and MC-YR. 
The side-chains of MC-LR consist of a hydrophobic leucine (L) residue and a basic 
arginine (R) residue. The variant MC-LW and MC-LF both contain bulky tryptophan 
(W) and phenylalanine (F) residues respectively. These residues may have negatively 
impacted the interaction of the MC antigen with the binding sites on the scFv molecules 
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(Egloff et al., 1997). In this report, it was shown by in silico docking analysis that 
microcystin has the potential to bind to different sites of the 2G1 scFv structure (Section 
5.3.2.5). Therefore, the 2G1 scFvs may bind microcystin and its variants in different 
ways and at different sites. Overall, the 2G1 scFv displayed the best specificity, with 
IC50 values in the range of 4.8 to 10.08 ng/mL, for all the variants tested, using 
Biacore™ inhibition analysis. 
 
SPR has become a widely used technique, because ‘real-time’ and ‘label-free’ assays 
can be performed in complex matrices without the need for sample clean-up. A number 
of SPR immunosensors have recently been described for microcystin in drinking water 
(Herranz et al., 2010). In one such method, a competitive inhibition format is used, in 
which MC-LR was immobilised onto an SPR chip functionalised with a self-assembled 
monolayer. In this format, the assay gave an IC50 of 0.67 µg/L and cross-reacted with 
MC-RR and MC-YR. An SPR inhibition immunoassay was also developed using a 
monoclonal antibody to microcystin with a Biacore™ 3000 biosensor (Hu et al., 2009). 
In this assay, a MC-BSA conjugate was immobilised onto a CM5 chip surface and 
inhibition occurred with MC-LR in solution. The assay was sensitive in the 1 -100 µg/L 
range. Additionally, a rapid SPR immunobiosensor assay was developed for detection 
of microcystin in blue-green algae food supplements (Vinogradova et al., 2011). The 
biosensor results were in good agreement with an established LC–MS/MS assay. The 
assay is advantageous because it employs a simple clean-up procedure, compared to 
chemical assays. The SPR assays developed in this research compared favourably with 
these assays in terms of sensitivity and specificity. SPR has been successfully employed 
to detect small molecules and haptens in a multitude of food and environmental samples 
(Dostálek et al., 2006; Shankaran et al., 2007). Alternative biosensor techniques 
developed for microcystin detection include molecular-imprinted polymer (MIP)-
sensors (Chianella et al., 2002), electrochemical immunosensors (Campàs et al., 2005; 
Campàs and Marty, 2007; Loyprasert et al., 2008) and evanescent wave immunosensors 
(Long et al., 2008; Long et al., 2009).  
 
This chapter also described the production and characterisation of rabbit polyclonal 
antibodies and their subsequent use in the development of fluorescence-based 
immunoassays for the detection of microcystin. The applicability of a glass slide-based 
biosensor for the detection of MC-LR was investigated. Two recombinant scFv 
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antibodies, 2G1 and C12, were biotinylated, using EDC-NHS coupling chemistry. In 
addition, the 2G1 scFv was also directly labeled with an Alexa Fluor
®
 647 dye molecule 
via a succinimidyl ester moiety. In parallel the rabbit IgG was also functionalised with 
biotin and Alexa Fluor
®
 647. Initially, all reagents were tested in a FLISA plate format. 
For indirect FLISA analysis, the MC-LR toxin competed for antibody binding with the 
immobilised microcystin conjugate. In addition, the biotinylated antibody was detected 
using a commercially available streptavidin-Alexa Fluor
®
 647 conjugate.  
 
A calibration curve was generated for the detection of MC-LR using the mutant C12 
scFv-biotin conjugate. This assay displayed an IC50 and a limit of detection of 6 and 0.6 
ng/mL, respectively. In contrast, the same clone displayed a limit of detection in a 
standard, ELISA format of 1.4 ng/mL. The introduction of fluorescence in combination 
with the biotin-streptavidin system resulted in an approximate 2-fold increase in assay 
sensitivity, bringing the detection limit below the WHO guideline value of 1 µg/L (1 
ng/mL). The assay performance of the 2G1-Alexa Fluor
®
 647 conjugate was compared 
with the biotinylated-2G1 conjugate by FLISA. Significantly, the biotinylated-2G1, in 
combination with the streptavidin conjugate, displayed a 13-fold increase in assay 
sensitivity, compared with the fluorescently-labelled 2G1 scFv (LODs of 17.7 and 1.4, 
respectively). The same comparison was carried out, between biotinylated-IgG and 
fluorescently-labelled IgG polyclonal antibody, but no significant shift in assay 
sensitivity was observed. Previously, Pyo et al. (2007) compared fluorescence and 
colloidal gold-based immunochromatographic strip assays for detection of MC-LR 
using a fluorophore-conjugated MC-LR and gold-conjugated MC-LR monoclonal 
antibody, respectively. This assay was capable of sensitively detecting MC-LR at the 
test site without having to transfer to the laboratory. Additionally, Yu et al. (2011) 
incorporated antibody-conjugated quantum dots and antigen-coated magnetic beads into 
a bead-based fluorescence assay for microcystin detection. The assay displayed a limit 
of detection of 0.03 µg/L and an assay time of 30 minutes. It is clear that fluorescence 
assay development can provide unique advantages in terms of low detection limits, 
accuracy and short assay times. 
 
Three highly sensitive FLISA assays, developed on black NUNC™ plates were 
transferred to an immunoassay on a functionalised glass slide for a ‘proof-of-concept’ 
316 
 
experiment. These assays incorporated the IgG-Alexa Fluor
®
 647 conjugate and the 
2G1-Alexa Fluor
®
 647, as well as the biotinylated C12 mutant scFv. The directly-
fluorescently-labeled antibodies were included, as only one inhibition step is required 
prior to detection, which dramatically shortens the immunoassay time. The poly-ʟ-
lysine functionalised glass slides can be efficiently coated with microcystin conjugate 
and blocked, prior to addition of the test sample. This resulted in a rapid and sensitive 
FLISA format for MC detection. The preliminary inhibition curves obtained on the slide 
immunoassays clearly demonstrate improved IC50 values, compared with the plate 
immunoassays. The 2G1-Alexa Fluor
®
 647 conjugate displayed a 6-fold increase in 
sensitivity (IC50 values of 38.52 and 6 ng/mL, for plate- and slide-based assays, 
respectively). Due to time constraints, it was not possible to determine an accurate LOD 
value. The biotinylated C12 scFv fragment also displayed a 6-fold increase in 
sensitivity, with IC50 values of 6.04 and 1 ng/mL for the plate- and slide-based assays, 
respectively.  
Recently, an ultra-rapid one-step fluorescence immunochromatographic assay was 
described for the detection of microcystin (Kim et al., 2003) which could detect 
contamination ‘on-site’ in 15 minutes. This assay utilised fabricated assay strips and a 
portable laser fluorescence scanner. Linder and co-workers reported the establishment 
of a highly sensitive immunoassay for the detection of MC-LR, based on the 
immobilisation of a biotin-MC-LR conjugate to the surface of a microplate and 
detection using a commercially-available monoclonal antibody, MC10E7 (Lindner et 
al., 2004). The immunoassay was used to detect microcystin in spiked water samples. It 
is apparent that the surface-based immunosensor format developed in this research 
displays great potential for the development of an ‘easy-to-use’, rapid and sensitive 
FLISA for microcystin detection. APTES-treated glass slides were also used in FLISA 
development, but the surfaces were not uniform and reproducible results could not be 
obtained. The novel slide dividers provided an effective method for the utilisation of 
plain, glass substrates for assay development. The rapid fabrication techniques used, 
allowed for the specific tailoring of the size, shape, well volume and substrate material, 
to meet the requirements for the various steps of assay development. In addition, the 
slide dividers can be made in large quantities and they are disposable, which is very 
convenient for toxin handling.  
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In conclusion, this chapter describes in detail the application of a random mutagenesis 
approach for the generation of improved anti-microcystin recombinant antibodies. The 
heavy chain of the 2H1 clone and the variable light chain genes of the pre-existing anti-
microcystin avian library, in combination with error-prone PCR, were used in the 
construction of a mutant avian library. A mutant clone, C12, was isolated which 
displayed improved sensitivity. The recombinant antibodies were incorporated into 
Biacore™-based immunoassay formats, in which the 2G1 scFv displayed the best 
microcystin sensitivity (1.7 ng/mL). Interestingly, in comparison to the parent 2H1 
antibody the C12 mutant scFv displayed better cross-reactivity to a panel of microcystin 
variants. It is probable that the small number of amino acid substitutions, in the 
framework region of the mutant sequence, has an effect on microcystin detection 
sensitivity and specificity. Mutations associated with affinity improvement are generally 
located in the CDR regions (Johnson and Wu, 1998; Lamminmaki et al., 1999). 
However, in this situation, a small number of framework mutations, resulted in 
improved binding capacity. These missense mutations may have caused slight shifts in 
the positioning of the CDR regions, thus improving antibody:antigen interaction. 
Fluorescence-based immunoassays were developed on glass substrates, with the mutant 
clone, C12, displaying high sensitivity, with an IC50 of approximately 1 ng/mL. With a 
limit of detection below 1 ng/mL, this assay format has the potential to be incorporated 
into a commercial, immunoassay microcystin detection system. 
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Chapter 7 
Overall Conclusions 
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7.1  Overall conclusions 
The research in this thesis describes an investigation of the immunomodulatory effects 
of phycotoxins and mycotoxins on murine macrophage function in vitro, using both 
‘real-time’ and end-point analysis. In addition, the production of immune recombinant 
libraries to the shellfish and water contaminants, microcystin and azaspiracid are also 
described. Furthermore, the generation, purification and characterisation of highly, 
sensitive single chain antibody fragments to microcystin, is discussed in detail. 
Following affinity maturation of an scFv fragment, sensitive ELISA, Biacore™ and 
fluorescence-based assays were developed for detection of microcystin and its variants, 
below the WHO regulatory limit.  
Chapter 3 contributed to the understanding of some of the biological processes 
underlying macrophage dysfunction in the presence of the toxins, azaspiracid-1, 
microcystin-LR and aflatoxins B1, B2 and G1. One of the key parameters under 
investigation was the effect of immunosuppression on the macrophage response to 
microbial pathogens (LPS) and, therefore, host resistance. Under the threat of infection, 
activated macrophages produce pro-inflammatory cytokines (TNF-α, IL-1, IL-6 and IL-
12p40) and anti-inflammatory cytokines (IL-10) to regulate the inflammatory response. 
In this report, the cytokine profile, following toxin exposure, provided vital information 
regarding the nature of the immunotoxic response. This is the first report of an 
investigation into the in vitro effects of AZA-1 on the murine macrophage cell line, 
J774A.1. AZA-1 significantly reduced the viability of the macrophages at a 
concentration of 100 pg/mL, in comparison to the control, but the effect was eliminated 
with the addition of stimulatory LPS (WST-1 assay). In the LDH cytotoxicity assay, the 
macrophages displayed a significant decrease in percentage cytotoxicity (i.e. increased 
cell survival), compared to the control, at concentrations of 0.1 and 0.01 pg/mL. This 
effect was replicated when the cells were exposed to toxin and LPS simultaneously. It is 
possible that a protection mechanism is activated in the macrophage cells when specific 
toxin concentrations (0.1 and 0.01 pg/mL) are reached, which aids in cell survival. 
However, at higher toxin concentrations (1-100 pg/mL), this unknown mechanisms may 
be overwhelmed, which results in cytotoxicity effects.  
The significant effects of AZA-1 on macrophage viability and cytotoxicity, lead to the 
further investigation of AZA-1 in vitro. It was discovered that the AZA-1 significantly 
suppressed the ability of macrophages to respond to LPS activation, through analysis of 
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the pattern of cytokine expression. AZA-1 significantly reduced the expression of pro-
inflammatory TNF-α and IL-6, in LPS-stimulated macrophages, thereby decreasing the 
macrophages ability to signal to other immune cells and to stimulate the inflammatory 
response to infection. In contrast, levels of pro-inflammatory IL-12p40 and anti-
inflammatory IL-10 were significantly increased, through AZA-1 exposure, but there 
was no significant effect on responsiveness to LPS stimulation. Overall, it is possible 
that AZA-1 can modulate the ability of murine macrophages to mount an inflammatory 
response to invasion by Gram-negative bacteria, as shown by cytotoxicity and cytokine 
analysis. The murine and human genomes are 85 % homologous (Makalowski et al., 
1996). Therefore, this murine model provides an insight into the possible threat that 
AZA-1 poses to the human immune system.  
In this chapter, it was also shown that macrophage function was down-regulated 
through exposure to the cyanobacterial toxin, microcystin. The anti-proliferative effect 
of microcystin on the murine macrophages, J774A.1 was significant, as this effect has 
not been demonstrated previously. Exposure to MC-LR resulted in a time-dependent 
increase in cytotoxicity, both in the presence and absence of LPS, as quantified by the 
LDH cytotoxicity assay. The inhibition of macrophage proliferation by a low MC-LR 
concentration (0.1 µg/mL) was also demonstrated, by WST-1 cell proliferation analysis. 
An approach was taken to investigate whether microcystin was involved in the 
inflammasome activation process. Significantly, the marine toxin, maitotoxin has been 
previously shown to modulate NLRP3 inflammasome activation, by inducing caspase-1 
production, which was dependent on activation of the pore-forming receptor, pannexin-
1 (Mariathasan et al., 2006; Pelegrin and Surprenant, 2007). 
The presence of two active markers of inflammasome activation, IL-1β and caspase-1 
were investigated. Significantly, IL-1β was dramatically decreased by MC-LR 
exposure. Additionally, it was demonstrated that inflammasome activation was possible 
in the murine macrophages, through co-stimulation with the LPS and ATP danger 
signals. It was also shown that inflammasome inhibition was possible, using the ATP-
sensitive K
+
 channel inhibitor, glyburide. Following MC-LR exposure, in ATP and 
LPS-stimulated macrophages, it appeared that the MC-LR toxin inhibited IL-1β 
production, but that this effect was independent of either LPS or ATP stimulation. In 
contrast, ATP exposure, both in the presence and absence of LPS stimulation, had no 
discernable effect on IL-1β production, in response to microcystin. Analysis of caspase-
1 activation, in relation to MC-LR provided a further insight into the mechanism of 
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apoptotic cell death following toxin exposure. It was shown that MC-LR induced 
caspase-1 activation, in an ATP-dependent manner. In LPS-stimulated macrophages, 
microcystin had no effect on caspase-1, compared with controls. However, in the 
presence of ATP and LPS, there was a dramatic increase in active caspase-1, following 
toxin exposure. It was therefore concluded that ATP is necessary for active caspase-1 
production following microcystin exposure, but it remains unknown if microcystin is 
involved in the inflammasome assembly or activation process. Further investigations 
into the effect of microcystin exposure on the inflammatory mediators, IL-1β and 
caspase-1 are warranted.  
The immunomodulatory effect of aflatoxin exposure on murine macrophages was also 
examined in detail. The major aim was to characterise the individual and combined 
effects of AFB1, AFB2 and AFG1 exposure based on cytokine expression profiles and 
cell surface receptor expression. Addition of the aflatoxins, AFB1 and AFB2, resulted in 
significantly increased IL-6 (0.1 ng/mL) and significantly deceased IL-10 (0.01 ng/mL) 
expression levels. However, AFB2 significantly decreased the expression of IL-12p40. 
In contrast, such an effect was not observed for AFB1. These results demonstrated that 
the toxic effects, induced by these aflatoxins, are dependent on variations in the ring 
structure of the three toxin isoforms.  
In studying the effect of multiple toxin isoforms on cytokine secretion, following LPS 
challenge, it was observed that AFB1 + AFB2 combined (0.01 ng/mL each), have an 
additive effect, by inducing IL-6 secretion. This is significant, as neither isoform 
modulated IL-6 secretion at this concentration independently. In analysing the effect of 
aflatoxin on IL-12p40 secretion, it was evident that all toxin combinations, at both low 
and high concentrations significantly reduced TNF-α expression. Moreover, exposure to 
AFB1 + AFG1 (0.01 ng/mL) and AFB1 + AFB2 (0.1 ng/mL) significantly reduced TNF-
α expression. Importantly, the majority of these effects, particularly for IL-12p40 
expression, were not observed when the macrophages were exposed to these toxins 
individually. In summary, these results suggest that aflatoxins inhibit the LPS-mediated 
activation of macrophages, thus inhibiting the host response to infection from Gram-
negative bacteria. This is the first report of the effect of aflatoxin mixtures on TNF-α, 
IL-6, IL-10 and IL12p40 expression in a murine macrophage model. Exposure of AFB1 
+ AFB2 significantly reduced CD14 cell surface receptor expression, both in the 
presence and absence of LPS. Significantly, this effect was not evident when cells were 
exposed to AFB1 or AFB2 alone. Additionally, AFB1 significantly reduced the 
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expression of the TLR ligand, TLR2. Interestingly, following LPS challenge, exposure 
to AFB2 and AFG1 significantly decreased TLR2 expression, thus inhibiting the ability 
of macrophages to respond to Gram-positive components. A further avenue of research 
would involve the study of the effects of aflatoxins on surface marker expression, in the 
presence of a TLR2 ligand, such as Pam3CSK4.  
The initial part of this research project focused on the deregulation of immune system 
function by naturally-occuring toxins. Due to the obvious threat posed to both human 
and animal by toxin exposure, sensitive methods for their detection have become a 
priority. A number of aflatoxin-specific antibodies have already been produced in the 
laboratory (Daly et al., 2000; Dunne et al., 2005). However, no immune recombinant 
antibodies exist to either microcystin or azaspiracid. Therefore, the primary objective of 
this thesis was the generation and characterisation of recombinant antibodies that 
recognise azaspiracid and microcystin. 
The beginning of chapter 4 described the generation and screening of a recombinant 
immune library to the phycotoxin, azaspiracid. A low titre rabbit immune scFv library 
was constructed and bio-panned. However, this library yielded no soluble AZA-1 
binders. Novel AZA-BTG and AZA-KLH conjugates were generated and attempts were 
made to characterise these toxin conjugates, by Biacore™ analysis. The latter part of the 
chapter described the generation and characterisation of novel azaspiracid protein 
conjugates, AZA-KLH and AZA-transferrin. However, no binding to the AZA-
transferrin-immobilised chip surface was observed. The AZA-KLH conjugate was used 
to immunise an avian host. However, no significant immune response to the AZA 
conjugate was observed. Azaspiracid proved to be a very difficult toxin target. In the 
future, if new well-characterised AZA conjugates become available, the existing 
recombinant library could be screened for novel binders. An isolated clone from this 
library would represent the only existing recombinant antibody to azaspiracid.  
Chapter 5 focused on the isolation and characterisation of novel avian anti-microcystin 
scFv fragments. As previously outlined, chickens provided a number of advantages for 
recombinant antibody generation. Careful consideration and deliberation was given to 
the custom synthesis of the MC-LR conjugates. Derivitisation and one-stage 
glutaraldehyde coupling was used for conjugate generation, through the N-
methyldehydroalanine residue of MC-LR. This residue is structurally separate from the 
Adda moiety, which is common to all microcystin variants. Antibody binding to the 
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Adda structure of the microcystin would, therefore, be advantageous for cross-reactivity 
purposes. The avian scFv library was constructed from the antibody variable regions 
genes of B-cells, derived from the spleen and bone marrow of an avian host, which was 
immunised with an MC-LR-BSA conjugate. The scFv library was screened using a MC-
LR-OVA conjugate. Two scFv fragments (2H1 and 2G1) were selected for further 
characterisation, based on their potential to compete with MC-LR in solution-phase 
inhibition assays. The 2H1 and 2G1 scFvs were cultured in large-scale and purified by 
immobilised metal affinity chromatography, via an incorporated hexahistidine tag. 
FPLC was used for removal of minor contaminants or ‘polishing’ of the scFvs, prior to 
immunoassay development and labelling.  
The 2H1 and 2G1 scFv fragments were successfully used in the development of an 
ELISA inhibition assay for MC-LR and the assays were validated using approved 
techniques. Under optimised conditions, the 2H1 and 2G1 scFv displayed limits of 
detection of 2.7 and 4.4 ng/mL, as quantified by extrapolating the zero value, minus 
three standard deviations, from a four-parameter fit equation. The range of these ELISA 
assays was found to be 3.1 to 25 ng/mL and both assays were accurate and reproducible 
within this range. This work is significant, as it demonstrates, for the first time, the 
generation of an anti-microcystin avian scFv, with sensitivity in the ng/mL range. 
The work described in chapter 6 focused on a mutagenesis approach for the generation 
of an improved anti-microcystin antibody fragment. A random mutagenesis strategy 
was chosen for scFv diversification. The 2H1 scFv fragment was chosen for 
mutagenesis experiments, based on previous ELISA data. A light chain shuffling 
strategy was employed, in which the parental heavy chain from the 2H1 scFv clone was 
shuffled with a library of light chains from the original un-panned scFv immune library. 
Error-prone PCR was also incorporated into the amplification of the light chain regions 
to add to the pre-existing diversity of the library. The mutant scFv library was bio-
panned with the MC-LR-OVA conjugate. Two bio-panning elution strategies were 
employed i.e. standard trypsin elution and competitive elution with free toxin. These 
strategies were used in order to maximise the chances of isolating an improved binder 
for microcystin. Analysis of the polyclonal phage pool from each round of bio-panning 
revealed that both methods produced large amounts of soluble, anti-microcystin scFv 
clones. This data showed that it was possible to co elute phage from the immunotube 
with toxin in solution. Such a strategy may aid in the isolation of binders with superior 
functionality in solution-phase and inhibition assay formats. 
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ELISA inhibition and sequencing analysis revealed one mutant clone, C12, which 
appeared to have a greater affinity for microcystin, in comparison to the 2H1 clone. An 
amino acid sequence alignment of the wild-type and mutant clones showed that they 
were genetically different. The clones had a number of amino acid substitutions in the 
framework region, but the majority of the sequences were identical. The only apparently 
significant amino acid substitution was the insertion of glutamic acid and threoine, in 
close proximity to the CDRL3 region. The lack of sequence variation between the 2H1 
and C12 clones, in combination with the modest improvement in microcystin binding, 
indicates that the parent scFv format was already substantially optimised for 
microcystin binding in vivo. No alternative light chain combinations were selected, 
despite the presence of a highly diverse avian light chain for selection of alternative 
binding partners. However, presence of a number of amino acid substitutions in the 
framework region, introduced through error-prone PCR, decreased the MC-LR 
concentration required to inhibit antibody binding by 50 % (IC50) by approximately 2-
fold. The C12 mutant is a novel affinity-improved recombinant avian anti-microcystin 
scFv. 
The Biacore™ proved to be an invaluable tool in the analysis of microcystin binders, 
especially in assay validation and the cross-reactivity analysis of microcystin variants. 
When the three antibodies were applied to the development of a Biacore™ inhibition 
assay, the 2H1 and C12 scFv displayed similar sensitivities (LODs: 13.8 and 14.8 
ng/mL). On this platform, the 2G1 scFv demonstrated a better sensitivity than 
previously shown on ELISA. In this situation, there was a clear advantage of using an 
SPR-based biosensor format over a conventional ELISA assay. The limit of detection of 
1.7 ng/mL compares favourably with other SPR-based methods in the published 
literature (Hu et al., 2009; Herranz et al., 2011). 
Cross-reactivity studies carried out using Biacore™ inhibition analysis, on all three 
scFv fragments (2H1,C12 and 2G1), revealed that the C12 mutant scFv displayed an 
improved specificity to the microcystin variants (MC-LA, MC-RR and nodularin), in 
comparison with the 2H1 parent clone. While the sensitivities of the 2H1 parent and 
C12 mutant scFvs were comparable in the Biacore™ inhibition analysis, the specificity 
profile of the C12 was altered for a number of variants, with an improved binding to 
some of the most commonly-occurring microcystins. Therefore, the incorporation of the 
C12 clone into a sensitive immunoassay format would give a better estimation of the 
total toxin content in a sample, compared to the 2H1 scFv fragment. 
325 
 
The purified scFv fragments, 2G1 and C12 were biotinylated, using EDC-NHS coupling 
chemistry . The FLISA-based immunoassay showed a 2-fold improvement in the limit 
of detection, compared with the un-biotinylated C12 antibody fragment in ELISA 
(LODs: 0.6 and 1.4 ng/mL, respectively). The FLISA-based immunoassay with the 
biotinylated 2G1 clone displayed an 3-fold improvement in assay sensitivity, compared 
with the 2G1 clone in ELISA (LODs: 1.4 and 4.4 ng/mL). The incorporation of a biotin 
label with a secondary detection element increased the assay sensitivity significantly. In 
this research, rabbit polyclonal antibodies to microcystin were also generated, purified 
and evaluated for incorporation into a sensitive immunoassay format for microcystin. 
The antibodies (IgG) were directly labelled with Alexa Fluor
® 
647 and biotinylated for 
detection with a streptavidin Alexa Fluor
® 
647 conjugate and the formats were found to 
have limits of detection of 0.3 and 0.2 ng/mL, respectively.  
The potential application of a disposable recombinant antibody-based bio-chip sensor, 
for the detection of microcystin, was also investigated. Initially, the fluorescent-based 
assays were developed on a microplate format, which proved to be highly sensitive. The 
microcystin conjugates were coated onto APTES-functionalised glass slides and 
inhibition was carried out on small spot areas, created using a custom built slide divider. 
This system enabled rapid, sensitive detection of microcystin, especially when directly 
labelled antibodies were utilised, as this system only requires one incubation step for 
detection. The use of fluorescence bio-chip platforms could potentially facilitate the 
generation of a highly sensitive, cheap, mass-produced disposable assay, for use in the 
laboratory or in situ testing environments. The 2G1-Alexa Fluor
®
 647 conjugate 
displayed a 6-fold increase in the IC50 value in the slide format, compared to the 
microplate format. The FLISA-based slide assay, employing the C12-Alexa Fluor
®
 647 
scFv fragment, was estimated to have a IC50 of 1 µg/L. Importantly, this LOD is at the 
required WHO detection limit. Although further work on developing the bio-chip assay 
is required, the applicability of this format for microcystin detection is a possibility. 
 This thesis work has shown that certain toxins from natural sources, for example, 
azaspiracid-1, microcystin-LR and aflatoxin B1, B2 and G1, have the ability to cause 
macrophage and, therefore, immune dysfunction. Many of the molecular processes 
involved in the immunotoxicity of phycotoxins and mycotoxins are still not fully 
understood. However, this research work has shed some light on the mechanisms in 
which toxins inhibit macrophage and host defence functionality, through deregulation of 
cytokine expression, TLR receptor expression and activation of apoptotic markers. In 
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addition, this work has also illustrated the utility of recombinant antibody technology 
for the production of anti-toxin antibodies. Furthermore, it has demonstrated that a 
random mutagenesis approach can improve the toxin binding capacity of a recombinant 
antibody fragment. Future work could include the development of a novel fluorescence-
based bio-chip, capable of detecting microcystin and its variants below the regulatory 
limit. It is necessary to test the cross-reactivity of the antibodies in a fluorescence 
format to the microcystin variants. Finally, it is imperative to validate the assay in a 
matrix, to analyse whether sensitive microcystin detection is possible in real samples, 
including river water and processed cyanobacterial extracts of the Microcystis species. 
These assays would then have to be correlated with currently-accepted detection 
methods, including HPLC and mass spectrometry. 
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